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Abstract 
The use of routinely collected, or administrative, data for measuring and monitoring patient safety in 
primary care is a relatively new phenomenon. With increasing availability of data from different 
sources and care settings, their application for adverse event surveillance needs evaluation. In this 
thesis, I demonstrated that data routinely collected from primary care and secondary care can be 
applied for internal monitoring of adverse events at the general practice-level in England, but these 
data currently have limited use for safety benchmarking in primary care. To support this statement, 
multiple approaches were adopted.  
In the first part of the thesis, the nature and scope of patient safety issues in general practice were 
defined by evidence from a literature review and informal consultations with general practitioners 
(GPs). Secondly, using these two methods, measures of adverse events based on routinely collected 
healthcare data were identified. Thirdly, clinical consensus guided the selection of three candidate 
patient safety indicators for investigation; the safety issues explored in this thesis were recorded 
incidents with designated adverse event diagnostic codes and complications associated with two 
common diseases, emergency admissions for diabetic hyperglycaemic emergencies (diabetic 
ketoacidosis, DKA and hyperglycaemic hyperosmolar state, HHS) and cancer.  
In the second part of the thesis, the contributions of routinely collected data to new knowledge 
about potentially preventable adverse events in England were considered. Data from a primary care 
trust (NHS Brent), national primary care data (from the General Practice Research Database, GPRD) 
and secondary care data (Hospital Episode Statistics, HES) were used to explore the epidemiology of, 
and patient characteristics associated with, coded adverse events and emergency admissions for 
diabetic hyperglycaemic emergencies and cancer. Low rates of adverse events were found, with 
variation by individual patient factors. Finally, recommendations were made on extending the uses 
of routinely collected data for patient safety monitoring in general practice. 
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Chapter 1: Introduction 
 
1.1 Chapter overview 
This chapter outlines the current climate of safety and quality measurement 
in healthcare, with particular focus on primary care. The main sources of 
patient safety data are then critiqued. In the last section of this chapter, the 
value of safety metrics derived from data collected routinely during patient 
care is considered in the context of the research questions that are 
proposed and answered in this thesis. 
 
1.2 Introduction 
There is evidence that, despite potential under-reporting in primary care, the proportion of 
reported adverse events (AEs) resulting in the most severe harm or patient death in this 
setting is higher than reported in all other healthcare settings. Estimates of patient harm, 
including their preventability, in non-acute care vary considerably within countries and 
internationally. Much of the research in this area has been conducted in the United States of 
America (US). Studies show that many of the AEs occurring in this setting are associated 
with medication or diagnosis errors.  
Routinely collected data have been used to develop screens for AEs occurring in hospital. 
These indicators are applied for early detection of sentinel and other serious iatrogenic 
events. Such flags are usually generated from electronic hospital discharge records collected 
for billing and insurance-related reimbursements. Arguably, the most well-known set of AE 
screens is the Patient Safety Indicators (PSIs), developed by the Agency for Healthcare 
Research and Quality (AHRQ) in the US.1 As clinical and non-clinical patient data are 
collected in primary care in England, there is scope to develop similar indicators for this care 
setting. In this first chapter, I present an overview of patient safety in English primary care 
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and define the key terms used throughout the thesis. I then describe the data sources and 
measurement techniques that are available for quality and safety monitoring. I end this 
chapter by contextualising the research questions that will be addressed in the remaining 
chapters. 
1.2.1 Estimates of harm in primary care 
Research on primary care safety has focused heavily on medical errors,2,3 and less so on 
actual AEs. Particular attention has been paid to drug-related events and diagnostic errors.4-
6 Few incidents of patient harm in primary care are reported, with approximately 0.36% of 
all reported events in England between July 2008 to June 2009 attributed to care in general 
practice (n=945,518).7 In spite of low levels of reporting, the proportion of reported 
incidents resulting in severe harm or death is relatively high in this care setting, with 1.7% of 
incidents associated with severe harm and 1.1% of incidents resulting in death.7 Estimates of 
preventable AEs from ambulatory care in the US suggest that nearly 10% of events lead to 
permanent injuries or death.8 An estimated 0.5% of all hospital admissions in the US are due 
to AEs outside of acute care, with 44% of these events deemed to be preventable.8 
Medication (31.7 %) and diagnosis-related problems (17.9%) are two main causes of AEs in 
non-acute care.8 Little is known about the epidemiology of patient safety incidents in 
primary care in the UK.2,3,9,10  
1.2.2 Quality and safety in primary care 
While patient safety is now firmly established within the main framework of healthcare 
research and practice across the world, momentum has tended to be behind improvements 
to the safety of hospital care.11 As mentioned in the previous section, the evidence base for 
medical errors and patient harm in primary care is limited, especially in areas such as the 
interface between care settings and in community care.3 However, knowledge and 
experience gained in secondary care of safety and risk management from other industries 
can provide a solid foundation to develop safety awareness and improvement in the non-
acute setting.  
Models of quality and safety in healthcare have evolved over the last decade. Quality spans 
multiple dimensions related to the functional purpose of an organisation to achieve 
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favourable outcomes for both the patient and itself (Figure 1.1). One internationally applied 
definition is “the degree to which health services for individuals and populations increase 
the likelihood of desired health outcomes and are consistent with current professional 
knowledge”.12 Distinctions between quality and safety are generally deemed unnecessary 
and may even be potentially counter-productive to improvements in healthcare. Patient 
safety, being typically concerned with the reduction and prevention of potential or actual 
harm to service users, is commonly perceived to be one element of the quality paradigm, 
which also includes efficiency and patient experience (Figure 1.1).10,13,14 Assessments of 
quality and performance have been established in the healthcare sector since the late 1980s. 
A commonly measured dimension of quality is performance, where measurement is made 
against explicit standards or criteria.15  
Figure 1.1 Dimensions of quality in healthcare 
 
Source: Kelley & Hurst 2006.16 
 
There is growing recognition of the need to address patient safety issues in primary care, 
partly due to practice-based payment for performance (PfP) and quality targets as part of 
service improvement initiatives.14 One example is the national auditing of cancer diagnoses 
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carried out on behalf of the Royal College of General Practitioners (RCGP), as part of cancer 
service reforms.17 Without precise identification and accurate measurement of errors and 
harm occurring in primary care, the true burden of AEs in this care setting and on the overall 
health system cannot be determined.18 Better measurement techniques along with more 
reliable data will support practice improvements, allow for economic evaluations of the 
costs of patient harm, and will improve the effectiveness of quality and safety improvement 
interventions. As well as the financial incentives for General Practitioners (GPs) and their 
practices, the use of safety measurements is of interest to other stakeholders such as 
patients, commissioners and policy makers. 
1.2.3 Importance of measuring patient safety 
A lack of standardised mechanisms to define, identify, record or investigate poor quality of 
care has plagued the National Health Service (NHS).19 The increasing complexity of changes 
to working practice, patient populations, and technological improvements make patient 
safety monitoring all the more important.20-22 In light of inadequate and ambiguous 
terminology in primary care and in safety research, primary care-oriented terminology and 
several patient safety taxonomies have been developed, such as the World Health 
Organization’s (WHO) International Classification for Patient Safety (ICPS).23 It is perhaps too 
early to tell whether the WHO ICPS will succeed where the majority of other classification 
systems have failed; the compendium of patient safety concepts requires widespread 
adoption if it is to be of benefit to researchers, healthcare professionals and patients. 
In the WHO ICPS, adverse events are defined as injuries caused by medical management 
and that are not due to the underlying disease, but that may increase length of hospital stay, 
result in temporary or permanent disability at the time of discharge, or both.23 Adverse 
events may or may not be due to medical errors, which can be defined as actions or 
omissions by staff at a general practice that were unanticipated, should not have happened, 
should not reoccur, and that may have or did result in harm to a patient, and may be 
preventable.9 Patient harm can be perceived as physical, psychological injury of temporary 
or permanent effect.23,24 
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1.3 Defining primary care 
Before examining patient safety in general practice, we must be able to define the care 
setting of interest. As mentioned in section 1.2.3, terminology used in primary care is often 
ambiguous. This lack of clarity can be partly explained by the structural variation in health 
systems, within and between countries, which has obstructed the creation of an universal 
definition of primary care. Development of a common description is also hindered by the 
unclear delineation between services offered in this setting and those offered in ambulatory 
care and secondary care. As a result of such organisational differences, comparison and 
generalisation of research methodologies or findings are not always possible.25  
In the international context, the terms “primary care” and “ambulatory care” are sometimes 
used interchangeably. This use is misleading as the “ambulatory care” setting encompasses 
a wider catchment of services than primary care, including services that may fall within 
secondary and tertiary settings. Ambulatory care may include community health centres, 
day surgery clinics, doctors’ offices and specialist treatment.26,27 Primary care is typically the 
first point of contact with health services, with treatment and continuity of care usually 
provided within the local community.28-30 
Non-acute care is commonly referred to as primary health care, primary care, primary 
medical care, general practice or family medicine.25,31 It is questionable whether these 
terms should be used interchangeably when they refer to different elements of the primary 
care infrastructure; some terms describe the type of care provided, the care system in 
operation or the types of clinicians involved.28 The term “primary medical care” is used 
synonymously with “primary care”, as “family medicine” is with “general practice”.29 The 
distinction between the former two and latter set of terms is that the latter set refers to one 
component of primary care or primary medical care.25 
1.3.1 Primary care in England 
Now that the care setting has been defined, I describe the setting in England. A strong 
primary care sector is crucial to support the rest of the UK’s health system.32,33 In England, 
elsewhere in the UK and countries with similar health systems, the majority of patient 
contact occurs in primary care. There are approximately 8,230 GP practices in England, with 
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the number of practices decreasing as the number of GPs per practice increases.34 Demand 
for consultations is rising, with an estimated 5.4 visits per patient every year.34-36 High 
priority is assigned to the diagnosis and management of chronic conditions, health 
promotion and disease prevention within primary care.13 Primary care professionals are also 
responsible for referrals to specialist care. 
Healthcare in the UK is undergoing unprecedented operational reforms, not least is the 
pressure on the NHS to save £15 to £20 billion by 2013/14.37 In the 2009/10 financial year, 
£8,321 million was invested in general practice in England, an increase of 4.57% from the 
previous financial year.38 Historically, approximately 80% of the NHS budget was allocated 
to Primary Care Trusts (PCTs) which commission primary and secondary care services in the 
local area.39 In one of the most radical and unpopular changes to the NHS, Strategic Health 
Authorities (SHAs) and PCTs will be fully dissolved during 2013 and services will then be 
commissioned by GP-led consortia.14 In the midst of these organisational changes, there 
have been attempts to improve efficiency by wider integration of information technology (IT) 
across health services. These efforts have been criticised for high costs, poor functionality 
and concerns about the privacy and security of patient information.40,41 The most ambitious 
of these projects is the partly-cancelled NHS National Programme for IT (NPfIT), one of the 
largest-scale healthcare information technology projects in the world.40-42 
Despite the ongoing structural flux, the role of primary care, and that of GPs in particular, as 
the gatekeeper of the health system has not changed. One transitional element of service 
delivery has been the relationship between the health professional and patient, with 
patients becoming increasingly more proactive in their care decisions. A report from the 
Picker Institute drawing from 26 national patient surveys reflects some of the main changes 
in patient opinions of UK health care since 2002.43 For example, patient trust in GPs 
remained consistent between 2004 and 2006 but 42% of patients felt that they had received 
inadequate information about side effects of new medications in primary care.43 At the 
national level, the health system has also been criticised for fragmented approaches to 
evaluation, failure to optimise resource use, delays in communication and in translating 
recommendations into changes in practice.44,45 
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1.4 Measurement methods 
In sections 1.2.2 and 1.2.3, I argued for the importance of using appropriate terms in 
translational research for healthcare policy and practice. Now I consider the collection of 
evidence (Figure 1.2). When measuring patient safety, the evidence must meet the explicit 
criteria of being technically sound, clinically relevant and fit for purpose. The hierarchical 
grading system shown in Figure 1.2 is one method of evaluating and categorising research 
evidence, based on the merits of study design and other study components of clinical 
interest (prevention, diagnosis, prognosis, therapy and harm).46 
Figure 1.2 Hierarchy of evidence-based research 
 
Source: Oxford Centre for Evidence-based Medicine.46 
 
The classic measurement method is to consider quality and safety in terms of structure, 
process and outcome (the Donabedian approach).47 Errors that occur during processes of 
care may be attributable to elements of the organisational structure. Expanding on the 
definitions from WHO ICPS (section 1.2.3), medical errors can be defined as failures in the 
course of planned medical treatment and may be associated with adverse patient outcomes, 
but errors do not always result in patient injury.48,49 Where physical or other injuries to 
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patients occur as a result of health treatment and are not caused by disease or illness, then 
these events are deemed adverse (iatrogenic) events.48,50 For instance, a GP may 
erroneously co-prescribe a potassium-sparing diuretic and an angiotensin-converting 
enzyme (ACE) inhibitor without valid indication.51 In this example, the active failure to 
prescribe appropriately resulted in the patient developing hyperkalaemia (medical error) 
and consequently admitted to hospital for the drug event (adverse outcome).51 This incident 
may have occurred at a GP practice where GPs ignore computer drug contraindication alerts, 
where there is a culture of non-adherence to drug prescribing guidelines or where staff are 
over-burdened and lack the resources or support to ensure appropriate and safe care. 
Without monitoring patient progress and outcome, it would be extremely difficult to 
determine whether a course of treatment has been appropriate and effective. In fact, such 
importance is placed on definable and measurable outcomes that national outcome 
measures have been proposed under the NHS Outcomes Framework.14 Hospital admissions, 
readmissions and death are common patient endpoints measured in healthcare. Of course 
these are crude measures of patient outcomes and represent small fragments of patient 
care. Regardless of whether they measure structure, process or outcome, indicators should 
be meaningful to patients and the public.14  
One investigative approach seeks the causes of errors and AEs, with contextual information 
collected to identify contributory and precipitating factors (Table 1.1). Several methods are 
reasonably well utilised in primary care, such as root cause analysis (RCA) and significant 
event audit (SEA), to examine failures and errors for specific events attributable to individual 
staff, processes of care and organisations, which may then also be translated into future 
improvements in care (Table 1.1). However, all these analysis methods are retrospective in 
nature and are not suitable for active patient safety surveillance, especially to detect errors 
or AEs in large populations, such as nationally.
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Table 1.1 Common methods for analysing causes of adverse events and medical errors 
Type of analysis Type of event Description Evaluation 
Cascade analysis Chain of events leading to error. Retrospective creation of storyline to identify 
causal factors and solutions through 
reporting. 
Goes further than RCA by identifying 
intermediary problems.52 
Failure modes and 
effects analysis (FMEA) 
Potential failure or error in system, 
design, process, product or service. 
Prospective, step-by-step identification and 
prevention of all potential failures using an 
interdisciplinary meeting approach.53 
Resource costly and questionable ability to 
affect design of existing processes.53 
Failure reporting 
analysis and corrective 
action system (FRACAS) 
All error events. Retrospective analysis of all observed error 
events to identify areas for corrective action. 
Often combined with other tools.54 
Unknown evidence. 
Global trigger tool Actual patient harm rather than 
MEs. 
Random medical record review for 
predetermined selection of triggers for 
certain AEs, especially ADEs.50 
Widely implemented in the US and are 
relatively quick to use.50 
Root cause analysis 
(RCA) 
Patient safety incidents causing 
serious harm or death and 
frequently occurring incidents. 
Retrospective, structured identification of all 
contributory and causal factors of AEs. Uses 
multidisciplinary approach. 
Useful for detecting system failures but may be 
affected by hindsight bias, resource costly and 




Analysis of any event deemed 
significant to patient care by any 
member of the healthcare team.55 
Retrospective structured investigation by 
team members, using action plans and peer 
review.55 
Examines positive and negative events. 
Subjective interpretation of ‘significant’. Needs 
standardisation in primary care.56,57 
Key: ADEs – adverse drug events; AEs – adverse events; FMEA - Failure modes and effects analysis; FRACAS - Failure reporting analysis and corrective action 
system; MEs – medical errors; RCA – root cause analysis; SEA – significant event analysis/audit; US – United States of America 
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1.4.1 Theoretical models 
The systematic methods to determine causes of errors and harm that were described in the 
previous section (section 1.4) were based on conceptual frameworks for risk analysis and 
management in healthcare and other industries. One of the most widely applied models is 
Reason’s organisational framework of accident causation.58-64 This model describes the 
onset of patient harm through circumstances which facilitate the occurrence of error (latent 
failures) and direct actions that cause patient harm (active failures).59 This human factors 
approach seeks to identify the effects of organisational processes, together with patient, 
staff, workplace or situational factors on the subsequent actions by staff and resulting 
patient outcomes.65 Organisational factors associated with latent and active errors and AEs 
can be measured using different methods (Figure 1.3). However, as shown in the diagram, 
few measurement methods capture all elements of care associated with errors and harm, 
and are seldom used as “one method for all purposes”.  
1.4.2 Multiple methods  
To better understand the processes of care involved in “near misses” and AEs, data should 
be collected from a selection of measurement techniques.62 As there may be little overlap in 
the types of errors and events detected by individual methods,6,62,66,67 application of 
qualitative surveys, collection of quantitative data and analysis of metrics may provide a 
more complete picture of patient care than from using a single methodology (Figure 
1.3).62,63,68,69 Triangulation will also compensate for methodological limitations associated 
with the respective individual measurement tools, such as the retrospective nature of 
methods to analyse causes of harm (section 1.4 and Table 1.1).68  
Together with medical records, which are usually resource intensive for secondary usages, 
administrative data can be used to detect potential medical errors, weaknesses in safety 
barriers and adverse patient outcomes (Figure 1.3). Although these aspects of the safety 
continuum can also be assessed by interviews and surveys, morbidity and mortality case 
conferences and observations, routinely collected data are most suited for semi- or fully-
automated computerised, real time surveillance. Uniquely, a monitoring system based on 
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such data can undergo active improvement with the addition of new or modified data, 
including data contributions from patients.
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Figure 1.3 Factors and measurement methods associated with patient harm 
 
Adapted from: Reason 1995;64 Vincent et al 1998;59 Michel 2003;62 Thomas & Petersen 2003.68
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1.4.3 Patient involvement 
As mentioned in section 1.3.1, patients are increasingly involved in all elements of care and 
service improvement. Learning from patient experiences is pivotal in raising standards of 
care and improving patient experiences. Indeed, patients may provide expert input as 
shown in Figure 1.2 (section 1.4). There are numerous established methods of data 
collection in healthcare, including many where patent input has an important role in alerting 
healthcare professionals to potential and actual adverse events, and in guiding 
investigations into patient harm (Figure 1.3). For example, patients’ observations of their 
healthcare experiences form the basis of clinical negligence claims and complaints, which 
can also precipitate, and most certainly feature in, audits and investigations into the quality 
and safety of care. Patients’ views are often sought by interviews and surveys, but they are 
also able to report safety concerns directly to health regulatory organisations such as the 
NHS Commissioning Board (formerly reported to the National Patient Safety Agency, NPSA*). 
1.5 Data sources 
I will now summarise individual data sources and methods used to measure medical errors 
and AEs, with evaluation of their applications in patient safety. 
1.5.1 Clinical negligence claims and complaints 
Historically, data from financial compensation claims for iatrogenic harm have played a 
central role in safety investigations.70,71 During the 2010/11 financial year, 8,655 clinical 
negligence claims were received by the NHS Litigation Authority (NHSLA) and £729 million 
was paid out.72 The advantages of using claims data for safety research include evidence 
from multiple perspectives gained during the claim process and the potential identification 
of errors in the course of the detailed cross-examination that may be missed by other 
methods.68,73 On the other hand, these data usually contain small numbers and results may 
                                                     
*
As part of the NHS reforms, the NPSA’s function was transferred to NHS Commissioning Board Special Health 
Authority in June 2012. 
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not be generalisable due to the specific nature of the circumstances under which the claims 
are made. The data are also affected by uncertain reliability and validity of reviewer 
assessments, reporting bias and hindsight bias.68,74,75 
1.5.2 Morbidity and Mortality case conferences  
Case conferences play a key role in medical education despite inconclusive evidence of 
learning derived from studying errors and AEs using these sources.62 The application of this 
data type in medicine extends to peer-reviewed journals dedicated solely to publishing case 
reports.76 The effectiveness of case conferences on learning is dependent on the motivation 
of the participants,77 and the method is subject to hindsight and reporting biases,68 with no 
standardised structure for conferences.62 The application of case conferences is much less 
well documented in non-acute care settings but may be comparable with SEAs (Table 1.1) 
performed within the NHS’s Quality and Outcomes Framework (QOF).57,78,79 
1.5.3 Audit and investigations 
In the UK, independent external assessments of the quality of healthcare have been carried 
out by three National Confidential Enquiries, commissioned by the NPSA.80 Additionally, 
there have been over 60 independent public and private inquiries since the 1970s.45 
National and local clinical audits also take place within NHS trusts and other areas of 
healthcare. These investigations may consider aspects of quality assessment beyond 
effectiveness, such as safety and service evaluation and improvement.81 Even though there 
is an established clinical governance infrastructure in primary care in England, there are also 
numerous barriers that prevent quality improvement.82,83 Audits and investigations require 
extensive resources, and there may be considerable delays from the event in question, 
assessments of the event, to the publication of findings and recommendations from the 
investigations.45 
1.5.4 Observation  
Direct observation is useful to identify active errors and to examine interactions between 
healthcare staff and patients.68,84 More AEs may be detected through observation than by 
other methods.85,86 Observation, whether by ethnographers physically in the environment 
or through filming, is seldom possible in healthcare due to confidentiality issues.68 
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Nevertheless, there are examples of its successful application in secondary care to identify 
errors and AEs related to medication and surgery.87,88 Interpretation and analysis of data 
collected by observation can be problematic because of the large amount of information 
collected, as well as there being reliability issues with observer training and potential 
hindsight bias.68 
1.5.5 Interviews and surveys 
Incorporating the views of patients on their health services experiences in monitoring of 
service quality is recommended.82 Interviews and surveys have typically been used for 
patient safety research in secondary care and primary care to gauge clinician and patient 
attitudes about safety culture and reporting,89,90 to measure prescription-related AEs63,69,91 
and to assess the effectiveness of computerised systems.92,93 These measurement methods 
are often used in conjunction with other measures.63,66,69,94 Recall and reporting biases are 
associated with interview studies, which are resource costly compared to other 
techniques.62,95 However, evidence from secondary care suggests that interviews can be 
used to reliably detect preventable AEs.96  
1.5.6 Reporting systems 
Voluntary reporting of errors, “near misses” and incidents of patient harm is widely used in 
healthcare.97-102 England has a national data collection system in the form of the National 
Reporting and Learning System (NRLS), launched by the NPSA in 2004. Like other 
measurement methods, reporting systems are only able to detect a limited range of safety 
incidents and it is often not possible to determine the causality of events.103 Difficulties in 
implementing and maintaining electronic reporting systems have been documented,104,105 
including under-reporting98,106 and inconsistent detection of certain errors and events in 
primary and secondary care.107,108 Yet there is evidence that NRLS data can be successfully 
translated into improvements to patient safety at the local level.109 Medication-related 
incidents are the most common type of AE occurring in primary care reported to the 
NRLS.110  
Adverse drug reactions or undesired effects suspected to have been caused by medications 
are also monitored through the Yellow Card Scheme by healthcare professionals and 
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patients. This national voluntary reporting initiative is run by the Medicines and Healthcare 
products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM), with 
the aim of assessing drugs’ side effects and their roles within the pharmaceutical market.111 
Comparisons of AEs detected by reporting, medical record review and patient survey 
suggest that reporting may under-detect AEs, especially preventable drug events.69 In spite 
of these disadvantages, the National Audit Office has recommended that PCTs should 
encourage all primary care service providers to have reporting systems in place.82 
1.5.7 Routinely collected data  
Given the limitations of the data sources described so far in this section, it is worthwhile 
considering how the wealth of data collected routinely as part of patient care can be used 
for measuring patient safety. Information is recorded every time a patient has contact with 
any element of the health system. I now describe the two main sources of data; medical 
(clinical) data and administrative (clinical and non-clinical) data.  
1.5.7.1 Medical records  
Medical record (or case note or chart) review is frequently used in research on AEs, to the 
extent that it is considered the ‘gold standard’ measure in comparative studies.96 One of the 
attractions of these data for secondary research purposes is that they are often available in 
electronic format, with electronic patient records (EPRs) being standard in many countries, 
including England. Computer-based flags for medical mistakes, such as diagnostic errors, 
have been developed as an ambulatory care safety tool in the US.112 Medical records have 
been used in global trigger tools and RCA methods (Table 1.1). Compared to paper care 
records, electronic patient information may contain richer clinical detail for identifying 
precipitating events or process errors associated with patient harm.113 The validity of 
investigations using medical records can be affected by inaccurate and incomplete records 
and variable reviewer reliability.114-116 There is also potential to under-estimate the number 
of preventable AEs, especially those that are medication-related.62 
1.5.7.2 Administrative data 
Information technology is driving changes in the delivery of healthcare. Patient-level data 
are routinely collected throughout the course of patient care for administrative purposes, 
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including reimbursement. Data from these systems are useful to indicate the processes of 
care associated with AEs which require more detailed examination.117,118 These data can 
also be used to track treatment across different levels of care.119 Examples of clinical-
administrative databases in the UK include Hospital Episode Statistics in England (HES), the 
Clinical Practice Research Datalink (CPRD) which has succeeded the General Practice 
Research Database (GPRD), and cancer registries. As the GPRD was still in operation at the 
time of analyses in this project, references will be made to this organisation rather than the 
CPRD. I will return to HES and GPRD in Chapter 3. 
1.6 Indicators and metrics 
Indicators, also referred to as screens and flags, are an integral component of quality 
improvement strategies in many health systems. Yet the term has been applied loosely and 
the structure of quality and safety indicators can be quite different from each other.15,120 
Indicators may be used to help prioritise care, facilitate accountability and transparency, 
and also aid monitoring and evaluation within and across service providers.15,120,121 These 
quantitative measures can be considered as markers of explicitly defined healthcare 
structures, processes or patient outcomes.120,121 Patient safety indicators typically identify 
cases or rates of patient harm (temporary or permanent physical or other disabilities, or 
death) that may be due to medical error and are amenable to organisational changes.120,122 
Good indicators should be reliable, valid, sensitive to change, comparable with other 
markers, measure clinically useful processes or outcomes, and not be affected by bias or 
random variation.120-122  
1.6.1 Indicators based on routinely collected data 
There are approximately 270 healthcare databases in active use in the UK.118 By making use 
of these available data, patient safety research would benefit from expertise gained from 
clinical and administrative applications of these data and also contribute to improving the 
quality of the data sources.123 In fact, the WHO has identified the development of better 
indicators as a priority in patient safety research.124 The following sections describe some of 
the reasons why routinely collected data are particularly suited for developing patient safety 
measures.  
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1.6.2 Computer systems and databases 
In recent years, a plural approach to IT has been adopted by the NHS following the failure of 
the centralised NpfIT project.42 In English primary care, there has been a history of using 
computerised clinical systems that spans circa three decades. Since 2007, GP practices have 
been able to select their preferred clinical information system from a selection of approved 
suppliers, under the GP Systems of Choice (GPSoC) scheme.125 The options include the LV, 
PCS and Web systems from Egton Medical Information Systems Ltd (EMIS), SystmOne from 
Computer Sciences Corporation Alliance, Vision from In Practice Systems Ltd (INPS) and 
Synergy and Premiere from iSOFT.126-129  
In addition, there are a number of clinical databases derived from these clinical systems. 
Both the General Practice Research Database (GPRD) and The Health Information Network 
(THIN) rely on the Vision system.130,131 Another widely used database of patient data for 
research is QResearch, derived from the EMIS systems.132 At the national level, data from 
individual practice computer systems are also extracted for QOF and currently stored in the 
Quality Management and Analysis System (QMAS).133 Prescribing Analysis and Cost (PACT) 
data are collected in England for monitoring and budget setting.133 From April 2013, a 
central extraction system will be introduced for all GP practices in England. One of the initial 
roles of the General Practice Extraction Service (GPES) will be to extract data from GP 
practice clinical systems for QOF.134 
1.6.3 Universal clinical language 
The standard clinical terminology used In England is the Read code system.135 It contains 
over 80,000 codes that comprehensively cover all elements of clinical practice, including 
signs and symptoms, diagnoses, treatments and investigations and administrative 
information (Figure 1.4).135 Read Codes are mapped to International Classification of 
Diseases and Related Health Problems 9th and 10th Revisions (ICD-9/10), Office of 
Population, Censuses and Surveys Classification of Surgical Operations and Procedures 4th 
revision (OPCS-4), British National Formulary (BNF) and the Anatomical Therapeutic 
Chemical Classification System (ATC).136 Further changes to the language system are being 
introduced, with Read Codes to be replaced by the Systematised Nomenclature of Medicine 
Clinical Terms (SNOMED CT).135 This system is already being used in countries including 
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Australia, Canada, Sweden and the US. SNOMED CT is planned for implementation across all 
NHS care settings.137 The adoption of standard clinical terms within a structured data system 
throughout the NHS, and the use of internationally applied clinical codes, provides a wealth 
of comparable data for research. 
Adapted from Dobrev et al, 2008.138  
 
1.6.4 Availability of data 
Data used for clinical and non-clinical purposes are already collected and therefore 
relatively easy to obtain and use (Figure 1.4).62 While the growth in data collected routinely 
benefits research, there is also recognition of the need to improve data quality and expand 
on the types of data being collated.115,139 Increasingly, more patient and practice-level 
primary care data are being stored electronically in England (Figure 1.5). This format enables 
ease of manipulation and quicker transfer of data between users compared with paper 
versions. Electronic patient databases often contain information on diseases, treatment 
decisions and patient outcomes (Figure 1.4), therefore making them suitable for use in 
epidemiological studies of patient safety.62 Linkage with other data sources, such as 
mortality data and surveys, can improve the validity of findings.62,118,140,141 However, as seen 
in the radar chart (Figure 1.5), application of IT varies among European GPs, including those 
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in the UK. Predominant uses are during consultations and data storage, with GPs in the UK 
making more use of IT during consultations and for transferring lab results from the 
laboratory than colleagues elsewhere in Europe.138 Beyond this, there is little evidence of 
electronic transmission of prescriptions from GPs to dispensing pharmacies or digitally-
signed prescriptions*, or electronic transfer of patient data to other care providers in the UK 
or the other 26 Member States of the European Union, and Norway.138 However, as stated 
in section 1.6.2, very soon data from clinical systems at all GP practices in England will be 
extracted by a central service for service improvement.134 
Figure 1.5 Information technology use by GPs in the UK compared to other European states 
 
Source: Dobrev et al, 2008.138  
 
1.6.5 Sentinel monitoring and active surveillance 
Patient harm is undesirable but some serious iatrogenic events should never happen, 
including wrong site surgery and wrong route of chemotherapy administration.143 These 
                                                     
*
The NHS Electronic Prescription Service (EPS) has been rolled out in two stages – release one (R1) in 2004/05 
and release two (R2) from 2009 onwards. There have been considerable delays in deploying EPS R2 with only 
263 GP practices having EPS R2 capabilities as of August 2012.
142
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events can act as signposts (sentinels) for processes of care that require further 
investigation. For example, excess mortality is commonly monitored in secondary care but 
less so in primary care.144-147 While routine mortality monitoring may be an ineffective 
signalling method for sentinel events,145 this technique can be useful for systematic 
assessment of care processes. In fact, there have been government recommendations for 
death registers to be set up in general practices and for the monitoring of mortality rates at 
the practice level.148  
As well as sentinel event monitoring, routinely collected data can be used to screen for 
other potentially avoidable failures in medical care. For example, diagnostic errors are one 
of the most common types of errors reported by healthcare professionals and patients in 
primary care.24,73,74,149 Computerised alerts such as drug contraindication warnings, can 
reduce and prevent errors that may result in harm to patients. Active monitoring systems 
can be applied at local or national levels to detect unusual patterns in patient outcomes for 
predicting future behaviour and outcomes. This type of system has been effectively applied 
in public health for preventing and monitoring disease epidemics.150  
1.6.6 Evidence of routine data-based monitoring 
Patient safety screens that use routinely collected data have been adopted in numerous 
health systems, firstly in the US and Australia but progressively in other countries.151 For 
example, the AHRQ PSIs (section 1.2) have been validated in several hospital populations in 
the US and adapted for use elsewhere, including England.152-156 Yet the contribution of these 
measures to safer care is not confirmed.62,151,152,157 In general, there are sparse published 
data on the effectiveness of routinely collected data-based safety measures in improving 
patient outcomes and reducing patient harm.123,151 Computerised patient data has been 
used less extensively to specifically monitor safety in primary care. The predominant area in 
this setting has been the development of indicators for preventable medication-related AEs 
using EPRs.158,159 
1.6.7 Validation of indicators 
In the last section, I stated that some safety measures derived from routinely collected data, 
especially the AHRQ PSIs, have been reasonably validated. Despite this, questions remain 
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over the validity of measures based on routinely collected data in identifying preventable 
iatrogenic events.151,157,160 Doubts have also been raised as to whether non-clinical 
databases contain the necessary data for adequate case-mix adjustment.118 These AE 
screens are also affected by unstable estimates due to the unavailability of suitable 
denominator data, although this issue could be circumvented by the use of surrogate 
markers.139 
1.6.8 Coding issues and data quality 
Data collected for purposes other than research may lack the clinical richness, or certain 
information such as disease severity, that assists patient safety evaluations. Indeed, data 
completeness and accuracy may vary across provider sites,115,140,141,161 and diagnosis coding 
can be (favourably or otherwise) biased by the financial incentives of PfP schemes.141,162,163 
Further discussion of data quality is made in Chapter 3. 
1.7 Aims of the research  
The topic of patient safety monitoring is well established in primary care yet the use of 
routinely collected data for this purpose is relatively new in England. The primary care 
setting encompasses numerous care disciplines and an attempt to address safety issues 
affecting multiple areas of care would be too ambitious for this doctoral project. 
Accordingly, in this thesis, I present research on safety measures that are specific to general 
practice. 
The research addressed the following aims: 
1. Explore the epidemiology of adverse events in general practice using routinely 
collected data. 
2. Examine how routinely collected data can be used in their current state for patient 
safety measurement within existing quality improvement systems. 
3. Consider what obstacles there might be against using routinely collected data for 
active patient safety surveillance in general practice, at local and national levels. 
4. Apply adverse events indicators for general practice that have been developed from 
available routinely collected data. 
Chapter 1: Introduction | 42 
 
1.7.1 Thesis outline 
To achieve the aims set out in the last section, a multi-method approach was adopted. This 
strategy combines evidence and consensus from the clinical setting and analyses using 
several datasets, to provide evidence on AEs in English general practice. In Table 1.2, I revisit 
the research aims in the context of the remaining chapters of this thesis. 
Table 1.2 Research aims mapped to thesis chapters 
Research aim Thesis chapter 
1. Explore the epidemiology of adverse events 
in general practice using routinely collected 
data. 
Chapter 2 - Literature review. 
Chapter 5 - Adverse events recorded in local data. 
Chapter 6 - Adverse events recorded in national data. 
Chapter 7 - Unplanned admissions for diabetic emergencies.  
Chapter 8 - First unplanned admissions for cancer. 
2. Examine how routinely collected data can be 
used in their current state for patient safety 
measurement within existing quality 
improvement systems. 
Chapter 2 - Literature review. 
Chapter 9 - Discussion. 
3. Consider what obstacles there might be 
against using routinely collected data for active 
patient safety surveillance in general practice, 
at local and national levels. 
Chapter 2 - Literature review. 
Chapter 9 - Discussion. 
4. Apply adverse events indicators for general 
practice that have been developed from 
available routinely collected data. 
Chapter 3 - Data sources. 
Chapter 4 - Methods. 
Chapter 5 - Adverse events recorded in local data. 
Chapter 6 - Adverse events recorded in national data. 
Chapter 7 - Unplanned admissions for diabetic emergencies.  
Chapter 8 - First unplanned admissions for cancer. 
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Chapter 2: Literature review 
 
2.1 Chapter overview 
This chapter begins to define the nature and extent of patient safety issues 
in primary care. Firstly, I determine what types of routinely collected data 
are used to measure adverse events in this care setting. Secondly, methods 
of measuring and monitoring patient safety using these data are identified. 
Finally, I explore the rates and types of adverse events detected from 
routinely collected data. 
 
2.2 Introduction 
A broad spectrum of conditions and diseases, which are often chronic and display relapsing-
remitting patterns, is treated and managed in the primary care setting. By comparison, 
acute episodes of illness are treated in hospital-based specialty care. Consequently, it can be 
far more difficult to delineate causal relationships between care and AEs in general practice 
and other areas of primary care. As described in Chapter 1 section 1.3.1, there is increasing 
and wider use of IT in general practice across England.138,139 Given this activity, it is 
surprising that there is little evidence of large scale or national efforts to use routinely 
collected data for active safety surveillance in this care setting.  
There is the potential and need to expand development of patient safety measures beyond 
secondary care, not least advocated by the Organisation for Economic Co-operation and 
Development (OECD).21,154 Newly created measures will complement existing safety 
monitoring instruments such as reporting and audit,67,96 allowing for detailed investigations 
to ascertain the causality of patient harm and identify remediable factors, where 
appropriate.164 In the previous chapter, I outlined the main advantages of using existing 
routinely collected data for quality and safety improvements.22,165 A main task of patient 
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safety initiatives is to assess the feasibility of developing AE screening tools using readily 
available datasets. 
2.3 Aims and objectives 
To inform the development of safety measures, there must be an understanding of current 
AEs occurring in primary (non-acute) care. In conjunction, the relationships between 
information systems and safety monitoring in primary care have to be considered. By 
synthesising these elements of patient safety, informed advances in the measurement and 
ultimately improvements to the safety of patient care can be made. 
2.3.1 Aims of the literature review 
This literature review aimed to describe how routinely collected (administrative) data are 
used for patient safety measurement and monitoring in primary care. The types of data 
available in primary care and the nature of medical errors and patient harm measured using 
these data were established. Particular attention was given to those AEs that may be 
amenable to organisational change. The findings of the review informed the quantitative 
analyses presented in later chapters of this thesis. 
2.3.2 Objectives of the literature review 
By consulting the available literature, this review attempted to: 
 Describe the routinely collected data used to measure and monitor adverse events in 
primary care. 
 Identify the types and rates of adverse events attributable to contact with primary 
care that are detected using routinely collected data.  
 Inform analyses of adverse events using routinely collected data from English 
primary care. 
2.4 Methods 
I performed a first search of the literature between August 2008 and March 2009. I then 
made a further search, replicating the original search strategy, in August 2009 to capture 
relevant literature published in the interim period. The literature review used a range of 
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sources, including electronic databases such as Excerpta Medica Database (Embase) and 
Medical Literature Analysis and Retrieval System Online (Medline) to identify peer-reviewed 
journal articles. Additional searches for relevant publications were made of paper and 
electronic documents in the public domain, along with websites and contact with experts in 
the field.  
2.4.1 Electronic databases 
Peer-reviewed material on patient safety measurement using routinely collected data was 
collected from several electronic databases (Table 2.1). A combination of Medical Subject 
Headings (MeSH) and non-MeSH terms were applied. 
Table 2.1 Electronic databases used in the literature search 
Database Search period Search details 
Applied Social Sciences Index 
and Abstracts (ASSIA) 
Earliest to 2010 Interface: CSA Illumina. Search screen: command. Search 
strategy: non-MeSH. Search field: keyword 
Cochrane Library  1800 to 2009 Title, Abstract or Keywords in all of the Cochrane Library. 
Search strategy: non-MeSH. 
Excerpta 
Medica (Embase)  
1980 to 2009 week 34 Interface: Ovid. Search method: advanced. Search strategy: 
MeSH and non-MeSH. 
Health Management Information 
Consortium (HMIC) 
1979 to July 2009 Interface: Ovid. Search method: Advanced. Search strategy: 
non-MeSH. 
Institute of Scientific Information 
(ISI) Web of Science  
All years Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S. Search 
strategy: non-MeSH. Search field: title, abstract, author 
keyword, keywords plus. 
Medical Literature Analysis and 
Retrieval System Online 
(Medline)  
1950 to present Interface: Ovid. Search method: advanced. Search strategy: 
MeSH and non-MeSH. 
PsycInfo  1806 to August week 3 
2009 
Interface: Ovid. Search method: advanced. Search strategy: 
MeSH and non-MeSH. 
 
2.4.2 Other data sources 
Further searches were made for all other relevant literature, including non-peer-reviewed 
material. The following sources were used: 
 Book chapters; 
 Conference proceedings; 
 Reference lists of published papers; 
 Technical and working papers and reports; 
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 Unpublished studies; 
 Websites (government and safety organisations); and 
 Experts in patient safety and/or primary care. 
The websites of governments, healthcare and safety and quality organisations, as well as 
academic institutions were searched to identify relevant reference publications and non-
peer reviewed literature (Table A.1). 
2.4.3 Search strategy 
So that a comprehensive set of relevant publications could be retrieved, a large number of 
appropriate and clearly defined search terms were used.166 These statements were selected 
from commonly applied terms found in the literature on patient safety and primary care. To 
identify suitable terms for the concepts under review, “free text”, index terms and 
synonyms were compiled.  
To ensure that the final list of search terms was adequate and usable in different databases, 
a comparison of search results from Embase and Medline databases was performed. The full 
set of terms used is shown in Figure 2.1. Previous literature searches on the same broad 
research topic have shown that the number and details of the results produced from these 
two databases are similar. In this review, the number of results was again similar between 
Embase (n=1326) and Medline (n=1364). The search string was amended according to the 
search functions and interface of the respective databases (Appendix 2). In each database, 
individual terms in the three search components (healthcare setting, measure and type of 
data) were searched first. After this initial process, terms within the individual search 
components were combined using the “OR” operator. Then the terms for all three search 
components were joined together using the “AND” operator. 
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Figure 2.1 Search strategy used to retrieve publications 
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2.4.4 Study selection  
The purpose of the review was to synthesise the evidence across primary care on how 
administrative data are applied in patient safety research and practice, and to consider what 
the potential uses are for these data in detecting and monitoring AEs. Accordingly, data at 
the individual patient and staff levels were of interest, along with research at practice, local 
and national levels. International data were also considered, where available and 
appropriate. Data on the severity of harm, risk factors and preventability also were 
extracted, where available. This information can be used to identify AEs that should never 
occur (especially harm resulting in severe and permanent injury or death), events that are 
amenable to organisational change, as well as inform strategies to reduce patient risk 
factors. 
2.4.4.1 Inclusion criteria 
Studies were selected for inclusion using the selection methodology used by the AHRQ 
during the development of the AHRQ PSIs.1 Studies on the quality of care were deliberately 
not excluded as safety is often perceived to be a dimension of quality.167 However, in order 
for these studies to be eligible for inclusion in the review, they had to meet the explicit 
inclusion criteria that follow: 
 Report original research (observational or experimental); and 
 Apply routinely collected data* collected in any healthcare setting; and  
 Measure at least one potential or actual adverse patient outcome(s)† that is explicitly 
attributed to contact with primary or ambulatory‡ care; and 
 Provide numerical results for the adverse patient outcome(s) measured (e.g. 
frequency of injury, hospital admission or death).  
                                                     
*
Routinely collected data were defined as patient information, usually in electronic format, collected clinical 




Adverse patient outcome (measurable patient endpoint) was defined as an unexpected outcome due to 




Ambulatory care was included in the literature search given the overlap in services provided in this setting 
and primary care. 
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2.4.4.2 Exclusion criteria 
The following criteria were used to exclude articles from the review: 
 Non-original research; and 
 No application of routinely collected data; and/or 
 Measurement of medical errors* rather than AEs†; or 
 Without explicit measurement of AEs that were attributed to treatment in primary 
or ambulatory care; or 
 Measurement of AEs but without providing numerical data for outcome measures; 
or 
 Predominantly reporting of diagnosis or treatment of specific diseases; or 
 Predominantly describing or evaluated teaching or research tools; or 
 Publications not in English. 
 
To aid the selection process, a hierarchy of exclusion criteria was applied. This ranking 
system facilitated the selection process, especially when there were multiple reasons for 
excluding a citation. The rankings in order of importance for exclusion were: 
1. Not healthcare-related. 
2. Not safety-related. 
3. Safety but not in a primary or ambulatory care setting. 
4. Not original research (e.g. review or discussion paper). 
5. No application of routinely collected data. 
6. No numerical data on any adverse patient outcomes measured. 
7. Predominantly reporting of diagnosis, treatment, teaching or research (including 
non-primary care studies). 
8. Non-English language publication. 
                                                     
*
Medical errors are actions or omissions by staff at a general practice that were unanticipated, should not have 




Adverse events are injuries caused by medical management and that are not due to the underlying disease, 
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2.4.5 Data extraction 
 Publications were initially screened for duplication by examining titles and abstracts. Where 
titles or abstracts were ambiguous or abstracts were not available, full versions of 
publications were obtained to determine eligibility for review. The reason(s) for exclusion 
was recorded for any publication deemed ineligible. For all publications, a set of data was 
extracted (Table 2.2).  
Table 2.2 Data extracted from publications 
Study section Data field 











Data sources/measurement Method 
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2.4.6 Data synthesis  
The STROBE structured checklist was used to guide the review process.169 After remaining 
ineligible studies were removed, the data fields shown in Table 2.3 were populated for each 
study by electronic data entry. 
Table 2.3 Data fields for data entry 
Indicator  Data 
Description Brief free text outline of study 
Drug group(s) Entered where applicable 
Drug name(s) Entered where applicable 
Patient outcome(s) Adverse patient outcome(s) measured 
ICD code(s) Entered where applicable and available 
Numerator/denominator values Entered where applicable and available 
Exclusion(s) Exclusion criteria, where applicable 
Data type(s) Sources of data used 
Source(s) Study reference(s) 
 
Studies reporting on drug-related incidents were only included in the review if patient 
outcomes were described and measured, and there were also measurements of the severity 
or preventability of the adverse drug event. Studies that solely reported on adverse 
reactions caused by medications were excluded as these events can be an expected 
outcome of treatment.170 Where there was insufficiently detailed information about the 
elements of care associated with medical errors and AEs, “treatment” was noted as the 
default care component related to the AE.  
2.5 Results 
From searching the electronic databases, 4,771 publications were retrieved (Figure 2.2). A 
further 258 publications were identified from “grey literature” and hand searching of 
publication reference lists. Of the abstracted 237 publications, 15 were included in the 
review. No publications were identified that specifically addressed the use of routinely 
collected data for patient safety measurement or monitoring in primary care.  
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Figure 2.2 Study selection process 
 Chapter 2: Literature review | 53 
 
The majority of studies included in the review were cross sectional (n=9/15), with the 
remainder using cohort or population-based designs (Table 2.4). One study used a simulated 
population dataset.145 Two thirds of studies took place in the US (n=10/15) with study 
periods spanning from 1990 to 2005, and publication dates from 1990 to 2008. The study 
time period was not reported for one study.171 The duration of data collection, or study 
period, ranged from three months to eight years.172,173 
The majority of studies used more than one type of data (n=12/15). The largest number of 
data sources used was in two related studies which drew from health provider reports, 
hospital discharge summaries, emergency department notes, computer-generated signals, 
electronic clinic notes and administrative incident reports.6,174 All but one study focused on 
adult care. Few studies placed an age restriction on their participants (n=6),94,164,174-177 
although the age range of patients in three studies with adult participants was 
unknown.112,172,178  
2.5.1 Assessment of reliability 
Approximately half of the studies that assessed medical records or reports used more than 
one reviewer.8,24,94,112,172,174,178,179 Where inter-rater agreement was calculated, good or 
excellent inter-rater agreement was reported,6,8,94,172,174,178 except in one study where poor 
agreement was documented.112 There was no evidence of quality assessment in three 
studies.171,176,180 Reporting of methodology varied, with only seven studies providing details 
of inclusion and/or exclusion criteria applied. There was a wide range of samples in the 
included studies, ranging from self-selected GP practices,171 groups of practices ranging 
from one to 30 sites,6,24,94,164,172,174,178 single hospitals, state-wide healthcare8,112,171,176,177,179-
181 to national level evaluations.173 Overall, definitions of AEs and other variables measured 
were clearly defined in the studies.
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Table 2.4 Characteristics of reviewed studies 
Study, Country Study period 
(months) 
Study design Methods Sample (N)  
(n=cases) 
Measures Results for primary/ambulatory care 




2004 - 2005 (24 
months) 
Cross sectional Medical records, 
surveillance data 
n=21,298  Emergency 
department visits 
3487 patients admitted.  
2.4 ADEs per 1,000 population, 95% CI 1.7-3.0. 
Field et al, US
6
 1999 - 2000 (12 
months) 





ADEs 421 preventable ADEs.  
5% ADEs identified through more than one source. 
Fischer et al, US
24
 1991 - 1996 (66 
months) 
Cross sectional Administrative data  N=948,628  
n=35  
AEs 29 preventable.  
3.7 AEs per 100,000 visits in 5.5 years. 
Gandhi et al, US
94
 1999 - 2000 (9 
months) 







62 potential ADEs, 3 preventable ADEs. 




1999 - 2000 (12 
months) 






ADEs 50.1 ADEs per 1,000 person-years.  
421 (27.6%) preventable, 13.8 per 1,000 person-
years. 









Administrative data N=405,000  Excess mortality 10 excess deaths per year. Large number of false 
alarms generated by all 3 models. 
Korst et al, US
181





Administrative data N=507,592  
n=1,853  
Females only 
Admission MediCal patients (odds ratio 1.60, 95% CI 1.46-
1.80) and patients of African American ethnicity 
(odds ratio 1.24, 95% CI 1.10-1.41) at greater risk 
of admission.  




1990 and 1996 
(24 months) 




Admission High continuity of care associated with reduced 
odds of ACS admission (adjusted odds ratio 0.67, 
CI 0.51-0.90). 




1999 - 2002 (36 
months) 





ADEs 1% incidence. Approx. 60% of events due to 4 
indicators. 









Administrative data N=13,706,765  
n=447,071  
Admission 0.50% of hospital episodes due to ADRs (1998-
2005). 76,692 hospital episodes due to ADRs 
(2004-2005). 







2001 - 2002 (5 
months) 





Admission 6.5% prevalence. 307 definitely avoidable ADRs, 
773 possible avoidable. 
Singh et al, US
112
 2004 - 2005 (12 
months) 




















Poor treatment for 
UTI, admission 
Most common error was failure to investigate 
possible UTIs (n=7). 




1996 - 1997 (9 
months) 








27% patients urgently readmitted within 3 
months. Patients seen by physicians who received 
discharge summary had decreased adjusted risk of 
readmission (relative risk 0.74, 95% CI 0.50-1.11).  




2001 - 2002 (10 
months) 
Cohort Computerised 
physician order entry 







Prescription filling identified as problematic by 
48% of patients. Approx. 81% of ADEs were 
reported electronically (n=17). 






Cohort Electronic portal 





decision to override 
alert  
3481 consecutive alerts assessed, 91 were 
overrode. ADEs in written prescriptions for alerted 
medication in 122 patients. 
Woods et al, US
8





Administrative data N=14,700  
n=587 
AEs, admission 70 AEs in ambulatory care, of which 31 were 
preventable.  
Key: ADE – adverse drug event; ADR – adverse drug reaction; AE – adverse event; Approx. – approximately; CUSUM – cumulative sum; PDRM – preventable drug-related 
morbidity; US – United States of America; UTI – urinary tract infection 
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2.5.2 Excluded studies 
During the initial stages of data processing, 1,544 out of 5,029 publications were excluded 
because of duplication. Further studies were removed due to unavailability in English 
(n=128/5,029). In the next stages, exclusions were made following assessment of studies’ 
titles and abstracts using the exclusion criteria listed in section 2.4.4.2. Out of the 3,064 
publications that were excluded, 39% were not experimental or observational studies, did 
not apply routinely collected data or did not provide numerical results (n=1,201/3,064). A 
small group of studies were excluded for not reporting healthcare-related research 
(n=60/3,064).  
After retrieval of full articles for the remaining 239 studies, the majority were excluded 
(n=222/239). The most common reason for exclusion at this stage of data extraction was no 
documentation of patients having had primary care contact prior to the occurrence of the 
AE(s) (n=114/222). Other excluded studies measured medical errors only or reported on 
hospitalised patients who had AEs in non-acute care but did not provide adequate details 
about the adverse patient outcomes.  
2.5.3 Sources of routinely collected data 
Most of the studies did not use data collected in primary care (Table 2.5). Paper or 
electronic hospital medical records, including prescription charts and computer-generated 
signals, were the most common data sources used in the included studies (n=17/35). 
Conversely, patient records from primary care or ambulatory care were only used in eight 
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Table 2.5 Frequency of data use in the reviewed studies, by type of data, n=35 
Type of data Frequency of use 
Hospital medical record/administrative data  15 
GP/ambulatory records 8 
Incident reports 4 
Patient surveys 3 
Population based data (including census) 2 
Clinician surveys 1 
Computer-generated signals 1 
Prescription charts 1 
 
2.5.3.1 Data from primary care 
Three out of the eight studies that incorporated primary care or ambulatory care data were 
conducted outside of the US. All of these three studies took place in the UK; one study was 
performed in Scotland and two in England. The eight studies used different types of GP data 
ranging from a simulated dataset, electronic patient records, to GP recall of their 
experiences. 
2.5.4 Measurement and monitoring 
There appears to be little overlap in the types of AEs detected by different measurement 
methods.6 Computer generated signals and electronic notes may be useful for flagging 
potential AEs. Yet these sources suffer from poor sensitivity.6 Both routinely collected data 
from primary and secondary care were used for case identification in the reviewed studies, 
and were often implemented in tandem with other data sources, such as medical 
records.112,164,177,180 
2.5.5 Types and rates of adverse events 
Patient outcomes that were explicitly described and measured in the studies included GP 
contact, hospital admissions and death (Table 2.6). In five studies, patient injuries were 
measured in the form of physical or mental disability, or injuries requiring further treatment. 
The categories of AEs applied in the reviewed studies broadly represent dispensing and 
prescribing of drugs, drug levels and laboratory results and treatment (including diagnostic 
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errors). Estimates of AEs in primary or ambulatory care derived from a single source of 
routinely collected data included 3.7 AEs per 100,000 visits over 5.5 years and 4.8 AEs per 
1,000 consultations.8,24 Not all studies included operational definitions for errors and patient 
harm. In seven studies, there was limited detail about the measures used and no reporting 
of numerator values for calculations.8,24,171,172,176,178,179  
2.5.5.1 Adverse drug events 
A higher prevalence of adverse drug events (ADEs) was noted in the older 
population.173,174,179 Gurwitz et al (2003) found a rate of 50.1 ADEs per 1,000 person-years in 
patients aged 65 years and older.174 Budnitz et al (2006) detected 4.9 adverse drug events 
per 1,000 population per year in patients of the same age range.179 In the general adult 
population, the incidence rate of ADEs was 1%, calculated by queries run on electronic data 
(n=507/49,658).164 These incidents were often attributed to the same types of drugs, with 
four indicators accounting for 59.6% of ADEs (n=302/507).164 These indicators represented 
cardiovascular medications, diuretics, non-opioid analgesics and anticoagulants (Table 
2.6).164,172,174,176 Drugs in these categories were frequently implicated in adverse incidents 
among older patients and associated with subsequent hospital admissions.173,174,179 
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Table 2.6 Examples of adverse events identified from the literature 
Patient 
outcome 
Adverse event Drug class (where applicable) Drug name or type “(where applicable)” 
Admission or emergency department contact 
 Acute urinary retention Analgesics; Anticholinergic agents Opiates 
 Adrenocortical failure - - 
 Anaphylaxis - - 
 Bradycardia Beta-blockers  
 Confusion and altered mental status Analgesics; Antidepressants Opiates 
 Constipation Analgesics; Antidepressants Opiates 
 Electrolyte disturbance Antidepressants; Diuretics; Hypertension and heart failure 
drugs 
ACE inhibitors/All receptor antagonists 
 Gastrointestinal complaints
*
 Analgesics; Anticoagulants; Antidepressants; Antiplatelet 
drugs; Corticosteroids; Drugs used in rheumatic diseases and 
gout  
Clopidogrel; Naproxen; NSAIDs; Prednisolone; 
Warfarin 
 Gestational pyelonephritis - - 
 Gout Diuretics  
 Haemorrhagic CVA Analgesics NSAIDs 
 Hyperglycaemia Corticosteroids Prednisolone 
 Hyponatraemia Antidepressants  
 Hypotension Hypertension and heart failure drugs; Antidepressants; Beta-
blockers; Diuretics 
ACE inhibitors/All receptor antagonists 
 Loss of seizure control Antiepileptic drugs Phenytoin  
 Malignant hyperthermia Anaesthetics and therapeutic gases  
 Mental disorders Opioids; Psychoactive drugs; Sedatives and hypnotics  
 Neurological condition
†
 -  
 Osteoporotic fracture Corticosteroids Prednisolone 
                                                     
*
Including bleeding, gastritis and peptic ulceration. 
†
Including dystonia. 





 -  
 Renal/genitourinary condition
†
  Analgesics; Diuretics; Hypertension and heart failure drugs ACE inhibitors/All receptor antagonists; NSAIDs 
 Systemic lupus erythematosus -  
 Systemic sclerosis -  
 Vomiting Analgesics Opiates 
Admission or emergency department contact; GP practice or hospital contact 
 Hyperthyroidism and hypothyroidism Thyroid and antithyroid drugs  
 Respiratory condition
‡
  Beta-blockers; Bronchodilators  
 Worsening of PD symptoms Drugs used in nausea and vertigo Metoclopramide 
 Anorexia, nausea and vomiting, diarrhoea, 
visual disturbances, fatigue 
Cardiac glycosides Digoxin; Digoxin immune FAB 
 Clinical jaundice Lipid-regulating drugs Statins 
 Diarrhoea PPIs  
Emergency department treatment 
 Epistaxis due to drug interaction Anticoagulants and analgesics Warfarin and aspirin 
 Fall or broken bone Sedatives and hypnotics  
GP practice or hospital contact 
 CHF and/or fluid overload, heart block or 
advanced bradycardia 
Drugs used in rheumatic diseases and gout; Hypertension and 
heart failure drugs; Positive inotropic drugs 
ACE inhibitors; Digoxin; NSAIDs 
 Hyperkalaemia Hypertension and heart failure drugs  
 Hypokalaemia Diuretics  
 Second myocardial infarction Antiplatelet drugs Aspirin 
 Peripheral oedema CCBs  
Other 
 Drug interaction Anticoagulants Warfarin and clarithromycin 
 Tremor Drugs used in diabetes  
                                                     
*
Including ototoxic hearing loss. 
†
Including impairment and scarring. 
‡
Including wheezing and exacerbation of asthma or COPD. 




 Emergency readmission within 3 months of 
discharge 
  
Key: AE - Adverse event; ACS - Ambulatory care sensitive (conditions); ACE inhibitors - Angiotensin-converting enzyme inhibitors; Beta-blockers - Beta-adrenoceptor blocking 
drugs; CCBs - Calcium channel blockers; CVA - Cerebrovascular accident; COPD - Chronic obstructive pulmonary disease; CHF - Congestive heart failure; Digoxin immune FAB - 
Digoxin immune antigen-binding fragments; NSAIDs - Non steroidal anti-inflammatory drugs; PD - Parkinson’s Disease; PPIs - Proton pump inhibitors 
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2.5.5.2 Severity of adverse events 
Six studies assessed the severity of patient injuries. The extent of harm was measured by 
patient endpoints such as admission, and reviewer assessments based on a rating scale or 
severity categories.8,24,94,174,179 For instance, Gurwitz et al (2003) labelled AEs by categories 
of “significant, serious, life-threatening, or fatal” and Fischer et al (1997) rated event 
severity from “emotional only”, “temporary-insignificant (no delay in recovery)” to 
“death”.24,174 Across the reviewed studies, there were few cases of the most severe patient 
harm compared to cases of less severe and more temporary types of injuries. The 
proportion of patients who had life threatening incidents of harm or died ranged from 0.7% 
to 10% of patients*. The smallest proportions of the most severe harm among patient 
groups were reported by Fischer et al (1997) and Gandhi et al (2005), with only a single case 
of fatal or life-threatening injury identified in each study, (n=1/29) and (n=1/62) 
respectively.24,94 In spite of their low incidence, the most severe cases of AEs were also 
those that were potentially preventable.8 
2.5.6 Other patient outcomes 
The reviewed studies measured patient endpoints other than the AEs themselves. I now 
describe the two main alternative outcomes that were recorded.  
2.5.6.1 Hospital admissions 
Access to secondary care was reported in 12 studies that investigated hospital admissions 
(n=9), readmissions (n=1), or emergency department visits (n=2). When looking at data from 
the US, Budnitz et al (2006) found that 16.7% (95% confidence interval (CI) 13.1-20.3) of 
patients with adverse drug reactions (ADRs) who were treated in the emergency 
department were subsequently hospitalised.179 When looking at admissions by age group, 
the annual rate of hospitalisation for ADEs was estimated to be highest in patients aged 65 
years and older at 1.6 admissions per 1,000 patients (95% CI 0.7-2.5).179  
                                                     
*
The proportion of patients who experienced the most severe adverse events would range between 0.7% and 
16.7% of all patients who had an adverse event if hospital admission is included as a measure of severity, 
based on Woods et al’s study (2007).
8
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In England, ADRs were responsible for 6.5% of admissions at two hospitals (95% CI 6.2-
6.9).176 Patients who were admitted for drug-related adverse reactions tended to be older 
than patients with other causes of admission (median age 76 versus 66 years, and inter-
quartile range (IQR) 65 to 83 versus 46 to 79 years, 95% CI 8-10).176 This study used a broad 
definition of ADRs that was originally proposed by Edwards and Aronson (2000), and found 
more female patients were admitted for ADRs than for other reasons (59% compared to 
52%, 95% CI 4-10).170,176 Applying a questionably more restrictive definition of ADRs based 
on ICD-10 codes, Patel et al (2007) estimated a lower rate of admissions due to the effects 
of drugs.173 They attributed 0.56% of admission episodes in England during 2005 to ADRs, 
identified through primary or secondary diagnoses.173  
2.5.6.2 Death 
Four studies measured the rate of death in patients who had an AE. In one other study, 
Guthrie et al (2008) determined the sensitivity of a statistical model to detect excess deaths 
in a population-based sample.145 The mortality rate was low in the four studies, ranging 
from 0.15% (n=28/18,820) to 3.5% (n=1/29) of patients.8,24,174,176 Bleeding was identified as 
a common cause of death (n=4/11),174 especially gastrointestinal bleeding associated with 
ADRs (n=15/28).176 Other causes of death associated with drugs included renal failure 
(n=5/28),176 drug toxicity (n=2/11)174 and peptic ulcer (n=1/11).174 
2.5.7 Risk factors and preventability  
Not only did the reviewed studies provide examples of routinely collected data used to 
estimate the occurrence of AEs in non-acute care, but some of the 15 studies also 
attempted to identify predictors and assess the preventability of these incidents. 
2.5.7.1 Causal factors for adverse events 
Two thirds of the studies investigated potential causes of AEs (n=10/15). The most common 
factors were prescribing errors,174 poor communication between clinicians178,180 and 
diagnostic errors.112,171 Diagnostic and treatment errors that included missed or delayed 
diagnoses, poor note taking and failure to investigate were common causes of AEs.8,24,112,171 
Such errors were attributed to between 24.4% (n=34/139) and 36% (n=466/1,296, 95% CI 
21.8-50.2) of AEs.8,112  
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2.5.7.2  Risk factors for adverse events 
Few studies considered risk factors for AEs, with no patterns identified.177,179-181 In a 
Canadian study, van Walraven et al (2002) found that poor continuity of care and the 
unavailability of hospital discharge summaries were associated with increased risk of AEs.180 
Another Canadian study, by Menec et al (2006), found that higher continuity of care was 
protective against admissions and readmissions for 28 ambulatory care sensitive (ACS) 
conditions (the AEs of interest) in patients aged 67 years or older (0.67, 95% CI 0.51-0.90).177 
2.5.7.3 Preventability of adverse events 
Approximately 76,000 hospital admissions per year are estimated to be due to preventable 
AEs in ambulatory care in the US, of which 10% result in death.8 Six out of the seven studies 
investigating the preventability of AEs were drug-related studies.6,94,164,174,176,178 Avoidable 
harm associated with drugs can be reliably detected using computer-generated signals.6 
Pirmohamed et al (2004) estimated that 71.8% of admissions in their English sample were 
due to potentially avoidable adverse drug reactions (n=880/1,225).176 Among these 
admissions, 12.2% were deemed definitely preventable.176 The proportion of ADEs assessed 
as avoidable in the seven studies ranged from 1% to 42.2%.164,174   
2.6 Discussion 
This review has examined the use of routinely collected data to measure AEs in primary care. 
I found evidence of data derived from hospital sources being used to detect patient harm in 
non-acute settings, within the limited range of routinely collected data. Research remains 
focused on drug-related events and the use of secondary care services. The frequency of 
ADEs, patient groups at high risk of events and some of the errors associated with these 
events are well documented. The 15 studies were mostly descriptive in nature, estimating 
the incidence or prevalence of potential or actual harm and/or explored potential risk 
factors for AEs. 
2.6.1 Sources of routinely collected data 
One of the objectives of this literature review was to explore the availability of routinely 
collected data in primary care. This review identified a small number of relevant studies, a 
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minority of which were conducted in the UK. As such, the list of data routinely collected and 
available for purposes other than originally intended in primary care is far from complete. 
Nevertheless, this review does offer an indication of how these data might be used in 
conjunction with other sources (Table 2.5). Electronic patient records from hospitals and GP 
practices were the routinely collected data sources that were most frequently used in the 
reviewed studies. 
2.6.2 Measurement and monitoring 
The second of the three study objectives was to identify how routinely collected data are 
used for measuring and monitoring patient harm in primary care. The findings emphasise 
the dominance of drug-related studies in the primary care domain and in nationally 
reported incidents of harm.7 This review found no patterns in the use of routinely collected 
clinical and non-clinical data for monitoring safety in primary care, perhaps partly explained 
by the disparity in research methods and study samples. As shown by the majority of studies 
that used multiple data sources, measurement of AEs and the effective tailoring of safety 
improvement strategies require information from more than one source to compensate for 
the limitations of individual sources. 
2.6.3 Types and rates of adverse events 
The third and final objective of the review was to identify the types of AEs recorded in 
routinely collected data and their estimated rates of occurrence. Given the myriad of 
designs adopted by the reviewed studies, it was difficult to derive a summative estimate of 
patient harm. This is a long-standing issue in patient safety research.21 Comparisons 
between studies were hampered by inconsistent definitions of measurements. Where rates 
of AEs were provided by authors, these estimates varied considerably because of the 
divergent patient populations and non-comparable units of measurement. Taking the 
findings of two reviewed studies, Fischer et al (1007) reported a rate of 3.7 AEs per 100,000 
consultations while Woods et al (2007) reported a rate of 4.8 AEs per 1,000 
consultations.8,24 Yet at the crude level, the number of AEs detected in the two studies was 
not too different at 35 AEs (Fischer et al) and 70 events (Woods et al, 2007).8,24  
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In earlier sections, I stated that ADRs and ADEs have consistently received more research 
attention and that severe AEs were less frequently identified than temporary or less serious 
injuries. Several studies concluded that events deemed to cause the most severe harm were 
potentially avoidable. The types of AEs detected in the reviewed studies were limited, with 
hospital admissions, death and drug-related events being the principal categories of patient 
harm measured. I have also noted the impact of study heterogeneity on the review process. 
Besides the issues I have already raised, there were also discrepancies in the care settings 
where studies took place, which included ambulatory care and outpatient departments. The 
poor representation of English primary care in the review and incompatibility with the care 
settings investigated emphasise the need for more research specific to general practice and 
other non-acute care settings in England. 
2.6.4 Limitations of the review 
As with all research using secondary sources of data, the accuracy of findings is dependent 
on the accuracy of original data entry. This is particularly true for studies reliant on routinely 
collected data. Due to the heterogeneous methodologies applied in the reviewed studies, it 
was not possible to perform detailed comparisons of study results, such as meta-analyses. 
Future reviews may choose to use a more sophisticated literature selection strategy for 
identifying studies based on specific AEs or patient outcome types. 
2.6.4.1 Excluded studies 
In earlier sections of this Discussion, I considered the findings in relation to the diverse 
characteristics of the studies. However, the review applied selection criteria that may have 
been overly-restrictive. That is, some studies focusing on ADRs but relevant to the review 
will have been excluded. Adverse reactions to drugs are often not attributable to unsafe 
care and, in many instances, are unavoidable. Conversely, detrimental effects of medication 
treatment contribute to morbidity and mortality and should be considered in future 
research.  
This review also excluded studies on medical errors without explicitly defined adverse 
outcomes. Errors do not always lead to actual AEs, although there is potential for harm, and 
can rarely be detected using routinely collected data. Despite this rationale and because 
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medical errors are an integral part of the patient safety paradigm, further research should 
consider the assessment of errors when measuring patient harm. Not least, in doing so, 
contributory factors and remedial steps in the health system can be ascertained. 
2.6.5 Generalisability 
Over half of the studies were carried out in the US and many of the findings may only be 
applicable to the US and countries with similar health systems. A small number of studies 
was reviewed, almost all of which contained adult samples, such as only patients aged 65 
years and older. Aside from other case-mix characteristics, the diseases encountered by 
patients of different age groups will vary. AEs will differ by disease and patient profiles (as 
well as other factors) and therefore the applicability of findings for other patient groups is 
constrained by the limited selection of reviewed studies.  
In section 2.5.5.2, I commented on the severity of AEs measured in the reviewed studies. 
The generalisability of the severity assessments is doubtful for the following reasons. Few 
studies assessed severity (n=6), they lacked common measurement techniques and there 
was insufficient evidence that the inter-rater reliability of case reviewers was determined. 
Recall my statement in section 2.6.4 on results being dependent on the accuracy of the data 
source. This line of reasoning is also true for measurement of the severity of patient harm. 
Events not severe enough to warrant medical treatment, that are undetected or where 
patients do not present for treatment, will be not be recorded in routinely collected data. 
Thus, these types of AEs may be under-represented in current estimates of patient harm but 
are nevertheless incidents that should be taken account of in safety improvements.  
2.6.6 Contributions of the review 
Tools for quality improvement in the NHS that incorporate routinely collected data have 
been steadily improving. In addition to software created by commercial companies, in-
house bespoke performance monitoring systems have been created for local needs by PCTs, 
the Public Health Observatories* and other organisations. These activities are not reflected 
                                                     
*
Public Health Observatories will become part of Public Health England from April 2013.
182
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in the volume of research based on routinely collected data for detecting and monitoring 
patient harm in primary care. This review has synthesised the literature on this topic. 
Studies from different countries have been compared to provide an international 
perspective, highlighting the need for more research in the English primary care setting.  
2.6.7 Recommendations from the review 
Remarkably little is known about the errors and AEs occurring in community care, dentistry 
and other areas of primary care. Based on the evidence from the 15 reviewed studies, 
future research, policy development and clinical practice should consider the following 
themes for improving patient safety in primary care: 
 Use multiple methods to detect AEs, incorporating quantitative and qualitative 
measures. 
 Further explore the suitability of routinely collected data for safety monitoring. 
 Identify risk factors for AEs. 
 Investigate common medical errors that result in patient harm, including diagnostic 
problems, communication breakdowns and management failures. 
 Evaluate the impact of AEs on patient outcomes. 
 Validate and review existing patient safety measurement tools. 
2.6.8 Findings from informal consultations with clinicians 
To supplement the evidence gained from the literature review on the nature and extent of 
patient safety issues in primary care, snapshot views were obtained from four GPs and a 
medical student in England on uses of routinely collected data for patient safety 
measurement in this care setting.183 All five discussions were conducted in person at the 
participants’ usual places of work or study between June 2010 and January 2011. The 
anecdotal findings provided an outline of patient safety concerns experienced by staff in 
general practice, as well an indication of staff awareness and uses of routinely collected 
data to improve patient safety.183 Opinions of how routinely collected data can be 
successfully adapted into safety monitoring tools were also obtained.183 
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During the discussions, participants assessed ten candidate patient safety indicators on their 
suitability for application in English general practice.183 The indicators assessed were 
identified from the literature review as being in current use or have the potential to be 
applied in this care setting, or identified as a national health priority for investigation by the 
Department of Health. This face validity exercise informed the quantitative analysis 
components of the project, presented in Chapters 5 to 8. Two of the indicators were 
selected for further investigation (admissions for short term complications of diabetes - 
emergency admissions for diabetic ketoacidosis and coma and first time emergency 
admissions for cancer). A third, general adverse event measure was included in analyses. I 
state the reasons for choosing each of the three measures in the next chapter and then each 
indicator is described in detail in later chapters. 
2.6.9 The next stages of the project 
As competition drives forward the collection of data in all areas of the NHS, there are ample 
opportunities to use these data for resource efficient safety monitoring. This review of the 
literature has demonstrated that further research is needed to determine the feasibility of 
measuring AEs using routinely collected datasets. The next steps will involve measurement 
of AEs attributed to primary care and detected by readily available data collected in the 
English health system (NHS). Estimates of patient harm generated by these data should be 
validated with other sources.62,184 In light of the limited use of routinely collected data for 
monitoring safety in the non-acute setting in England, barriers to their use and solutions to 
these problems will also be explored in this thesis.
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Chapter 3: Data sources  
 
3.1 Chapter overview 
Recall the research aims set out in Chapter 1. In Chapters 1 and 2, I assessed 
the scope of routinely collected data to monitor, and provide information 
about, patient harm in primary care (research aims 1, 2 and 3) and 
identified measures of potential AEs (research aims 1 and 2). To quantify 
the epidemiology of AEs in general practice (research aim 1) and to further 
explore methods in which routinely collected data can be used for safety 
measurement (research aim 4), analyses were conducted using multiple 
data sources. In this chapter, I state the rationale for the three indicators 
selected for analyses in Chapters 5 to 8 and present an overview of the data 
sources used.  
  
3.2 Selection of the three measures 
A list of indicators that are research-operational or in current clinical use was compiled from 
the literature review reported in Chapter 2 and Department of Health policy publications 
(Chapter 2 section 2.6.8). From this list, a set of ten potential patient safety indicators were 
shortlisted for assessment by four GPs and one medical student. The assessments were 
performed during informal consultations which are not reported in this thesis due to their 
supplementary nature to this project, but they are described in the referenced 
publication.183 Out of the ten indicators assessed by the reviewers, two were selected for 
analysis. One other general AE measure was included in the analyses. All the indicators were 
selected because of their inter-setting applicability; the impact of the respective diseases 
and conditions spans across the entire health system. The three AE measures were: 
 Adverse events (AEs) with assigned complication codes, 
 Emergency admissions for diabetic emergencies, and  
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 First emergency admissions for cancer. 
 
3.3 Rationale for the selection 
The measures were chosen because of the relatively high prevalence of the associated 
disease (diabetes), burden to the health system (AEs, diabetes and cancer), presence of 
disease-specific measures (diabetes and cancer) and relevance to current national health 
frameworks and initiatives (diabetes and cancer).  
3.3.1 Adverse events with designated codes 
Both empirical research and the informal consultations (Chapter 2) highlighted the 
prevalence of drug-related harm in safety awareness and research.183 Iatrogenic AEs with 
designated diagnosis codes include ADEs but also refer to non-drug related events, such as 
intra-procedure misadventures. There are built-in codes specifically for these events in the 
primary care and secondary care information systems that were available for use in this 
research. As such, it was possible to calculate a baseline rate of explicitly identified incidents 
beyond what is already known about ADEs. 
3.3.2 Emergency admissions for diabetes and cancer 
Aside from investigating AEs directly, the consequences of potentially unsafe care also need 
to be considered. For any disease or condition, emergency admission is an undesirable 
outcome, and particularly so for undiagnosed diseases, as well as being costly to service 
providers. These types of health service uses are well recorded in routinely collected data. 
Diabetes and cancer are key target areas for improvements to services and patient 
outcomes that have been identified by the UK government and echoed by health interest 
groups and third sector parties. Both diseases have national clinical guidelines for treatment 
and management. Adherence to protocols and guidance are likely to improve the outcomes 
of patients with these diseases and reduce the likelihood of patients experiencing disease-
related AEs.  
Unplanned admissions for diabetic emergencies (namely diabetic ketoacidosis and diabetic 
coma) were assessed as a promising adverse event measure based on routinely collected 
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data.183 Despite receiving a lower overall score, “first time emergency admission for cancer 
in patients without a prior cancer diagnosis”, was also selected for further investigation. 
There were three main reasons for selecting this indicator. Firstly, improving cancer 
outcomes is a government priority. Secondly, relevant outcome data are available for its 
measurement. Thirdly, I investigated this measure in a collaborative project with colleagues 
in the Department of Primary Care and Public Health at Imperial College London, the output 
of which feeds into this project and is reported in Chapter 8.185 Each of the measures is 
contextualised in the relevant chapters but before presenting the analyses, it would be 
helpful to firstly describe the data used in this project and also the analysis methods applied 
(Chapter 4).  
3.4 Data sources 
Given the evidence of the strengths and limitations of respective data sources (Chapter 1 
section 0), one can expect that comprehensive examination of AEs requires the use of 
multiple measurement methods.96,184 Safety improvement strategies that make use of 
existing resources are preferable, as is the streamlining of the number of indicators.14 It is 
with these caveats in mind that I drew on a selection of data sources to address the aims of 
this project. Before I present the quantitative methods used in this project, it would be 
helpful to outline the data sources used (Table 3.1). In the next sections, I will describe each 
of the sources in turn.
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Table 3.1 Data sources, coding and measures 
Care setting Data source Coding Measure 
Primary care  Primary Care Trust - NHS Brent READ chapters S, T, U Adverse events 
Secondary care  Hospital Episode Statistics (HES) ICD-10 blocks S00-T98, V01-
Y98 
First-time emergency admission for cancer 
Combined General Practice Research Database 
(GPRD) 
READ, ICD-10 and Townsend 
scoring 
Adverse events 
Emergency admissions for diabetic 
hyperglycaemic emergencies 
First-time emergency admission for cancer 
Other Index of Multiple Deprivation (IMD)  Postcodes Deprivation score for patients’ place of residence 
and GP practices in 2007 
 NHS Information Centre Practice codes 
- 
Full Time Equivalent (FTE) GPs in 2010 
National Diabetes Audit results for rates of 
diabetes and diabetic complications 
 National Statistics Postcode Directory 
(NSPD)  
Lower Super Output Areas 
(LSOAs) 
Rural/urban classification for patients’ place of 
residence and GP practices in 2010 
 Quality and Outcomes Framework 
(QOF) 
Practice codes Practice performance 
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3.5 Data from a Primary Care Trust 
The Applied Research Unit at NHS Brent is affiliated with the Department of Primary Care 
and Public Health at Imperial College London (hereafter referred to as PCPH).186 Through 
this association, I obtained access to anonymised electronically recorded patient data from 
the PCT. At the time of analyses, there were 97 primary care practice sites in NHS Brent, 
including services such as Accident and Emergency Primary Medical Service and Community 
Dermatology.187,188 Of these practice sites, 79 were general practices,187 and 26 of these 
general practices were voluntary participants of the Brent Clinical Information Management 
System (CIMS) project. This scheme collected clinical, administrative and demographic data 
about patients, including details of treatment and prescribing, coded using the Read 
classification system. Data from the CIMS project were collected from the PCT by PCPH in 
2007 for patients registered at participating practices in NHS Brent during the 2007 calendar 
year.  
3.5.1 Ethical considerations 
Approval to use CIMS data from NHS Brent was received by PCPH for research projects 
conducted within the department from Brent Local Research Ethics Committee. The 
electronic data were in a pseudo-anonymised format and stored on a computer server that 
was physically housed at the South Kensington campus of Imperial College London. Remote 
access to the data was obtained to enable the data to be transferred to a secure, private 
computer network at the Dr Foster Unit (DFU) at Imperial College London, where I carried 
out all the analyses for this project.  
3.5.2 Description of the dataset 
The dataset from NHS Brent consisted of data files for each of the Read Code 5-byte (version 
2) chapters A-Z, with additional data files for ethnic coding and GP practice details. The data 
fields within this dataset were arranged by patient observation. Each consultation record 
contained data on practice identification number, local patient identification number, Read 
code, a 30 character description of the consultation, the date of consultation, age of patient 
and sex of patient.   
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3.6 Hospital Episode Statistics (HES) 
Hospital Episode Statistics (HES) is a “data warehouse” that contains information on all 
patient contact with the NHS and associated NHS treatment in England.189 The DFU has 
permission from the National Information Governance Board for Health and Social Care 
(NIGB) to hold HES data under Section 251 of the National Health Service Act 2006. Data in 
HES is stored by episodes of care for each Finished Consultant Episode (FEC) of care under a 
consultant or allied health professional.189 The end of an episode of care is indicated by 
discharge from hospital (including internal and external transfers) or admission to the care 
of another consultant.189 Three datasets are available which contain data on admissions, 
outpatients and accident and emergency contacts, respectively.190 
3.6.1 Characteristics of HES data 
For the purposes of this project, inpatient HES data were used and so only the HES 
admissions dataset will be described in this section. HES data are available by financial year 
(1st April to 31st March of the following year) and contain approximately 16 million episodes 
of care records per year.190 For each record, there are over 50 fields available to be 
populated.190 As well as patient’s demographic data (including date of birth and sex), 
information is also recorded on where they were treated (hospital site and NHS trust), when 
the admission occurred (admission and discharge dates) and clinical details of diagnosis and 
treatment, including whether the admission was planned or not.190 Since 2007-08, the HES 
admissions dataset contains 20 diagnosis fields, with the first field denoting the primary 
reason for admission.190 There are also 24 procedure and operation fields, the first of which 
denotes the main operation of the episode.190 
3.6.2 Data cleaning  
When HES data are received at DFU, these data are cleaning by DFU data management staff 
and further processed by colleagues at Dr Foster Intelligence (DFI).191 For example, 
unfinished or duplicate episodes, incomplete spells, invalid discharge date, age group, sex, 
elective admission status or length of stay are removed before the data are used for 
research. 
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3.7 General Practice Research Database  
As mentioned in Chapter 1 section 1.5.7, the GPRD was superseded by the Clinical Practice 
Research Datalink (CPRD) in April 2012 but as the former was in operation at the time of the 
project, references will be made to the GPRD and not CPRD throughout this thesis. The 
GPRD has been used extensively for epidemiological and healthcare research. It is well 
validated and renowned for its representational coverage of the UK population.  
3.7.1 Data coverage 
Data provided by the GPRD for this research were from the October 2010 build of the GPRD 
database. For this time period, the GPRD contained data for 12.1 million patients.130 This 
number included the up-to-research-standard records of 4.87 million currently actively 
registered patients, and 5.77 million inactive patients who either died or were transferred 
out of the participating practice.130  
3.7.2 Strengths and weaknesses of GPRD data  
3.7.2.1 Strengths of the database 
 Wide international use of database with validation for many diseases, conditions and 
treatments, 192-195 including comparison with HES.192  
 Population coverage - approximately 8% of UK population and over 590 GP practices. 
 Detailed datasets of clinical and non-clinical data. 
 Linkage available with disease registries, secondary care and death data. 
 Data have received “preliminary cleaning” by GPRD to ensure they meet “research 
standard”. 
3.7.2.2 Weaknesses of the database 
 Only general practices using the Vision computer system can participate in GPRD.130 
 Voluntary participation by practices with pay incentive (10p per patient per year).130 
 Limited free linked data available under a MRC license for academic institutions 
(correct at time of application for GPRD data. The MRC licence has since expired and 
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a new arrangement for access to data should be made to the CPRD via the 
Independent Scientific Advisory Committee, ISAC).130 
3.7.3 GPRD for monitoring adverse events 
Patient harm associated with drugs or other forms of treatment in general practice have 
been well investigated using GPRD data.192,195-197 Yet fewer studies have taken advantage of 
the longitudinal nature of the database to explore non-drug-related AEs.197,198  
3.7.4 Dataset for this project 
Data were obtained under the Data Linkage Scheme. Integrated hospital admissions data 
from Hospital Episode Statistics (HES), central mortality data from the Office of National 
Statistics (ONS) and social deprivation by Index of Multiple Deprivation (IMD) 2007 scores 
were included in the dataset. It was therefore possible to conduct a detailed exploration of 
the relationships between potential risk factors, AEs, and other patient outcomes.  
3.7.5 Data cleaning 
The raw dataset contained records for 100,000 patients who were registered at 584 
participating GP practices during the study period (1st January 1999 to 31st December 2008). 
Basic cleaning of the dataset removed the records of: 
1. Patients with invalid sex field, n=3. 
2. Patients missing valid clinical, medical or consultation data, n=404. 
3. Patients without valid Read coded fields, n=2,047. 
4. Patients missing registration date, year of birth or where the first registration date at 
the GP practice was after the date of the patient’s first ever recording in the 
computer system, n=3. 
5. Patients residing outside of England, n=18,328. 
6. Patients who did not have any consultations (in any location, with any type of staff) 
during the study period, n=4,452. 
Once cleaned, data for 74,763 patients registered at 457 practices remained. More cleaning 
was carried out for the analyses reported in Chapters 6 to 8. The results of this data 
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preparation are reported in the respective chapters. In the next sub-sections, I describe 
nuances of the dataset that are worthy of note and that had implications for the analyses. 
3.7.6 Registration period 
In the GPRD dataset, unique patient identifiers are GP practice-dependent; new patient 
identifiers are assigned to patients when they join a practice. Thus, it is not possible to track 
patients who transfer out of one practice and who then register with other practices. Given 
this artefact of the dataset, only the first registration period of each patient at their current 
GP practice was included in analyses. 
3.7.7 Ethnicity 
Data on patients’ ethnic classification were only available through the linked HES data, i.e. 
only patients who had an admission record also had valid ethnicity data. It follows then that 
ethnicity status was recorded for approximately a quarter of the patients in the original raw 
dataset (24,307/100,000 patients). Ethnicity data were provided in 13 categories (including 
a category for "data not entered"). Due to small numbers and to improve consistency when 
comparing results, I aggregated the ethnicity groups into 6 categories that correspond with 
the current ethnicity categories used by HES and ONS.189,199 
3.7.8 Referrals 
The recording of referrals in the GPRD dataset was poor.  
3.7.9 Social deprivation 
Only 35,207/100,000 patients in the raw GPRD dataset had a valid Index of Multiple 
Deprivation (IMD) score. A code for missing deprivation status was created for analyses. 
Deprivation was measured by population weighted quintiles provided by GPRD and derived 
from IMD scores. 
3.7.10 Data on admissions 
Admissions are reliably recorded in English general practice and have been used in prior 
primary care studies.197,200 Nevertheless, completeness of admission information can be 
improved by linkage with secondary care data. In the GPRD dataset, diagnoses on admission 
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and date of admission from linked HES data improved the accuracy of estimates on 
hospitalisations associated with safety incidents occurring in non-acute care.  
3.7.11 Recording of death 
Similar to the availability of linked admissions data, causes and date of death provided 
through linked data from the ONS enabled more accurate estimates of patient outcomes 
that occur after AEs. Within the core GPRD dataset, death data are reportedly well recorded 
and derived using an in-house algorithm.201 The linked ONS central mortality data are 
extracted mainly from death certificates.202 During cleaning of the dataset, I discovered that 
the GPRD and ONS death fields in the obtained dataset did not fully match. However, the 
discrepancies were few in number. For example, 30 records with valid ONS death data were 
missing date and causes of death in the corresponding GPRD fields.  
Nevertheless, these records did contain date of death as indicated from HES or ONS data. 
There were also 8 records where the date of death in GPRD and ONS fields did not match. 
The difference in the recorded date of death ranged between 1 and 40 days, with the date 
in the ONS derived field preceding over the date in the GPRD field. These differences may be 
attributed to variation in data processing between GP practices participating in the GPRD 
and the ONS, with the ONS providing absolute recording of deaths. 
3.7.12 Data fields not used 
A variable for life events was derived for each patient based on whether there had ever 
been Read codes indicating divorce, bereavement, homelessness or unemployment in their 
records. Place of residence was also derived from the “Residence Types” code in the GPRD 
data, which was used to generate a binary flag to indicate whether patients lived alone. 
Data were too poorly populated for all three variables for them to be included in the 
analyses. 
3.8 Other data sources 
Together with the three main datasets, further data were obtained from several publically 
available data sources. I now describe each of the additional datasets in relation to the 
analyses conducted. 
Chapter 3: Data sources | 80 
 
3.8.1 Index of Multiple Deprivation (IMD), 2007 
The Index of Multiple Deprivation (IMD) measures socio-economic deprivation across seven 
domains; “income deprivation”, “employment deprivation”, “health deprivation and 
disability”, “education, skills, and training deprivation”, “barriers to housing and services”, 
“living environment deprivation” and “crime” are measured.203 Higher IMD scores indicate 
greater deprivation. 
In the GPRD dataset, deprivation scores for patients derived using the IMD for 2007 were 
provided and applied in Chapters 6 to 8. For analyses using the HES standalone dataset 
(Chapter 8), the IMD scores for patients’ place of residence and GP practices were mapped 
by postcodes. IMD scores by postcodes have been previously created by a colleague at DFU, 
whereby IMD scores by Lower Super Output Area (LSOA) were mapped to postcodes using a 
postcode to geography level lookup table. 
3.8.2 NHS Information Centre 
In Chapter 7 – Emergency admissions for diabetic hyperglycaemic emergencies, 
comparisons were made between the study results and nationally reported data on 
admission rates. These national data were obtained from the NHS Information Centre (and 
in conjunction with QRESEARCH) and the National Diabetes Audit (NDA).204-206 In Chapter 8, I 
use data on the number of full time equivalent (FTE) GPs, excluding GP retainers and 
registrars in 2010. These data were previously obtained from the NHS Information Centre by 
a colleague in PCPH for departmental use.207 These data were available by age group, sex 
and country of primary medical qualification.  
3.8.3 National Statistics Postcode Directory (NSPD) 
For the analyses in Chapter 8, the rural/urban classification for patients’ place of residence 
and GP practices were defined using the 2010 National Statistics Postcode Directory (NSPD), 
from the ONS.208 Classifications were available at the LSOA level, which were then mapped 
to the corresponding postcodes of patients’ homes and GP practices using the online 
GeoConvert tool from the Census Dissemination Unit at the University of Manchester.209 
The three categorises used were: 
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 Urban >10K; 
 Town and fringe and village; and 
 Hamlet and isolated dwellings. 
3.8.4 Quality and Outcomes Framework data 
The Quality and Outcomes Framework (QOF) was first implemented in England in the 
2004/05 financial year. This is a voluntary performance-related payment system for NHS GP 
practices.210 It enables comparisons to be made on the quality and delivery of health 
services, using points-based indicators within four domains (clinical, organisational, patient 
experience and additional services).210 Higher scores indicate better performance, with a 
maximum attainable score per practice of 1,000 points. Annual results are publically 
available at national, local and practice levels. 210 QOF data for the most recent financial 
year available (2010/11) contains data on 134 indicators, with data collected from 8,245 GP 
practices for over 55 million patients in England (99.7% of registered patients).211  
In Chapter 8, five QOF measures were mapped to practices using the unique identifier code 
assigned to each practice. The overall practice performance, two cancer indicators and two 
patient experience of access indicators were assessed by averaging each indicator score 
over the years of the study (the patient experience indicators were only available for the 
latter two years of the study period). These data were downloaded from the NHS 
Information Centre for Health and Social Care’s website for the three years covering 1st 
April 2007 to 31st March 2010 (from 1st April 2008 for the two patient experience 
measures).212 
The cancer indicators were: 
 CANCER 01 – “register of patients with a diagnosis of cancer excluding non-melanotic 
skin cancers from 1st April 2003”, and  
 CANCER 03 – “percentage of patients with cancer who have been diagnosed within 
the last 18 months and have had a patient review recorded as occurring within 6 
months of the practice receiving confirmation of the diagnosis”.212  
The patient experience of access indicators were: 
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 Patient Experience 07 – “percentage of patients who were able to obtain a 
consultation with a GP within 2 working days”, and 
 Patient Experience 08 – “percentage of patients who were able to book an 
appointment with a GP more than 2 days ahead”.212 
3.9 Elements of analyses 
3.9.1 Follow-up time 
The amount of time individual patients’ contribute to the study, time at risk, was calculated 
separately for the three AE measures.213 The unit of calculated follow-up time was years. 
Only approximate estimates were possible using year of birth as patients’ dates of birth 
were unavailable in the GPRD dataset. The calculations took into account of leap years:213 
          (     )   
(                   )
      
 
Where: 
End date = Date of death, transfer out of practice or study end date (31st December 2008), 
whichever occurred first OR date of AE of interest. 
Start date = Study start date (1st January 1999) or first registration date at practice if date of 
birth was after 1st January 1999, whichever occurred last. 
3.9.2 Patient endpoints 
After experiencing an AE in general practice, patients may be admitted to hospital and/or 
die. These endpoints are routinely and reliably recorded. Even though these and other 
patient outcomes are not always attributable to unsafe care, further investigations are 
warranted when these outcomes are preceded by iatrogenic harm. Admission rates can be 
inaccurate markers of healthcare quality.214,215 Yet unplanned admissions can also be valid 
indicators of poor quality or unsafe care in the primary care setting. For example, if an 
admission with a primary diagnosis of a potential AE occurs soon after a GP consultation, 
the patient’s pre-admission contact with health services should be examined to identify the 
root cause of the cause of admission and remedial factors, if applicable.  
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3.9.3 Defining emergency admission 
As defined in HES, an emergency admission is one that is not from a waiting list, booked or 
planned.189 instead, a patient is admitted by accident and emergency (A&E) services, GP, 
bed bureau, consultant outpatient clinic or other means including the A&E department of 
another care provider.189 This definition was used in the analyses reported in Chapters 6 to 
8. 
3.9.4 Comorbidities 
To determine the effects of comorbidities on patient safety outcomes in this project, and to 
assess the validity of two commonly applied comorbidity measures, the Charlson 
Comorbidity Index and the John Hopkins Adjusted Case Group (ACG) Case-Mix System were 
used. A further composite comorbidity measure based on Charlson Index disease groupings 
was applied. I now describe these three comorbidity measures. 
3.9.4.1 Adjusted Case Group (ACG) System 
The ACG case mix system was created at Johns Hopkins University in the US specifically for 
use in ambulatory (or non-acute) care and has been applied internationally, including in 
English general practice.216-218 This adjustment method takes into consideration the 
potential for patients to have multiple diagnoses over a set period of time and the ACG 
system can be used to predict healthcare use.219,220 Unlike other risk adjustment methods, 
the ACG system takes into account clinical need of patients and the burden of diseases 
when assigning patients to comorbidity groups. It has been used to assess comorbidities in 
the UK using GPRD data.218,221 
The structure of the system is as follows: 
1. Adjusted clinical groups (ACGs) – 106 mutually exclusive health status categories 
based on morbidity, age and sex. These are used for calculating costs.  
2. The ACGs are used to assign patients to Resource Utilisation Bands (RUBs), 
indicating severity of morbidity. The six RUB groups are: 
o 0 – No or only invalid diagnoses 
o 1 – Healthy user 
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o 2– Low 
o 3 – Moderate 
o 4 – High 
o 5 – Very high 
3. Aggregated diagnosis groups (ADGs) – All ICD-10 (and Read codes) are categorised 
into 32 morbidity markers per patient. These unique morbidity groupings are based 
on “…specific clinical criteria and demand on healthcare services”.222 Patients are 
assigned to single or multiple ADGs. The ADGs can be aggregated into 12 Collapsed 
ADGs (CADGs). Due to copyright restrictions, the mapping of ADGs to CADGs could 
not be reproduced in this thesis. ADG assignment is based on 5 dimensions: 
o Duration 
o Severity 
o Diagnostic certainty 
o Type of etiology 
o Expected need of specialty care 
4. Expanded diagnosis clusters (EDCs) – There are 5 MEDC types (Administrative, 
Medical, Surgical, Obstetric/Gynaecological and Psychosocial). Within these types, 
there are 27 Major EDC (MEDCs) clinical categories/disease clusters. Each ICD/Read 
code is mapped to one of 267 EDCs. Within each EDC, the associated ICD and Read 
codes share similar diagnostic (and therapeutic) characteristics.  
3.9.4.2 Use of ACG measures in this project 
The ACG software was applied only to the GPRD dataset. Comorbidity measures were 
created for the entire dataset, with no distinction made between the three AE measures or 
measure-specific criteria. As such, the end date used to derive ACG weights for each patient 
was either date of death, date of transfer out of practice or the study end date, whichever 
occurred first. By ignoring end dates relevant to the individual AE measures, the derived 
ACG variables were not valid for use in all analyses. To explain, some conditions included in 
developing the ACG weights will have occurred after the outcome(s) of interest. To include 
these conditions in analyses where the response variable is the outcome of interest would 
bias the results. Where variables derived from the ACG software have been used, this is 
denoted in the relevant sections of the thesis. It should also be noted that original US 
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spellings are retained for ACG derived variables and intentionally used throughout this 
thesis. 
3.9.4.3 ACG derivations 
To derive the ACG weights, only Read codes in the medical history category of the GPRD 
dataset (“enttype=2”) were used as the quality of coding in other categories, such as 
Disease Registries and Diabetes, was unknown and potentially inconsistent and/or poor. The 
ACG software distinguishes between data for patients aged <65 years (labelled by ACG as 
"non-elderly") and patients aged ≥65 years (labelled "elderly"). Therefore the dataset was 
processed in two batches, using the "lenient diagnostic certainty" option which does not 
limit the number of diagnoses per patient included in processing, unlike the "stringent 
diagnostic certainty".223 Patients were assigned up to 32 ADGs, presented as binary flags. 
These flags were aggregated into CADGs, with a third binary measure of MEDC flags. Counts 
of the number of EDCs per patient (maximum 267) were also included in analyses, and a 
fifth and final ACG measure of categories derived from RUB scores. 
3.9.4.4 Charlson Index 
The Charlson Index was originally developed for use in the hospital setting to predict 
mortality within one year of admission. The index has been extensively used in healthcare 
research, with up-to-date translations for the ICD-10 classification system.224 In the primary 
care setting, the index has been adapted for use with Read and OXMIS coding.225,226  
The original Charlson Index and Khan et al's adaptation for Read/OXMIS codes were derived 
from 17 disease categories (Table 3.2). Khan et al’s version consists of 3,156 codes and was 
adapted from Deyo et al’s modification of the Charlson Index.226 No changes were made to 
the original specification. In line with Khan et al’s methodology, the overlaps in 13 
Read/OMXIS codes corresponding to diabetes and peripheral vascular disease were coded 
as diabetes.226 Cancers were coded into separate groups, with exclusions for benign cancer 
(B7), cancer in situ (B8) and neoplasms of uncertain behaviour (B9).226 
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Table 3.2 Disease categories used to derive Charlson Index scores 
Charlson disease category Score weight 
AIDS 6 
Cancer 2 
Cerebrovascular disease 1 
Chronic pulmonary disease 1 
Congestive heart disease 1 
Dementia 1 
Diabetes 1 
Diabetes with complications 2 
Hemiplegia 2 
Metastatic tumour 6 
Mild liver disease 1 
Moderate liver disease 3 
Myocardial infarction 1 
Peptic ulcer disease 1 
Peripheral vascular disease 1 
Renal disease 2 
Rheumatological disease 1 
 
There is a relative dearth of studies comparing the performance of different versions of the 
Charlson Indices on UK primary care data. Studies in secondary care indicate that 
Elixhauser’s comorbidity index performs better than Deyo et al’s.227-229 Ideally, I would have 
compared two commonly used adaptations of the Charlson Index - Deyo et al’s and 
Elixhauser et al’s indices.230,231 The Elixhauser modified Charlson Index contains 30 disease 
categories, in contrast to the 17 disease groups in the original Charlson and Deyo et al’s 
adapted indices.230-232 Given the potentially cumbersome nature of analyses using 30 
disease groups and issues surrounding small numbers, and the lack of evidence on using the 
Charlson Index on non-hospital data, only Deyo et al’s version of the Index was used in this 
project. 
3.9.4.5 Disease group flags  
In addition to the comorbidity measures created using the ACG software and the Charlson 
Index, I applied disease flags in the analyses. These binary flags corresponded to the 17 
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disease categories used to derive Charlson comorbidity scores for each patient. As 
mentioned in section 3.9.4, an extra 18th (composite) flag was created to indicate whether a 
patient had any of the 17 diseases.  
3.9.5 Continuity of care 
Continuity of care, described as “the quality of care over time”, can be considered in terms 
of longitudinal, relational, flexible and team boundaries.233,234 Continuity of care is 
particularly important for patients with chronic conditions and who may access health 
services more frequently than other patients.234,235 
3.9.5.1 The Continuity of Care (COC) Index 
The distribution of consultations by individual patients among staff members was measured 
by the Continuity of Care (COC) Index.236 The COC has the advantage of not requiring data 
on patients' designated doctor (or other relevant staff member), and takes into account the 
consultation patterns and total numbers of consultations of individual patients.236 Only 
patients who had at least two consultations during the study period were allocated a COC 
score, as recommended by the Index’s creators.236 By excluding patients who had less than 
two consultations, it was possible to reduce potential bias arising from complete 
discontinuity caused by infrequent consultations. Only consultations at the GP practice or by 
telephone and with a doctor or nurse were used to calculate COC scores.236 The formula for 
calculating each patient’s COC score is:236      
     
∑   
  
      
  (     )
 
Where  
 n = total number of consultations (at GP practice or by telephone) 
              = number of visits to clinician j 
 s = number of clinicians (GPs or nurses) 
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Possible COC values range from 0 to 1. The COC score was converted to a categorical 
variable (low, moderate and high continuity of care) based on rankings weighted by the 
sample population.  
3.10 Software 
The following software items were used in the project: 
 Endnote X3 and X4; 
 GeoConvert from the Census Dissemination Unit (CDU), University of Manchester; 
 GPRD Gold Browsers July 2010; 
 Johns Hopkins ACG® System 9.01i; 
 Windows Media Player version 11; 
 Microsoft Office Word and Excel 2007 and 2010; 
 NHS Clinical Terminology Browser Version 1.04; and  
 SAS Version 9.2 TS Level 2MO. 
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Chapter 4: Analysis methods  
 
4.1 Chapter overview 
In this chapter, I outline the statistical methods used in Chapters 5 to 8. In 
the previous chapter, I gave an overview of the measures and data sources 
included in the analyses. I begin this chapter by revisiting these two 
components of the analysis. Then, I describe the analysis techniques that 
feature in the following chapters. Finally, I consider alternative statistical 
methods to those applied. 
 
4.2 The adverse event measures  
Recall the measures described in Chapter 3: 
 Adverse events (AEs) with assigned complication of care codes, 
 Unplanned admissions for diabetic emergencies, and  
 First unplanned admissions for cancer. 
These measures were investigated using a number of data sources, of which the main 
datasets are outlined in the following section. Definitions, including diagnosis codes, are 
provided in the relevant chapters (Chapters 5 to 8). 
4.3 The data sources 
Also recall the main datasets described in Chapter 3: 
 Data from a PCT, NHS Brent, 
 Secondary care data from the Hospital Episodes Statistics (HES), and 
 Primary care data from the General Practice Research Database (GPRD). 
I will refer to these measures and datasets throughout this chapter. 
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4.4 Analyses at patient-level 
A combination of patient-level and practice-level analyses are presented in the subsequent 
four chapters. Before describing the analysis techniques used in practice-level analyses 
(section 4.7), I explain how patient-level analyses in Chapters 5 to 8 were performed. 
Further methodological detail on chapter-specific analyses can be found in the respective 
chapters. 
4.4.1 Estimates of rates 
Chapters 5 to 8 include calculated rates of AEs. The types of data and measures used differ 
between the chapters (Table 4.1). 
Table 4.1 Rate estimates by thesis chapter and data type 
Chapter Type of data Type of rate Unit of measurement 
Chapter 5 - Adverse 
events recorded in local 
data 
Local (NHS Brent) Point prevalence Consultations (per 1,000 
consultations) 
Chapter 6 - Adverse 
events recorded in 
national data 
National (GPRD) Incidence 
 
Person time (per 1,000 person 
years) 
Chapter 7 - Unplanned 
admissions for diabetic 
emergencies  
National (GPRD) Incidence – crude 
 
Incidence - adjusted 
Person time (per 1,000 person 
years) 
Population (per 100,000 
population) 
Chapter 8 - First 
unplanned admissions for 
cancer 
National (HES and 
GPRD) 
Incidence – crude 
and adjusted 
Person time (per 10,000 person 
years) 
 
4.4.2 Crude calculations 
Descriptive analyses are presented in Chapter 5 to 8. In each chapter, initial descriptive 
bivariate analyses explored the associations between the predictor variables and the 
outcomes of interest. The associations between variables were examined using chi-square 
tests (categorical data), Mann Whitney U tests (non-normally distributed ordinal data), t-
tests (normally distributed continuous data) and Spearman rank correlation (non-normally 
distributed data). The results of these analyses are not reported in full, but where 
appropriate.  
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In Chapters 6 to 8, the main statistical measure of interest was the relative risk (or risk ratio, 
RR). Odds ratios (ORs) were also estimated in Chapter 8 (section 4.5). Following descriptive 
analyses, these measures were calculated by crude and then multiple regression, which 
adjusts for potential confounders. Additional adjustments were made for clustering of 
patients at GP practices (section 4.8.1). 
4.5 Regression modelling 
To calculate ORs for binary outcomes, logistic regression is conventionally used. In these 
models, the outcome (probability of its occurrence) is transformed by the logit link function 
to derive log odds for the outcome.237 This method is applied in Chapter 8.  
I now turn to the calculation of RRs, which are easier to interpret from raw results than ORs. 
The first step in deciding which type of regression to use is to determine how the outcome 
of interest is distributed. A Poisson distribution would be appropriate for ordinal (count) 
outcomes (such as number of AEs or number of admissions), where the outcome is rare (low 
probability of occurrence) and there is a large enough number of the outcome for the data 
to be approximated to the normal distribution.238 This assumption is valid for the analyses of 
Chapters 6 and 7. Poisson regression is fitted on a log scale, with the outcome transformed 
using the log link function.238  
For dichotomous outcomes (such as death status or whether a first-time admission is an 
emergency or not), modelling based on the binomial distribution is more appropriate. The 
conventional approach is to approximate ORs to RRs using logistic regression but this has 
the disadvantage of potentially over-estimating RRs, especially if the outcome is not rare. An 
alternative is to use log-binomial regression, which was used in Chapters 6 to 8. Like Poisson 
regression, this method for calculating RRs requires the data to be transformed using the log 
link function. While the log of the odds of the outcome is used to generate ORs, the log of 
the risk of the outcome is used to calculate RRs.239 Log binomial regression for calculating 
the relative risk of dichotomous outcomes has been documented in the literature since the 
mid-1980s but is not commonly applied.240-242  
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4.5.1 Technical issues 
The relatively low reported use of log-binomial regression is partly due to its technical 
caveats. The key issue is model non-convergence.240,243,244 Failed convergence is often 
caused by estimates being on the boundary of the parameter space* (often due to the 
inclusion of continuous covariates and/or poor selection of starting values for the 
parameters in the model).241,245 In such a situation, modified Poisson regression using the 
Generalized Estimating Equations (GEE) method can be applied even for dichotomous 
and/or common outcomes.246-248 Furthermore, problems of misclassification (using an 
incomplete set of predictor variables) and large standard errors (SEs) when there is a binary 
outcome can be resolved by using this method.244 I will return to Poisson regression with 
GEE later (section 4.8.2.2).  
Other technical problems experienced in regression analyses arise from correlated 
observations (such as repeated events in patients) and clustering (such as patients within a 
GP practice) which violated the assumptions of chosen statistical distributions and result in 
over-dispersion. Excess of zero counts in datasets also affected model fit. These scenarios 
occurred in this project and their impact on the statistical choices that I made will be 
explained in the following sections. 
4.5.2 Generalized linear models  
Unlike general linear models where the predictor variables and outcome are assumed to 
have a linear relationship, Poisson and log-binomial regression use (logarithmic) 
transformation of the outcome to derive a linear relationship.249 These models are known as 
generalized linear models. The RRs (and ORs using log-binomial regression) are calculated as 
Maximum Likelihood Estimates (MLEs)†.  
4.5.3 Multiple regression 
This type of regression is used when the independent effect of each predictor on the 
outcome is of interest and simultaneous control of multiple confounders is sought.250 In the 
                                                     
*
Invalid parameter values, outside of the 0-1 interval.  
†
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next sections, I explain how adjusted regression models were built in (used in Chapters 6 
and 8) and discuss solutions to the technical issues encountered during this process (section 
4.5). 
4.6 Model fitting 
To account for variation in person-time contributed by individual patients to the study, 
follow-up time as person years was included as an offset (constant) term (log of follow-up 
years) in crude and adjusted models, where applicable. Where models contained an offset 
term, this is indicated in the relevant sections of Chapters 6 and 7. Crude and adjusted 
models were developed using the PROC GENMOD procedure in SAS. PROC GENMOD has the 
benefit of allowing both continuous and discrete predictor variables to be fitted and also 
accommodates solutions to non-convergent models.  
4.6.1 Selection of variables 
The stepwise method was used to select variables for multiple regression models. This 
method was chosen over the other two most common selection methods (backwards and 
forwards elimination) because it allows for greater flexibility in deciding which variables to 
keep in the model.251 The stepwise process is not without faults though, including potential 
over-estimation of model performance.249,251 All predictors were included in the initial 
model and then eliminated one at a time on the basis of their p-values.249,252 A p-value of 
0.1 was used in crude analyses as the threshold for variables to be retained and included in 
the initial adjusted models. Predictors with p-values of 0.05 or less were considered 
statistically significant and retained for model fitting. 
4.6.2 Contribution of predictor variables 
Separate models were fitted for each of the comorbidity variables; models for Charlson 
score, disease categories based on the Charlson Index, ADGs, ACGs, MEDCs, RUBs and count 
of EDCs were fitted to examine the explanatory power of each measure (Chapter 3 section 
3.9.4 for information about comorbidities).  
To crudely assess the contribution (statistical significance) of each predictor variable in the 
model, the Wald statistic was used. Final decisions on the retention of predictors in 
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regression models were made using likelihood ratio values as Wald statistics are prone to 
under-estimation caused by inflation of the SE when the regression coefficient is large and 
also when sample sizes are small (less of an issue in this project).253,254 
4.6.3 Goodness of fit 
In unadjusted analyses, the model’s dispersion parameter can be used to assess the model’s 
fit (how much of the variance of the outcome is explained by the predictor variables): 
                      
                      
                   (  )
 
Models with a dispersion parameter greater than 1 are assume to have a poor fit. The fit of 
crude models were assessed using Akaike and Bayesian Information Criteria (AIC and BIC, 
respectively), with smaller values indicating better model fit.255 When GEE is used, the AIC 
and BIC measures are no longer valid (and not given in PROC GENMOD). In this situation, 
model fit can be assessed by the Quasi-Likelihood under the Independence model Criterion 
(QIC).256 As with AIC and BIC values, smaller QIC values indicate better model fit .256 In 
adjusted analyses, the model fit was also assessed graphically in plots of the residuals* by 
the predicted values.255,258 
4.7 Analyses at practice-level 
To assess whether there was variation in recorded AEs by GP practice, the rate of AEs was 
calculated for each GP practice in Chapter 6. To control for variation in rates due to 
particular patient profiles, the age and sex of patients were adjusted for (standardised by). 
Of the two methods to produce rates that are comparable between patient groups with 
different age and/or sex structures, the indirect method was used. Standard populations 
(stratified by age and sex) required for direct standardisation were not available for the 
outcome of interest.259 
                                                     
*
In regression, residuals refer to the difference between the outcome and the predicted values.
257
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4.7.1 Standardisation of adverse event measures 
Neither practice list sizes nor national data for AEs by age and sex were available to 
calculate indirectly standardised rates of adverse events (Chapter 6). Therefore, the internal 
method of indirect standardisation by age and sex was applied, with the expected numbers 
(denominator values) derived from the sample.260 The standardisation method can be 
presented as:204 
                                  
                         
                         
                 
Where the expected number of events is calculated by:255  
                                                                                 
To calculate the indirectly standardised rate, the standardised adverse event ratio was 
multiplied by 100. 
It was assumed that there was consistency in the standardised adverse event ratio within 
age groups and sex of patients. It was also assumed that the sum of observed values was 
equal to the sum of expected values, or expressed differently, the marginal mean of ratios 
was fixed at 1.261 An advantage of using indirect standardisation is that this method 
produces more robust results than direct standardisation when there are small numbers of 
the outcome(s) of interest or unstable rates.262 This argument is valid for the analyses in 
Chapter 6 as adverse events were rare and there was variation in this outcome between 
patients by age and sex. When creating funnel plots of the indirectly standardised rates of 
adverse events (Chapter 6 section 6.4.2), 95% (2SD) and 99.8% (3SD) control limits for the 
data were calculated using the exact method based on the Poisson distribution.  
4.8 Technical issues revisited 
I now further consider the difficulties associated with regression modelling that were 
described in section 4.5.1 and set out solutions to these problems. 
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4.8.1 Clustering of patients 
The analyses in this project feature repeated measures at patient and practice levels. It thus 
follows that assumptions of events occurring randomly or independently of each other are 
void. Therefore, clustering (or heteroscedasticity) at the practice-level and/or repeated 
events in individual patients must be taken into account in adjusted analyses.  
4.8.2 Over-dispersion 
Where the variance of the outcome is considerably larger than the mean, over-dispersion 
(or heterogeneity) is suspected. This interpretation has an element of subjectivity. As an 
arbitrary guide, a variance value ≥1 unit of the mean may be considered “large” for Poisson 
models.263 For both Poisson and binomial models, the dispersion parameter can be 
calculated to test for over-dispersion (section 4.6.3). A ratio value greater than 1 indicates 
over-dispersion and that the distribution is unsuitable for the data.263,264 In this situation, 
there may be under-estimation of the SEs that result in the production of narrower 
confidence intervals than are appropriate for the data.263,264 
In the previous section, I stated two causes of over-dispersion (repeated measures and 
clustering). Other reasons for over-dispersion include misclassification, non-linear terms and 
interactions between predictors. Where the causes of over-dispersion are not assumed to 
lie in these reasons, there are several methods to manage variability greater than one would 
expect to find in a Poisson distribution. These methods will now be discussed. 
4.8.2.1 Robust standard errors 
Huber’s sandwich variance estimator is used to derive robust parameter values (MLEs) 
without reliance on assumptions about the underlying model, which itself may be incorrect. 
This method is commonly referred to “sandwich” estimation because the estimated 
variance matrix lies between the matrices of the original model-based variance.265 Poisson 
regression with robust error variance (sandwich estimation) is performed in PROC GENMOD 
by using the “repeated” statement to invoke the Generalised Estimating Equations (GEE) 
method (section 4.8.2.2).244  
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4.8.2.2 Generalised Estimating Equations (GEE) method  
The Generalised Estimating Equations (GEE) method can compensate for clustering and 
over-dispersion. This method is particularly useful when data are longitudinal and not 
normally distributed (determined by running normal quantile-quantile (Q-Q) plots of the 
outcome and also by examining the residuals of the adjusted models). GEE uses both quasi-
likelihood estimation and robust SEs (section 4.8.2.1) to correct for clustering.266 Missing 
data are assumed to be missing at random in GEE, thus Wald tests were applied to 
determine the effects of clustering on the SEs.266 
In the PROC GENMOD procedure, GEE is invoked by using the “repeated” statement.244 
After the “repeated” statement, the unit of repetition should be declared using the 
“subject” statement. To account for over-dispersion in PROC GENMOD, the “subject” would 
be the patient (referring to the unique patient identifier code in analyses).244 In the case of 
accounting for clustering of patients within practices, the “subject” would now be GP 
practice (referring to the unique practice identifier code in analyses) and thus changing from 
the use of an individual identifier to a cluster identifier.247  
In all analyses incorporating GEE presented in this thesis, the independent working 
correlation structure for modelling the associations between repeated measures was 
applied.265,267 This is the default working correlation matrix for GEE in PROC GENMOD and 
was selected based on the assumption that observations within subject (events at a GP 
practice) were not equally correlated.244 Analyses using GEE benefit from minimal penalties 
for model misclassification (using the wrong working correlation structure).268 
4.8.2.3 Adjustment using goodness of fit ratios 
Alternatively, a factor for over-dispersion can be included in the model based on the square 
root of the deviance or Pearson chi square value over the degrees of freedom (df). The scale 
parameter is available through the “PSCALE” (for Pearson chi square) and "DSCALE" (for 
deviance) functions in PROC GENMOD. These functions adjust the SEs of the regression 
coefficient (multiplies SEs by the scale parameter) to produce more conservative estimates 
of the SEs, using the quasi-likelihood method.258  
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4.8.3 Excess zeros counts 
When an ordinal outcome variable is used (such as count of AEs and count of admissions), 
there are likely to be excess zero counts (no occurrence of the event of interest). 
Continuous outcomes were presented graphically to detect this phenomenon in the data. 
Statistical solutions to address excess zeros are outlined in the next section and also 
discussed in the respective chapters (Chapters 6 and 7).  
4.8.4 Solutions to excess zeros and over-dispersion 
4.8.4.1 Negative binomial regression 
So far I have discussed two methods to address over-dispersion (application of GEE and 
scale parameters). Now I will briefly outline some modelling techniques that are suitable 
when there are excess zero counts and over-dispersion. The first model is negative binomial 
(NegBin) regression. This type of regression accommodates over-dispersed data but may 
produce poor fitting models when there are “excess zeros”, given inclusion of unobserved 
heterogeneity in the model.269  
4.8.4.2 Zero-inflated regression models 
A second option would be to build a zero-inflated model, either zero-inflated Poisson (ZIP) 
or zero-inflated negative binomial (ZINB) versions.270 The latter, ZINB, is advantageous when 
the data are over-dispersed.258 Both NB regression and ZINB regression use the gamma 
distribution to account for over-dispersion.258 Either NB regression or ZIP regression would 
account for both excess zero counts and over-dispersion but unlike NB regression, ZIP 
regression does not consider between-subject heterogeneity. Zero-inflated and negative-
binomial regression models can be built in PROC GENMOD. 
4.8.4.3 COPY algorithm 
Where regression models fail to converge, alternative methods for calculating RRs include 
applying robust Poisson regression (section 4.8.2.1), the COPY method using log-binomial 
regression or non-linear least squares.271 The COPY method produces approximate MLEs 
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(section 4.5.2) but this method is affected by outliers and model misspecification*.241,245 The 
algorithm is used to create one dataset with a given number (c-1) simulations of the original 
data and one copy (c) of the dataset with reversed values of the outcome variable.245 The 
estimated SE is then multiplied by the square root of the number of simulations (c) to take 
into account of the inflated sample size. A minimum of 100 simulations, or copies, is 
recommended, although models that used 1,000 copies or more have resulted in 
approximated MLEs close to the MLEs of the original dataset.245,271,272  
4.8.4.4 Non-linear least squares estimation 
Poor model fit indicated by the MLE being on the boundary of the parameter space (and 
ultimately non-convergence) may require the use of estimators not restricted to a specific 
distribution.258 By fitting models using the least squares method, parameter values are 
derived from the minimum residual sum of squares.258,273 In SAS, non-linear least squares 
regression is calculated using the PROC NLIN procedure.258 This approach is more 
challenging than Poisson regression and the associated variations that have been mentioned 
already, from both mathematical and programming perspectives. Given the alternative 
modelling approaches already proposed in this chapter to address the technical issues 
raised and the requirement of switching to a different SAS procedure, non-linear least 
squares regression was not attempted in this project. 
4.8.4.5 Comparison of methods 
I assessed the performance of models by applying the Vuong test. This distribution-free test 
was used to compare firstly, Poisson models with GEE and ZIP models, and secondly, NegBin 
models with ZINB models, using a SAS macro downloaded from the SAS website.274,275 
Better performance of original Poisson with GEE models or NegBin models, compared to 
zero-inflated models, was determined by non-statistically significant Z scores in the Vuong 
test.275,276  
                                                     
*
This is caused by erroneous assumptions about the model, such as incorrectly retained or removed variables, 
use of an incorrect function or inappropriate distribution. 
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4.9 Alternative analysis approaches 
There are two additional statistical approaches that could be considered for tackling excess 
zeros and over-dispersion. The first is Cox proportional hazards survival analysis (commonly 
referred to as Cox regression). Although this method can take into account unequal patient-
time, it was not applied in this project because the rare nature of the outcomes of interest 
(and high amount of censoring) would have resulted in inflated SEs and potentially incorrect 
RR estimates.245 Indeed, the performance of Cox regression does not seem to be superior to 
Poisson regression with robust variance estimates or log-binomial regression in models with 
binary outcomes.241  
The second approach is hurdle modelling, which is suitable for repeated outcomes (such as 
multiple AEs and readmissions).277 However, hurdle analyses cannot be performed by the 
PROC GENMOD procedure in SAS. Finally, multi-level modelling can take into account 
clustering and over-dispersion. This approach may be favoured over GEE models when there 
is more than one cluster level, which GEE is unable to accommodate. Multi-level models can 
also not be built in PROC GENMOD. To maintain analytical consistency, and because of the 
availability of alternative modelling techniques within the preferred PROC GENMOD 
procedure, I did not use Cox regression, hurdle or multi-level models. Relatively new 
statistical solutions to the issues of over-dispersion, multi-level clustering and excess zero 
counts are possible when using software other than SAS, but this was beyond the scope of 
this project.278 
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Chapter 5: Adverse events recorded in local data 
 
5.1 Chapter overview 
This chapter presents descriptive analyses of data from NHS Brent on 
adverse events that were captured in a computerised medical system. The 
analyses offer insights into data recording at the local level, the types of 
events that are recorded and highlight some of the limitations of using 
relatively small datasets to detect potentially harmful incidents. 
 
5.2 Local data 
Use of population-level databases for performance monitoring, service planning and 
resource allocation, payment, and to some extent for research, is well established in 
primary care.279 Much of the available data is routinely collected, including General Medical 
Services (GMS) data, Prescribing Analysis and Cost (PACT) data and the raw data entered 
onto computer systems at individual GP practices. Novel methods of monitoring AEs can be 
developed from the data-rich environment of general practice. Before sophisticated data-
driven safety tools can be built, the scope of recorded AEs has to be examined. With this 
rationale in mind, I conducted descriptive analyses to determine the types and frequencies 
of AEs recorded in routinely collected data from a London PCT. 
5.2.1 The Borough of Brent 
Brent, in north-west London, is served by NHS Brent (formerly Brent Teaching Primary Care 
Trust). In the 2008/09 financial year, the PCT received £432 million in funding from the 
government, of which £61 million was allocated to primary care services including 31 
community services.187 A further £39 million was spent on drugs prescribed in general 
practice.187  
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Brent is the most ethnically and culturally diverse Borough in London. Over half of the 
263,500 residents (55%) are from black and minority ethnic groups.280 According to the 2001 
Census, 36% of Brent residents were born outside of the UK.280 Approximately 35.5% of all 
Brent residents are aged between 25 and 44 years and half of its residents from ethnic 
minority groups are under 30 years of age.280,281 Compared to national rates, Brent has a 
greater proportion of unemployed residents (4.98% versus 3.35%) and single parent 
households (8.19% versus 6.42%).281 Approximately 32.4% of households in Brent have at 
least one person with a limiting long term illness.281 By considering the demography of its 
population, one can then begin to consider the health challenges facing Brent. 
5.2.2 Definition of adverse event 
Consistently applied definitions will facilitate the design of, and comparison with, future 
studies. In the first chapter, I characterised “medical error”, “adverse event” and “patient 
harm” (Chapter 1 section 1.2.3). I now revisit these definitions specifically for this chapter. 
In the following analyses, AEs are defined as temporary or permanent injuries caused by 
medical management and are not due to underlying disease nor are expected outcomes of 
treatment.24,282,283 AEs can be caused by medical errors arising from actions or omissions 
that are unanticipated, unintended and should not reoccur.9 To demonstrate, imagine the 
scenario where a GP fails to prescribe appropriately by co-prescribing a potassium-sparing 
diuretic and an angiotensin-converting enzyme (ACE) inhibitor to a patient without valid 
indication.51 As a result of adhering to this prescription, the patient develops hyperkalaemia 
and requires admission to hospital.51 
5.2.3 Objectives of the analyses 
To achieve the study aim stated at the end of Chapter 1, the analyses in this chapter were 
intended to: 
 Determine the types of AEs that are identified by designated Read codes for 
complications of care and are recorded electronically at GP practices in Brent that 
participated in the Clinical Information Management System (CIMS) project.  
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Determine the rates of AEs that are identified by designated Read codes for 
complications of care and are recorded electronically at GP practices in Brent that 
participated in the Clinical Information Management System (CIMS) project. 
5.3 Methods 
The dataset analysed has been described in Chapter 3 section 3.5.  
5.3.1 Data extraction 
AEs that may be attributable to medical care were identified through the Clinical Terms 
stored in the electronic CIMS. Valid AEs (as defined in section 5.2.2) were mapped to the 
following Read Code chapters: 
 “Injury and Poisoning” (Chapter S); 
 “Causes of injury and poisoning” (Chapter T); and  
 “External causes of morbidity and mortality” (Chapter U).284  
A full list of the Read Codes used in the analysis is shown in Table A.9. The Clinical 
Terminology Browser Version 1.04 was used to identify the appropriate codes to be applied 
in the data extraction and analysis.284 Where ethnicity was analysed, categories from the 
2001 Census were applied.199  
5.4 Results 
Before presenting the estimated rate of AEs, I describe the demography of the study sample. 
5.4.1 Patient characteristics 
Data were available from 25 practices out of the 26 GP practices participating in CIMS. 
Records were available for 73.7% of registered patients at the 25 practices 
(n=78,027/105,877). After cleaning of duplicate or missing data, 81.6% of the original 
consultation records remained valid (n=1,118,072/1,370,659). The average age of patients 
was 37 years (n=78,027), ranging from under 1 year to 104 years. Across the six age groups, 
the largest proportion of patients were aged between 25 and 44 years (38.6%; n=78,027) 
(Figure 5.1).  
Chapter 5: Adverse events recorded in local data | 104 
 
Figure 5.1 Population distribution of Brent CIMS dataset, n=78,027 
 
 
The sample contained slightly more male patients (52.1%; n=40,675/78,027) than female 
patients. Ethnicity was recorded for 43.1% of patients (n=33,649/78,027) and available for 
619,992 consultations (Table 5.1). Approximately half of patients with recorded ethnicity 
were of Asian ethnicity (n=17,111/33,649). 
Table 5.1 Age, sex and ethnicity of patients in the Brent CIMS dataset, n=33,649 
  Ethnicity* 
White Black Asian Other Mixed NOS† 
Sex Male 3999 1826 8914 754 551 152 
 Female 5002 2482 8197 910 690 172 
Age group (years) 0-15  731 605 2387 144 143 78 
 16-24  1063 453 2043 327 159 48 
 25-44  3174 1487 6775 717 470 138 
 45-64  1993 983 4078 310 264 32 
 65-84  1719 762 1729 145 200 24 
 ≥85 321 18 99 21 5   4 
 
                                                     
*
Missing ethnicity data for 44,378 patients.  
†
Not otherwise specified. 
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Patients of white ethnicity tended to be older than patients of other ethnicities, with an 
average age of 44 years (n=9,001/33,649; range from under 1 year to 104 years). In contrast, 
patients of Asian ethnicity had an average age of 37 years (n=17,111/33,649; range from 
under 1 year to 102 years). Patients of “Other” ethnicities tended to be youngest out of all 
patients with known ethnicity, with an average age of 36 years (n=1,664/33,649; range from 
under 1 year to 96 years).  
5.4.2 Data representativeness 
The representativeness of CIMS data to the Brent population was assessed using data from 
the 2001 Census for the Borough of Brent, London and England on age, sex and ethnicity. 
For the first comparison variable of age, compared to the rest of England, Brent has a 
relatively young population with 33.3% of the Borough’s residents being aged 24 years or 
under (n=87,749).281 In the study sample, 27.8% of patients were in the same age group 
(n=21,660) (Figure 5.2). There was a greater proportion of people aged between 25 and 64 
years in the study sample (60.6%; n=47,266) compared to the official estimates for Brent 
(55.2%; n=145,478).281 In terms of the older population, there was little difference in the 
proportion of people aged 65 years and older recorded in the 2001 Census and the CIMS 
dataset (11.5%; n=30,237 compared to 11.7%; n=9,101, respectively).281 
Figure 5.2 Representativeness of sample by age group, compared to the Borough of Brent, 
London and England 
 






















Age group (years) 
Brent CIMS Borough of Brent London England
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On the second of the three comparison markers (Figure 5.3), compared to the Borough of 
Brent (48.5%), London (48.4%) and England (48.7%), there was a greater proportion of male 
patients in the Brent CIMS dataset (52.1%; n=78,027).281  
Figure 5.3 Representativeness of sample by sex, compared to the Borough of Brent, London 
and England 
 
Source: Office of National Statistics.281 
 
For the final comparison by ethnicity (Figure 5.4), compared to the Borough of Brent 
(27.7%), London (12.1%) and England (4.6%), the proportion of Asian patients in the Brent 
CIMS dataset was greatest (51.3%; n=33,325).281 Although less of a marked increase, the 
proportion of patients classed as being of “Other” ethnicity was also greater in the CIMS 
dataset (5%; n=33,325) compared to the other datasets. Conversely as depicted in Figure 
5.4, the proportion of patients of white ethnicity in the CIMS is considerably smaller (27.0%; 
n=33,325) than in the Borough of Brent (45.3%), London (71.2%) and England (90.9%).281 
The proportion of patients of black ethnicity in the CIMS dataset (12.9%; n=33,325) was 
smaller than recorded for the Borough of Brent (19.9%), but larger than for London (10.9%) 
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Figure 5.4 Representativeness of sample by ethnicity, compared to the Borough of Brent, 
London and England* 
 
Source: Office of National Statistics.281 
 
5.4.3 Complications of care  
Overall, a rate of 1.67 AEs per 1,000 consultations was recorded among patients in Brent 
(n=1,118,072; 95% CI 1.59-1.74). There was wide variation in the number of cases of AEs at 
the 23 GP practices with recorded AEs, ranging from 0.28 AEs per 1,000 consultations to 
2.74 AEs per 1,000 consultations. 
The rate of recorded complications related to surgery in the CIMS dataset was 0.44 cases of 
complications per 1,000 consultations (n=1,118,072; 95% CI 0.41-0.47). Female patients 
experienced more complications (59.9%), with 38.3% of complications recorded in women 
aged between 25 years and 64 years (n=188/491). Patients aged 15 years or less (3.26%) 
and those aged 85 years or older (4.28%) were least likely to have a surgical complication. 
                                                     
*
Data for the “Not otherwise specified” (NOS) ethnicity category were not available in the comparison datasets 
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In 77.0% of surgical complications, the cause was “Other procedure complications not 
elsewhere classified” (n=378/491). Nearly two thirds of complications in this category 
occurred in female patients (n=235/378; 62.2%). Four out of five of the most common 
surgical complications fell into the “Other procedure complications not elsewhere classified” 
category (Table 5.2). The exception was mechanical complications, which falls into the 
category of “Complications of certain procedures”. Where ethnicity was indicated, 
complications were most frequently recorded in patients of Asian (n=107/262) and white 
(n=101/262) ethnicities. 
Table 5.2 The five most frequently recorded surgical complications (rate per 1,000 
consultations), n=409/491 
Type of surgical complication Cases, n Rate 
Postoperative infection (includes wound infections) 285 0.25 
Other procedure complication NEC* 48 0.04 
Mechanical complications 43 0.04 
Operation wound disruption 19 0.02 
Peri-operative haemorrhage or haematoma 14 0.01 
 
5.4.4 Medical accidents 
Few accidents occurring during medical or surgical care were recorded in the CIMS dataset. 
There was a rate of 0.05 medical accidents per 1,000 consultations (n=1,118,072; 95% CI 
0.04-0.06). A greater proportion of medical accidents were recorded in male patients (61.8%; 
n=34/55). By age group, more medical accidents occurred in patients aged between 45 
years and 64 years (30.9%; n=17/55). The most common type of recorded medical accident 
was accidental cut, puncture, perforation or haemorrhage during medical care (n=49/55). In 
60.7% of cases, the patient was of Asian ethnicity (n=17/28).  
5.4.5 Adverse drug events 
The rate of adverse drug events (ADEs) was 1.18 per 1,000 consultations (n=1,118,072; 95% 
CI 1.11-1.24). Among the 23 practices where patients had recorded ADEs, there were 2 or 
                                                     
*
Not elsewhere classified. Includes surgical emphysema, failed intubation and postoperative pain. 
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fewer cases of ADEs per 1,000 consultations. The rate ranged between 0.10 ADEs per 1,000 
consultations to 2.32 ADEs per 1,000 consultations in the 23 practices. 
Looking at events corresponding to Read Chapter T (“Causes of injury and poisoning”) codes, 
the rate of adverse drug reactions (ADRs) was 0.76 per 1,000 consultations (n=1,118,072; 95% 
CI 0.74-0.79). The results in Table 5.3 show that over half of the drug-related events 
recorded with Read Chapter T codes occurred in female patients (57.2%; n=487/851). In 
contrast, the number of drug-related events recorded with Read Chapter U (“External 
causes of morbidity and mortality”) codes was similar among male and female patients 
(52.1%; n=243/467). For events recorded with codes from either Read Chapter, the most 
events were recorded in patients aged between 65 and 84 years (Table 5.3). I will return to 
the results by Read Chapter U in a later sub-section of this chapter, section 5.4.6. 
Table 5.3 Cases of adverse drug events by age and sex, n=1,317 
Characteristic 
Read Chapter T Read Chapter U 
Brent pop. size280,281 
n (%) n (%) 
Sex Female 487 57.2 223 47.9 135,658 
Male 364 42.8 243 52.1 127,806 
Age group (years) 0-15  55 6.5 12 2.6 52,169 
16-24  42 4.9 <5 - 35,580 
25-44  167 19.6 48 10.3 93,601 
45-64  236 27.7 168 36.1 51,877 
65-84  315 37.0 220 47.2 26,828 
≥85 36 4.2 15 3.2 3,409 
 
5.4.5.1 Events by drug categories 
Data on ADRs corresponding to Read Chapter T codes were mapped to categories from the 
British National Formulary (BNF). These categories are based on the systems of the body 
and elements of medical care (Table 5.4).285 No drug name was available in 106 cases of 
adverse reactions. Drugs used to treat infections were most frequently associated with 
ADRs and include those from the penicillin family, which accounted for 22.4% of recorded 
ADRs (n=191/851). Systemic antibiotics, drugs primarily affecting the autonomic nervous 
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system and those that affect the cardiovascular system were among the medications most 
commonly recorded as causing adverse reactions (Table 5.4). 
Table 5.4 Adverse drug reactions by British National Formulary body system category (rate per 
1,000 consultations), n=851  
Body system category Cases, n Rate 
Infections 311 0.28 
Cardiovascular system 226 0.20 
Central nervous system 124 0.11 
General (including ADRs NOS and diagnostic agents/kits)* 108 0.10 
Immunological products and vaccines 40 0.04 
Other† 30 0.01 
Endocrine system 12 0.03 
 
5.4.5.2 Adverse drug events by age 
In patients aged under 16 years, antibiotics were the predominant cause of ADRs (n=38/55). 
Amoxicillin (n=17) and penicillin (n=13) were the two most frequently identified types of 
antibiotics. Vaccines were also frequently associated with ADRs (n=12/55). Likewise, 
antibiotics were associated with 66.7% of drug-related events in young adults aged between 
16 and 24 years (n=28/42). Antibiotics were also a common cause of recorded ADRs in 
patients aged between 25 and 44 years, accounting for 47.9% of adverse reactions 
(n=80/167). In 11.4% of ADRs occurring in patients in this age group, no named drug was 
associated with the event (n=19/167).  
Among adults aged between 45 and 64 years, 30.9% of ADRs were caused by antibiotics 
(n=73/236), while statins (n=27) and beta-blockers (n=25) also frequently caused adverse 
effects. Of all drug types, patients aged 65 to 84 years were most likely to experience 
adverse effects from antibiotics (n=91/315). In another 14.9% of cases, reactions not 
otherwise specified were responsible (n=47/315), with statins contributing to a further 12.4% 
of ADRs in this age group. In older patients aged 85 years and older, 22.2% of adverse 
                                                     
*
NOS –Not otherwise specified. 
†
Includes anaesthesia; eye, ear, nose, and oropharynx, and skin; gastro-intestinal system; malignant disease 
and immunosuppression; musculoskeletal and joint diseases; nutrition and blood; obstetrics, gynaecology, and 
urinary-tract disorders; respiratory system. 
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reactions were attributed to antibiotics (n=8/36) and the same number of events was 
caused by drugs without a specified name.  
5.4.6 External causes of morbidity and mortality 
Chapter U was introduced to the 5-byte (version 2) Read codes following the addition of 
“Chapter XX External causes of morbidity” to the ICD-10.286,287 The new Chapter U is an 
updated version of Read Chapter T – “Causes of injury and poisoning”.287 There were 467 
drug or associated substance-related complications of care recorded with Chapter U codes 
(Table 5.5). The fewer events identified by codes from this newer Read chapter compared to 
Chapter T codes may be due to its relatively recent addition to the Read coding system. 
Table 5.5 The five most frequently recorded types of drug associated with complications of care 
mapped to Read Chapter U codes (rate per 1,000 consultations), n=400/467  
Type of drug Cases, n Rate 
Angiotensin-converting-enzyme (ACE) inhibitors 238 0.21 
Angiotensin II receptor antagonists (ARBs) 110 0.10 
Antibiotics 25 0.02 
Statins 19 0.02 
Calcium-channel blockers 16 0.01 
 
Nearly half of ADR cases identified by Read Chapter U codes occurred in patients aged 
between 65 and 84 years (47.2%; n=467). Few cases were recorded in patients aged under 
25 years (n=15). Out of all the events identified with Chapter U codes, one case was not a 
drug-related event but involved ophthalmic diagnostic and monitoring devices. Overall, the 
most common type of drug associated with recorded adverse effects was ACE inhibitors, 
accounting for 51.0% of all drug-related events with Read Chapter U codes (n=467) (Table 
5.5). Where ethnicity was recorded, 45.7% of complications related to drugs or biological 
substances occurred in patients of Asian ethnicity (n=370). 
5.4.7 Other incidents of patient harm 
There was a rate of 0.35 “other” (not otherwise stated) AEs per 1,000 consultations 
(n=1,118,072; 95% CI 0.32-0.38). These events were more common among female patients 
(61.7%; n=243/394) and nearly half of all recorded cases were in patients aged between 25 
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and 44 years (47.7%; n=394). There were 221 cases of suicide and intentional self-harm in 
the CIMS dataset and 162 cases of self-poisoning. Less than 3% of “other AEs” were coded 
as other types of external causes of morbidity and mortality, including 9 cases relating to 
injury by MRI contrast media.  
5.5 Discussion 
This study examined AEs recorded using Read codes in English general practice, from a small 
dataset from a PCT. There were low rates of undesirable events, with adverse effects of 
drugs being the most common type of recorded incident. Other types of AEs that were 
detected included medical and surgical complications and acts of self-harm and suicidal 
intent. Some of these events are likely to indicate episodes of patient harm that occurred in 
secondary care but were either not detected in that care setting or did not manifest before 
discharge from hospital.155  
5.5.1 Evidence on drug-related events 
A relatively high number of drug-related events were recorded in patients aged 65 years and 
older. Other studies conducted in the UK and the US have found similar results.173,179 My 
analyses indicate that drugs with long established clinical usage often cause adverse effects, 
echoing the findings Pirmohamed et al and Budnitz et al.176,179 Furthermore, I found that 
8.96% of patient records where an ADR was noted did not contain information about the 
drug category or drug name. 
5.5.2 Study strengths and limitations 
Studies on AEs in English general practice have typically focused on measuring drug-related 
morbidity and mortality. In this study, I attempted to capture a broader sense of potential 
patient harm, regardless of whether the incident was drug-related or not. This inclusive 
approach was reflected in the selection of AEs based on the presence of a corresponding 
Read code for an iatrogenic event.  
These analyses were of a preliminary and descriptive nature, using diagnoses mapped to 
only three chapters of the Read system. Although there is an extensive range of clinical 
practice terms in the system, the Read codes are arranged within a rigid coding hierarchy. 
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Consequently, it is possible that events without a designated AE code but nonetheless 
eligible for inclusion in this study may have been missed. As outlined in Chapter 3, there was 
limited clinical detail contained in the dataset from NHS Brent. One example of its restrictive 
nature was the lack of information about patients’ treatments and their diseases and 
conditions. Due to this, it was not possible to adjust for potential confounders such as 
comorbidities, disease severity and polypharmacy, nor evaluate the preventability of 
recorded events.  
5.5.3 Implications for further analyses 
The analyses of data from one computer system at one PCT have highlighted elements of 
data management that are crucial for successful monitoring of patient harm. No single 
method of safety measurement is adequate.7,173,288,289 The results of this study suggest that 
routinely collected data from general practice may be suitable to flag up unusual patterns in 
patient outcomes. Given the low number of events detected at the local level, attention 
should also be turned into using data collected nationally on a routine basis to develop 
safety surveillance tools for general practice. 
5.6 Conclusions 
In this chapter, I have described the types of AEs recorded in routinely collected, electronic 
general practice data. These events include incidents following procedures or surgeries and 
adverse drug reactions. The quality of data within general practice information systems is 
relatively good compared to other care settings. This is largely due to collection of these 
data for quality monitoring and performance-based financial incentives. Even so, early 
detection and screening systems for patient harm that rely solely on these data can only 
identify potential medical errors and AEs. In order to improve the clinical value of AE 
measurement in general practice and elsewhere in primary care, multiple data sources 
should be used. 
  
 Chapter 6: Adverse events recorded in national data | 114 
 
 
Chapter 6: Adverse events recorded in national data 
 
6.1 Chapter overview 
In Chapter 5, I explored the epidemiology of adverse events recorded at the 
local level. This chapter quantifies and describes the nature and extent of 
adverse events in general practice at the national level, using GPRD data. 
Analyses extend to a comparison of local and national estimated rates of 
adverse events. The chapter ends with a discussion on the suitability of 
GPRD data for this type of research and the comorbidity measures applied. 
 
6.2 Rationale 
When considering the epidemiology of recorded adverse events (AEs) and the potential for 
routinely collected data to be used in patient safety surveillance, it is logical to firstly 
consider the role of existing data. The use of available data sources for quality measurement 
may be preferable to develop new datasets in times of financial restraints.165 As there are 
designated diagnosis codes for AEs in secondary care (ICD 10 codes) and primary care (Read 
codes), it would be prudent to explore how well these codes are populated and to describe 
the AEs that they correspond to. 
Studies often use data from one care setting and from few sources, which may under-
estimate the true rate of patient harm.173,290,291 A review of the literature (Chapter 2) found 
that research on AEs was focused on drug-related events, relied on data routinely collected 
in hospitals and was under-representative of primary care in England. The range of patient 
outcome measured in these studies is limited, typically focusing on admissions (including 
length of hospital stay and high dependency care), readmissions and mortality. It is 
therefore important to incorporate data from multiple sources and care settings to form a 
more complete understanding of AEs occurring in non-acute care. 
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6.2.1 Definition of outcomes 
An operational definition of “adverse event” was provided in the previous chapter (Chapter 
5 section 5.2.2). Emergency admission was defined in Chapter 3 section 3.9.3 and deaths 
were described in Chapter 3 section 3.7.11. 
6.2.2 Aims and objectives 
From the published literature and analyses presented in Chapter 5, one might expect that 
certain patient groups experience more AEs, including older patients, ethnic minority groups 
and patients with more complex care needs.91,292,293 However, the relationships between 
other characteristics, such as the level of continuity of care received by a patient, and 
patient harm are less established.235,294  
6.2.2.1 Aims of analysis 
With gaps in knowledge about risk factors for AEs in general practice, this study was 
intended to quantify the rate of AEs recorded in the English general practice care setting. 
The second aim was to identify predictors for patient harm recorded in routinely collected 
electronic data. The third aim was to explore the outcomes of patients who experience 
recorded safety incidents.  
6.2.2.2 Objectives of analysis 
The following objectives were set to meet the three aims of this study: 
1. Measure the incidence of adverse events (AEs) in the English general practice 
population, identified by diagnosis codes designated for complications of care in the 
Read classification system (Read chapters S, T and U). 
2. Identify patient risk factors associated with recorded AEs in the English general 
practice population, identified by Read codes for complications of care. 
3. Explore the health service use of patients with recorded adverse events in the 
English general practice population, identified by Read codes for complications of 
care. 
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4. Explore the outcomes (emergency admissions and death) of patients with recorded 
AEs in the English general practice population, identified by Read codes for 
complications of care. 
6.3 Methods 
6.3.1 Study design 
This study was cross-sectional in design. The analyses were hypothesis generating, intended 
to assess the suitability of routinely collected data for measuring AEs in general practice.  
6.3.2 Data extraction 
The method of extracting records of interest from the GPRD dataset has been stated in 
Chapter 4 and the same process as set out in Chapter 5 was used to identify AEs. In short, 
diagnosis codes were extracted from three Read Code chapters that describe external 
causes of injury and poisoning and include diagnosis codes for complications of medical and 
surgical care. The Read chapters were: 
  “Injury and Poisoning” (Chapter S); 
 “Causes of injury and poisoning” (Chapter T); and  
 “External causes of morbidity and mortality” (Chapter U).284  
6.3.3 Cleaning of adverse event records 
Exclusion criteria were implemented to improve the accuracy of estimating the incidence of 
AEs. These criteria are explained in the following three sub-sections. 
6.3.3.1 Ordering by first consultation 
Recorded AEs were only study-valid if they occurred after the first consultation of the 
patient’s first registration period with the current GP practice. This criterion was also 
applied to patient outcomes of emergency admission and death (outcomes were valid only 
if they occurred after the first consultation). This rule reduced the likelihood of capturing 
events and outcomes attributable to care other than at the current GP practice. 
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6.3.3.2 Multiple code entries 
Only the first occurrence of a Read code for an AE per consultation record was included in 
the study. Subsequent recordings of identical read codes during the same consultation were 
excluded as these codes may be due to data entry errors, and would not contribute new 
information to the study. Where there were multiple different Read codes for complications 
of care for a single consultation, further investigation was carried out to determine the 
validity of these codes. Read terms and classifications were used to guide this process. In all 
detected cases, multiple Read codes were associated with the same AE and so these records 
were processed as one AE per consultation. 
The date associated with the AE (event date) was the same as the consultation date in the 
majority of cases. A minority of events occurred before the date of the consultation 
associated with the AE. For these cases, data cleaning excluded the following events: 
 Records of allergy/intolerance but without an associated consultation date. 
 Records of allergy/intolerance and linked to a previous consultation that occurred 
more than one year ago but without supporting AE codes. 
 Linkage to a previous consultation that occurred up to one year ago, not recorded in 
the "medical history" section and not a surgical AE. 
6.3.3.3 Lag time 
When looking at repeated events, a patient's risk period can be defined as either discrete 
(new event cannot occur until previous event has ended) or continuous. The latter type of 
risk period may be more realistic, in that patients can experience multiple AEs during the 
same time period. No guidance was available in the literature on defining a suitable 
"washout" period for measuring AEs in the non-acute setting. Therefore, to distinguish 
between new events and existing recorded events for an individual patient, an arbitrary 
time interval was applied whereby events occurring less than 30 days apart were considered 
to be related. In this scenario, only the index event was eligible for inclusion in analyses.  
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6.3.4 Statistical method 
Related to lag time, valid repeated (multiple) events at patient and practice levels will 
influence the statistical approach used. To take into account the potential clustering of AEs 
(outcome of interest) by patient, a continuous version of the outcome variable was used in 
the form of the rate of events (per person). Clustering of patients at practices was managed 
by applying the Generalized Estimating Equation (GEE) method. As explained in Chapter 4 
section 4.5, the log transformation of patients’ follow-up time was included as an offset 
term in the regression models for predicting the risks of having an AE and emergency 
admission. Further details of GEE and the statistics for this chapter are provided in Chapter 4.  
6.4 Results 
In this section, I present the estimated rates of AEs and then crude and adjusted results by 
type of outcome (AEs, admissions and then death). The patterns of service use in patients 
who had at least one AE are also described. 
6.4.1 Incidence of adverse events 
There were 2,048 AEs (1,817 AE codes) recorded in 1,774 patients at 387 GP practices 
between 1999 and 2008. Thus, 2.37% of the study population experienced at least one AE 
during the study period (n=74,763). Table 6.1 shows that the most AEs experienced by a 
patient during the study period was 9 events (n=1 patient). Less than an eighth of patients 
who had an AE experienced more than one AE (12.3%; n=218/1,774). In all except 30 cases 
of AEs, the event was recorded on the same day as the consultation. 
Table 6.1 Number of adverse events per patient, n=74,763 
Adverse events, n Patients, n (%) 
0 72989 (97.6) 
1 1556 (2.08) 
2 184 (0.25) 
3 26 (0.03) 
4 1 (<0.01) 
5 2 (<0.01) 
6 4 (0.01) 
9 1 (<0.01) 
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Patients were followed up for 341,261 person-years. The average follow-up time for all 
patients in the study sample was 7 (SD 3.51) years, compared to 5 (SD 2.87) years for 
patients who had at least one AE, p<0.001 (Table 6.2). 
Table 6.2 Follow-up time of patients, n=74,763 
Follow-up time (years) 
Patients, n 
RRs (95% CI) P-value 
All ≥1 adverse event (%) 
<1 5628 196 (3.48) 3.94 (3.24-4.78) <.001 
1-3 16227 542 (3.34) 3.27 (2.81-3.81) <.001 
4-6 12186 550 (4.51) 4.21 (3.66-4.85) <.001 
7-10 40722 486 (1.19) 1  
 
The overall incidence was 6.0 AEs per 1,000 person-years (95% CI 5.74-6.27). The rate of AEs 
increased over the study period (Figure 6.1). The lowest incidence of AEs was in the first 
year of the study, 1999, when there were 3.79 events per 1,000 person-years (95% CI 3.05-
4.66). The highest rate was in 2007, when there were 7.60 events per 1,000 person-years 
(95% CI 6.77-8.51). 
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Over the ten years of the study, the rate of AEs was lower in male patients who had an 
overall rate of 5.54 events per 1,000 person-years (n=854/2,048; 95% CI 5.18-5.93) 
compared to 6.38 events per 1,000 person-years in female patients (n=1194/2,048; 95% CI 
6.02-6.75). In male patients, the incidence ranged from 2.98 events per 1,000 person-years 
(95% CI 2.04-4.21) in 1999 to 7.13 events per 1,000 person-years (95% CI 5.96-8.47) in 2007. 
In female patients, the lowest rate was 4.46 events per 1,000 person-years (95% CI 3.39-
5.76) in 1999 while the highest rate was 8.0 events per 1,000 person-years (95% CI 6.85-9.28) 
in 2007.  
The demography of patients who had at least one AE was compared with the overall 
population by age and sex, using data for 2004 as a proxy for the middle year of the study. 
There were proportionally fewer younger patients who had AEs compared to their 
representation in the overall population, especially for patients aged less than 15 years at 
entry to the study (Figure 6.2). The opposite was true for the oldest patients, who were 
over-represented in the proportion of patients who experienced at least one AE. Over a 
quarter of AEs (26.5%) occurred in female adults aged between 65 and 84 years 
(n=3,341/37,816). The fewest events were recorded in female children aged from under one 
year to 14 years (1.15%; n=3,250/37,816). 
Figure 6.2 Age and sex of all patients compared to patients with at least one adverse event, 
2004 
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Overall, the highest rate of events occurred in the oldest patients (aged 85 years and over), 
who experienced 18.8 events per 1,000 person-years (95% CI 16.0-21.9) (Table 6.3).  
Table 6.3 Incidence rate of adverse events by age group (rate per 1,000 person-years), n=2,048 
events 
Age group (years) Adverse events, n Person time (years) Rate (95% CI) 
0-14 76 60277 1.26 (0.99-1.58) 
15-44 526 132270 3.98 (3.64-4.33) 
45-64 543 86666 6.27 (5.75-6.82) 
65-84 742 53474 13.9 (12.9-14.9) 
≥85 161 8575 18.8 (16.0-21.9) 
 
There were notable fluctuations in the rate of AEs by age groups over the study period. 
Marked variation in the incidence rate was seen in older patients, especially in adults aged 
85 years or older in whom the rate of events ranged from 9.21 events per 1,000 person-
years (95% CI 3.70-19.0) in 2001 to 31.7 events per 1,000 person-years (95% CI 21.9-44.3) in 
2007. A rise in new cases of recorded AEs was also seen in patients aged between 65 and 84 
years over the ten years studied. In patients of this age group, the lowest rate was 6.86 
events per 1,000 person-years (95% CI 4.40-10.2) in 1999 and increased to 21.3 events per 
1,000 person-years (95% CI 17.8-25.2) in 2007 (Figure 6.3).  
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Figure 6.3 Incidence rate of adverse events by age group and year (per 1,000 person-years) 
  
 
6.4.2 Incidence rate by practice 
On average, there were 164 (SD 84.3) patients per practice included in the study, ranging 
from 19 to 595 patients per practice (n=457 practices). The majority of practices (84.9%) had 
registered patients with at least one recorded AE during the study period. On average, these 
practices had 4 (SD 3.94) patients who had one or more events, ranging from 1 to 30 
patients per practice (n=388 practices). Exploring the rate of AEs by practice, five practices 
were above the 99.8% control limit indicating that these practices had more cases of AEs 
than would be expected given the total number of registered patients at those practices, 
after adjustment for age and sex of the practice population. There were 61 practices that 
fell below the 99.8% limit, indicating that these practices had fewer cases of AEs than would 
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Figure 6.4 Incidence rate of adverse events, indirectly standardised by age group and sex, 1999-
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6.4.3 Risk factors for adverse events 
6.4.3.1 Crude associations with adverse events 
In crude calculations, all variables were significant at the 95% level except for deprivation, 
mild liver disease and consultation within 30 days after hospital discharge (Table 6.4). There 
were no patients in the sample with recorded Auto-Immune Deficiency Disease (AIDs) so 
this variable was excluded from further analyses and will not be reported hereafter. P-
values for the calculations in this section are p<0.0001 unless reported otherwise. 
Patients who were most at risk of having an AE were those aged 65 to 84 years old when 
they entered the study (RR 11.9, 95% CI 9.90-14.3), female (RR 1.31, 95% CI 1.20-1.43), 
married (RR 3.06, 95% CI 2.34-3.99), registered at practices in the North West (RR 1.46, 95% 
CI 1.05-2.04; p=0.026) or the South East Coast regions (RR 1.45, 95% CI 1.04-2.04; p=0.030). 
Patients who were registered at their practice for the longest periods of time (RR 1.36, 95% 
CI 1.18-1.57), with the highest continuity of care scores (RR 7.27, 95% CI 4.66-11.3) or a high 
number of consultations at the GP practice, by telephone or home visit (RR 7.79, 95% CI 
6.39-9.49) were also at greater risk of having an AE. Patients of unknown ethnicity were 
statistically least at risk of having an AE compared to patients of known ethnicity (RR 0.56, 
95% CI 0.34-0.90; p=0.016).  
An elevated comorbidity status (measured by the Charlson Index score) also raised the risk 
of having an AE, albeit a small increase (RR 1.05, 95% CI 1.05-1.06). High resource users, 
defined by the Resource Utilization Band (RUB) score, were most at risk of an AE (RR 54.1, 
95% CI 17.4-168). Further results by comorbidities can be found in the Appendices (Table 
A.10).  
Patients who had a consultation within 30 days after a referral request (RR 1.98, 95% CI 
1.60-2.45) or a consultation within 30 days of hospital discharge (RR 4.23, 95% CI 1.06-16.9; 
p=0.041) were at greater risk of an AE. There was a positive linear relationship between the 
number of admissions that patients had during the study period and their risk of having an 
AE; patients who had 5 or more admissions were most at risk of an AE (RR 5.17, 95% CI 4.61-
5.79). 
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Table 6.4 Risk factors for reported adverse events, crude results from Poisson regression using 
the generalized estimating equations (GEE) method 
Characteristic 
Patients, n 
RR (95% CI) P-value All ≥1 adverse 
event 
(%) 
Age group at study start (years)     <0.0001 
 0-14 20952 131 (0.63) 1  
15-44 32176 542 (1.68) 2.58 (2.14-3.11) <0.0001 
45-64 13582 547 (4.03) 5.36 (4.45-6.45) <0.0001 
65-84 7149 525 (7.34) 11.9 (9.90-14.3) <0.0001 
≥85 904 29 (3.21) 7.95 (5.50-11.5) <0.0001 
Sex     <0.0001 
 Male 36089 743 (2.06) 1  
Female 38674 1031 (2.67) 1.31 (1.20-1.43) <0.0001 
Ethnicity     <0.0001 
 Asian 585 15 (2.56) 1  
Black 441 15 (3.40) 1.26 (0.63-2.49) 0.514 
Mixed 148 4 (2.70) 1.34 (0.49-3.63) 0.567 
White 15909 688 (4.32) 1.26 (0.78-2.03) 0.350 
Other 355 8 (2.25) 0.69 (0.30-1.59) 0.380 
Unknown 57325 1044 (1.82) 0.56 (0.34-0.90) 0.016 
Marital status     <0.0001 
 Single 5019 61 (1.22) 1  
Married 7082 282 (3.98) 3.06 (2.34-3.99) <0.0001 
Other status 1359 50 (3.68) 3.7 (2.62-5.23) <0.0001 
Unknown 61303 1381 (2.25) 1.94 (1.51-2.48) <0.0001 
Deprivation     0.174 
 Least deprived 41787 933 (2.23) 1  
Quintiles 2,3,4 19482 502 (2.58) 1.09 (0.99-1.21) 0.083 
Most deprived 6954 178 (2.56) 1.09 (0.94-1.26) 0.278 
Unknown 6540 161 (2.46) 1.14 (0.98-1.33) 0.099 
Practice region     <0.0001 
 East Midlands 1491 30 (2.01) 1  
East of England 10765 288 (2.68) 1.28 (0.92-1.79) 0.139 
London 4215 114 (2.70) 1.35 (0.95-1.92) 0.098 
North East 3526 98 (2.78) 1.27 (0.89-1.83) 0.192 
North West 8079 248 (3.07) 1.46 (1.05-2.04) 0.026 
South Central 9122 212 (2.32) 1.08 (0.77-1.52) 0.655 
South East Coast 7493 219 (2.92) 1.45 (1.04-2.04) 0.030 
South West 9830 200 (2.03) 1.04 (0.74-1.46) 0.817 
West Midlands 11988 177 (1.48) 0.82 (0.58-1.15) 0.243 
Yorkshire & The Humber 8254 188 (2.28) 1.16 (0.82-1.62) 0.405 
Length at practice (years)     <0.0001 
 Low 24925 209 (0.84) 1  
Moderate 24918 565 (2.27) 0.83 (0.72-0.97) 0.017 
High 24920 1000 (4.01) 1.36 (1.18-1.57) <0.0001 
Continuity of care     <0.0001 
 Low 9572 19 (0.20) 1  
Moderate 21711 522 (2.40) 5.67 (3.63-8.86) <0.0001 
High 21678 687 (3.17) 7.27 (4.66-11.3) <0.0001 
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Not valid 21802 546 (2.50) 6.6 (4.23-10.3) <0.0001 
Number of all consultations     <0.0001 
 Low 25051 51 (0.20) 1  
Moderate 24944 318 (1.27) 4.01 (2.99-5.38) <0.0001 
High 24768 1405 (5.67) 15.8 (12.0-20.0) <0.0001 
Consultation
*
     <0.0001 
 No 4465 12 (0.27) 1  
Yes 70298 1762 (2.51) 4.53 (2.63-7.81) <0.0001 
Number of consultations
†
     <0.0001 
 Low 25709 98 (0.38) 1  
Moderate 24064 316 (1.31) 2.1 (1.69-2.62) <0.0001 
High 24990 1360 (5.44) 7.79 (6.39-9.49) <0.0001 
Referral     0.011 
 No 69907 1595 (2.28) 1  
Yes 4856 179 (3.69) 1.21 (1.05-1.40) 0.009 
Number of referrals     0.013 
 0 69907 1595 (2.28) 1  
1 2942 103 (3.50) 1.11 (0.91-1.34) 0.305 
≥2 1914 76 (3.97) 1.37 (1.11-1.68) 0.003 
Referral ≤30 days before next consultation     <0.0001 
 No 73391 1697 (2.31) 1  
Yes 1372 77 (5.61) 1.98 (1.60-2.45) <0.0001 
Admission     <0.0001 
 No 58153 935 (1.61) 1  
Yes 16610 839 (5.05) 2.49 (2.28-2.71) <0.0001 
Number of admissions     <0.0001 
 0 58153 935 (1.61) 1  
1 6566 160 (2.44) 1.22 (1.04-1.43) 0.014 
2 3462 139 (4.02) 1.93 (1.63-2.28) <0.0001 
3-4 3380 196 (5.80) 2.67 (2.31-3.08) <0.0001 
≥5 3202 344 (10.7) 5.17 (4.61-5.79) <0.0001 
Admission ≤30 days before next 
consultation 
    0.099 
 No 74750 1772 (2.37) 1  
Yes 13 2 (15.4) 4.23 (1.06-16.9) 0.041 
Charlson Index score, mean (SD) 0.59 (2.45) 2.04 (4.73) - 1.05 (1.05-1.06) <0.0001 
Resource utilization band (RUB)     <0.0001 
 Healthy 6762 2 (0.03) 1  
Low to moderate 42428 329 (0.78) 8.39 (2.69-26.1) <0.0001 
High to very high 25373 1443 (5.69) 54.1 (17.4-168) <0.0001 
 
  
                                                     
*
At GP practice, telephone or home visit. 
†
At GP practice, telephone or home visit. 
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6.4.3.2 Model selection for adjusted analyses 
Before presenting the results of adjusted regression analyses, it would be helpful to explain 
the process of selecting regression models. The choice between different modelling 
methods is further explained in section 6.3.4 and Chapter 4. 
The mean of the response variable (number of AEs) was approximately equal to the variance 
(0.027 compared to 0.037, respectively). Assuming that the data fit a Poisson distribution, 
the variance to mean ratio did not indicate the presence of over-dispersion (Chapter 4 
section 4.8.2 for definition). However, there were excess zero counts of the response 
variable (Chapter 4 section 4.8.3), as 97.6% of patients in the sample did not have an AE 
during the study period. To begin exploring the modelling options, adjusted regression 
models were fitted using NB regression but this approach produced models of poor fit 
(Chapter 4 section 4.6.3 for details of goodness-of-fit assessments). Therefore, further 
models were produced using Poisson with GEE and ZIP regression. As the data were not 
over-dispersed (which can occur when there are excess zero counts) and in favour of 
adjusting for clustering of patients at practices which is not possible by ZIP regression in 
PROC GENMOD, Poisson regression with GEE was used in final adjusted modelling. The 
limitations of this choice are addressed in the Discussion (section 6.5.2) and Chapter 4. 
Eight models were developed to assess the contribution of the different comorbidity 
measures and to prevent collinearity (linear associations between these variables). The 
model containing disease flags based on disease categories used to derive Charlson Index 
scores performed best, producing a QIC score of 11625.7 (Table 6.5). Although this QIC 
score is high, indicating that the model is a sub-optimal fit for the data, the score is much 
lower than for the null model (QIC score of 91087.4). 
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Table 6.5 Fit of adjusted Poisson regression models for predicting risk factors for having an 
adverse event, using the generalized estimating equations (GEE) method 
Model Comorbidity variables 
Quasi-Likelihood under the 
Independence model Criterion (QIC) 
1 Charlson score 95118.6 
2 Composite Charlson Index measure 95163.1 
3 Disease flags derived from Charlson Index scoring 11625.7 
4 Aggregated Disease Groups (ADGs) 93607.0 
5 Collapsed Aggregated Disease Groups (CADGs) 91836.2 
6 Major Expanded Diagnosis Clusters (MEDCs) 97751.3 
7 Number of Expanded Diagnosis Cluster (EDC) groups 95418.5 
8 Resource Utilization Band (RUB) 95218.2 
9 Null model  91087.4 
 
6.4.3.3 Adjusted associations with adverse events 
After adjusting for other variables and clustering of patients at practices, there was no 
longer a statistically significant difference between male and female patients in their risks of 
having an AE (p=0.871) (Table 6.6). Ethnicity (p=0.480), marital status (p=0.228), practice 
region (p=0.208) and continuity of care (p=0.279) were also no longer significant predictors 
of having an AE.  
Compared to patients of other ages, patients aged between 65 and 84 years were still most 
at risk of having an AE (adjusted RR of 4.55, 95% CI 3.66-5.64 compared to unadjusted RR of 
11.9, 95% CI 9.90-14.3). Patients registered at practices in the North West of England were 
still at greater risk of having an AE compared to patients of practices in other regions (RR 
1.51, 95% CI 1.00-2.27; p=0.048). Other predictors of an AE were a high number of 
consultations at the practice, by telephone or home visit (RR 1.49, 95% CI 1.10-2.02; 
p=0.010) and having five or more admissions (RR 1.99, 95% CI 1.58-2.50). 
In contrast to crude results, longer length of time registered at the practice had a protective 
effect against having an AE (RR 0.45, 95% CI 0.38-0.52 and RR 0.44, 95% CI 0.38-0.52 for 
moderate and long lengths of registration time, respectively). Similarly, having at least one 
referral request was protective against having an AE (RR 0.56, 95% CI 0.43-0.74 for one 
referral and RR 0.61, 95% CI 0.44-0.84; p=0.003 for two or more referral requests). Yet 
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patients who had a referral request within 30 days of their next consultation remained more 
at risk of an AE (RR 1.87, 95% CI 1.24-2.80; p=0.003). 
Comorbidities* associated with greater risk of an AE were diagnoses of diabetes without 
complications (RR 1.30, 95% CI 1.10-1.54; p=0.002), hemiplegia (RR 2.03, 95% CI 1.08-3.80; 
p=0.028), myocardial infarction (RR 1.61, 95% CI 1.20-2.15), peptic ulcer disease (RR 1.66, 95% 
CI 1.29-2.14), peripheral vascular disease (RR 1.63, 95% CI 1.33-2.01) and renal disease (RR 
1.39, 95% CI 1.17-1.64).  
  
                                                     
*
Recorded in patient’s records and may have occurred at any time.  
Chapter 6: Adverse events recorded in national data | 130 
 
Table 6.6 Risk factors for reported adverse events, adjusted results from Poisson regression 
using the generalized estimating equations (GEE) method 
Characteristic 
Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Age group at study start (years)  <0.0001  <0.0001 
 0-14 1  1  
15-44 2.58 (2.14-3.11) <0.0001 2.06 (1.68-2.52) <0.0001 
45-64 5.36 (4.45-6.45) <0.0001 2.91 (2.37-3.57) <0.0001 
65-84 11.9 (9.90-14.3) <0.0001 4.55 (3.66-5.64) <0.0001 
≥85 7.95 (5.50-11.5) <0.0001 3.96 (2.53-6.19) <0.0001 
Sex  <0.0001  0.871 
 Male 1  1  
Female 1.31 (1.20-1.43) <0.0001 1.01 (0.91-1.11) 0.871 
Ethnicity  <0.0001  0.480 
 Asian 1  1  
Black 1.26 (0.63-2.49) 0.514 1.50 (0.74-3.04) 0.261 
Mixed 1.34 (0.49-3.63) 0.567 1.80 (0.59-5.49) 0.299 
White 1.26 (0.78-2.03) 0.350 0.90 (0.54-1.48) 0.669 
Other 0.69 (0.30-1.59) 0.380 0.83 (0.36-1.89) 0.652 
Unknown 0.56 (0.34-0.90) 0.016 0.85 (0.51-1.41) 0.524 
Marital status  <0.0001  0.228 
 Single 1  1  
Married 3.06 (2.34-3.99) <0.0001 1.22 (0.94-1.58) 0.134 
Other status 3.70 (2.62-5.23) <0.0001 1.16 (0.79-1.69) 0.457 
Unknown 1.94 (1.51-2.48) <0.0001 1.07 (0.84-1.35) 0.603 
Practice region  <0.0001  0.208 
 East Midlands 1  1  
East of England 1.28 (0.92-1.79) 0.139 1.32 (0.85-2.04) 0.211 
London 1.35 (0.95-1.92) 0.098 1.40 (0.73-2.66) 0.310 
North East 1.27 (0.89-1.83) 0.192 1.48 (0.95-2.30) 0.081 
North West 1.46 (1.05-2.04) 0.026 1.51 (1.00-2.27) 0.048 
South Central 1.08 (0.77-1.52) 0.655 1.18 (0.79-1.76) 0.427 
South East Coast 1.45 (1.04-2.04) 0.030 1.36 (0.90-2.03) 0.141 
South West 1.04 (0.74-1.46) 0.817 1.17 (0.77-1.78) 0.470 
West Midlands 0.82 (0.58-1.15) 0.243 1.01 (0.66-1.53) 0.983 
Yorkshire & The Humber 1.16 (0.82-1.62) 0.405 1.30 (0.84-2.02) 0.244 
Length at practice (years)  <0.0001  <0.0001 
 Low 1  1  
Moderate 0.83 (0.72-0.97) 0.017 0.45 (0.38-0.52) <0.0001 
High 1.36 (1.18-1.57) <0.0001 0.44 (0.38-0.52) <0.0001 
Continuity of care  <0.0001  0.279 
 Low 1  1  
Moderate 5.67 (3.63-8.86) <0.0001 0.92 (0.81-1.05) 0.206 
High 7.27 (4.66-11.3) <0.0001 0.92 (0.78-1.09) 0.342 
Not valid 6.60 (4.23-10.3) <0.0001 0.67 (0.40-1.12) 0.123 
Number of all consultations  <0.0001  <0.0001 
 Low 1  1  
Moderate 4.01 (2.99-5.38) <0.0001 3.93 (2.61-5.91) <0.0001 
High 15.8 (12.0-20.9) <0.0001 7.37 (4.78-11.4) <0.0001 




  <0.0001  <0.0001 
 Low 1  1  
Moderate 2.10 (1.69-2.62) <0.0001 0.93 (0.69-1.25) 0.618 
High 7.79 (6.39-9.49) <0.0001 1.49 (1.10-2.02) 0.010 
Number of referrals  0.013  <0.0001 
 0 1  1  
1 1.11 (0.91-1.34) 0.305 0.56 (0.43-0.74) <0.0001 
≥2 1.37 (1.11-1.68) 0.003 0.61 (0.44-0.84) 0.003 
Referral ≤30 days before next consultation  <0.0001  0.008 
 No 1  1  
Yes 1.98 (1.60-2.45) <0.0001 1.87 (1.24-2.80) 0.003 
Number of admissions  <0.0001  <0.0001 
 0 1  1  
1 1.22 (1.04-1.43) 0.014 0.97 (0.78-1.20) 0.750 
2 1.93 (1.63-2.28) <0.0001 1.21 (0.96-1.53) 0.106 
3-4 2.67 (2.31-3.08) <0.0001 1.28 (1.01-1.61) 0.038 
≥5 5.17 (4.61-5.79) <0.0001 1.99 (1.58-2.50) <0.0001 
Disease flags  
Cancer  <0.0001  0.320 
 No 1  1  
Yes 3.16 (2.58-3.86) <0.0001 1.13 (0.90-1.43) 0.293 
Cerebrovascular disease  <0.0001  0.107 
 No 1  1  
Yes 3.81 (3.18-4.57) <0.0001 1.23 (0.97-1.56) 0.083 
Congestive heart disease  <0.0001  0.256 
 No 1  1  
Yes 4.52 (3.66-5.59) <0.0001 1.18 (0.90-1.53) 0.232 
Chronic pulmonary disease  <0.0001  0.171 
 No 1  1  
Yes 1.46 (1.31-1.63) <0.0001 1.10 (0.97-1.24) 0.157 
Dementia  0.001  0.406 
 No 1  1  
Yes 2.45 (1.54-3.90) <0.0001 0.82 (0.49-1.37) 0.446 
Diabetes without complications  <0.0001  0.005 
 No 1  1  
Yes 3.46 (3.06-3.92) <0.0001 1.30 (1.10-1.54) 0.002 
Diabetes with complications  <0.0001  0.377 
 No 1  1  
Yes 4.95 (3.59-6.82) <0.0001 1.21 (0.82-1.78) 0.343 
Hemiplegia  <0.0001  0.115 
 No 1  1  
Yes 4.40 (2.36-8.19) <0.0001 2.03 (1.08-3.80) 0.028 
Metastatic tumour  <0.0001  0.950 
 No 1  1  
Yes 3.36 (1.90-5.92) <0.0001 1.02 (0.55-1.89) 0.949 
Moderate liver disease  0.008  0.336 
 No 1  1  
Yes 7.62 (2.46-23.7) <0.0001 2.97 (0.85-10.4) 0.088 
Myocardial infarction  <0.0001  0.009 
 No 1  1  
 Yes 4.76 (3.82-5.93) <0.0001 1.61 (1.20-2.15) 0.001 
                                                     
*
At GP practice, telephone or home visit. 
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Peptic ulcer disease  <0.0001  0.004 
 No 1  1  
Yes 4.08 (3.27-5.09) <0.0001 1.66 (1.29-2.14) <0.0001 
Peripheral vascular disease  <0.0001  <0.0001 
 No 1  1  
Yes 5.29 (4.35-6.43) <0.0001 1.63 (1.33-2.01) <0.0001 
Renal disease  <0.0001  0.001 
 No 1  1  
Yes 4.50 (3.95-5.13) <0.0001 1.39 (1.17-1.64) <0.0001 
Rheumatological disease  <0.0001  0.146 
 No 1  1  
Yes 3.26 (2.67-3.98) <0.0001 1.18 (0.96-1.46) 0.113 
  
6.4.4 Service use 
Certain consultation and referral characteristics were associated with greater risk of having 
an AE. I now examine patients’ patterns of service use. 
6.4.4.1 Consultations prior to index adverse event 
On average, patients who had at least one AE had 69 (SD 61.1) consultations at any time 
before their index AE (p<0.001) and an average of 39 (SD 46.5) consultations with a doctor 
or nurse at the practice, by telephone or on home visit (p<0.001). Less than 1% of patients 
who had at least one AE did not have any consultations with a doctor or nurse at the 
practice, by telephone or home visit before their index AE (n=16/1,774; p<0.001). 
During the year before their first AE, 96.3% of patients had at least one consultation at the 
GP practice, by telephone or home visit (n=1,708/1,774; 19,466 consultations). On average, 
patients had 11 (SD 16.9) consultations each at any of the three locations, ranging from 1 to 
200 consultations. For the 13,601 consultations with valid recording of consultation length, 
the average length of consultations was 10.5 (SD 16.3) minutes. 
6.4.4.2 Referrals requests before index adverse event 
Of the patients who had at least one AE, 8.17% (n=145/1,774) had at least one referral 
before their index AE (RR 1.33, 95% CI 1.06-1.68; p=0.016). Over half of these patients only 
had one referral (53.1%; n=77/145). In the year before their index AE, 1.35% of patients had 
at least one referral (mean 1, SD 0.28 referrals), ranging from 1 to 2 referrals per patient 
(n=24/1,774 patients, 26 referrals). Where the referral speciality was known, 38.9% of 
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referrals were to urology (n=7/18 referrals). The other known specialties were general 
surgery (n=6 referrals), ophthalmology (n=3 referrals) and trauma and orthopaedics (n=2 
referrals). Approximately half of referrals in the year preceding the first AE were recorded as 
routine (n=13/26), with the remaining referrals recorded as two week wait (n=1) or of 
unknown urgency status (n=12). 
6.4.4.3 Consultations after index adverse event 
Most patients who had at least one AE had one or more consultations following their index 
event (97.6%; n=1,731/1,774). Out of the 66,965 consultations that patients had after their 
first AE, 81.4% were at the GP practice, by telephone or home visit (n=54,524/66,965). On 
average, patients who had at least one AE had 32 (SD 35.3) consultations in any of the three 
locations after their index AE and during the study period, ranging from 1 to 392 
consultations per patient. 
6.4.4.4 Referrals requests after index adverse event 
In 2.25% of patients who had at least one AE, a referral request was made after their index 
AE (n=40/1,774 patients, 74 referrals). On average, patients had 2 (SD 3.96) referral 
requests each, ranging from 1 to 26 referrals post-index AE per patient during the study 
period. Where referral speciality was known, two thirds of referrals were for urology 
(n=36/55 referrals). Referrals were also made to general surgery (n=12 referrals), 
ophthalmology (n=3), oral surgery (n=1) and trauma and orthopaedics (n=2). No speciality 
coding was provided for a quarter of referral requests post-index AE (n=19). The majority of 
referrals were recorded as routine (n=59/74), with 6 urgent referrals, 1 two week wait and 8 
referrals where the urgency status was unknown.  
6.4.5 Risk factors for emergency admissions 
In the next section of the Results, I describe the predictors of unplanned admissions 
identified from crude and adjusted analyses. 
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6.4.5.1 Crude associations with emergency admissions 
There were 55,320 admissions among 16,610 patients during the study period (Table 6.7). P-
values for in this section are p<0.0001 unless reported otherwise. Analyses were performed 
to determine whether having an AE was an independent predictor of emergency admission, 
as a proxy measure of an adverse outcome. In Table 6.7 and Table 6.9, AE variables are the 
last to be presented and are in bold typeface. In crude analyses, having an AE was 
associated with increased risk of emergency admission (RR 2.82, 95% CI 2.73-2.90), patients 
who had more than one AE were at greatest risk (RR 3.69, 95% CI 3.44-3.96). Other risk 
factors for having an (all-cause) unplanned admission were older age (85 years or older) at 
study entry (RR 5.29, 95% CI 4.98-5.63), being female (RR 1.31, 95% CI 1.29-1.33), white 
ethnicity (RR 1.07, 95% CI 1.01-1.14; p=0.028), marital status other than single or married 
(RR 2.35, 95% CI 2.20-2.52) and living in areas of unknown deprivation status (RR 4.87, 95% 
CI 4.74-50). 
Patients registered at practices in the South East Coast region (RR 2.03, 95% CI 1.89-2.18), 
who had a high continuity of care score (RR 3.50, 95% CI 3.29-3.71), high number of 
consultations at the GP practice, by telephone or home visit (RR 3.47, 95% CI 3.37-3.57), 
with two or more referral requests during the study period (RR 1.59, 95% CI 1.53-1.65) or a 
referral within 30 days of their next consultation (RR 1.74, 95% CI 1.67-1.82) were also at 
greater risk of an emergency admission. There was a small but statistically significant 
difference in the risk of admission between patients by Charlson Index score (RR 1.05, 95% 
CI 1.00-1.05). Conversely, patients who were the highest resource users, as measured by the 
Resource utilization band (RUB) score, had an increased risk of admission (RR 9.00, 95% CI 
8.18-9.90). Further results by comorbidity markers can be found in the appendices (Table 
A.11). 
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Table 6.7 Risk factors for emergency admission during study period, crude results from Poisson 
regression using the generalized estimating equations (GEE) method 
Characteristic 
Patients with ≥1 emergency 
admission, n 
RR (95% CI) P-value 
All ≥1 adverse 
event 
(%) 
Age group at study start (years)     <0.0001 
 0-14 3134 48 (1.53) 1  
15-44 6373 251 (3.94) 1.69 (1.65-1.74) <0.0001 
45-64 3813 276 (7.24) 2.45 (2.38-2.52) <0.0001 
65-84 2909 254 (8.73) 4.76 (4.62-4.90) <0.0001 
≥85 381 10 (2.62) 5.29 (4.98-5.63) <0.0001 
Sex     <0.0001 
 Male 7157 347 (4.85) 1  
Female 9453 492 (5.20) 1.31 (1.29-1.33) <0.0001 
Ethnicity     <0.0001 
 Asian 367 15 (4.09) 1  
Black 263 14 (5.32) 1.06 (0.97-1.16) 0.201 
Mixed 84 3 (3.57) 0.77 (0.66-0.90) 0.001 
White 11705 650 (5.55) 1.07 (1.01-1.14) 0.028 
Other 230 6 (2.61) 0.71 (0.64-0.79) <0.0001 
Unknown 3961 151 (3.81) 0.08 (0.07-0.08) <0.0001 
Marital status     <0.0001 
 Single 777 22 (2.83) 1  
Married 1873 136 (7.26) 1.99 (1.89-2.08) <0.0001 
Other status 380 20 (5.26) 2.35 (2.20-2.52) <0.0001 
Unknown 13580 661 (4.87) 1.63 (1.56-1.70) <0.0001 
Deprivation     <0.0001 
 Least deprived 3836 181 (4.72) 1  
Quintiles 2,3,4 7582 398 (5.25) 4.20 (4.11-4.29) <0.0001 
Most deprived 2530 129 (5.10) 3.66 (3.56-3.76) <0.0001 
Unknown 2662 131 (4.92) 4.87 (4.74-5.00) <0.0001 
Practice region     <0.0001 
 East Midlands 170 9 (5.29) 1  
East of England 2888 141 (4.88) 1.71 (1.60-1.84) <0.0001 
London 918 34 (3.70) 1.52 (1.40-1.63) <0.0001 
North East 606 29 (4.79) 1.01 (0.93-1.10) 0.758 
North West 2032 143 (7.04) 1.65 (1.53-1.77) <0.0001 
South Central 2171 107 (4.93) 1.53 (1.42-1.64) <0.0001 
South East Coast 2173 123 (5.66) 2.03 (1.89-2.18) <0.0001 
South West 1933 84 (4.35) 1.12 (1.04-1.21) 0.002 
West Midlands 1923 85 (4.42) 1.25 (1.16-1.34) <0.0001 
Yorkshire & The Humber 1796 84 (4.68) 1.37 (1.27-1.47) <0.0001 
Length at practice (years)     <0.0001 
 Low 3210 78 (2.43) 1  
Moderate 6188 282 (4.56) 0.78 (0.76-0.80) <0.0001 
High 7212 479 (6.64) 0.92 (0.89-0.94) <0.0001 
Continuity of care     <0.0001 
 Low 673 4 (0.59) 1  
Moderate 5085 262 (5.15) 2.72 (2.56-2.89) <0.0001 
High 6006 338 (5.63) 3.50 (3.29-3.71) <0.0001 
Not valid 4846 235 (4.85) 3.15 (2.97-3.35) <0.0001 
Number of all consultations     <0.0001 
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 Low 2174 15 (0.69) 1  
Moderate 5064 110 (2.17) 1.78 (1.72-1.85) <0.0001 
High 9372 714 (7.62) 4.76 (4.61-4.92) <0.0001 
Consultation
*
     <0.0001 
 No 317 3 (0.95) 1  
Yes 16293 836 (5.13) 3.04 (2.79-3.31) <0.0001 
Number of consultations
†
     <0.0001 
 Low 2639 28 (1.06) 1  
Moderate 4884 122 (2.50) 1.52 (1.47-1.57) <0.0001 
High 9087 689 (7.58) 3.47 (3.37-3.57) <0.0001 
Referrals      <0.0001 
 No 15202 751 (4.94) 1  
Yes 1408 88 (6.25) 1.46 (1.42-1.50) <0.0001 
Number of referrals     <0.0001 
 0 15202 751 (4.94) 1  
1 930 48 (5.16) 1.37 (1.33-1.42) <0.0001 
≥2 478 40 (8.37) 1.59 (1.53-1.65) <0.0001 
Referral ≤30 days before consultation     <0.0001 
 No 16134 806 (5.00) 1  
Yes 476 33 (6.93) 1.74 (1.67-1.82) <0.0001 
Charlson Index score 1.14 (3.59) 2.40 (5.46)  1.05 (1.05-1.05) <0.0001 
Resource utilization band (RUB)     <0.0001 
 Healthy 383 0 - 1  
Low to moderate 6647 96 (1.44) 2.34 (2.13-2.58) <0.0001 
High to very high 9566 743 (7.77) 9.00 (8.18-9.90) <0.0001 
Adverse event     <0.0001 
 No 15771 0 - 1  
Yes 839 839 (100) 2.82 (2.73-2.90) <0.0001 
Number of adverse events, mean 
(SD) 
0.06 (0.27) 1.15 (0.44)  1.67 (1.65-1.70) <0.0001 
Multiple adverse events     <0.0001 
 No 16506 735 (4.45) 1  
Yes 104 104 (100) 3.69 (3.44-3.96) <0.0001 
 
6.4.5.2 Model selection for adjusted analyses 
There was an excess of zero counts in the sample, with 77.8% of patients not having any 
admissions during the study period. The data was also over-dispersed, with the variance of 
the continuous response variable (number of admissions) being much larger than the mean 
(9.39 compared to 0.74, respectively). Along with Poisson with GEE, adjusted regression 
models were also built with NB and ZIP regression to determine the most appropriate 
method for the data. Similar to the reasoning in section 6.4.3.2, Poisson with GEE was 
                                                     
*
At GP practice, telephone or home visit. 
†
At GP practice, telephone or home visit. 
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selected for final adjusted regression analyses because of the ability to adjust for clustering 
of patients at practices. 
Eight regression models were fitted, one for each of the comorbidity measures (Table 6.8). 
The best fitting model for predicting emergency admissions was model 3 which included 
comorbidity disease flags derived from Charlson Index categories (Table 6.8). The QIC score 
for this model was 5736.1, indicating that the model performed much better than the null 
model which had a QIC score of 47049.3. 
Table 6.8 Fit of adjusted Poisson regression models for predicting risk factors for admission, 
using the generalized estimating equations (GEE) method 
Model Comorbidity variables 
Quasi-Likelihood under the 
Independence model Criterion (QIC) 
1 Charlson score 3087.1 
2 Composite Charlson Index measure 23355.6 
3 Disease flags derived from Charlson Index scoring 5736.1 
4 Aggregated Disease Groups (ADGs) 18180.4 
5 Collapsed Aggregated Disease Groups (CADGs) 20375.7 
6 Major Expanded Diagnosis Clusters (MEDCs) 18793.0 
7 Number of Expanded Diagnosis Cluster (EDC) groups 23555.5 
8 Resource Utilization Band (RUB) 22542.4 
9 Null model  47049.3 
 
6.4.5.3 Adjusted associations with emergency admissions 
After adjusting for all other variables and taking into account of clustering of patients at 
practices, having an AE was still associated with increased (though weaker) risk of admission 
(RR 1.27, 95% CI 1.14-1.42) (Table 6.9). The risk of admission between male and female 
patients was no longer statistically significant (p=0.216). Likewise, marital status (p=0.181), 
number of referral requests (p=0.062) and referrals within 30 days of the next consultation 
(p=0.173) were also no longer associated with the risk of unplanned admission. Adjusted 
risk factors for emergency admission were age 85 years or older on entry to the study (RR 
2.25, 95% CI 1.95-2.59), living in the most deprived areas (RR 1.17, 95% CI 1.06-1.29; 
p=0.001) and having a high number of consultations in any primary care location (RR 2.17, 
95% CI 1.89-2.49). 
Chapter 6: Adverse events recorded in national data | 138 
 
Although the number of referral requests was no longer statistically significant at the 95% 
level, patients who had two or more referrals remained at greater risk of an admission (RR 
1.19, 95% CI 1.02-1.40; p=0.028). Patients of unknown ethnicity were less at risk of 
emergency admission compared to patients with known ethnicity (RR 0.11, 95% CI 0.09-
0.14). By comorbidities, the diseases associated with greatest risk of (all-cause) emergency 
admission were cancer (RR 2.08, 95% CI 1.82-2.37) and metastatic tumour (RR 2.12, 95% CI 
1.51-2.98), moderate liver disease (RR 2.29, 95% CI 1.11-4.74; p=0.026) and hemiplegia (RR 
4.18, 95% CI 2.26-7.73). 
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Table 6.9 Risk factors for emergency admission during study period, adjusted results from 
Poisson regression using the generalized estimating equations (GEE) method 
Characteristic Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Age group at study start (years)  <0.0001  <0.0001 
 0-14 1  1  
15-44 1.69 (1.65-1.74) <0.0001 1.41 (1.31-1.53) <0.0001 
45-64 2.45 (2.38-2.52) <0.0001 1.52 (1.37-1.69) <0.0001 
65-84 4.76 (4.62-4.90) <0.0001 1.86 (1.67-2.07) <0.0001 
≥85 5.29 (4.98-5.63) <0.0001 2.25 (1.95-2.59) <0.0001 
Sex  <0.0001  0.216 
 Male 1  1  
Female 1.31 (1.29-1.33) <0.0001 1.03 (0.98-1.09) 0.215 
Ethnicity  <0.0001  <0.0001 
 Asian 1  1  
Black 1.06 (0.97-1.16) 0.201 1.16 (0.88-1.53) 0.300 
Mixed 0.77 (0.66-0.90) 0.001 0.88 (0.69-1.11) 0.267 
White 1.07 (1.01-1.14) 0.028 1.00 (0.88-1.14) 0.995 
Other 0.71 (0.64-0.79) <0.0001 0.77 (0.59-1.01) 0.056 
Unknown 0.08 (0.07-0.08) <0.0001 0.11 (0.09-0.14) <0.0001 
Marital status  <0.0001  0.181 
 Single 1  1  
Married 1.99 (1.89-2.08) <0.0001 1.04 (0.92-1.19) 0.510 
Other status 2.35 (2.20-2.52) <0.0001 0.95 (0.79-1.14) 0.592 
Unknown 1.63 (1.56-1.70) <0.0001 1.09 (0.96-1.24) 0.202 
Deprivation  <0.0001  <0.0001 
 Least deprived 1  1  
Quintiles 2,3,4 4.2 (4.11-4.29) <0.0001 1.05 (0.97-1.14) 0.224 
Most deprived 3.66 (3.56-3.76) <0.0001 1.17 (1.06-1.29) 0.001 
Unknown 4.87 (4.74-5.00) <0.0001 0.62 (0.52-0.74) <0.0001 
Practice region  <0.0001  0.051 
 East Midlands 1  1  
East of England 1.71 (1.60-1.84) <0.0001 0.92 (0.59-1.42) 0.703 
London 1.52 (1.40-1.63) <0.0001 1.12 (0.71-1.75) 0.628 
North East 1.01 (0.93-1.10) 0.758 0.88 (0.53-1.45) 0.611 
North West 1.65 (1.53-1.77) <0.0001 0.93 (0.60-1.44) 0.748 
South Central 1.53 (1.42-1.64) <0.0001 1.04 (0.67-1.60) 0.869 
South East Coast 2.03 (1.89-2.18) <0.0001 1.00 (0.65-1.56) 0.986 
South West 1.12 (1.04-1.21) 0.002 0.81 (0.52-1.24) 0.328 
West Midlands 1.25 (1.16-1.34) <0.0001 0.94 (0.61-1.45) 0.767 
Yorkshire & The Humber 1.37 (1.27-1.47) <0.0001 1.06 (0.68-1.65) 0.793 
Length at practice (years)  <0.0001  <0.0001 
 Low 1  1  
Moderate 0.78 (0.76-0.80) <0.0001 0.58 (0.54-0.62) <0.0001 
High 0.92 (0.89-0.94) <0.0001 0.51 (0.47-0.55) <0.0001 
Continuity of care  <0.0001  <0.0001 
 Low 1  1  
Moderate 2.72 (2.56-2.89) <0.0001 1.06 (1.00-1.12) 0.068 
High 3.50 (3.29-3.71) <0.0001 1.08 (1.00-1.18) 0.054 
Not valid 3.15 (2.97-3.35) <0.0001 0.78 (0.68-0.89) <0.0001 
Number of all consultations  <0.0001  <0.0001 
 Low 1  1  
Moderate 1.78 (1.72-1.85) <0.0001 1.49 (1.35-1.64) <0.0001 
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High 4.76 (4.61-4.92) <0.0001 2.17 (1.89-2.49) <0.0001 
Number of consultations
*
  <0.0001  <0.0001 
 Low 1  1  
Moderate 1.52 (1.47-1.57) <0.0001 0.90 (0.82-0.99) 0.032 
High 3.47 (3.37-3.57) <0.0001 1.02 (0.90-1.15) 0.758 
Number of referrals  <0.0001  0.062 
 0 1  1  
1 1.37 (1.33-1.42) <0.0001 0.95 (0.85-1.07) 0.419 
≥2 1.59 (1.53-1.65) <0.0001 1.19 (1.02-1.40) 0.028 
Referral ≤30 days before next consultation  <0.0001  0.173 
 No 1  1  
Yes 1.74 (1.67-1.82) <0.0001 1.13 (0.95-1.34) 0.172 
Disease flags  
Cancer  <0.0001  <0.0001 
 No 1  1  
Yes 5.40 (5.23-5.56) <0.0001 2.08 (1.82-2.37) <0.0001 
Cerebrovascular disease  <0.0001  0.563 
 No 1  1  
Yes 2.59 (2.49-2.70) <0.0001 1.03 (0.93-1.14) 0.561 
Congestive heart disease  <0.0001  <0.0001 
 No 1  1  
Yes 4.86 (4.67-5.05) <0.0001 1.65 (1.44-1.89) <0.0001 
Chronic pulmonary disease  <0.0001  0.010 
 No 1  1  
Yes 1.40 (1.37-1.43) <0.0001 1.09 (1.02-1.17) 0.008 
Dementia  <0.0001  0.083 
 No 1  1  
Yes 2.33 (2.12-2.55) <0.0001 0.84 (0.69-1.02) 0.075 
Diabetes without complications  <0.0001  0.020 
 No 1  1  
Yes 2.36 (2.30-2.43) <0.0001 1.16 (1.03-1.30) 0.014 
Diabetes with complications  <0.0001  0.035 
 No 1  1  
Yes 3.21 (2.97-3.46) <0.0001 1.30 (1.05-1.62) 0.017 
Hemiplegia  <0.0001  0.101 
 No 1  1  
Yes 10.1 (9.35-12.0) <0.0001 4.18 (2.26-7.73) <0.0001 
Metastatic tumour  <0.0001  0.009 
 No 1  1  
Yes 9.64 (9.03-10.3) <0.0001 2.12 (1.51-2.98) <0.0001 
Mild liver disease  <0.0001  0.059 
 No 1  1  
Yes 3.18 (2.82-3.59) <0.0001 1.51 (1.05-2.18) 0.027 
Moderate liver disease  <0.0001  0.073 
 No 1  1  
Yes 11.3 (9.41-13.5) <0.0001 2.29 (1.11-4.74) 0.026 
Myocardial infarction  <0.0001  0.003 
 No 1  1  
 Yes 3.39 (3.23-3.57) <0.0001 1.31 (1.13-1.52) <0.0001 
Peptic ulcer disease  <0.0001  0.019 
 No 1  1  
                                                     
*
At GP practice, telephone or home visit. 
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Yes 2.57 (2.43-2.71) <0.0001 1.26 (1.06-1.49) 0.009 
Peripheral vascular disease  <0.0001  0.078 
 No 1  1  
Yes 3.67 (3.51-3.84) <0.0001 1.18 (1.00-1.39) 0.055 
Renal disease  <0.0001  0.051 
 No 1  1  
Yes 3.05 (2.96-3.14) <0.0001 1.15 (1.01-1.30) 0.040 
Rheumatological disease  <0.0001  0.302 
 No 1  1  
Yes 2.45 (2.34-2.56) <0.0001 1.07 (0.94-1.22) 0.294 
Adverse event  <0.0001  <0.0001 
 No 1  1  
Yes 2.82 (2.73-2.99) <0.0001 1.27 (1.14-1.42) <0.0001 
 
6.4.5.4 Admissions for adverse events 
In 3.59% of all admissions, an AE was recorded as a cause of admission (n=1, 987/55,320 
admissions). Few patients who had one or more admissions for an AE also had at least one 
AE before their first AE admission (1.29%; n=16/1,238). All except 5 of these patients had 
one AE before their admission; the five patients experienced two AEs each.  
6.4.6 Admissions prior to index adverse event 
Out of the patients who had an AE, 28.2% also had at least one admission in the year before 
their index AE (n=500/1,774 patients, 978 admissions). On average, these patients had 2 (SD 
2.21) admissions each in the year prior to their first AE, ranging from 1 to 31 admissions per 
patient. In 46 of these admissions, AE was a recorded cause of admission.  
6.4.6.1 Admissions after index adverse event 
Out of the patients who had an AE, 31.2% had at least one admission after their initial AE 
(n=553/1,774 patients). In these patients, there were 2,087 admissions during the study 
period with an average of 4 (SD 5.59) admissions per patient, ranging from 1 to 92 
admissions. An adverse event was recorded as a cause of admission in 5.94% of these 
admissions (n=124/2,087). 
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6.4.7 Risk factors for deaths 
In the next section of the Results, I describe the predictors of death identified from crude 
and adjusted analyses. 
6.4.7.1 Crude associations with death 
There were 3,963 deaths during the study period, including 108 deaths following AEs. For 
the same reason as investigating emergency admissions, the independent risk of having an 
AE on death as a potential iatrogenic outcome was assessed. AE variables are the last to be 
presented in Table 6.10 and Table 6.12 and are in bold typeface. Among patients who had at 
least one AE, 10.0% died during the study period (n=178/1,774). The average age of the 178 
patients who had at least one AE and also died was 77 (SD 13.8) years, ranging from 22 to 
101 years. Another 59 patients who had at least one AE died after the end of the study 
(during 2009 or 2010). P-values in this section are p<0.0001 unless reported otherwise.  
No patients who died had a consultation within 30 days of a hospital discharge and 
therefore this variable has been excluded from analyses. A crude model with Charlson Index 
score as the predictor for death failed to converge. Therefore, this variable is not reported in 
the crude results. The average Charlson score of patients who died was 2.62 (SD 5.93), 
compared to an average score of 4.37 (SD 7.78) in patients who had at least one AE and died.  
In crude analyses, having an AE (RR 1.90, 95% CI 1.64-2.19), and in particular more than one 
AE (RR 2.47 95% CI 1.76-3.47), increased the risk of death (Table 6.10). Other risk factors for 
death were older age at entry into the study (RR 467, 95% CI 326-670 for patients aged 85 
years or older), being female (RR 1.09, 95% CI 1.02-1.16, p=0.008), white ethnicity (RR 5.03, 
95% CI 2.79-9.04), marital status other than single or married (RR 11.6, 95% CI 8.67-15.4) 
and living in areas of unknown deprivation status (RR 1.48, 95% CI 1.33-1.63). Registration at 
practices in the West Midlands compared to other regions of England had a protective 
effect against death in crude analyses (RR 0.56, 95% CI 0.45-0.69). 
Patients also had increased risk of death if they were registered with the practice for the 
longest lengths of time (RR 1.61, 95% CI 1.49-1.74), followed-up for between 4 and 6 years 
(RR 1.14, 95% CI 1.03-1.27; p=0.010) or with a high continuity of care score (RR 1.18, 95% CI 
1.05-1.32; p=0.005). A high number of consultations at the GP practice, by telephone or 
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home visit (RR 1.45, 95% CI 1.35-1.56), two or more referral requests (RR 1.52, 95% CI 1.30-
1.77), five or more admissions during the study period (RR 6.48, 95% CI 6.00-7.00) and high 
resource use as measured by the Resource Utilization Band score (RR 8.23, 95% CI 6.27-10.8) 
were also crude predictors of death. Further results by comorbidities are in the Appendices 
(Table A.12). 
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Table 6.10 Risk factors for death during study period, crude results from log-binomial 
regression using the generalized estimating equations (GEE) method 
Characteristic 
Deaths, n 
RR (95% CI) P-value All ≥1 adverse 
event 
(%) 
Age group at study start (years)     <0.001 
 0-14 33 1 (3.03) 1  
15-44 222 8 (3.60) 4.74 (3.24-6.94) <0.0001 
45-64 749 36 (4.81) 36.8 (25.6-53.0) <0.0001 
65-84 2328 113 (4.85) 217 (151-310) <0.0001 
≥85 631 20 (3.17) 467 (326-670) <0.0001 
Sex     0.008 
 Male 1816 81 (4.46) 1  
Female 2147 97 (4.52) 1.09 (1.02-1.16) 0.008 
Ethnicity     <0.001 
 Asian 12 0 - 1  
Black 9 0 - 1.09 (0.46-2.61) 0.843 
Mixed 2 1 (50.0) 0.73 (0.16-3.26) 0.680 
White 1557 77 (4.95) 5.03 (2.79-9.04) <0.0001 
Other 12 0 - 1.82 (0.81-4.08) 0.145 
Unknown 2371 100 (4.22) 2.18 (1.21-3.92) 0.009 
Marital status     <0.001 
 Single 58 4 (6.90) 1  
Married 406 16 (3.94) 4.79 (3.65-6.30) <0.0001 
Other status 189 12 (6.35) 11.6 (8.67-15.4) <0.0001 
Unknown 3310 146 (4.41) 4.55 (3.51-5.88) <0.0001 
Deprivation     <0.001 
 Least deprived 1915 86 (4.49) 1  
Quintiles 2,3,4 1227 52 (4.24) 1.38 (1.29-1.48) <0.0001 
Most deprived 382 18 (4.71) 1.19 (1.07-1.33) 0.001 
Unknown 439 22 (5.01) 1.48 (1.33-1.63) <0.0001 
Practice region     <0.001 
 East Midlands 93 1 (1.08) 1  
East of England 604 29 (4.80) 0.90 (0.73-1.11) 0.314 
London 279 11 (3.94) 1.07 (0.85-1.34) 0.589 
North East 186 12 (6.45) 0.84 (0.66-1.07) 0.152 
North West 473 15 (3.17) 0.94 (0.75-1.16) 0.548 
South Central 500 24 (4.80) 0.88 (0.71-1.09) 0.253 
South East Coast 487 26 (5.34) 1.05 (0.85-1.30) 0.663 
South West 506 15 (2.96) 0.82 (0.66-1.01) 0.063 
West Midlands 402 18 (4.48) 0.56 (0.45-0.69) <0.0001 
Yorkshire & The Humber 433 27 (6.24) 0.84 (0.67-1.04) 0.113 
Length at practice (years)     <0.001 
 Low 1040 24 (2.31) 1  
Moderate 1214 56 (4.61) 1.16 (1.06-1.25) 0.001 
High 1709 98 (5.73) 1.61 (1.49-1.74) <0.0001 
Follow-up time (years)     <0.001 
 <1 486 6 (1.23) 1  
1-3 1255 32 (2.55) 0.88 (0.79-0.97) 0.014 
4-6 1238 65 (5.25) 1.14 (1.03-1.27) 0.010 
7-10 984 75 (7.62) 0.26 (0.23-0.28) <0.0001 
Continuity of care     <0.001 
 Low 411 6 (1.46) 1  
Moderate 603 32 (5.31) 0.57 (0.50-0.65) <0.0001 
High 1240 70 (5.65) 1.18 (1.05-1.32) 0.005 
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Not valid 1709 70 (4.10) 1.63 (1.45-1.82) <0.0001 
Number of all consultations     <0.001 
 Low 860 3 (0.35) 1  
Moderate 1100 29 (2.64) 1.23 (1.13-1.35) <0.0001 
High 2003 146 (7.29) 2.27 (2.10-2.46) <0.0001 
Consultation
*
     0.001 
 No 249 4 (1.61) 1  
Yes 3714 174 (4.68) 0.79 (0.69-0.90) <0.0001 
Number of consultations
†
     <0.001 
 Low 1163 22 (1.89) 1  
Moderate 1064 28 (2.63) 0.92 (0.85-1.00) 0.051 
High 1736 128 (7.37) 1.45 (1.35-1.56) <0.0001 
Referral     <0.001 
 No 3609 165 (4.57) 1  
Yes 354 13 (3.67) 1.39 (1.25-1.54) <0.0001 
Number of referrals     <0.001 
 0 3609 165 (4.57) 1  
1 201 9 (4.48) 1.31 (1.14-1.50) <0.0001 
≥2 153 4 (2.61) 1.52 (1.30-1.77) <0.0001 
Referral ≤30 days before next consultation     0.078 
 No 3874 174 (4.49) 1  
Yes 89 4 (4.49) 1.21 (0.99-1.48) 0.068 
Admission     <0.001 
 No 2023 81 (4.00) 1  
Yes 1940 97 (5.00) 3.28 (3.09-3.49) <0.0001 
Number of admissions     <0.001 
 0 2023 81 (4.00) 1  
1 426 8 (1.88) 1.80 (1.62-1.99) <0.0001 
2 335 6 (1.79) 2.72 (2.43-3.03) <0.0001 
3-4 442 17 (3.85) 3.68 (3.33-4.05) <0.0001 
≥5 737 66 (8.96) 6.48 (6.00-7.00) <0.0001 
Resource utilization band (RUB)     <0.001 
 Healthy 134 0 - 1  
Low to moderate 1008 3 (0.30) 1.76 (1.33-2.32) <0.0001 
High to very high 2819 175 (6.21) 8.23 (6.27-10.8) <0.0001 
Adverse event     <0.001 
 No 3785 0 - 1  
Yes 178 178 (100) 1.90 (1.64-2.19) <0.0001 
Multiple adverse events     <0.001 
 No 3934 149 (3.79) 1  
Yes 29 29 (100) 2.47 (1.76-3.47) <0.0001 
Admission for adverse event     <0.001 
 No 3682 152 (4.13) 1  
Yes 281 26 (9.25) 4.45 (4.00-4.96) <0.0001 
 
  
                                                     
*
At GP practice, telephone or home visit. 
†
At GP practice, telephone or home visit. 
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6.4.7.2 Model selection for adjusted analyses 
As used for crude estimates of risk factors for death, adjusted models were built using log-
binomial regression with GEE to account for patient clustering by practice. These models 
failed to converge (Chapter 4 section 4.5.1). To overcome this problem, modified Poisson 
regression models using GEE were applied instead.  
In section 6.4.7.1, I reported that the crude log-binomial model of Charlson Index score as 
the predictor of death failed to converge. In spite of the original exclusion, Charlson score 
was included in the Poisson with GEE models (Table 6.11). The model with Charlson score 
achieved relatively reasonable fit (QIC score of 21800.1) but the best performing model 
featured a count of Expanded Diagnosis Cluster (EDC) groups. This model achieved a much 
lower QIC score than the null model (QIC score of 21475.3 compared to 32959.3, 
respectively).  
Table 6.11 Fit of adjusted Poisson regression models for predicting risk factors for death, using 
the generalized estimating equations (GEE) method 
Model Comorbidity variables 
Quasi-Likelihood under the 
Independence model Criterion (QIC) 
1 Charlson score 21800.1 
2 Composite Charlson Index measure 21872.6 
3 Disease flags derived from Charlson Index scoring 21993.2 
4 Aggregated Disease Groups (ADGs) 22678.3 
5 Collapsed Aggregated Disease Groups (CADGs) 23398.2 
6 Major Expanded Diagnosis Clusters (MEDCs) 22604.4 
7 Number of Expanded Diagnosis Cluster (EDC) groups 21475.3 
8 Resource Utilization Band (RUB) 21967.8 
9 Null model  32959.3 
 
6.4.7.3 Adjusted associations with death 
After adjustment and taking clustering into account, there was no longer any statistical 
difference in the risk of death among patients who had an AE and patients who had not 
(p=0.396) (Table 6.12). Having an admission for an AE (RR 1.22, 95% CI 1.09-1.37) or five or 
more admissions (RR 1.89, 95% CI 1.71-2.10) remained predictors of death. Patients’ age at 
study entry remained a strong predictor of death with patients aged 85 years or older at 
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greatest risk of death (RR 212, 95% CI 145-310). Female patients were less at risk of death 
compared to male patients (RR 0.85, 95% CI 0.81-0.89). Compared to patients of known 
ethnicity, patients of unknown ethnicity were at greater risk of death (RR 1.70, 95% CI 1.06-
2.72; p=0.027). Patients living in areas of unknown deprivation status (RR 1.30, 95% CI 1.19-
1.43) or who had been registered with the practice for the longest lengths of time (RR 1.94, 
95 % CI 1.79-2.11) remained most at risk of death. Patients with a high number of 
consultations at any location (RR 1.32, 95% CI 1.18-1.48) or a high continuity of care score 
(RR 1.23, 95% CI 1.15-1.33) were at greater risk of death, but having a high number of 
consultations at the practice, by telephone or home visit with a GP or nurse was not 
significantly associated with risk of death (RR 0.95, 95% CI 0.85-1.04; p=0.266).  
Patients registered at practices in the West Midlands compared to other regions (RR 0.65, 
95% CI 0.49-0.86, p=0.003) and patients who were followed up for between 7 and 10 years 
(RR 0.09, 95% CI 0.08-0.10) were less at risk of death. Patients with any comorbidity, as 
measured by the Charlson Index, had almost five times greater risk of death than patients 
without any of the comorbid diseases (RR 4.87, 95% CI 4.58-5.17). Specifically, patients with 
recorded chronic pulmonary disease (RR 11.6, 95% CI 10.8-12.5), dementia (RR 10.4, 95% CI 
9.36-11.6), metastatic tumour (RR 13.2, 95% CI 11.7-14.8) or moderate liver disease (RR 12.3, 
95% CI 8.62-17.7) were at greatest risk of death. 
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Table 6.12 Risk factors for death during study period, adjusted results from Poisson regression 
using the generalized estimating equations (GEE) method 
Characteristic 
Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Age group at study start (years)  <0.0001  <0.0001 
 0-14 1  1  
15-44 4.74 (3.24-6.94) <0.0001 4.55 (3.12-6.64) <0.0001 
45-64 36.8 (25.6-53.0) <0.0001 38.9 (26.8-56.6) <0.0001 
65-84 217 (151.3-310) <0.0001 147 (101-213) <0.0001 
≥85 467 (326-670) <0.0001 212 (145-310) <0.0001 
Sex  0.008  <0.0001 
 Male 1  1  
Female 1.09 (1.02-1.16) 0.008 0.85 (0.81-0.89) <0.0001 
Ethnicity  <0.0001  <0.0001 
 Asian 1  1  
Black 1.09 (0.46-2.61) 0.843 1.01 (0.56-1.83) 0.971 
Mixed 0.73 (0.16-3.26) 0.680 2.18 (0.61-7.82) 0.233 
White 5.03 (2.79-9.04) <0.0001 1.44 (0.90-2.31) 0.126 
Other 1.82 (0.81-4.08) 0.145 1.21 (0.62-2.35) 0.578 
Unknown 2.18 (1.21-3.92) 0.009 1.70 (1.06-2.72) 0.027 
Marital status  <0.0001  0.129 
 Single 1  1  
Married 4.79 (3.65-6.30) <0.0001 1.09 (0.87-1.36) 0.454 
Other status 11.6 (8.67-15.4) <0.0001 1.17 (0.93-1.48) 0.180 
Unknown 4.55 (3.51-5.88) <0.0001 1.19 (0.96-1.46) 0.114 
Deprivation  <0.0001  <0.0001 
 Least deprived 1  1  
Quintiles 2,3,4 1.38 (1.29-1.48) <0.0001 1.14 (1.04-1.25) 0.007 
Most deprived 1.19 (1.07-1.33) 0.001 1.26 (1.13-1.41) <0.0001 
Unknown 1.48 (1.33-1.63) <0.0001 1.30 (1.19-1.43) <0.0001 
Practice region  <0.0001  0.002 
 East Midlands 1  1  
East of England 0.90 (0.73-1.11) 0.314 0.85 (0.65-1.11) 0.233 
London 1.07 (0.85-1.34) 0.589 0.81 (0.62-1.07) 0.139 
North East 0.84 (0.66-1.07) 0.152 0.86 (0.65-1.14) 0.302 
North West 0.94 (0.75-1.16) 0.548 0.83 (0.63-1.09) 0.189 
South Central 0.88 (0.71-1.09) 0.253 0.76 (0.58-1.00) 0.047 
South East Coast 1.05 (0.85-1.30) 0.663 0.74 (0.56-0.96) 0.025 
South West 0.82 (0.66-1.01) 0.063 0.84 (0.64-1.10) 0.200 
West Midlands 0.56 (0.45-0.69) <0.0001 0.65 (0.49-0.86) 0.003 
Yorkshire & The Humber 0.84 (0.67-1.04) 0.113 0.79 (0.60-1.03) 0.086 
Length at practice (years)  <0.0001  <0.0001 
 Low 1  1  
Moderate 1.16 (1.06-1.25) 0.001 1.82 (1.69-1.97) <0.0001 
High 1.61 (1.49-1.74) <0.0001 1.94 (1.79-2.11) <0.0001 
Follow-up time (years)  <0.0001  <0.0001 
 <1 1  1  
1-3 0.88 (0.79-0.97) 0.014 0.63 (0.58-0.69) <0.0001 
4-6 1.14 (1.03-1.27) 0.010 0.51 (0.46-0.56) <0.0001 
7-10 0.26 (0.23-0.28) <0.0001 0.09 (0.08-0.10) <0.0001 
Continuity of care  <0.0001  <0.0001 
 Low 1  1  
Moderate 0.57 (0.50-0.65) <0.0001 1.12 (1.03-1.22) 0.006 
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High 1.18 (1.05-1.32) 0.005 1.23 (1.15-1.33) <0.0001 
Not valid 1.63 (1.45-1.82) <0.0001 1.11 (0.98-1.26) 0.101 
Number of consultations  <0.0001  <0.0001 
 Low 1  1  
Moderate 1.23 (1.13-1.35) <0.0001 1.15 (1.05-1.26) 0.004 
High 2.27 (2.10-2.46) <0.0001 1.32 (1.18-1.48) <0.0001 
Consultation
*
  0.001  0.531 
 No 1  1  
Yes 0.79 (0.69-0.90) <0.0001 0.96 (0.84-1.09) 0.530 
Number of consultations
†
  <0.0001  0.542 
 Low 1  1  
Moderate 0.92 (0.85-1.00) 0.051 0.97 (0.90-1.05) 0.480 
High 1.45 (1.35-1.56) <0.0001 0.95 (0.85-1.04) 0.266 
Referral  <0.0001   
 No 1  1  
Yes 1.39 (1.25-1.54) <0.0001 1.09 (0.95-1.23) 0.210 
Number of referrals  <0.0001  0.712 
 0 1  1  
1 1.31 (1.14-1.50) <0.0001 1  
≥2 1.52 (1.30-1.77) <0.0001 0.97 (0.81-1.16) 0.712 
Referral ≤30 days before consultation  0.078  0.739 
 No 1  1  
Yes 1.21 (0.99-1.48) 0.068 0.97 (0.80-1.17) 0.739 
Admission  <0.0001   
 No 1  1  
Yes 3.28 (3.09-3.49) <0.0001 1.48 (1.35-1.63) <0.0001 
Number of admissions  <0.0001  <0.0001 
 0 1  1  
1 1.80 (1.62-1.99) <0.0001 1  
2 2.72 (2.43-3.03) <0.0001 1.12 (1.02-1.23) 0.013 
3-4 3.68 (3.33-4.05) <0.0001 1.24 (1.13-1.36) <0.0001 
≥5 6.48 (6.00-7.00) <0.0001 1.89 (1.71-2.10) <0.0001 
Expanded Diagnosis Clusters (EDCs) groups  <0.0001  0.498 
 Low 1  1  
Moderate 1.58 (1.43-1.74) <0.0001 1.03 (0.95-1.12) 0.439 
High 3.01 (2.75-3.30) <0.0001 1.00 (0.90-1.10) 0.963 
Adverse event  <0.0001  0.396 
 No 1  1  
Yes 1.90 (1.64-2.19) <0.0001 0.95 (0.83-1.08) 0.403 
Multiple adverse events  <0.0001  0.970 
 No 1  1  
Yes 2.47 (1.76-3.47) <0.0001 0.99 (0.72-1.37) 0.970 
Admission for adverse event  <0.0001  0.001 
 No 1  1  
Yes 4.45 (4.00-4.96) <0.0001 1.22 (1.09-1.37) 0.001 
 
                                                     
*
At GP practice, by telephone or home visit.  
†
At GP practice, by telephone or home visit.  
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6.4.8 Performance of comorbidity measures 
The output of analyses in this chapter presented an opportunity to compare the 
performance of Khan et al’s version of the Charlson Index and the ACG software. When 
selecting which comorbidity measure to include in adjusted regression models for predicting 
the risk of having an adverse event, none of the ACG variables performed better than the 
disease flags derived from the Charlson Index (section 6.4.3.2). The two models with CADGs 
and ADGs performed better than the model with Charlson Index scores. In fact, 
performance of the CADG model was similar to that of the null model.  
For predicting the risk of an emergency admission, Charlson Index based-disease flags 
performed best again (section 6.4.5.2). All comorbidity measures performed better than the 
null model. The models with ADGs, MEDCs, CADGs and RUBs fitted the data better than the 
model containing Charlson Index scores. Like with modelling the risk of emergency 
admission, all models with comorbidity measures performed better than the null model in 
predicting the risk of death (section 6.4.5.2). The model containing EDC counts performed 
best, followed by the model with Charlson Index scores. 
6.5 Discussion 
I begin the final section of this chapter with a précis of the study results, comparing these 
findings from national data with those from local data in Chapter 5. The section concludes 
with reflections on the study’s methodological limitations. 
6.5.1 Summary of main findings 
The first objective of this chapter was to measure the incidence of AEs in the English general 
practice population. Between 1999 and 2008, an incidence rate of 6.0 AEs per 1,000 person-
years was detected in national GPRD data (n=341,261 person-years; 95% CI 5.74-6.27). 
Analyses of local data from NHS Brent collected in 2007 produced an estimated rate of 1.67 
AEs per 1,000 consultations (n=1,118,072 consultations; 95% CI 1.59-1.74). Those analyses 
in Chapter 5 also identified 491 surgical complications, 1,317 ADEs and a further 467 AEs 
recorded as external causes of morbidity and mortality at 23 GP practices. In this chapter, 
2,048 recorded AEs were identified in 1,774 patients at 387 GP practices between 1999 and 
2008. It is difficult to compare these two sets of results with published estimates given the 
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heterogeneity of study methods and limited research within the NHS (Chapter 2 section 
2.5.3.1). The estimated rate using NHS Brent data is far lower than de Wet and Bowie’s 
(2009) estimate of 28.4 incidents of harm per 1,000 consultations which was derived from 
trigger tool assessment of electronic records at five Scottish practices.295 On the other hand, 
that rate of 1.67 AEs per 1,000 consultations is comparable to estimates of 0.037 AEs per 
1,000 consultations and 4.8 AEs per 1,000 consultations from two US studies that used 
larger samples than de Wet and Bowie.8,24  
The second objective was to identify patient risk factors for recorded AEs. In analyses from 
Chapter 5 and this chapter, adverse events were more commonly recorded in older patients, 
especially those aged 65 and 84 years. This predictor is well documented in the 
literature.177,179,295 Other risk factors identified in this chapter were registration at practices 
in the North West of England, having a high number of consultations at the practice, by 
telephone or home visit, 30 days or less between referral and the next consultation and 
having five or more admissions. Patients with recorded hemiplegia, myocardial infarction, 
peptic ulcer disease or peripheral vascular disease had at least one and a half times greater 
risk of having an AE compared to patients without the respective diseases. 
The third objective was to explore the health service use of patients with recorded AEs. The 
majority of patients who had an AE also had at least one consultation at the GP practice, by 
telephone or home visit in the 12 months before their index AE and also following this AE. 
Few patients had a referral request before their first AE, with up to two referrals per patient 
being made. Even fewer patients had a referral request after their index AE, 8.17% of 
patients before compared to 2.25% of patients after. Other referral details were sparsely 
populated in the dataset. The paucity of similar research conducted in England mean that 
interpretation of the findings relating to the second and third study objectives is difficult. 
Yet it also demonstrates the importance of developing the research area and the value of 
this study to the field. 
The fourth and final objective was to explore the outcomes (emergency admissions and 
death) of patients with recorded AEs. Older patients (especially aged 85 years or older), 
patients who lived in the most deprived areas and patients with a high number of 
consultations (in any primary care location) were most at risk of an emergency (all-cause) 
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admission. The associations between increasing patient age, and deprivation status, with 
emergency admissions in England have been described by Bankart et al (2011), among 
others.214,296-298 Patients who had at least one AE were also at greater risk of admission but 
not of death. However, patients who had at least one admission for an AE, or five or more 
(all-cause) admissions, were at greater risk of death. While longer registration time at the 
practice was protective against an emergency admission, this factor was a predictor for 
death, as was having a high continuity of care score. Patients with metastatic tumour or 
moderate liver disease had higher risk of an emergency admission and death. The 
monotonic association between secondary care service use denoted by the number of 
admissions, but not of GP consultations*, and mortality risk is logical given that patients with 
more severe or complex diseases may have greater intensity of hospital contact but not 
necessarily of more general practice care. 
6.5.2 Methodological issues 
The cohort approach to the analyses in this chapter used the AE variable as both predictor 
and outcome measures. By doing so, I was able to explore the temporal sequencing 
between AEs and multiple outcomes (admissions and death). I now reflect on the study’s 
technical deficits, expanding on the discussion of section 6.5.1, and in terms of future 
research. The first caveat of the analyses is the measurement of many predictors and 
outcomes. By multiple statistical testing, it is possible that spurious statistically significant 
associations between variables were identified. To somewhat counter this issue, a higher 
threshold for statistical significance is recommended for more conservative estimates 
(Chapter 4 section 4.6.1). 
6.5.2.1 Accurate identification of cases 
Despite the cleaning process undertaken (section 6.3.3) to improve the accuracy of case 
ascertainment, false positive cases of AEs might have been included in the study. While data 
are collected for research by the GPRD, they are not intended specifically for investigating 
patient safety. Incidents occurring as part of the disease process, expected treatment 
effects or events related to previous AEs may have been unintentionally coded as AEs. The 
                                                     
*
At GP practices, by telephone or home visit with a GP or nurse.  
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reviewed studies in Chapter 2 highlighted the research practice of using multiple data 
sources to enhance data quality. Individual datasets may be affected by a number of biases 
related to reimbursement, management, patient groups and the nuances of the software 
itself.299,300 In this study, additional information from case notes and interviews with 
patients and practice staff would have facilitated the distinction between discrete episodes 
of AEs. 
6.5.2.2 Case-mix adjustments 
In order to identify remediable factors in the organisation and delivery of care in general 
practice, key drivers of quality and safety must be identified. Very few practice variables 
were available in the GPRD dataset, with no data on list size or staff demography. The data 
were unsuitable for linkage to other sources due to their anonymised nature. These 
properties of the dataset narrowed the list of potential confounders that could be adjusted 
for and also restricted the examination of processes of care that may be associated with 
patient harm. Characteristics including patient age, continuity of care, deprivation, length of 
registration time at practice and geographical region of the practice were identified as risk 
factors for having an AE and/or emergency admission and/or death. To better 
understanding the roles of patient and practice characteristics, one also needs to consider 
how they may modify the effects of other characteristics on the outcomes of interest. 
6.5.2.3 Temporal incongruence  
In section 6.5.2, I commented on the exploration of causality in this study. Both a high 
number of consultations* and admissions were associated with greater risk of having an AE. 
Having a high number of consultations (in any primary care location) was also associated 
with increased risk of an emergency admission. For these two predictors, no distinction was 
made on whether the proposed risk factors occurred before or after the outcome. As such, 
the roles may be reversed. For example, having a higher number of admissions may predict 
patients’ high number of consultations. To establish causality, it will be necessary to 
delineate the chronology of events in future research. 
                                                     
*
In any primary care location, or specifically at GP practice, telephone or home visit. 
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Similarly, although marital status was not significantly associated with any of the three 
outcomes, this variable represented patients’ “current status” at the time of data 
submission by the GP practice to GPRD, and not patients’ status at the time of the event(s) 
of interest. Hence, associations between this variable, other predictors and outcomes may 
be inaccurate. Another time-related issue is the possible lag between adverse event, or 
symptom onset, and related consultation. Delayed presentation may affect event recording, 
even though the “event date” field in patient records is intended for recording the date 
associated with the event. Patient delays to consultation may also affect the distinction 
between separate AE episodes, particularly if events occur close together in time. 
Furthermore, the recording of event dates is dependent on the recall of patients, which can 
be erroneous. Not least, the arbitrary lag time I set to distinguish between AE episodes may 
be an inappropriate length, although there is no indication of this from the literature 
(section 6.3.3.3). A final note on event ordering; this study analysed data only from patients’ 
first registration period at a GP practice. Some patients may have had multiple valid 
transfers out of a practice over the study period. Bias from excluding such patients, and 
others by transfer status, was briefly explored during data cleaning. No significant 
differences were identified in the age or sex of patients who transferred out of their current 
practice and those who did not. Likewise, there was no statistically significant difference in 
the two characteristics between patients who had multiple transfers out and patients with 
either just one or no transfer out of their current GP practice.  
6.5.2.4 Comorbidity measures 
Earlier in this Discussion (section 6.5.2.2), I addressed the subject of inadequate comorbidity 
adjustment. In this section, I return to that topic in more detail. No comorbidity measure 
accounts for all co-existing conditions in a studied population. The Charlson Index (and its 
modified versions) is perhaps the most widely used comorbidity measure in health research 
and, consequently, also well validated in different populations.224-226 Still, there is little 
documentation of its use in English general practice and so the use of Khan et al’s version of 
the Index (and two additional Index-derived measures) in this project contributes evidence 
for its validation for this setting (Chapter 3 section 3.9.4.4). Some technical qualities of Khan 
et al’s adaptation require attention, namely the use of fewer diagnosis codes compared to 
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other versions, such as Elixhauser’s modified Index.301 This second measure has 
demonstrated better performance in non-acute populations (Chapter 3 section 3.9.4.4 for 
further discussion).302 Khan et al’s modified measure was based on an ICD-9-CM code 
version of the Charlson Index.226 Due to this, the resulting translation for Read codes may be 
affected by incomplete mapping between taxonomies but, nevertheless, may still be most 
appropriate for the English general practice population.  
Like the Charlson Index, ACG measures have been used in ambulatory care populations, 
including GPRD samples.221,303 The value of time-naïve ACG fields for case-mix adjustment in 
this project has been contemplated in Chapter 3 section 3.9.4.2. Paediatric and obstetric 
data are often excluded from Charlson Index derivations. Data separation also features in 
the use of the ACG software, with separate calculation of ACG weights for adult and children 
recommended.304 Neither the suggested modifications to Charlson or ACG measures were 
applied in this project. As the ACG software was designed for the US population, the default 
case-mix weights are set for that population and may not be accurate for the English general 
practice population.305 
Overall, neither set of comorbidity measures displayed absolute best performance. The 
Charlson Index score performed less well than Charlson-based disease flags in modelling the 
risk of adverse events and emergency admissions. The latter measure performed best out of 
all comorbidity measures for these two outcomes. In models to predict death, the two 
measures had similar performances to each other but counts of EDCs from the ACG 
software was the best performing comorbidity measure. Besides the restrictions described 
already in this section and in Chapter 3, a further technical issue to note is the inclusion of 
conditions and diseases that may have resolved, which is related to the time-naivety of the 
ACG variables.221 The potential problem of misclassification can only be rectified through 
the use of additional data as suggested in section 6.5.2.1. 
6.5.3 Patient outcomes 
First-time and subsequent AEs were included in calculations. To inform service delivery and 
patient safety monitoring, more sophisticated analyses should determine whether having a 
first AE predicts the occurrence of future adverse events. As stated in section 6.5.1, the 
estimated rate of AEs was lower than some reported rates for the non-acute setting. 
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Plausible independent and combined reasons for the low incidence rate in this study are: 
lack of presentation in general practice (AEs causing low levels of patient harm); 
presentation in secondary care instead of general practice (AEs causing high levels of patient 
harm); failure to record AEs using the designated complication of care codes; failure to 
diagnose AEs; and failure to capture AEs that do not correspond to the basic set of diagnosis 
codes used in the analyses. 
Some of the measured AEs have corresponding external causes of morbidity and mortality 
(ICD-10 Y codes). These codes are typically used for secondary diagnoses. As primary and all 
secondary HES and ONS diagnosis fields were included in the analyses, it is unlikely that 
valid diagnoses in the ICD-10 “Y” code block will have been excluded. No attempt was made 
to link AEs with subsequent outcomes (emergency admissions and death). Although a 
temporal relationship was identified in the measurement of admissions and death 
subsequent to AEs and/or admissions for AEs, direct causality was not established but 
should be explored in future research. 
6.5.4 Implications for clinical care and health policy 
This study has applied national data from ten years, using validated coding systems and 
outcome measures, to identify temporal trends in the epidemiology of recorded AEs in 
general practice in England. The rates of AEs were low, but concur with findings from other 
studies, although further external validation is recommended. Within the framework for 
measuring and monitoring patient harm, there must be room to assess the amenability of 
detected events. As suggested in section 6.5.2.1, some AEs may not be due to medical 
errors or indeed be preventable. There is a growing evidence base around preventable ADEs 
in the non-acute setting but information on non-drug related incidents in general practice 
and elsewhere in primary care is still fragmented, locally-orientated and without definitive 
priorities for service improvement or research (Chapters 2 and 5). The identified high-risk 
patient groups for adverse events and other adverse outcomes (emergency admission and 
death) will inform safety improvement initiatives and steer research on patient harm.  
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Chapter 7: Unplanned admissions for diabetic 
emergencies 
 
7.1 Chapter overview 
This chapter examines the recording of unplanned (emergency) admissions 
for diabetic ketoacidosis and coma using GPRD data. I identify risk factors 
for this outcome and describe the health service use of patients who had 
one or more of these admissions. In the final section of the chapter, the 




I gave justifications for examining emergency admissions for diabetic emergencies in 
Chapter 3 section 3.3. In the next section of this chapter (section 7.2.8), I develop the 
rationale for this study. Before this, I describe diabetes, its complications and their 
treatments within the context of the NHS. 
7.2.1 Definition of diabetes 
Diabetes mellitus (DM) is a group of disorders that share common features, notably 
impaired glucose metabolism.306 Diabetes is a chronic and progressive disease. The most 
common are Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) and, to a 
lesser extent, gestational diabetes. Symptoms of diabetic disorders include weight loss, 
blurred vision, polydipsia, polyuria, polyphagia, repeated skin infections and tiredness.307-309 
T1DM often has a rapid onset and commonly occurs at a younger age compared to T2DM.308  
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Signs of T1DM also include hyperglycaemia (random testing of blood glucose concentration 
higher than 11 mmol/litre and ketonuria), acidosis and ketonaemia.308,310 In contrast, 
patients with T2DM may present with non-specific symptoms or be asymptomatic.309,311 
Patients are considered to have T2DM if they do not have T1DM, monogenic or secondary 
diabetes.311 Diabetes is diagnosed by the presence of the acute hyperglycaemic symptoms 
listed at the start of this paragraph and/or the following test results with at least two tests 
performed on different days: 
 Fasting plasma glucose ≥ 7.0mmol/litre (l) or 126mg/decilitre (dl), or 
 Random venous plasma glucose concentration ≥ 11.1mmol/l or 200mg/dl, or 
 2 hour plasma glucose concentration ≥ 11.1mmol/l or 200mg/dl 2 hours after 75g 
oral glucose tolerance test (OGTT).306,309 
7.2.2 Prevalence of diabetes 
Diabetes is a major global health problem, with a worldwide projected prevalence of 4.4% 
by 2030.312 Approximately 90% of people with diabetes have T2DM. Historically, T1DM has 
been the most prevalent form of diabetes in younger people. It is most commonly 
diagnosed in children aged between 10 and 14 years.313 In recent years, not only has there 
been a continuing rise in the incidence of T1DM in children,314,315 but there are also more 
diagnoses of T2DM in young people across the world.316-318 Approximately 23,000 people 
aged under 25 years have been diagnosed with diabetes in the UK, of which 20,500 people 
were diagnosed with T1DM.319 
In England, 2.9 million adults have been diagnosed with diabetes and the prevalence is 
expected to reach 4 million people by 2025.210,320 The accuracy of diabetes diagnosis in the 
UK has been under scrutiny, with undiagnosed diabetes estimated to affect one percent of 
the UK population.321-323 As a consequence of the rising new cases of diabetes, there are 
considerable demands on health resources. A key method of ameliorating the burdens of 
diabetes care on the health and social system is the reduction of preventable diabetic 
complications. 
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7.2.3 Diagnosis, treatment and management 
To address the challenge of meeting the needs of patients with diabetes, one needs to 
consider the schema of public health - prevention, diagnosis, treatment and management. 
In England there are national policies that cover these four tenets for a number of diseases 
and conditions, with the aims of improve the quality of care and reducing variation in 
patient outcomes across the country. For diabetes, there is the National Service Framework 
(NSF) for diabetes.324,325 Despite almost a decade of implementing the NSF, there remains 
unacceptable national discrepancies in the quality of care for patients with diabetes.326 
I now briefly map diabetes to the mentioned schema, at the point of diagnosis. Diabetes can 
be diagnosed by symptoms, during a routine health check or when a patient presents with a 
diabetic, typically hyperglycaemic, emergency. Confirmation of diagnosis is through 
measurement of glycaemic status. Treatment for diabetes may involve insulin and/or 
medication. Education and lifestyle changes, such as controlled diet and exercise, are 
important in managing diabetes. There is a strong emphasis on diabetes care being 
delivered by integrated multidisciplinary teams (MDTs), including a structured educational 
programme on treatment regime, diet and self-management.308,311 For patients aged under 
18 years who have suspected T1DM, same day referral to specialist paediatric diabetes care 
is recommended by the National Institute for Clinical Excellence (NICE).308  
7.2.4 Diabetic complications  
Compared to the general population of the same age, patients with T1DM have 
approximately 2.6 times greater risk of death and patients with T2DM have approximately 
1.5 times greater risk of death.327 Along the continuum of undesirable outcomes in patients 
with diabetes, a wide range of complications are associated with the disease. While the 
aetiologies of insulin-dependent and non-insulin dependent diabetes are markedly different, 
the sequelae of the two disorders are similar.310 These can be classed as macrovascular 
(such as cardiovascular disease - angina, myocardial infarction, cardiac failure and stroke), 
microvascular (such as diabetic retinopathy, neuropathy and nephropathy) and other 
complications (such as sexual dysfunction, complications during pregnancy, depression and 
psychological ill-health).306,308,311 
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7.2.5 Diabetic emergencies 
Acute diabetic complications resulting in medical emergencies can arise from extremely high 
blood glucose levels (hyperglycaemia). In patients with T1DM, diabetic ketoacidosis (DKA) is 
the more common form of hyperglycaemic emergency. In patients with T2DM, 
Hyperosmolar Hyperglycaemic State (HHS) also known as hyperosmolar non-ketotic (HONK) 
coma is more common.307 Patients may also fall into a diabetic coma when they have low 
blood glucose levels (hypoglycaemia). These hyperglycaemic and hypoglycaemic 
complications are hereafter collectively referred to as diabetic emergencies. Such states, 
especially diabetic ketoacidosis, can be secondary to severe acute diseases, such as 
myocardial infarction and pneumonia.328 Other precipitating factors include poor insulin 
management (including non-compliance) and excess alcohol intake.328-330  
7.2.5.1 Treating diabetic emergencies 
Hospital treatment of diabetic emergencies is needed, unless there is an absence of 
dehydration or acidosis, in accordance with established clinical guidelines.307-309,331 These 
emergencies affect a large proportion of patients with diabetes; approximately 11% of 
patients in England with T1DM experienced an episode of DKA between 2004 and 2009.332 
Even though the mortality rate for patients with DKA is declining in England (estimated at 
less than five percent of patients), emergency admissions for this preventable complication 
are increasing.333 In England, the (indirectly standardised by age and sex) rate of admissions 
for DKA was 2.17 admissions per 10,000 resident population in 2002 compared to 2.68 
admissions per 10,000 resident population in 2008.205 Between April 2009 and March 2010, 
there were 14,183 emergency admissions for DKA in England, of which 20 percent were 
patients aged under 15 years.334 Over half of patients aged under 20 years who are admitted 
for diabetes do not have a prior diagnosis of diabetes.335 
There are a number of conditions that can arise during treatment of diabetic emergencies, 
and which may be useful external markers of the severity of the admission.310 Four of the 
most common and serious adverse effects of treatment are (with corresponding ICD-10 
diagnosis code in brackets): 
 Hyperkalaemia (E87.5) and hypokalaemia (E87.6); 
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 Hypoglycaemia (E16.0, E16.1 and E16.2); 
 Cerebral oedema (G93.6); and 
 Pulmonary oedema (J81). 
7.2.6 Burden of care 
Diabetes-related care is extremely costly, requiring approximately ten percent of the NHS 
budget, equating to approximately £9 billion per year.320 The estimated cost of managing 
the most common type of diabetes, T2DM, is between £1,080 and £1,738 per patient, per 
year.336-338 One in ten patients admitted to hospital has diabetes. These patients account for 
an approximate excess of 81,000 bed days per year (based on the mean length of stay) and 
experience longer hospital stays and more readmissions than patients without 
diabetes.337,339,340 As well as hospital costs and social services (such as residential or nursing 
care homes), additional management of microvascular and macrovascular complications 
contributes to an estimated spend of £5,132 per patient with diabetic complications.337,341 
Patients with diabetic complications, especially microvascular complications, are also more 
likely to have loss of earnings compared to patients with no complications.342 
7.2.7 Recording of diabetes and diabetic complications 
Data on diabetes care are collected for reimbursement, quality monitoring and research. 
Consequently, data for the whole country are available albeit with inconsistent quality.133 
Discharge coding of diabetes is poor for inpatient care, with approximately 24% of patients 
missing appropriate codes.343 Within primary care, where the majority of diabetes care 
occurs, there are known coding and classification errors, including incorrect and under-
diagnosis of diabetes.323,344,345 Across classification systems, there are also irregularities in 
coding (Chapter 1 section 1.6.8). I will return to diagnosis coding later (section 7.3.1). 
7.2.8 Rationale for analysis 
I now summarise the issues raised so far in this chapter and in doing so, clarify the reasons 
for conducting this research. Firstly, acute diabetic emergencies can have potentially long 
term effects, such as permanent neurological impairment, and place great burdens on the 
health service. As diabetic emergencies are preventable, these conditions warrant 
investigation for the purpose of health service improvement. This belief is supported by 
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evidence of considerable variation across England in the rates of admissions for DKA and the 
treatment of this and other diabetic emergencies.332,346 Partly as a consequence of 
regulatory performance reporting, national data collected on the management of diabetic 
emergencies are available for secondary analysis. These data have already shown promise 
for measuring the quality of primary care services.297,347-349  
Theoretically, with the availability of effective treatments and explicit protocols for 
managing diabetes and associated complications, there should be low rates of serious 
morbidity and mortality in patients with diabetes (patient compliance permitting).350 Of 
course, in reality, the situation is far more complex because patients with diabetes often 
have multiple chronic comorbidities as well as episodes of acute complications. As well as 
the behaviour of patients themselves affecting their outcomes, provider behaviour is also 
important. Studies have found complex associations between practice characteristics, such 
as nurse staffing levels, and diabetes care in primary care.351-354  
In short, DKA and other acute emergencies are serious but avoidable complications of 
diabetes. Data on their treatments are captured in primary and secondary care computer 
systems. By examining emergency admissions for DKA and diabetic coma and patients’ 
access of services, we can better understand the patient and organisational factors 
associated with the occurrence of these diabetic complications. 
7.2.8.1 Aims of analysis 
This study explores the characteristics of patients who had one or more emergency 
admissions for a diabetic emergency, namely diabetic ketoacidosis or coma due to 
hyperglycaemia or hypoglycaemia, in England between 1999 and 2008. Routinely collected 
data were used to address the objectives set out in the next section (section 7.2.8.2). 
7.2.8.2 Objectives of analysis 
The three objectives of the analyses were: 
1. Determine the incidence of emergency admissions for diabetic ketoacidosis and diabetic 
(hyperglycaemic or hypoglycaemic) coma using linked GPRD and HES data in: 
a. all patients; and 
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b. patients diagnosed with diabetes. 
2. Identify predictors of emergency admissions for diabetic ketoacidosis or diabetic 
(hyperglycaemic or hypoglycaemic) coma in patients diagnosed with diabetes. 
3. Describe the patterns of service use (consultations and emergency admissions) of 
patients who have at least one emergency admission for diabetic ketoacidosis or 
diabetic (hyperglycaemic or hypoglycaemic) coma. 
7.3 Methods 
A cross-sectional approach was used to measure the rate of unplanned admissions for 
diabetic emergencies. Crude and adjusted (indirectly standardised by age and sex) rates 
were calculated for the two denominator populations – all patients and patients with known 
diabetes. Analyses were focused on patients with diabetes as the conditions of interest are 
predominantly complications of the disease and preventable in diagnosed patients. For 
more details about the standardisation method, Chapter 4 section 4.7.1. 
7.3.1 Defining diabetes 
Read codes for diabetes were extracted from the NHS Clinical Terminology Browser 
(Appendices Table A.13).284 Further aggregation of diabetes types was made to avoid 
problems with small numbers in analyses (Table 6.1).  
Table 7.1 Original and aggregated groupings of diabetes by type 
Type of diabetes Aggregated group 
Type 1 (Insulin-dependent) diabetes mellitus Type 1 
Type 2 (non-insulin-dependent) diabetes mellitus Type 2 
Gestational diabetes mellitus  Other 
Malnutrition diabetes mellitus Other 
Neonatal diabetes mellitus  Other 
Other diabetes mellitus Other 
Unspecified diabetes mellitus Other 
 
To ensure complete identification of patients with diabetes, as well as using Read codes for 
the corresponding types of diabetes shown in Table 7.1, the description of the medical code 
(unique GPRD code for the term selected by the person who entered the data at GP practice) 
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was also used to select patients who did not have a diabetes diagnosis recorded elsewhere 
(Appendices Table A.14). These diabetes-related terms were grouped as shown in Table 7.2. 
Table 7.2 Clinical entries related to diabetes 
GPRD Entity Code Category 
18 Diabetic register 
22 Diabetes annual check 
26 Current Diabetes status 
59 Ankle neuropathy 
65 Diabetic consultation 
91 Diabetes concerns 
97 Insulin dosage 
117 Foot pulse right leg 
118 Foot pulse left leg 
134 Visual acuity right eye 
135 Visual acuity left eye 
 
7.3.2 Diseases associated with diabetes 
To meet the overarching study aim and study objective number 3, diagnoses related to 
diabetes were identified to better ascertain the service use and outcome (death) of patients 
diagnosed with diabetes and who had at least one diabetic emergency admission. Diabetes-
related diagnoses used in the 2010/11 National Diabetes Audit were applied, along with 
adapted version of diagnoses grouped by McEwen et al*.355,356 Other diagnoses related to 
diabetes were added, including drug-related outcomes in young people with T1DM.329 
7.3.3 Defining diabetic emergency 
In section 7.2.7 and Chapter 1 section 1.6.8, I raised the issue of variation in coding between 
classification systems. One example is the lack of distinction between hyperglycaemic and 
hypoglycaemic comas in the ICD-10 system where diabetes mellitus with any coma is 
denoted by the fourth character subdivision of “.0” and ketoacidosis with the subdivision of 
                                                     
*
McEwen et al are reported to have included ICD-10 codes V00-V89. I have used an expanded set of codes, 
ICD-10 V01-99, as there is no ICD-10 V00 code block and there also seems to be no good reason to exclude the 
V90-99 codes.
355
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“.1”. In contrast, there is separation of diabetic comas in the Read classification system 
(Appendices Table A.15).  
In these analyses, HES data were used to identify emergency admissions for hyperglycaemic 
emergencies and therefore the ICD-10 coding distinctions applied. The definition of 
emergency admission has been stated in Chapter 3 section 3.9.3. Guided by these 
classifications, diabetic emergencies were categorised as being either diabetic ketoacidosis 
or diabetic coma. All causes of admission recorded in the HES linked dataset with ICD-10 
E10-E14 codes and the fourth character of “.0” or “.1” were mapped to the appropriate 
complication. For convenience, emergency admissions for diabetic emergencies will 
hereafter be referred to by the abbreviation DEA (diabetic emergency admission). 
7.3.4 Selection of predictor variables 
Variables included in the analyses were chosen because of their known or suspected 
associations with diabetes and diabetic complications.219,348,351,354,357  
7.3.5 Type of analysis 
Only crude analyses were performed in this study. The decision not to conduct adjusted 
analyses was made in light of the exploratory nature of the study and the low numbers of 
patients with diabetes and DEAs identified over the ten years studied. As explained in 
Chapter 4 section 4.6, the log transformation of patients’ follow-up time was included as an 
offset term in the regression models for predicting the risk of DEAs. 
7.4 Results 
Before presenting the estimated incidence of DEAs and analyses of risk factors and service 
usage, I describe the demography of the study sample.  
7.4.1 Patient characteristics 
The cleaned GPRD dataset (Chapter 3 section 3.7.5) contained the records of 74,763 
patients at 457 GP practices. Among these patients, 1,359 were identified with a primary 
care diagnosis of diabetes (identified by Read codes) at 217 GP practices. There were 1,616 
diagnoses of diabetes among the 1,359 patients (Table 7.3). Out of these diagnoses, 5.57% 
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of diagnoses were for type 1 diabetes, T1DM, (n=90/1,616) and 39.1% of diagnoses were for 
type 2 diabetes, T2DM (n=632/1,616). The majority of “Other diabetes” diagnoses were for 
unknown subtype (95.8%; n=460/480) (section 7.3.1). Comparing the types of diagnoses by 
sex, there was little difference in the number of T1DM diagnoses among male and female 
patients (n=49 and n=48, respectively). For recorded T2DM diagnoses, there were more 
diagnoses in male patients (52.5%; n=350/667) than female patients (47.5%; n=317/667). 
There was little difference the number of “Other diabetes” diagnoses between the sexes, 
with 49.3% of recorded and inferred (from medical code descriptions, section 7.3.1) 
diagnoses in male patients (n=660/1,338) compared to 50.7% of diagnoses in female 
patients (n=678/1,338). For T1DM, diagnoses were more common in younger patients, with 
45.3% of diagnoses recorded in patients aged up to 44 years (n=44/97). For T2DM, 54.9% of 
diagnoses were in patients aged 65 years or older and there were no diagnoses in patients 
aged less than 15 years (n=366/667). For “Other diabetes”, there were few recorded 
diagnoses at either extreme of age groups, with the most diagnoses in patients aged 
between 45 and 64 years out of all age groups (n=484/1,338). 
Table 7.3 Types of diabetes diagnoses by age group and sex, n=1,359 patients 
Age group (years) 
T1DM T2DM Other diabetes 
Males Females Males Females Males Females 
n (%) n (%) n (%) n (%) n (%) n (%) 
0-14 3 6.12 7 14.6 0 - 0 - 29 4.39 30 4.42 
15-44 18 36.7 16 33.3 20 5.71 28 8.83 135 20.5 153 22.6 
45-64 16 32.7 14 29.2 146 41.7 107 33.8 265 40.2 219 32.3 
65-84 11 22.6 11 22.9 167 47.7 163 51.4 208 31.5 233 34.4 
≥85 1 2.04 0 - 17 4.86 19 5.99 23 3.48 43 6.34 
 
There were 32 patients who had one or more DEAs during the study period. Three of these 
patients did not have a primary care diagnosis of diabetes during the study period. Of the 
remaining 29 patients who were diagnosed with diabetes, 27 patients were diagnosed 
before their index DEA. The type of diabetes was unknown in approximately half of patients 
with a recorded diagnosis (48.1%; n=13/27), while 37% of patients received a diagnosis of 
T1DM before their first DEA (n=10/27). Only one patient who had a DEA also had a recorded 
complication of treatment, hypokalaemia, for the same admission (section 7.2.5).  
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7.4.2 Multiple admissions 
The majority of patients had one DEA during the study period, ranging up to 6 DEAs per 
patient. The most DEAs occurred in 2008 (n=10) and the fewest DEAs occurred in 1999 and 
2002, when there was only one DEA during each year (Table 7.4).  
Table 7.4 Number of diabetic emergency admissions (DEAs) by discharge year, n=32 patients 
Discharge year DEAs, n (%) Patients, n 
1999 1 (2.38) 1 
2000 3 (7.14) 3 
2001 3 (7.14) 3 
2002 1 (2.38) 1 
2003 2 (4.76) 2 
2004 6 (14.3) 5 
2005 8 (19.2) 7 
2006 6 (14.3) 6 
2007 2 (4.76) 2 
2008 10 (23.8) 7 
 
7.4.3 Incidence 
There were 42 DEAs in 32 patients at 28 GP practices between 1999 and 2008. The overall 
follow-up time was 341,261 person years. From the sample of 74,763 patients, there was a 
rate of 0.12 DEAs per 1,000 person years during the study period. 
7.4.3.1 Incidence in patients with diabetes 
Over the ten years studied, there were 3.97 DEAs per 1,000 person years in patients with 
diabetes, with 10,571 person years of follow-up time. There were marked fluctuations in the 
overall rate of DEAs, ranging from 0.94 DEAs per 1,000 person years in 2002 to 9.47 DEAs 
per 1,000 person years in 2008 (Figure 7.1). 
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Figure 7.1 Rates of diabetic emergency admissions and diabetes by year, 1999-2008 
 
 
There was wide variation between patients of different age groups in the rate of DEAs. 
Limited interpretations of the rates can be made given the low number of admissions during 
the study period. There were no admissions in at least three years for patients in each of the 
five age groups. The number of male (n=15) and female (n=14) patients who had at least 
one DEA was similar but the number of DEAs per patient was greater in male patients, and 
so there was a greater rate of DEAs in male patients compared to female patients, 4.67 
DEAs per 1,000 person years compared to 3.26 DEAs per 1,000 person years.  
Figure 7.2 shows that compared to the age and sex distribution of the study sample, the 
greatest proportion of DEAs was in male patients aged between 15 and 44 years (n=13/42 
admissions). Compared to the proportion of patients in the diabetic sample, the proportion 
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Figure 7.2 Age and sex distribution of patients diagnosed with diabetes compared to those who 
had one or more diabetic emergency admissions, 1999-2008 
 
 
The rate of diabetic emergency admissions ranged from 1.97 DEAs per 1,000 person years in 
patients aged between 65 and 84 years to 34.1 DEAs per 1,000 person years in patients 
aged 0 to 14 years during the study period (Table 7.5). 
Table 7.5 Incidence rate by age group and follow-up time, per 1,000 person years 
Age group (years) DEAs, n Person time (years) Incidence rate (95% CI) 
0-14 3 88.0 34.1 (7.03-99.7) 
15-44 19 971.9 19.6 (11.8-30.5) 
45-64 7 3435.7 2.04 (0.82-4.20) 
65-84 10 5077.3 1.97 (0.94-3.62) 
≥85 3 997.8 3.01 (0.62-8.79) 
 
The prevalence of diabetes in the study population (in bold blue type) was lower than 
published national rates, based on data available during study period (Table 7.6). In fact, 
unlike the national trend of increasing prevalence, there was a decrease from 4.05 cases per 
100 patients in 1999 to 2.69 cases per 100 patients in 2008. However, when comparing the 
estimated prevalence (cumulative frequency rather than point prevalence) from these 
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analyses with published estimates only for the three years where data from all sources were 
available, the estimated rates from this study lie between those from the National Diabetes 
Audit, QRESEARCH and QOF.206,210,326  
Table 7.6 Comparison of national and study prevalence rates of diabetes mellitus (per 100 
patients), 1999-2008  
Dataset 
Year 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
NDA*     3.25 3.51 3.74 3.79 3.91 4.13 
QOF†      3.34 3.55 3.65 3.87 4.07 
QRESEARCH‡   1.18 1.36 1.58 1.96 2.27 2.57   
Study§ 4.05 3.86 3.28 3.23 3.20 2.86 2.82 2.72 2.70 2.69 
Sources: NHS Information Centre for Health and Social Care210,326 and QRESEARCH.206 
The estimated crude and standardised rates of DEAs fluctuated over the study period (in 
bold blue type), which was not reflected in the published estimates (Table 7.7). The crude 
rate of DEAs per 100,000 population was lower than published rates. Conversely, age and 
sex standardised rates of DEAs in the study sample were higher for 4 out of the 7 years 
where published data were available. 
Table 7.7 National and study incidence rates of emergency admissions for diabetic ketoacidosis 
and diabetic coma (per 100,000 population), 1999-2008  
Type of rate 
Year 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Crude**    21.5 21.5 22.5 24.4 25.8 26.6 26.8 
Crude 4.18 11.7 9.5 3.0 5.9 15.9 20.7 14.9 4.9 24.8 
Age and sex standardised††    21.7 21.5 22.6 24.4 25.8 26.7 26.8 
Age and sex standardised 11.4 31.8 26.0 8.2 16.1 36.2 49.7 40.8 13.6 47.8 
Sources: NHS Information Centre for Health and Social Care.204,210  
                                                     
*
NDA data are for 1
st
 January to 31
st
 March of the following year. Patients with a first diabetes diagnosis during 
the audit year are excluded. 
†
QOF data are for the financial year - 1st April to 31st March of the following year.   
‡
QRESEARCH data are point prevalence estimates on 1
st
 April of a given year. 
§
Study data are cumulative frequency counts for a calendar year.  
**
Denominator: ONS mid-year resident population estimate. 
††
Denominator: ONS mid-year resident population estimate. 
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7.4.4 Methodological issues 
Given the excess of zero counts of the response variable (number of DEAs) in the study 
sample, modelling using zero-inflated Poisson (ZIP) regression was considered (Chapter 4 
section 4.8.4.2). Despite the skewness, there was little variation in the number of recorded 
DEAs in the sample. All except five out of 1,359 patients had either no admissions or one 
admission for a diabetic emergency during the study period. With this distribution, one 
might consider fitting a binomial regression model using a binary outcome flag for “one or 
more DEAs” and “no DEAs”. However, to incorporate the differences in the length of time 
that patients were included in the study (Chapter 4 section 4.5), Poisson regression with a 
continuous outcome variable was more appropriate for calculating relative risks. The second 
stage of crude analyses featured the generalized estimating equations (GEE) method to 
account for clustering at the practice-level (Chapter 4 section 4.8.2.2). 
7.4.4.1 Exclusions from analyses 
Several disease groups that feature in Charlson Index score categories were not included in 
crude or adjusted analyses due to low numbers or no occurrences of these diseases in the 
study sample during the study period. These diseases were cancer, cerebrovascular disease, 
hemiplegia, moderate liver disease, renal disease and rheumatological disease.  
Crude Poisson regression models for several comorbidity markers failed to converge due to 
all patients having the condition. No outputs are provided for these conditions: 
 Chronic Medical: Unstable - ADG 10; 
 Chronic Specialty: Stable-Ear, Nose, Throat - ADG 13; 
 Chronic Specialty: Unstable-Orthopedic - ADG 16; 
 Chronic Specialty: Unstable-Ear, Nose, Throat - ADG 17; 
 Chronic Medical: Stable - CADG6; and 
 Endocrine - MEDC 6. 
7.4.4.2 Final dataset for analyses 
As stated in section 7.4.1, there were three patients who had DEAs but did not have a 
diagnosis of diabetes during the study period. These patients were excluded from further 
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analyses as the denominator group of interest was patients with diabetes. Thus, the 
following analyses used data on 1,359 patients who had a recorded diagnosis of diabetes at 
any time up to the end of the study period, including 29 patients who had at least one DEA, 
from 217 GP practices. Due to small numbers in some categories, the 10 original practice 
regions were combined into the four NHS SHA clusters (Appendices Table A.16).358 P-values 
reported in this section are p<0.0001 unless stated otherwise. 
7.4.5 Risk factors for diabetic emergency admissions 
On average, patients were 57 years old (SD 17.3 years) when they entered the study 
(n=1,359). Patients who had at least one DEA were younger (mean 46 years, SD 22.1 years, 
n=29) than those who did not have any DEAs during the study period (mean 57 years, SD 
17.1 years, n=1,330), p=0.011. In the overall sample, the average length of time that 
patients were registered at their GP practice before exiting the study was 18.9 (SD 14.9) 
years. Patients who had at least one DEA tended to have been registered for longer (mean 
19.7 years, SD 14.8 years) than the other patients, although this difference was not 
statistically significant (p=0.781). 
There was also no statistically significant difference in follow-up time between patients with 
diabetes who had at least one DEA (mean 8.43 years, SD 2.29 years) and those who did not 
(mean 7.76 years, SD 3.13 years), p=0.135. The Charlson Index score was low in both groups, 
but significantly different between patients who had at least one DEA (mean score 0.17, SD 
0.38) and patients who did not have a DEA (mean score 3.26, SD 6.83, n=1,330), p=0.005. 
Patients who had at least one DEA had fewer consultations at the GP practice, by telephone 
or home visit during the study period (mean 37.2 consultations, SD 35.2 consultations) than 
patients who did not have any DEAs (mean 78.6 consultations, SD 65.5 consultations, 
n=1,330), p<0.0001. Similarly, patients who had at least one DEA also had fewer admissions 
overall during the study period (mean 2.93 admissions, SD 2.42 admissions) compared to 
patients who did not have a DEA (mean 4.95 admissions, SD 7.90 admissions, n=1,155), 
p<0.0001. There was no difference in the number of referrals between those patients who 
had a DEA (mean 1.50 referrals, SD 0.58 referrals) and patients who did not (mean 1.92 
referrals, SD 2.13 referrals, n=156), p=0.693. 
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7.4.6 Crude associations with diabetic emergency admissions 
In crude analyses, the 95% significance level was assigned as the cut-off for determining the 
statistical significance of variables. At this level, ethnicity (p=0.068), number of consultations 
at the GP practice, by telephone or home visit (p=0.003) and the Charlson score (0.006) 
were associated with having a DEA.  
Table 7.8 presents the crude Poisson regression results. Compared to patients with diabetes 
aged under 15 years (reference group), older patients were less at risk of having a DEA. In 
patients aged between 15 and 64 years when they entered the study, the relative risk (RR) 
was 0.27, 95% CI 0.08-0.90; p=0.032. In patients aged 64 years and older the RR was lowest 
at 0.22 (95% CI 0.06-0.80, p=0.021). Patients who had the most consultations at the GP 
practice, by telephone or home visit were least at risk of having a DEA (RR 0.29, 95% CI 0.11-
0.77; p=0.013). Patients with higher Charlson Index scores were also less at risk of a DEA (RR 
0.76, 95% CI 0.62-0.92; p=0.006). Further results by comorbidities are reported in the 
Appendices (Table A.17). These results include lower risk of DEA in patients with diabetes 
and chronic pulmonary disease (COPD) compared to patients without COPD (RR 0.24, 95% CI 
0.06-0.99; p=0.048). Patients with diabetes and mild liver disease were at greater risk of a 
DEA than patients without mild liver disease (RR 6.75, 95% 0.93-49.19; p=0.059). 
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Table 7.8 Risk factors for diabetic emergency admission (DEA) in patients with diabetes, crude 
results from Poisson regression 
Characteristic 
Patients with diabetes, n 




Age group at start of study (years)     0.141 
 <15 31 3 (9.68) 1  
15-64 841 18 (2.14) 0.27 (0.08-0.90) 0.032 
≥65 487 8 (1.64) 0.22 (0.06-0.80) 0.021 
Sex     0.297 
 Male 691 15 (2.17) 1  
Female 668 14 (2.10) 0.71 (0.38-1.35) 0.300 
Ethnicity     0.068 
 White 304 4 (1.32) 1  
Non-white 965 24 (2.49) 2.61 (0.93-7.36) 0.069 
Unknown 90 1 (1.11) 0.89 (0.10-7.92) 0.913 
Marital status     0.118 
 Married 196 2 (1.02) 1  
Status other than married 76 2 (2.63) 2.78 (0.39-19.74) 0.306 
Unknown 1087 25 (2.30) 3.45 (0.83-14.36) 0.088 
Deprivation (quintiles)     0.279 
 Least deprived 309 6 (1.94) 1  
Quintiles 2,3,4 184 3 (1.63) 0.67 (0.17-2.59) 0.561 
Most deprived 627 14 (2.23) 1.23 (0.51-2.94) 0.643 
Unknown 239 6 (2.51) 1.98 (0.77-5.11) 0.157 
Practice region     0.598 
 London 333 6 (1.80) 1  
Midlands and East 409 11 (2.69) 1.3 (0.50-3.34) 0.593 
North 466 9 (1.93) 1.78 (0.74-4.30) 0.198 
South 151 3 (1.99) 1.34 (0.39-4.56) 0.645 
Time at practice (years)     0.975 
 Low 445 8 (1.80) 1  
Moderate 458 12 (2.62) 0.94 (0.40-2.22) 0.890 
High 456 9 (1.97) 1.02 (0.44-2.38) 0.968 
Continuity of care     0.432 
 Low or moderate 882 21 (2.38) 1  
High 446 8 (1.79) 0.73 (0.35-1.49) 0.386 
Not valid 31 0 - - - 
Consultations
†
     0.003 
 Low 438 12 (2.74) 1  
Moderate 456 11 (2.41) 1.14 (0.56-2.32) 0.711 
High 465 6 (1.29) 0.29 (0.11-0.77) 0.013 
Referrals     0.973 
 No 1199 25 (2.09) 1  
Yes 160 4 (2.50) 1.02 (0.40-2.60) 0.973 
Charlson Index score, mean (SD) 3.20 (6.77) 0.83 (2.04)  0.76 (0.62-0.92) 0.006 
Resource Utilization Band (RUB)     0.727 
 Healthy, low or moderate 232 5 (2.16) 1  
High to very high 1127 24 (2.13) 1.18 (0.46-3.01) 0.733 
                                                     
*
DEA – Diabetic emergency admission. 
†
At GP practice, by telephone or home visit. 
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7.4.6.1 Crude associations with diabetic emergency admissions, adjusted 
for GP practice 
The crude Poisson regression model for grouped continuity of care scores, with adjustment 
for clustering of patients in practices did not converge and so no results for this model are 
reported in Table 7.9. Once clustering was accounted for, only the number of consultations 
at GP practice, by telephone or home visit (p=0.031) and Charlson score (p=0.022) were 
statistically significantly associated with having a DEA in patients with diabetes. The relative 
risks did not differ between unadjusted (crude) and adjusted (for clustering) results, but 
confidence intervals were generally wider in the adjusted results and p-values also changed 
accordingly.  
Compared to patients aged under than 15 years, adults remained less at risk of an 
unplanned admission for a diabetic emergency. The RR was 0.27 (95% CI 0.08-0.87; p=0.028) 
for patients aged between 15 and 64 years and RR 0.22 (95% CI 0.06-0.87; p=0.031) for 
patients aged 65 years and older. Compared to patients who had fewer consultations at the 
practice, by telephone or home visit, patients who had the greatest number of consultations 
were least at risk of a DEA (RR 0.29, 95% CI 0.11-0.78; p=0.015). A higher Charlson score had 
a protective effect against DEAs (RR 0.76, 95% CI 0.59-0.96; p=0.022). Patients with diabetes 
and COPD remained less at risk of a DEA than patients without COPD (RR 0.24, 95% CI 0.06-
0.97; p=0.045) while patients with mild liver disease were more at risk of a DEA (RR 6.75, 95% 
CI 1.19-38.4; p=0.031). Further results by comorbidities are in the Appendices (Table A.18). 
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Table 7.9 Risk factors for diabetic emergency admission (DEA) in patients with diabetes, crude 
results from Poisson regression using the generalized estimating equations (GEE) method 
Characteristic 
Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Age group at start of study (years)  0.141  0.392 
 <15 1  1  
15-64 0.27 (0.08-0.90) 0.032 0.27 (0.08-0.87) 0.028 
≥65 0.22 (0.06-0.80) 0.021 0.22 (0.06-0.87) 0.031 
Sex  0.297  0.487 
 Male 1  1  
Female 0.71 (0.38-1.35) 0.300 0.71 (0.28-1.82) 0.479 
Ethnicity  0.068  0.138 
 White 1  1  
Non-white 2.61 (0.93-7.36) 0.069 2.61 (0.88-7.72) 0.082 
Unknown 0.89 (0.10-7.92) 0.913 0.89 (0.10-7.58) 0.912 
Marital status  0.118  0.102 
 Married 1  1  
Status other than married 2.78 (0.39-19.7) 0.306 2.78 (0.39-19.7) 0.306 
Unknown 3.45 (0.83-14.4) 0.088 3.45 (0.80-14.8) 0.095 
Deprivation (quintiles)  0.279  0.583 
 Least deprived 1  1  
Quintiles 2,3,4 0.67 (0.17-2.59) 0.561 0.67 (0.18-2.46) 0.545 
Most deprived 1.23 (0.51-2.94) 0.643 1.23 (0.46-3.30) 0.682 
Unknown 1.98 (0.77-5.11) 0.157 1.98 (0.50-7.86) 0.330 
Practice region  0.598  0.827 
 London 1  1  
Midlands and East 1.30 (0.50-3.34) 0.593 1.30 (0.46-3.66) 0.626 
North 1.78 (0.74-4.30) 0.198 1.78 (0.57-5.56) 0.320 
South 1.34 (0.39-4.56) 0.645 1.34 (0.34-5.22) 0.678 
Time at practice (years)  0.975  0.986 
 Low 1  1  
Moderate 0.94 (0.40-2.22) 0.890 0.94 (0.38-2.33) 0.896 
High 1.02 (0.44-2.38) 0.968 1.02 (0.32-3.28) 0.977 
Consultations
*
  0.003  0.031 
 Low 1  1  
Moderate 1.14 (0.56-2.32) 0.711 1.14 (0.45-2.88) 0.776 
High 0.29 (0.11-0.77) 0.013 0.29 (0.11-0.78) 0.015 
Referral   0.973  0.977 
 No 1  1  
 Yes 1.02 (0.40-2.60) 0.973 1.02 (0.34-3.07) 0.977 
Charlson Index score 0.76 (0.62-0.92) 0.006 0.76 (0.59-0.96) 0.022 
Resource Utilization Band (RUB)  0.727  0.714 
 Healthy, low or moderate 1  1  
High to very high 1.18 (0.46-3.01) 0.733 1.18 (0.47-2.93) 0.725 
 
  
                                                     
*
At GP practice, by telephone or home visit. 
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7.4.7 Health service use 
I now describe patients’ health service access (consultations and emergency admissions) 
before and after their first unplanned admission for a diabetic emergency.  
7.4.7.1  Consultations prior to index diabetic emergency admission 
The majority of patients who had at least one DEA also had one or more consultations (in 
any location and with any type of staff) in the 12 months preceding their index DEA 
(n=27/32 patients, 377 consultations). In the 6 months before the index DEA, 78.1% of 
patients had at least one consultation (n=25/32 patients, 106 consultations). On average, 
these patients had 4 (SD 3.78) consultations each, ranging from 1 to 14 consultations per 
patient, in any location and with any staff type. Patients who had consultations at the 
practice, by telephone or home visit during the 6 month period had a total of 80 
consultations (n=21 patients). On average, these patients had 4 (SD 2.75) consultations each, 
ranging from 1 to 10 consultations per patient. The majority of the 80 consultations were 
recorded as taking place with a GP (n=58; 72.5%). 
7.4.7.2 Consultations after index diabetic emergency admission 
Out of the 32 patients who had at least one DEA, 84.4% had one or more consultations at 
the GP practice, by telephone or home visit after their index DEA but also during the study 
period (n=27/32 patients, 656 consultations). Among these 27 patients, there was an 
average of 24 (SD 24.7) consultations per patient after the first DEA, ranging from 1 to 81 
consultations per patient. From the 517 consultation records with valid time data, the 
average length of consultations post index DEA was 11 (SD 13.9) minutes, ranging from 1 to 
249 minutes.  
7.4.7.3 Admissions 
On average, patients with diabetes had 4.31 (SD 7.50) admissions (all-cause), ranging from 0 
to 189 admissions during the study period. There was little difference in the number of 
admissions (all-cause) between patients who had at least one DEA (median 3, IQR 2-5 
admissions) and patients who did not have any DEAs (median 3, IQR 1-5 admissions).  
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7.4.7.4 Admissions before index diabetic emergency admission 
In the 12 months before the index DEA, 28.1% of patients had an admission (n=9/32 
patients, 10 admissions), 8 of these admissions (n=7 patients) occurred in the 6 months 
preceding the first DEA. Patient had an average of 1 (SD 0.33) admission each in the 6 
months prior to the first DEA, ranging from 1 to 2 admissions per patient. The causes of 
these admissions included T1DM (n=1 admission), T2DM (n=6), stroke (n=2) and respiratory 
disease (n=2). Admissions may have had multiple recorded causes.  
7.4.7.5 Admissions after index diabetic emergency admission 
After their index DEA, 56.3% of patients had at least one further admission during the study 
period (n=18/32 patients, 53 admissions). These patients had an average of 3 (SD 2.53) 
admissions each, ranging from 1 to 11 admissions per patient. In the majority of admissions, 
diabetes was recorded as a cause of admission (n=42/53). Cardiovascular disease was also a 
common diagnosis (n=11/53). Less than one fifth of subsequent admissions were for 
diabetic emergencies, which included one admission for diabetic coma (n=5/18 patients, 
n=10/53 admissions).  
7.4.8 Deaths 
Of all the patients with diabetes, 256 died during the study period and one more patient 
died who had at least one DEA but was not diagnosed with diabetes before death (Table 
7.10). Two deaths were of patients with recorded T1DM and 29 deaths were of patients 
with recorded T2DM. The remaining patients who died had recorded “Other diabetes” 
diagnoses. Over two thirds of patients with diabetes who died did not have diabetes listed 
as a cause of death (68.8%; n=176/256). Diabetes was recorded as the underlying cause of 
death of 12 patients with diabetes (4.69%) and as an additional cause of death of 68 
patients (26.6%). Other causes of death included cardiovascular disease (26.2%; n=67/256), 
neoplasms (18.4%; 47/256), infection (6.25%; n=16/256) and renal failure (1.17%; n=3/256).  
There were only three alcohol-related deaths, where one case was the underlying cause of 
death related to alcohol (alcoholic cirrhosis of liver). Alcoholic cirrhosis of liver, acute 
intoxication and alcoholic liver disease (unspecified) were recorded as secondary causes of 
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death of the three patients. None of these patients had T1DM or an unplanned admission 
for a diabetic emergency. 
As for the four conditions that are potential complications of treating diabetic emergencies 
(section 7.2.5), three patients had pulmonary oedema recorded as a secondary cause of 
death and heart failure as the underlying cause. The eight patients who had one or more 
DEAs and died during the study period were aged between 38 years and 88 years at death, 
with an average age of 71.3 (SD 18.6) years. Six of these deaths were caused by diabetes, 
including one death attributed to diabetic ketoacidosis. In four out of the six deaths, the 
underlying cause of death was diabetes.  
7.4.8.1 Crude associations with death 
In addition to the comorbidity markers not presented in earlier results due to non-
convergence of models (section 7.4.4.1), three other ACG flags (pregnancy - CADG 12, 
genetic - MEDC 12 and neonatal - MEDC 18) and the mild liver disease comorbidity flag were 
omitted from the results that follow as there were no deaths in patients who met the 
criteria for any these categories. In crude analyses using log-binomial regression, the models 
for grouped continuity of care scores and follow-up time (with death as the binary response) 
did not converge and so no results are reported for these two explanatory variables. P-
values reported in this section are p<0.0001 unless stated otherwise. 
Among the 1,359 patients with diabetes, 73.0% of patients were of non-white ethnicities, 
n=187/256 (Table 7.10). Patients in this sub-group had less risk of death (RR 0.87, 95% CI 
0.79-0.96; p=0.007) compared to patients of white ethnicity, being registered at practices in 
northern areas of England increased the risk of death in patients with diabetes (RR 1.17, 95% 
CI 1.01-1.35; p=0.031). The Charlson Index and the majority of other comorbidity measures 
did not display statistically significant associations with risk of death in the study sample 
(Table 7.10 and Appendices Table A.19). Further results by comorbidities are in the 
Appendices (Table A.19). Unsurprisingly, patients with diabetic complications were at 
increased risk of death (RR 1.17, 95% CI 1.07-1.29; p=0.003) compared to patients without 
complications (Table A.19). However, having a DEA was not a significant predictor of death 
in patients with diabetes, p=0.725.  
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Age group at start of study (years)     0.648 
 0-14 0 0 - - - 
15-44 6 0 - 1  
45-64 55 1 (1.82) 1.23 (0.77-1.98) 0.391 
65-84 175 6 (3.43) 1.24 (0.78-1.97) 0.369 
≥85 20 0 - 1.30 (0.80-2.13) 0.286 
Age group at study exit (years)     0.465 
 0-14 0 0 - - - 
15-44 1 0 - 1 - 
45-64 28 1 (3.57) 1.70 (0.42-6.84) 0.457 
65-84 154 4 (2.60) 1.68 (0.42-6.74) 0.462 
≥85 73 2 (2.74) 1.57 (0.39-6.30) 0.525 
Sex     0.172 
 Male 123 3 (2.44) 1  
Female 133 4 (3.01) 1.07 (0.97-1.19) 0.174 
Ethnicity     0.059 
 White 62 1 (1.61) 1  
Non-white 187 6 (3.21) 0.87 (0.79-0.96) 0.007 
Unknown 7 0 - 0.96 (0.73-1.26) 0.767 
Marital status     0.186 
 Married 29 0 - 1  
Status other than married 9 0 - 0.73 (0.49-1.10) 0.136 
Unknown 218 7 (3.21) 0.94 (0.82-1.08) 0.378 
Deprivation (quintiles)     0.775 
 Least deprived 53 3 (5.66) 1  
Quintiles 2,3,4 36 0 - 1.08 (0.92-1.27) 0.372 
Most deprived 126 3 (2.38) 1.00 (0.87-1.15) 0.961 
Unknown 41 1 (2.44) 0.99 (0.83-1.18) 0.876 
Practice region     0.105 
 London 61 1 (1.64) 1  
Midlands and East 81 2 (2.47) 1.11 (0.95-1.29) 0.185 
North 96 3 (3.13) 1.17 (1.01-1.35) 0.031 
South 18 1 (5.56) 1.00 (0.77-1.29) 0.976 
Time at practice     0.397 
 Low 89 2 (2.25) 1  
Moderate 83 2 (2.41) 0.97 (0.86-1.09) 0.614 
High 84 3 (3.57) 0.92 (0.81-1.04) 0.182 
Number of consultations
†
     0.128 
 Low 106 5 (4.72) 1  
Moderate 81 2 (2.47) 0.89 (0.79-1.00) 0.060 
High 69 0 - 0.92 (0.81-1.04) 0.166 
Referral      0.730 
 No 214 5 (2.34) 1  
Yes 42 2 (4.76) 1.02 (0.90-1.17) 0.723 
                                                     
*
DEA – Diabetic emergency admission. 
†
At GP practice or by telephone and with GP or nurse. 
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Number of admissions     0.685 
 Low 39 1 (2.56) 1  
Moderate 96 3 (3.13) 0.95 (0.82-1.09) 0.452 
High 121 3 (2.48) 0.94 (0.82-1.08) 0.356 
Charlson Index score 4.95(8.28) 0.57(1.51)  1.00 (0.99-1.01) 0.511 
Resource Utilization Band (RUB)     0.355 
 Low to moderate 29 2 (6.90) 1  
High to very high 227 5 (2.20) 0.93 (0.81-1.07) 0.298 
Diabetic emergency admission (DEA)     0.725 
 No 249 0 - 1  
Yes 7 7 (100) 0.94 (0.66-1.34) 0.746 
 
7.4.8.2 Crude associations with death, adjusted for GP practice 
The following results are from crude log-binomial analyses that took into account clustering 
of patients at practices (Table 7.11). After adjusting for clustering by GP practice, non-white 
patients with diabetes remained less at risk of death compared to white patients (RR 0.87, 
95% CI 0.79-0.97; p=0.010). Patients with diabetes registered at practices in northern 
England were still at greater risk of death compared to patients of practices in other regions 
of England (RR 1.17, 95% CI 1.03-1.33; p=0.020). Further results by comorbidities are in the 
appendices (Table A.20), these include greater risk of death in patients with unspecified 
diabetic complications (RR 1.17, 95% CI 1.06-1.29; p=0.001) compared to patients without 
any diabetic complications. Also, patients with diabetes and recorded myocardial infarction 
were at greater risk of death (RR 1.17, 95% CI 1.05-1.31; p=0.004).  
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Table 7.11 Risk factors for death in patients with diabetes, crude results from log-binomial 
regression using the generalized estimating equations (GEE) method 
Characteristic 
Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Age group at start of study (years)  0.648  0.720 
 <15 - - - - 
15-44 1  1  
45-64 1.23 (0.77-1.98) 0.391 1.23 (0.76-1.99) 0.394 
65-84 1.24 (0.78-1.97) 0.369 1.24 (0.77-1.99) 0.377 
≥85 1.30 (0.80-2.13) 0.286 1.30 (0.80-2.12) 0.283 
Age group at death (years)  0.465  0.595 
 <15 - - - - 
15-44 1  1  
45-64 1.70 (0.42-6.84) 0.457 1.70 (0.42-6.83) 0.457 
65-84 1.68 (0.42-6.74) 0.462 1.68 (0.41-6.83) 0.466 
≥85 1.57 (0.39-6.30) 0.525 1.57 (0.39-6.30) 0.525 
Sex  0.172  0.180 
 Male 1  1  
Female 1.07 (0.97-1.19) 0.174 1.07 (0.97-1.19) 0.176 
Ethnicity  0.059  0.058 
 White 1  1  
Non-white 0.87 (0.79-0.96) 0.007 0.87 (0.79-0.97) 0.010 
Unknown 0.96 (0.73-1.26) 0.767 0.96 (0.73-1.26) 0.767 
Marital status  0.186  0.197 
 Married 1  1  
Status other than married 0.73 (0.49-1.10) 0.136 0.73 (0.50-1.07) 0.105 
Unknown 0.94 (0.82-1.08) 0.378 0.94 (0.84-1.05) 0.263 
Deprivation (quintiles)  0.775  0.732 
 Least deprived 1  1  
Quintiles 2,3,4 1.08 (0.92-1.27) 0.372 1.08 (0.91-1.27) 0.377 
Most deprived 1.00 (0.87-1.15) 0.961 1.00 (0.87-1.16) 0.964 
Unknown 0.99 (0.83-1.18) 0.876 0.99 (0.81-1.19) 0.885 
Practice region  0.105  0.126 
 London 1  1  
Midlands and East 1.11 (0.95-1.29) 0.185 1.11 (0.96-1.28) 0.160 
North 1.17 (1.01-1.35) 0.031 1.17 (1.03-1.33) 0.020 
South 1.00 (0.77-1.29) 0.976 1.00 (0.72-1.37) 0.980 
Time at practice  0.397  0.341 
 Low 1  1  
Moderate 0.97 (0.86-1.09) 0.614 0.97 (0.87-1.08) 0.592 
High 0.92 (0.81-1.04) 0.182 0.92 (0.82-1.03) 0.141 
Number of consultations
*
  0.128  0.095 
 Low 1  1  
Moderate 0.89 (0.79-1.00) 0.060 0.89 (0.79-1.00) 0.058 
High 0.92 (0.81-1.04) 0.166 0.92 (0.81-1.03) 0.154 
Referral   0.730  0.726 
 No 1  1  
Yes 1.02 (0.90-1.17) 0.723 1.02 (0.90-1.17) 0.724 
Number of admissions  0.685  0.640 
                                                     
*
At GP practice or by telephone and with GP or nurse. 
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 Low 1  1  
Moderate 0.95 (0.82-1.09) 0.452 0.95 (0.82-1.09) 0.460 
High 0.94 (0.82-1.08) 0.356 0.94 (0.82-1.07) 0.332 
Resource Utilization Band (RUB)  0.355  0.343 
 Low to moderate 1  1  
High to very high 0.93 (0.81-1.07) 0.298 0.93 (0.80-1.07) 0.320 
 
7.5 Discussion 
In the final section of this chapter, I present the key findings from the analyses and interpret 
the results in the context of existing evidence, before suggesting directions for further 
investigation.  
7.5.1 Summary of main findings 
The first objective of this chapter was to determine the incidence of emergency admissions 
for diabetic ketoacidosis and diabetic hyperglycaemic or hypoglycaemic coma (collectively 
referred to as DEAs). There was a low rate of DEAs in the study sample, estimated at 0.12 
admissions per 1,000 person years between 1999 and 2008. In patients with diagnosed 
diabetes, the rate was higher at 3.97 admissions per 1,000 person years during the same ten 
year period. 
The second objective was to identify predictors of DEAs in patients diagnosed with diabetes. 
Older age was associated with a lower risk of DEAs, patients with diabetes aged 65 years or 
older being least at risk of a DEA (RR 0.22, 95% CI 0.06-0.87; p=0.031). A high number of 
consultations at the GP practice, by telephone or home visit also had a protective effect 
against DEAs in patients with diabetes (RR 0.29, 95% CI 0.11-0.78; p=0.015). Patients with 
diabetes and more and/or complex comorbidities, measured by the modified Charlson Index, 
were least at risk of a DEA (RR 0.76, 95% CI 0.59-0.96; p=0.022).  
The third objective was to describe the patterns of service use (consultations and 
emergency admissions) of patients who have at least one DEA. In the 6 months prior to the 
index DEA, 65.6% of patients with diabetes had at least one consultation at the GP practice, 
by telephone or home visit (n=21/32; 80 consultations) and 21.9% of patients with diabetes 
had an emergency admission (n=7/32; 8 admissions). There were eight deaths of patients 
who had one or more DEAs during the study period. Diabetes was recorded as the 
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underlying cause of death for six of the deaths. After adjusting for clustering of patients at 
practices, non-white ethnicity remained a protective factor against death in patients with 
diabetes (RR 0.87, 95% CI 0.79-0.97; p=0.010). Patients with diabetes registered at practices 
in northern areas of England (RR 1.17, 95% CI 1.03-1.33; p=0.020) and those who had 
diabetes and myocardial infarction (RR 1.17, 95% CI 1.05-1.31; p=0.004) were at greater risk 
of death. Patients who had diabetic complications, though not specifically diabetic 
ketoacidosis or diabetic coma, also had greater risk of death (RR 1.17, 95% CI 1.06-1.29; 
p=0.001). 
7.5.2 Estimating rates 
As with all analyses using data collected for other purposes, the quality of data may be sub-
optimum for the needs of the research. In this study, calculations were affected by low 
numbers of both the numerator and denominator populations of interest. To meet the 
project aims of exploring several safety measures in general practice, the dataset obtained 
from the GPRD contained records for a cross sectional selection of patients at participating 
practices. For this reason, the dataset contained far fewer records for patients with the 
conditions of interest than if the cohort consisted only of the patient sub-groups of interest 
(patients with diabetes and patients who had one or more DEAs).  
Nevertheless, the GPRD contains a representative sample of the general population and so, 
if there was a reasonable number of patients with the outcome in the dataset, one might 
expect calculated rates to be similar to published national estimates. The definition of 
“reasonable number” is subjective, yet in this study with 42 DEAs in 32 patients at 28 GP 
practices over a ten year period, one might consider the number to be low. Hence, caution 
must be made in interpreting the results. Findings of low rates and wide variation may also 
be artefacts of coding practices, whereby the recording of the variables of interest (such as 
diabetes) remains poor as the population increases. I will return to coding concerns later 
(section 7.4.7.5). 
7.5.2.1 Rates of diabetes and diabetic emergency admissions 
Even though there were few records of DEAs during the study period, this finding is of value 
given limited research about predictors for DEAs, especially using national datasets. The 
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availability of data over 10 years in this study also contributes to our understanding of 
national trends in DEAs over time. It is difficult to compare the results to published data 
given the unstable rates due to low numbers in this study. For example, contrary to results 
from the National Diabetes Audit (NDA), I found that the overall rate of diabetic emergency 
admissions was higher in male patients than female patients despite there being only one 
more male patient than female patients (Table 7.7).359 The NDA data are less complete than 
QOF data and dependent on voluntary participation but, like in this study, it includes all 
patients with diabetes in analyses, regardless of age. Both the NDA and these analyses 
identified more male than female patients registered with diabetes, although population 
prevalence models used by the NDA predict a greater prevalence of diabetes in 
females.326,360  
7.5.3 Risk factors 
The finding that a high number of consultations at the GP practice, by telephone or home 
visit and the presence of complex and/or multiple comorbidities have protective effects 
against DEAs in patients with diabetes may seem counter-intuitive at first. Yet one might 
reason that increased contact with health services improves disease management and 
patient adherence to treatment, as well as prevention of disease complications. The 
relationships between patient factors were not investigated in this study but there are likely 
to be interactions between the volume of consultations, comorbidities and care needs. To 
screen for potential patient harm and be of relevance to clinical practice, further exploration 
of the associations between such characteristics must be made. 
7.5.4 Deaths in patients with diabetes 
As well as exploring risk factors for DEAs in patients with diabetes, this study also 
investigated predictors for death in these patients. In crude analyses, having one or more 
unplanned admissions for diabetic emergencies was not found to be a statistically significant 
predictor of death (p=0.725).  
Excess deaths attributable to diabetes or of patients with diabetes are a public health 
concern, given that patients with diabetes have a markedly increased risk of death and the 
potential avoidability of many of these deaths.361 Gulliford and Charlton (2009) and Walker 
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et al (2011) showed that for patients with T2DM aged 30 years or older, relative mortality 
was higher in female patients, those who were younger at diagnosis and also within the first 
two years after diagnosis.357,362 Studies have shown wide variation across England in 
admission rates for diabetes (and acute diabetic complications) even where there is high 
attainment in incentivised quality measures for the disease.219,348 Studies commonly identify 
an association between deprivation and adverse patient outcomes but socioeconomic 
deprivation demonstrates a complex relationship with other factors, including age and sex 
of patients.348,357 
The results in this chapter indicated no distinction between types of diabetes in the relative 
risk of death. In crude regression analyses, with adjustment for clustering of patients at 
practices, no statistically significant difference was found between male and female patients 
in their risk of death (p=0.180). I included patients of all ages in the analyses and did not 
calculate age at diagnosis (unlike Gulliford and Charlton, 2009). Instead, I used ages at study 
entry and exit.362 Neither of the age variables were significant risk factors for death (p=0.720 
for age at study entry and p=0.595 for age at study exit). Deprivation, as measured by 
population-weighted quintiles converted from IMD scores, was not found to be a significant 
predictor of unplanned admissions for diabetic emergencies or death in patients with 
diabetes. However, the results may have been affected by how the IMD quintile variable 
was derived. The quintiles were accurate for the original GPRD dataset but I did not re-
calibrate the quintiles in the final dataset after data cleaning; the quintiles were not 
weighted to the sample population but were weighted to the GPRD population. 
Cardiovascular disease was the main cause of death in patients with diabetes in this study 
and patients who had a recording of myocardial infarction were at greater risk of death, 
reflecting evidence from the literature. There were few cases where diabetic emergencies 
and other diabetic complications were identified as a cause of death. It has been suggested 
that drug and alcohol-related deaths are common in young patients with T1DM.330 With low 
numbers of patients with a recorded T1DM diagnosis over the ten year study period (1.07% 
of those diagnosed), it is difficult to generate meaningful interpretations of the results. Of 
the three patients with diabetes whose deaths were attributed to alcohol, none of them had 
a recorded diagnosis of T1DM. Under-reporting of diabetes in death certificates may also 
detrimentally affect the accuracy of estimates in this study.355,363,364  
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7.5.5 Undiagnosed diabetes 
It is recognised that diagnosis of diabetes suffers from miscoding, misclassification and 
misdiagnosis.321,323 There is controversy over the number of patients who present with DKA 
but who do not have a prior diagnosis of diabetes, with estimates from European countries 
ranging from 12.8% to over 50%.335,365 Delayed diagnosis of T1DM, and hence lack of 
diabetes management, may be a reason for the increasing frequency of DEAs.366,367 I did not 
explore this proposition because of the low numbers of patients who had a DEA in the 
sample. The picture is further clouded by indications that non-recording of diabetes in 
patients who are admitted to hospital and known to have diabetes does not have a 
detrimental effect on length of stay, day case admissions or readmissions.368 This finding by 
Whitson et al suggests that diabetes may often be appropriately recorded in secondary care. 
Yet there remain the issues of non-diagnosis and delayed treatment of diabetes in general 
practice.365,366  
7.5.6 Impact of general practice organisation 
The anonymised nature of the GPRD dataset and limited detail about practices hampered 
the investigation of practice risk factors for DEAs. For example, one might expect the rates 
of DEAs to be lower at practices that offer diabetes clinics or specialist diabetes care.369 
Other practice characteristics such as baseline prevalence of diabetes, staffing levels and 
staffing types can also affect the number of diabetes-related admissions.347 In this study, 
continuity of care was not found to be associated with risk of having a DEA but with more 
practice data, the nuances of continuity of care can be further explored. These aspects 
include practice size (ratio of staff to list size) and patient preferences for treatment and 
outcomes.347,370,371 
7.5.7 Methodological issues 
The analyses in this chapter benefitted from the availability of a large dataset with data 
spanning 10 years. It was possible to explore temporal trends in unplanned emergency 
admissions for diabetic emergencies and to perform preliminary investigations of service 
use prior to and after the DEAs. However, there were low numbers of the outcomes of 
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interest and therefore, interpretation of the results must be cautious. In the following 
sections, I outline the main methodological limitations of this study. 
7.5.7.1 Selected variables 
In observational research, there will be residual confounders. In these analyses, a small 
selection of variables was included and some potentially important factors were not 
accounted for. Certain patient characteristics are associated with increased risk of diabetic 
ketoacidosis and other diabetic emergencies, including younger age, lower body mass, 
lower parental educational attainment, preceding infection and psychological 
illness.335,365,372 These known risk factors were not included in the analyses, except for age 
as a generic confounder, but they should be considered in future research, where possible 
and appropriate.  
7.5.7.2 Accurate identification of patients 
As diabetes is under-diagnosed and inconsistently coded, I attempted to improve the 
accuracy of identifying recorded diabetes diagnoses by including patients who did not have 
a recorded diagnosis but where coding indicated that diabetes was likely to be present 
(section 7.2).373 It is known that data for younger patients are more prone to inconsistent 
coding.345  
7.5.7.3 Data quality 
The dataset was obtained under the now defunct MRC licence for academic research and so 
the granted linked HES and ONS data (GPRD Integrated dataset) were of a restricted nature 
(unlike the non-academic GPRD GOLD dataset, which allows for more extensive data 
extraction). Despite being nationally representative, data submitted to the GPRD by 
individual practices still varies in quality. For example, there were a large number of zero 
values for the length of consultation. Data in this field not only documents the duration of 
consultations, but also logs the length of time that the record was accessed (hence the 
consultation entries for less than one minute in length).374 It is difficult to determine which 
records were for genuine consultations and which were not. 
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7.5.7.4 Limitations of data linkage 
One major restriction of the GPRD integrated dataset was the availability of hospital data, 
and associated ethnicity status, for only 24,307 out of the 100,000 patients in the original 
dataset. There were even fewer records with linked death data from the ONS, with valid 
data for only 3,094 patients. Unlike the presence of a designated main (underlying) cause of 
death field, the dataset did not contain a field for the primary cause of admission. 
Therefore, it was not possible to distinguish between the main and secondary causes of 
admission or to accurately attribute admissions to diabetes (and diabetic complications). 
When determining the temporal placements of admissions, the date of discharge was used 
as date of admission was not available. As admission date missing, length of hospital stay 
was not measurable. The length of time between general practice contact and admission 
was also only crudely estimated using discharge date.  
7.5.7.5 Coding inconsistencies 
With the narrower definition of diabetes since the coding rules for QOF changed in 2006, 
one would expect more similarity between the prevalence estimates from the analyses and 
the QOF estimates from 2006 onwards (Table 7.6). Rather than the expected pattern, this 
study showed a slight decline in the prevalence of diabetes. This finding may be due to 
changes in coding practices over time beyond the QOF rules. The dataset is also affected by 
another caveat of GPRD data – incorrect recording of diagnosis date.375 Instead of recording 
the first date that a patient presents with a disease or condition, used as a proxy measure of 
the index diagnosis, the date might instead be indicative of other events, including the first 
time that the information is entered onto the computer system or the first recording of an 
event that was discussed in a previous consultation.375 There are secondary fields that may 
assist in determining the appropriateness of dates, such as episode type, but the 
completeness and accuracy of these fields are also uncertain. 
7.5.8 Further research 
To develop the analysis beyond that presented in this chapter, greater use of the GPRD 
dataset could be made. For example, indicators for family groups and also whether patients 
were receiving state welfare benefits could be used as proxy measures for risk factors 
Chapter 7: Unplanned admissions for diabetic emergencies | 190 
 
identified in other studies.335,365,372 Other methods to improve the accuracy of identifying 
patients with diabetes include using prescribing data and clinical intermediate outcome 
markers such the levels of blood glucose (glycosylated haemoglobin, HbA1C), blood pressure 
or cholesterol.321,345,376 These measures can be used to assess the adequacy of diabetes 
control and overall quality of care. Additional data on the involvement of diabetes specialist 
teams in hospital admissions would improve assessments of adherence to policies on the 
management of diabetic emergencies.310 Information on the number of bed days is also 
needed to determine whether younger patients are spending less time in hospital with DEAs 
than in previous years.335,377  
7.5.9 Conclusion 
These analyses were intended to provide a better understanding of the characteristics of 
patients with diabetes who have unplanned admissions for diabetic emergencies. As 
expected given the relatively young age of patients with T1DM which is most commonly 
associated with diabetic ketoacidosis, I found that adults were at less risk of having a DEA. 
Patients who had more consultations at the GP practice, by telephone or home visit and 
those who had more complex care needs were less likely to have a DEA. Admissions and 
consultations in the 6 months prior to the first DEA were common.  
Although there were few deaths attributable to diabetic emergencies in patients with 
diabetes, there was a statistically significant difference in the risk of death between patients 
of white and non-white ethnicities. Patients with diabetes registered at practices in 
northern England, and those with recorded diabetes and myocardial infarction, were at 
greater risk of death. Based on these preliminary findings, further research may assist the 
identification of patients who are at the greatest risk of harm. Through engaging these 
patients in self-management, their quality of life can be improved and the burdens on the 
health system can also be reduced.  
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Chapter 8: First unplanned admissions for cancer 
 
8.1 Chapter overview 
This chapter contains the final analyses of the project. I examine the 
recording of first time unplanned (emergency) admissions for cancer in 
national data, as a proxy measure of cancer diagnosis by the emergency 
route. I present two separate pieces of analyses identifying risk factors for 
such admissions, firstly using secondary data from HES and then using 
general practice data from the GPRD. Results from both sets of analyses are 
then compared and discussed. 
 
8.1.1 Acknowledgements 
I conducted the analyses presented in section 8.2 (Study 1 – analyses using HES data) as part 
of a study in collaboration with Alex Bottle (lead researcher), Camille Parsons, Azeem 
Majeed, Michael Soljak and Paul Aylin at the Department of Primary Care and Public Health, 
Imperial College London. Preliminary analysis was performed by Camille Parsons. I 
conducted the final analyses for this study, with statistical input from Alex Bottle. All 
analyses of Study 2 (section 8.4) were performed by me. 
8.2 Rationale 
Cancer is the leading cause of mortality in adults aged under 75 years in England, with new 
cancer diagnoses estimated to reach 299,000 cases by 2020.378,379 Over 30% of cancers are 
preventable and the majority of cancers are responsive to treatments.380 As the delivery of 
chemotherapy and adjuvant regimes becomes more sophisticated and advances continue in 
our genetic understanding of the disease, we must ensure that patients receive safe and 
high quality care that enables them to achieve the best health outcomes possible. While 
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cancer survival rates are improving for the most common cancers (breast, lung, prostate and 
colon) in England, there is controversy over the quality, and in particular the efficiency, of 
cancer services compared to other countries.381-383 Numerous studies have found the 
outcomes of patients with cancer to be relatively worse in England than in other countries in 
Europe, Canada and the United States of America.384-386 It is believed that diagnostic errors 
and delays combined with late diagnosis of cancers are largely attributable to the relatively 
poor survival and high mortality rates.386,387 
To reduce late diagnosis, as part of the government’s Cancer Reform Strategy, the National 
Awareness and Early Diagnosis Initiative (NAEDI) was set up to promote the risks and 
symptoms of cancer among the general population, and to encourage early presentation 
and improve uptake of screening programmes.378 Economic modelling for the five most 
common cancers in either sex, taking into account cancer stage at diagnosis, has 
demonstrated that earlier diagnosis improved patient outcomes (life expectancy) and 
increases cost-effectiveness in the NHS.388 Analyses by the National Audit Office indicate 
that 532,000 bed days and £106 million per year can be saved through reductions in the 
number of emergency admissions and length of hospital stays.389 At the local level, variation 
in the quality of cancer care across England has been noted. Differences extend from 
spending on cancer care, urgent referral rates, emergency admissions, to consultation 
patterns prior to referral.83,389-391  
8.2.1 Role of primary care in cancer care 
To improve the consistency of cancer care in England and to reduce diagnostic delays, 
primary care engagement is crucial.392,393 The majority of patients begin their cancer care 
journey with one or more consultations with their GP, who act as the gatekeeper to further 
investigations and specialised treatment. Due to this, it is vital that GPs appropriately refer 
patients with suspected cancer for timely diagnosis and treatment. At any point along the 
primary care pathway (Figure 8.1), errors or inappropriate care may cause delays in referral 
and/or diagnosis.387,394  
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Figure 8.1 Primary care patient pathway 
 
Source: National Patient Safety Agency, 2010.394  
8.2.2 Definition of delayed and late diagnosis 
Before exploring the emergency route to cancer diagnosis, it would be helpful to consider 
the terminology commonly associated with the early stages of a patient’s cancer journey. 
The main two elements are presentation and diagnosis. The negative descriptions attached 
to these elements are typically “delayed”, “late” and “missed”. Presentation concerns the 
behaviour of patients in seeking health services. Diagnosis typically refers to health 
professional or health provider behaviour, but can be mediated by patient behaviour. 
Distinct patient groups have been identified as having greater risk of late presentation for 
suspected cancers.387,395 It is not within the scope of my study to examine patient 
presentation and so I will proceed with a focus on the element of diagnosis. 
Taking perhaps the most obvious description, “missed”, we can define this as the failure to 
correctly diagnosis a cancer, whether cancer has been suspected or not. The definition of 
diagnosis as “late” is inconsistently applied but usually refers to cancer diagnosed at a late 
stage with considerable tumour growth and potential metastases.396,397 The final description, 
“delayed” can refer to multiple points before diagnosis whereby timely diagnosis is 
1 
•Health seeking behaviour 
•Patient seeks assistance for symptom or concern  
2 
•Access 
•Appointment with GP or nurse 
3 
•Clinical assessment 
•Evaluation of symptoms 
4 
•Test ordering 
•Access and management of tests and imaging 
5 
•Follow up with results 
6 
•Referral to secondary care 
7 
•Assessment in secondary care 
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prevented. This includes the mediating effect of patient delay on prompt diagnosis, from 
initial signs and symptoms to contact with a health professional (usually a GP).395  
As stated previously (section 8.2), delayed diagnosis is a key reason for poor patient 
outcomes, and can be attributed to patient, clinician or health provider behaviours. 
Common causes of delay by clinicians include misdiagnosis, inadequate examination, use of 
inappropriate tests and failing to act upon negative or inconclusive test results.387,394,398 
There are many causes of health system delays, including inadequate communication 
between primary and secondary care and errors in the processing of referral requests and 
results of investigations.387,399 To improve patient outcomes, both “delayed” and “late” 
diagnoses of cancer need to be reduced. For this to be possible, the choices that patient 
make in accessing cancer care within the context of their overall health service usage must 
be understood. 
8.2.3 Cancer diagnosis through the emergency route 
Patients who are diagnosed with cancer via the emergency route (by unplanned admission) 
typically have later stage diseases and poor prognoses.391,400 Emergency admission was 
defined in Chapter 3 section 3.9.3. Almost a quarter of patients diagnosed with cancer in 
England during 2007 presented as emergencies (23%, n=225,965), with wide variation in the 
number of admissions by cancer type and patient characteristics as well as between 
PCTs.389,401 The presence of an active malignancy is a predictor of 7-day mortality in patients 
admitted as an emergency.402 Any of these findings alone make reasonable grounds for 
further investigation but their collective presence indicates that closer examination is 
warranted for patients diagnosed with cancer by emergency presentation.  
Research evidence shows that certain patient groups, such as those living in more deprived 
areas, with rarer cancers or who are relatively younger or older, represent a greater 
proportion of first emergency admissions for cancer.391,403-405 With this knowledge, one 
might hypothesise that patients who are diagnosed with cancer during an emergency 
admission may have fewer comorbidities, and therefore have had fewer consultations and 
referrals prior to diagnosis, compared to patients diagnosed through the standard route of 
GP referral for specialist assessment.391 The relationships between living in rural areas, 
distance to facilities for investigations and treatment, population demography, as well as 
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primary care attributes such as size of GP practices and GP training also warrant further 
attention.406,407 
8.2.4 Aims and objectives 
As part of the government priority to improve cancer outcomes, the number of patients 
diagnosed with cancer from emergency presentations must be reduced. In the next sub-
section, I set out the overall aims and objectives of the two studies presented in this chapter. 
Study-specific aims are provided later. 
8.2.4.1 Overall aims 
To achieve improvements in cancer care, the characteristics of patients who are diagnosed 
by the emergency route and their access of health services prior to diagnosis must be better 
understood.  
8.2.4.2 Overall objectives 
To meet the aim stated in the previous section, the following objectives were identified: 
1. Measure the rate of first emergency (unplanned) admissions for cancer. 
2. Identify patient risk factors for first emergency admissions for cancer.  
3. Identify GP practice risk factors for first emergency admissions for cancer.  
8.2.5 Structure of this chapter 
Unlike the presentation of analyses on adverse events in separate chapters (Chapters 5 and 
6), analyses on first emergency admissions for cancer using GPRD and HES data are 
presented here in a single chapter. As a precursor to analyses with integrated HES, ONS and 
GPRD linked data, the ability to detect new cases of cancer using only data from secondary 
care (HES) was assessed. The methods and results of the two studies are presented 
separately. Descriptions of variables used in these analyses, cross-mapping of codes and 
descriptions of HES and GPRD data are documented in Chapter 3. 
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8.3 Study 1 – analyses using HES data 
These analyses investigated the associations between patient and practice factors and first 
emergency admissions for cancer. Unlike anonymised GPRD data, HES data contains patient 
and practice identifiers that enable linkage with other data sources.  
8.3.1 Aims of study 1 
The first set of analyses in this chapter identified patient and GP practice risk factors for first 
unplanned (emergency) admissions for cancer in England, as a proxy measure of cancer 
diagnosis via the emergency route. 
8.3.2 Methods 
HES data for three financial years of 2007/8, 2008/9 and 2009/10 were analysed. The study 
sample consisted of all patients who had a first admission for cancer by any admission 
method, of which patients who had an emergency admission were of interest. Inpatients, 
day cases and regular day or night attenders with a primary cancer diagnosis were included. 
Patients’ records were tracked back over 3 years to improve the accuracy of identifying true 
first cancer admissions. 
8.3.2.1 Case ascertainment 
Patients may have an unplanned admission for expected side effects of treatment, cancer 
symptoms or for comorbid conditions. The possibility of including these ineligible cases is 
reduced by investigating only those patients with a first emergency admission during the 
study period and with a first (primary) diagnosis of cancer (ICD-10 codes C00–C96, excluding 
ICD-10 codes C44 and C97.  
8.3.2.2 Selection of variables  
The variables included in analyses are shown in Table 8.1. 
.  
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Table 8.1 Patient and practice characteristics measured in the study 
Patient factors Practice factors 
Age GP age (whether 50 or older) 
Sex GP sex (proportion of female patients) 
Ethnicity Country of medical qualification 
Cancer type Practice list size 
Deprivation Number of full time equivalent (FTE) GPs in the practice 
Rurality of residence Deprivation of GP practice location 
 Rurality of practice location 
 QOF performance 
 
8.3.2.3 Statistical method 
First unplanned cancer admissions were analysed as a binary outcome measure (whether 
first cancer admissions were unplanned or not unplanned). Bivariate associations between 
patient and practice factors and the outcome were explored using chi-square test, 
Pearson’s/Spearman’s correlation coefficient and t-test/analysis of variance. Crude 
regression analyses to calculate odds ratios for the first cancer admission being unplanned 
were conducted. Adjusted regression was then performed, taking into account of clustering 
of patients in practices by using Generalised Estimating Equation (GEE). Further details 
about the statistical methods are provided in Chapter 4. 
8.3.3 Results 
Before presenting the analyses of risk factors, I describe the demography of the sample.  
8.3.3.1 Study sample 
During the three years studied, there were 4,272,780 patients who had an admission with a 
primary diagnosis of cancer. Following exclusion of patients who did not have a first time 
admission during the study period, who had an admission in the three years prior to their 
index admission, patients with a primary diagnosis code of malignant neoplasms of skin 
(ICD-10 code C44) or malignant neoplasms of multiple sites (ICD-10 C97) or patients of 
ineligible practices (missing QOF data, invalid practice codes, list size less than 500 patients), 
there remained 639,064 patients who had a first time admission for cancer. Of these 
patients, 21.8% had an unplanned admission (n=139,351/639,064). 
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8.3.3.2 Crude results 
Table 8.2 shows that out of all patients who had a first admission for cancer, the greatest 
proportions of emergency admissions were in younger and older patients, especially 
patients aged 85 years or older (44.9%; n=22,367/49,786) and patients aged under 5 years 
(38.3%; n=783/2,044). Slightly more male patients had an emergency admission for cancer 
(22.8% compared to 20.9% of female patients who had an admission for cancer). Where 
ethnicity was known, patients of “other” ethnicities had the greatest proportion of 
emergency admissions (24.3%; n=1,455/5,978). Unplanned admissions were also greater in 
patients who were diagnosed with pancreatic cancer, acute leukaemia or bladder cancer 
(49%, 49.2% and 56.2%, respectively). Patients with Non-Hodgkin’s lymphoma and lung 
cancer had the lowest proportion of emergency admissions (2.2% and 4.1%, respectively). 
Deprivation showed a linear relationship with emergency admissions for cancer, with the 
greatest proportion of unplanned admissions (26.4%) recorded in patients living in the most 
deprived areas (quintile 5). 
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Table 8.2 Characteristics of patients with a first cancer admission, 2007/08-2009/10 
Characteristic 
Patients with first cancer admission, n 
All Emergency (%) P-value 
Age group (years)      <0.0001 







5-14 2503 814 (32.5) 
15-44 50666 7041 (13.9) 
45-64  211785 32054 (15.1) 
65-74 175011 34225 (19.6) 
75-84 147269 42067 (28.6) 
≥85 49786 22367 (44.9) 
Sex      <0.0001 
 Male 312951 71349 (22.8)   
 Female 326113 68002 (20.9) 
Ethnic group      <0.0001 






Mixed 2063 401 (19.4) 
Asian 11389 2486 (21.8) 
Black 9385 2092 (22.3) 
Other 5978 1455 (24.3) 
Not known 78592 15080 (19.2) 
Cancer type      <0.0001 






















Bladder 48333 3696 (56.2) 
Brain & central nervous system 13170 6484 (7.60) 
Breast 101506 4170 (9.40) 
Cervix 5964 779 (7.30) 
Chronic leukaemia 7192 1716 (13.9) 
Colorectal 80508 17285 (27.7) 
Kidney 13653 3157 (39.7) 
Larynx 4764 661 (18.0) 
Lung 62442 24803 (4.10) 
Melanoma 18933 414 (6.50) 
Multiple myeloma 9654 2674 (21.5) 
Non-Hodgkin’s lymphoma 23541 5318 (2.20) 
Oesophagus 18946 3407 (22.6) 
Oral 9863 721 (11.7) 
Ovary 12079 3493 (23.9) 
Pancreas 13225 7436 (49.0) 
Prostate 55275 6487 (38.6) 
Stomach 13970 3684 (23.1) 
Testis 4732 445 (28.9) 
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Uterus 16017 1036 (26.4) 
Other 96961 37398 (13.1) 
Deprivation (quintiles)      <0.0001 






2 136924 27519 (19.8) 
3 133580 28537 (21.6) 
4 122964 28304 (24.0) 
5 (Most deprived) 113717 29436 (26.4) 
6 (Unknown) 655 182 (29.5) 
Rurality of residence      <0.0001 




Town and fringe 72445 14897 (20.6) 
Village, hamlet and isolated dwellings  70170 13297 (18.9) 
Not resident in England 409 118 (28.9) 
Year of diagnosis      <0.0001 
 2007 206656 46421 (22.5)   
 
 
2008 214097 46713 (21.8) 
2009 218311 46217 (21.2) 
Note: Table has been published in Bottle et al, 2012.185 
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8.3.3.3 Adjusted results 
Once adjusted for all other variables and clustering of patients at GP practices, compared to 
the oldest patients (aged 85 years or older), patients aged between 15 and 44 years were 
least likely to have an emergency admission for cancer with odds ratio (OR) 0.15, 95% 
Confidence Interval (CI) 0.14-0.15; p<0.0001. The adjusted results in Table 8.3 also show 
that patients who were female (OR 1.07, 95% CI 1.05-1.08; p<0.0001), Asian (OR 1.16, 95% 
CI 1.08-1.24; p<0.0001), with brain and central nervous system cancers (OR 1.99, 95% CI 
1.92-2.07; p<0.0001), with pancreatic cancer (OR 1.91, 95% CI 1.84-1.99; p<0.0001), living in 
the most deprived (quintile 5) areas (OR 1.46, 95% CI 1.12-1.89; p<0.0001) or living in urban 
areas (OR 1.04, 95% CI 1.01-1.06; p=0.002) were most likely to have a first admission for 
cancer that was unplanned. 
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Table 8.3 Associations between patient characteristics and first unplanned admissions for 
cancer, crude and adjusted results 
Patient characteristic 
Crude Adjusted 
ORs (95% CI) P-value ORs (95% CI) P-value 
Age group (years)   <0.0001   <0.0001 
 0-4 0.76 (0.70-0.83) <0.0001 0.20 (0.18-0.22) <0.0001 
5-14 0.59 (0.54-0.64) <0.0001 0.17 (0.15-0.19) <0.0001 
15-44 0.20 (0.19-0.20) <0.0001 0.15 (0.14-0.15) <0.0001 
45-64  0.22 (0.21-0.22) <0.0001 0.20 (0.19-0.20) <0.0001 
65-74 0.30 (0.29-0.30) <0.0001 0.26 (0.25-0.26) <0.0001 
75-84  0.49 (0.48-0.50) <0.0001 0.43 (0.42-0.44) <0.0001 
≥85 1  - 1  - 
Sex   <0.0001   <0.0001 
 Male 1  - 1  - 
Female 0.89 (0.88-0.90) <0.0001 1.07 (1.05-1.08) <0.0001 
Ethnicity   <0.0001   <0.0001 
 White 1  - 1  - 
Mixed 0.83 (0.81-0.85) <0.0001 0.87 (0.85-0.89) <0.0001 
Asian 1.13 (1.06-1.20) <0.0001 1.16 (1.08-1.24) <0.0001 
Black 1.01 (0.96-1.06) 0.828 1.12 (1.05-1.18) 0.241 
Other 0.98 (0.94-1.03) 0.404 1.03 (0.98-1.08) 0.212 
Not known 0.85 (0.76-0.94) 0.003 0.93 (0.83-1.04) <0.0001 
Cancer type   <0.0001   <0.0001 
 Acute leukaemia 1.53 (1.46-1.60) <0.0001 1.78 (1.69-1.87) <0.0001 
Bladder 0.13 (0.13-0.14) <0.0001 0.10 (0.10-0.10) <0.0001 
Brain & central nervous system 1.55 (1.49-1.60) <0.0001 1.99 (1.92-2.07) <0.0001 
Breast 0.07 (0.07-0.07) <0.0001 0.07 (0.07-0.08) <0.0001 
Cervix 0.24 (0.22-0.26) <0.0001 0.30 (0.28-0.32) <0.0001 
Chronic leukaemia 0.50 (0.47-0.53) <0.0001 0.48 (0.45-0.51) <0.0001 
Colorectal 0.44 (0.43-0.45) <0.0001 0.37 (0.36-0.38) <0.0001 
Kidney 0.48 (0.46-0.50) <0.0001 0.50 (0.48-0.52) <0.0001 
Larynx 0.26 (0.24-0.28) <0.0001 0.26 (0.23-0.28) <0.0001 
Lung 1.05 (1.03-1.07) <0.0001 0.95 (0.93-0.98) <0.0001 
Melanoma 0.04 (0.03-0.04) <0.0001 0.04 (0.03-0.04) <0.0001 
Multiple myeloma 0.61 (0.58-0.64) <0.0001 0.55 (0.52-0.58) <0.0001 
Non-Hodgkin’s lymphoma 0.47 (0.45-0.48) <0.0001 0.47 (0.45-0.49) <0.0001 
Oesophagus 0.35 (0.34-0.36) <0.0001 0.30 (0.28-0.31) <0.0001 
Oral 0.13 (0.12-0.14) <0.0001 0.13 (0.12-0.14) <0.0001 
Ovary 0.65 (0.62-0.68) <0.0001 0.68 (0.65-0.71) <0.0001 
Pancreas 2.05 (1.97-2.12) <0.0001 1.91 (1.84-1.99) <0.0001 
Prostate 0.21 (0.21-0.22) <0.0001 0.20 (0.19-0.20) <0.0001 
Stomach 0.57 (0.55-0.59) <0.0001 0.45 (0.43-0.47) <0.0001 
Testis 0.17 (0.15-0.18) <0.0001 0.30 (0.27-0.33) <0.0001 
Uterus 0.11 (0.10-0.12) <0.0001 0.11 (0.10-0.11) <0.0001 
Other 1  - 1  - 
Deprivation (quintiles)   <0.0001   <0.0001 
 1 (least deprived) 1  - 1  - 
2 1.05 (1.03-1.07) <0.0001 1.04 (1.02-1.07) <0.0001 
3 1.13 (1.11-1.16) <0.0001 1.12 (1.09-1.15) <0.0001 
4 1.25 (1.22-1.27) <0.0001 1.20 (1.17-1.23) <0.0001 
5 (most deprived) 1.61 (1.35-1.91) <0.0001 1.46 (1.12-1.89) <0.0001 
6 (unknown) 1.46 (1.43-1.49) <0.0001 1.36 (1.32-1.40) <0.0001 
Rurality of residence   <0.0001   <0.0001 
 Urban >10K 1.12 (1.09-1.14) <0.0001 1.04 (1.01-1.06) 0.002 
Town and fringe 1  - 1   
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Village, hamlet and isolated dwellings 0.90 (0.88-0.93) <0.0001 0.96 (0.93-0.99) 0.003 
Not resident in England  1.57 (1.26-1.96) <0.0001 1.03 (0.72-1.48) 0.876 
Year of diagnosis   <0.0001   <0.0001 
 2007 1  - 1  - 
2008 0.96 (0.95-0.98) <0.0001 0.96 (0.94-0.97) <0.0001 
2009 0.93 (0.91-0.94) <0.0001 0.91 (0.90-0.93) <0.0001 
Note: Table has been published in Bottle et al, 2012.185 
 
Table 8.4 shows that patients of GP practices where none of the GPs received their medical 
qualification in the UK had a slightly higher odds of a first emergency admission (OR 1.08, 95% 
CI 1.04-1.11; p<0.0001). Patients registered at practices that received higher overall QOF 
performance scores were less likely to have an emergency admission for cancer (OR 0.94, 95% 
CI 0.91-0.97; p<0.0001). Patients at practices that had a greater mean score for provision of 
appointments within two working days were also less likely to have an unplanned admission 
(OR 0.85, 95% CI 0.79-0.92; p<0.0001). 
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Table 8.4 Association between GP practice characteristics and first unplanned admissions for 
cancer, crude and adjusted results 
Practice characteristic 
Crude Adjusted 
ORs (95% CI) P-value ORs (95% CI) P-value 
List size per 10,000 patients 0.94 (0.92-0.95) <0.0001 0.97 (0.95-0.99) 0.014 
FTE per 10,000 patients 0.98 (0.97-0.99) <0.0001 0.99 (0.98-1.00) 0.001 
Single handed practices         
 Single GP 1.16 (1.12-1.19) <0.0001 1.01 (0.96-1.06) 0.628 
>1 GP 1  - 1  - 
GPs aged 50 years and over   <0.0001   0.486 
 None 1 <0.0001 1   
Some  0.97 (0.95-0.99) 0.015 1.00 (0.97-1.02) 0.797 
All 1.10 (1.06-1.14) <0.0001 1.02 (0.98-1.06) 0.343 
GPs qualified in the UK   <0.0001   <0.0001 
 None 1.23 (1.19-1.26) <0.0001 1.08 (1.04-1.11) <0.0001 
Some  1.06 (1.04-1.08) <0.0001 1.04 (1.02-1.06) 0.001 
All 1  - 1  - 
Female GPs   <0.0001   0.31 
 None 1  - 1   
Some  0.88 (0.86-0.90) <0.0001 0.98 (0.95-1.01) 0.205 
All 0.98 (0.93-1.04) 0.553 1.02 (0.96-1.08) 0.594 
Practice deprivation average score
*
 1.01 (1.01-1.01) <0.0001 1.00 (1.00-1.00) 0.002 
Practice deprivation quintile
†
         
 <5 1  - 1  - 
5 (most deprived) 1.23 (1.21-1.26) <0.0001 1.01 (0.98-1.03) 0.576 
Practice deprivation quintile
‡
   <0.0001   <0.0001 
 1 (least deprived) 1  - 1  - 
2 1.03 (1.01-1.05) 0.011 0.95 (0.93-0.98) <0.0001 
3 1.08 (1.06-1.11) <0.0001 0.92 (0.90-0.95) <0.0001 
4 1.16 (1.14-1.19) <0.0001 0.91 (0.88-0.93) <0.0001 
5 (most deprived) 1.31 (1.27-1.34) <0.0001 0.93 (0.90-0.96) <0.0001 
Rurality of practice
§
   <0.0001   0.33 
 Urban >10K 0.95 (0.90-0.99) 0.01 1.02 (0.99-1.06) 0.192 
Town and fringe 1   1   
Village, hamlet and isolated dwellings  1.13 (1.11-1.16) <0.0001 0.99 (0.95-1.04) 0.809 
QOF total practice performance score
**
 0.85 (0.83-0.88) <0.0001 0.94 (0.91-0.97) <0.0001 
QOF CANCER01 indicator         
 Diagnosis always recorded 1  - 1  - 
Diagnosis sometimes or never recorded 0.90 (0.61-1.32) 0.576 0.75 (0.55-1.01) 0.052 
QOF CANCER03 indicator         
 Patient always reviewed 1  - 1   
Patient sometimes or never reviewed 1.02 (1.00-1.03) 0.06 1.01 (0.99-1.02) 0.567 
QOF PE07 indicator
††
 0.72 (0.68-0.77) <0.0001 0.85 (0.79-0.92) <0.0001 
QOF PE08 indicator
‡‡
 0.83 (0.79-0.87) <0.0001 0.98 (0.92-1.04) 0.52 
 Note: Table has been published in Bottle et al, 2012.185 
                                                     
*
Deprivation variables were included in the models one at a time. 
†
Deprivation variables were included in the models one at a time. 
‡
Deprivation variables were included in the models one at a time. 
§
Data missing for 1,013 patients at 10 practices. 
**
Per 100 points.  
††
Appointments within 2 working days (48 hours). 
‡‡
Appointments more than 2 days in advance. 
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I discuss these results and those of study 2 in section 8.4.4. 
8.4 Study 2 – analyses using GPRD data 
To improve the accuracy of case ascertainment (correct identification of patients with a first 
emergency admission for cancer), additional information is required beyond hospital data. 
When only secondary care data are used, false positive classification of patients as new 
cases may occur in patients with no previous admission for cancer. On the contrary, these 
patients may have existing cancer diagnoses not recorded in secondary care data. 
8.4.1 Aims of study 2 
The second set of analyses in this chapter continued to explore risk factors for first 
unplanned admissions for cancer in England. As with study 1, this outcome was considered 
to be a proxy measure of cancer diagnosis via the emergency route. In addition, I estimated 
the incidence of cancer diagnosis by emergency admission and explored patients’ use of 
health services before admission. 
8.4.2 Methods 
Data were obtained for patients registered at GP practices that contributed to the GPRD 
during the study period, 1st January 1999 to 31st December 2008.  
8.4.2.1 Case ascertainment  
Patients were identified as having a first diagnosis of cancer if they had a valid recorded 
cancer diagnosis in their general practice records or their emergency admission records, 
defined by Read codes and ICD-10 codes, respectively. Of these patients, those who were 
diagnosed by an emergency admission were identified. The diagnosis codes used in sample 
selection are documented in Appendices Table A.21 and excluded codes in Appendices 
Table A.22. 
Eligible patients were those who had a first recorded cancer diagnosis at any time between 
1st January 1999 (or date of study entry, whichever occurred last) and 31st December 2008 
(or date of study exit, whichever occurred first). To ensure that the diagnosis corresponded 
to the patient’s first-ever diagnosis, diagnoses beginning from the first record were checked 
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for valid cancer codes. Where patients had a valid diagnosis of cancer prior to their first 
diagnosis during the study period, these patients were excluded as false positive cases. 
8.4.2.2 Selection of variables 
Given limited information about GP practices in the GPRD dataset, only patient 
characteristics were measured, except for the geographical region of the GP practice 
location. The selected variables were, in alphabetical order: 
 Admissions before diagnosis;  
 Age at diagnosis; 
 Comorbidity (derived from Charlson Index score and Johns Hopkins ACG case-mix 
system); 
 Consultations before diagnosis;  
 Continuity of care;  
 Ethnicity; 
 Follow-up time; 
 Length of time at practice; 
 Marital status; 
 Deprivation status; 
 Practice region; 
 Referrals before diagnosis; and  
 Sex. 
Further information about the selection of variables can be found in Chapter 3. 
8.4.2.3 Statistical method 
Details of the analysis techniques used in this study have been described in Chapter 4. Crude 
and adjusted analyses to identify predictors for diagnosis of cancer by emergency admission 
were conducted using the PROC GENMOD procedure in SAS. As the outcome of interest was 
discrete in nature, taking one of two values, the data were assumed to fit a binomial 
distribution. Accordingly, the “log” link function was used in PROC GENMOD to generate 
crude relative risks, RRs (Chapter 4 section 4.5.1). Adjusted RRs were calculated using 
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Poisson regression with GEE because models using log-binomial regression with GEE failed 
to converge (Chapter 4 section 4.5.1). 
8.4.3 Results 
Before presenting the estimated incidence of first unplanned admissions for cancer and 
analyses of risk factors and service use, I describe the demography of the sample.  
8.4.3.1 Patient characteristics 
Out of the 74,763 patients in the cleaned dataset, 5,870 patients had a first diagnosis of 
cancer at 445 GP practices during the ten years studied. Of these patients, 13.9% were 
diagnosed during an unplanned admission (n=817/5,870). The majority of patients who 
received a new cancer diagnosis during an emergency admission had one recorded cancer 
diagnosis, based on ICD-10 codes (81.0%; n=731/903) with a maximum of two cancer 
diagnoses during one episode of care. The number of new cancer diagnoses recorded by 
ICD-10 codes mapped to Read codes ranged between one diagnosis per patient (60.5%; 
n=715/1,181) and four diagnoses per patient (0.34%; n=4/1,181). Almost all patients who 
were diagnosed with cancer for the first time by a non-emergency route had only one 
recorded cancer diagnosis (99.3%; n=5,035/5,071).  
Table 8.5 shows the cancer type that was most commonly recorded as the cause of 
emergency admission was “Other” types of cancer (21.4%; n=193/902), followed by breast 
cancer (13.6%; n=123/902), then colorectal cancer (11.5%; n=104/902). 
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Table 8.5 Number of first unplanned admissions by cancer type (ICD-10 codes), n=902 
diagnoses 
Cancer type Frequency, n (%) 
Acute leukaemia 8 (0.89) 
Bladder 54 (5.99) 
Brain & CNS 16 (1.77) 
Breast 123 (13.6) 
Cervix 7 (0.78) 
Chronic leukaemia 9 (1.00) 
Colorectal 104 (11.5) 
Kidney 21 (2.33) 
Larynx 2 (0.22) 
Lung 95 (10.5) 
Melanoma 10 (1.11) 
Multiple myeloma 16 (1.77) 
Non-Hodgkin’s lymphoma 37 (4.10) 
Oesophagus 31 (3.44) 
Oral 11 (1.22) 
Ovary 18 (2.00) 
Pancreas 16 (1.77) 
Prostate 84 (9.31) 
Stomach 17 (1.88) 
Testis 8 (0.89) 
Uterus 22 (2.44) 
Other cancer 193 (21.4) 
 
Comparison of cancer types by diagnosis route (emergency admission versus non-
emergency routes) was difficult because two different classification systems are used in 
primary and secondary care (Read codes and ICD-10 codes, respectively). A crude match of 
ICD-10 codes to Read codes was performed so that it was possible to compare the 
frequency of different cancer types by diagnosis routes (Appendices Table A.21). 
The following table provides the frequencies of diagnoses by cancer type for both settings, 
using Read codes (Table 8.6). The largest proportion of diagnoses through emergency 
presentations were for cancers of the genitourinary system (43.5%; n=448/1,030) and 
cancers of the digestive system (19.3%; n=199/1,030). By filtering diagnoses to include only 
those recorded in diagnoses by both emergency and non-emergency routes, cancers of the 
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bone, connective tissue, skin and breast were most frequently diagnosed (57.2%; 
n=309/540).  
Table 8.6 Number of cancer diagnoses by route to diagnosis, using Read codes 
Read classification system Diagnosis route, n 
Code Type of malignant neoplasm Emergency (%) Non-
emergency 
(%) 
B0 Lip, oral cavity and pharynx 18 (1.75) 7 (0.14) 
B1 Digestive organs and peritoneum 199 (19.3) 59 (1.16) 
B2 Respiratory tract and intrathoracic organs 110 (10.7) 36 (0.71) 
B3 Bone, connective tissue, skin and breast 149 (14.5) 309 (6.09) 
B4 Genitourinary organ 448 (43.5) 68 (1.34) 
B5 Other and unspecified sites 18 (1.75) 31 (0.61) 
B6 Lymphatic and haemopoietic tissue 88 (8.54) 30 (0.59) 
B7 Benign neoplasms 0 - 3850 (75.9) 
B8 Carcinoma in situ 0 - 33 (0.65) 
B9 Neoplasms of uncertain behaviour 0 - 45 (0.89) 
BA Unspecified nature neoplasm 0 - 2 (0.04) 
BB Morphology of neoplasms 0 - 590 (11.6) 
Bz Neoplasms Not Otherwise Specified 0 - 11 (0.22) 
 
8.4.3.2 Incidence of cancer diagnosis by emergency admission 
Out of 5,870 patients with a first-time diagnosis of cancer between 1999 and 2008, 13.9% of 
patients were diagnosed during an emergency admission (n=817/5,870). The overall 
incidence of first recording (as a proxy for diagnosis) of cancer by emergency admission 
during the study period was 2.51 patients per 10,000 person years. Over the ten years 
included in the study, the rate of cancers diagnosed by the emergency route declined, with 
a slight fluctuation in the penultimate year, 2007 (Figure 8.2). There was a greater overall 
decrease in the incidence rate in male patients compared to female patients but the rate 
remained higher in male patients in the final year of the study (2.98 patients per 10,000 
person years compared to 2.22 patients per 10,000 person years). 
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Figure 8.2 Incidence rate of first unplanned admissions for cancer by sex and year (per 10,000 
person years), 1999-2008  
 
 
To explore the age and sex distribution of patients who were diagnosed via unplanned 
admissions, I took a snapshot view of a single year of the study. Data for the calendar year 
2004 (crude surrogate for the middle year of the study period) showed that when compared 
to the overall sample of patients who received a first cancer diagnosis in that year, there 
was a disproportionally greater number of older patients who were diagnosed via an 
unplanned admission, especially for female patients aged between 65 and 84 years at 
diagnosis (Figure 8.3). Less than 5% of male and female patients diagnosed by emergency 
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Figure 8.3 Age and sex distribution of all patients with a first diagnosis of cancer compared to 
patients diagnosed through the emergency route, 2004 
 
 
The next figure, Figure 8.4, depicts the temporal trend in first diagnoses by age group. 
Patients aged less than 15 years were excluded from calculations due to small numbers. 
Similarly, because few patients aged 85 years or older had a first diagnosis of cancer by 
emergency admission, the 65 or older and 85 or older age groups were combined. Figure 8.4 
shows that the incidence rate of first recorded diagnoses of cancer by unplanned admission 
decreased over time in all three age groups. The most marked decline was in patients aged 
65 years or older, especially between 1999 and 2002. 
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8.4.3.3 Risk factors for cancer diagnosis by emergency admission 
In the next section of the Results, I describe the predictors of first cancer diagnosis by 
unplanned admission identified from crude and adjusted analyses. 
8.4.3.4 Crude associations with cancer diagnosis by emergency admission 
No patients in the sample had records for AIDs, congestive heart disease, diabetes with 
complications or hemiplegia. Therefore no results are reported for the corresponding 
comorbidity flags. Crude models of the risk of cancer diagnosis by emergency admission for 
certain comorbidities did not converge. The respective diseases were cerebro-vascular 
disease, dementia, mild liver disease, moderate liver disease, peptic ulcer or peripheral 
vascular disease. Therefore no results are reported for these variables. A model with 
Charlson Index score as the continuous explanatory variable also did not converge. All p-
values reported in this section are p<0.0001 unless stated otherwise. 
Crude regression models for all variables except those mentioned in the previous sub-
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time registered at the GP practice, follow-up time and continuity of care showed a positive 
linear relationship with risk of diagnosis by the emergency route. Female patients were less 
at risk of diagnosis by this route than male patients (RR 0.73, 95% CI 0.64-0.83). Although 
ethnicity was a crude predictor of diagnosis by emergency admission, the risk was not 
statistically different between patients of different ethnicities. Where deprivation status 
was recorded, patients living in areas classed as not the most or least deprived areas had 
greatest risk of cancer diagnosis via emergency admission (RR 3.51, 95% CI 2.98-4.14).  
Patients who were married (RR 3.19, 95% CI 1.78-5.72) compared to patients who were 
single, and those who were registered at practices on the South East coast (RR 4.63, 95% CI 
1.93-11.09) or the North West (RR 4.17, 95% CI 1.74-10.0) compared to other regions of 
England were most at risk of a first cancer diagnosis by the emergency route. Patients with 
at least one condition measured by the Charlson Index were also more at risk (RR 6.55, 95% 
CI 5.88-7.30). In particular, patients with chronic pulmonary disease were 6 times more 
likely to be diagnosed by an emergency admission than patients without this condition (RR 
6.08, 95% CI 5.28-6.99). 
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Table 8.7 Risk factors for first diagnosis of cancer, crude results from log-binomial regression 
using the generalized estimating equations (GEE) method 
Characteristic 
Patients, n 





Age group at diagnosis (years)     <0.0001 
 0-14 439 6 (1.37) 1  
15-44 2347 3 (0.13) 1.43 (0.69-2.96) 0.340 
45-64 1680 12 (0.71) 8.46 (4.22-17.0) <0.0001 
65-84 1197 12 (1.00) 18.1 (9.05-36.1) <0.0001 
≥85 207 16 (7.73) 25.2 (12.5-50.8) <0.0001 
Sex     <0.0001 
 Male 2418 400 (16.5) 1  
Female 3452 417 (12.1) 0.73 (0.64-0.83) <0.0001 
Ethnicity     <0.0001 
 Asian 29 6 (20.7) 1  
Black 30 8 (26.7) 1.29 (0.51-3.26) 0.592 
Mixed 8 2 (25.0) 1.21 (0.30-4.88) 0.790 
White 1924 617 (32.1) 1.55 (0.76-3.17) 0.230 
Other 28 6 (21.4) 1.04 (0.38-2.83) 0.945 
Unknown 3851 178 (4.62) 0.22 (0.11-0.46) <0.0001 
Marital status     <0.0001 
 Single 313 12 (3.83) 1  
Married 802 98 (12.2) 3.19 (1.78-5.72) <0.0001 
Other status 128 23 (18.0) 4.69 (2.41-9.13) <0.0001 
Unknown 4627 684 (14.8) 3.86 (2.20-6.74) <0.0001 
Deprivation (quintiles)     <0.0001 
 Least deprived 2990 187 (6.25) 1  
Quintiles 2,3,4 1738 382 (22.0) 3.51 (2.98-4.14) <0.0001 
Most deprived 716 132 (18.4) 2.95 (2.40-3.63) <0.0001 
Unknown 426 116 (27.2) 4.35 (3.54-5.36) <0.0001 
Practice region     <0.0001 
 East Midlands 122 5 (4.10) 1  
East of England 835 140 (16.8) 4.09 (1.71-9.78) 0.002 
London 345 51 (14.8) 3.61 (1.47-8.83) 0.005 
North East 252 38 (15.1) 3.68 (1.49-9.11) 0.005 
North West 615 105 (17.1) 4.17 (1.74-10.0) 0.001 
South Central 763 92 (12.1) 2.94 (1.22-7.09) 0.016 
South East Coast 622 118 (19.0) 4.63 (1.93-11.1) 0.001 
South West 834 84 (10.1) 2.46 (1.02-5.94) 0.046 
West Midlands 746 90 (12.1) 2.94 (1.22-7.10) 0.016 
Yorkshire & The Humber 736 94 (12.8) 3.12 (1.29-7.50) 0.011 
Time at practice (years)     <0.0001 
 Low 1957 176 (9.00) 1  
Moderate 1957 279 (14.3) 1.59 (1.33-1.89) <0.0001 
High 1956 362 (18.5) 2.06 (1.74-2.44) <0.0001 
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Follow-up time (years)     <0.0001 
 <1 988 82 (8.30) 1  
1-3 2032 271 (13.3) 1.61 (1.27-2.03) <0.0001 
4-6 1571 226 (14.4) 1.73 (1.36-2.20) <0.0001 
7-10 1279 238 (18.6) 2.24 (1.77-2.84) <0.0001 
Continuity of care     <0.0001 
 Low 5378 409 (7.61) 1  
Moderate 164 134 (81.7) 10.7 (9.55-12.1) <0.0001 
High 162 131 (80.9) 10.6 (9.43-12.0) <0.0001 
Not valid 166 143 (86.1) 11.3 (10.1-12.7) <0.0001 
Any consultation before diagnosis     <0.0001 
 No 752 218 (29.0) 1  
Yes 5118 599 (11.7) 0.40 (0.35-0.46) <0.0001 
Consultation before diagnosis
*
     0.031 
 No 2242 340 (15.2) 1  
Yes 3628 477 (13.2) 0.87 (0.76-0.99) 0.030 
Consultation ≤30 days before diagnosis     <0.0001 
 No 5734 704 (12.3) 1  
Yes 136 113 (83.1) 6.77 (6.11-7.50) <0.0001 
Consultation ≤7 days before diagnosis     <0.0001 
 No 5830 782 (13.4) 1  
Yes 40 35 (87.5) 6.52 (5.70-7.46) <0.0001 
Referral     <0.0001 
 No 5839 800 (13.7) 1  
Yes 31 17 (54.8) 4.00 (2.89-5.54) <0.0001 
Referral ≤30 days before diagnosis     0.006 
 No 5866 814 (13.9) 1  
Yes 4 3 (75.0) 5.41 (3.06-9.55) <0.0001 
Admission before diagnosis, mean (SD) 0.11 (0.32) 0.04 (0.20) - - <0.0001 
Charlson Index score     <0.0001 
 0 5785 745 (12.9) 1  
1 43 39 (90.7) 7.04 (6.27-7.92) <0.0001 
≥2 42 33 (78.6) 6.10 (5.14-7.24) <0.0001 
Composite Charlson Index measure      <0.0001 
 No 5749 718 (12.5) 1  
Yes 121 99 (81.8) 6.55 (5.88-7.30) <0.0001 
Chronic pulmonary disease     <0.0001 
 No 5809 768 (13.2) 1  
Yes 61 49 (80.3) 6.08 (5.28-6.99) <0.0001 
Diabetes     <0.0001 
 No 5843 796 (13.6) 1  
                                                     
*
At GP practice, telephone or home visit and with GP or nurse. 
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Yes 27 21 (77.8) 5.71 (4.62-7.06) <0.0001 
Myocardial infarction     0.017 
 No 5865 814 (13.9) 1  
Yes 5 3 (60.0) 4.32 (2.11-8.87) <0.0001 
Renal disease      <0.0001 
 No 5854 803 (13.7) 1  
Yes 16 14 (87.5) 6.38 (5.24-7.76) <0.0001 
Rheumatologic disease     0.017 
 No 5865 814 (13.9) 1  
Yes 5 3 (60.0) 4.32 (2.11-8.87) <0.0001 
 
8.4.3.5 Model selection for adjusted analyses  
As explained in section 8.4.2.3, log-binomial models using GEE for adjusted regression did 
not converge. Of the three Poisson with GEE models for the different comorbidity measures 
that were statistically significant at the 95% level in crude analyses (Table 8.7), the model 
with grouped Charlson score performed best (lowest QIC score) and so this variable was 
carried forward for adjusted analyses. As multiple consultation and referral variables were 
included in adjusted calculations, eight separate models were run for the variable 
combinations to reduce collinearity caused by correlated variables. The performances of 
these models are shown in Table 8.8. The model with consultation ≤7 days before diagnosis 
and referral ≤30 days before diagnosis performed best, producing a QIC score of 6317.1, and 
was used in final adjusted analyses (Table 8.8). However, this model’s QIC score was 670.5 
points greater than the null model’s score, indicating sub-optimum fit. 
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Table 8.8 Fit of adjusted Poisson regression models for predicting risk factors for first 
emergency admissions for cancer, by consultation and referral variable, using the generalized 
estimating equations (GEE) method 
Consultation variable 
Quasi-Likelihood under the 
Independence model Criterion (QIC) 
Referral before 
diagnosis 
Referral ≤30 days 
before diagnosis 
Consultation ≤30 days before diagnosis 6353.2 6320.3 
Consultation ≤7 days before diagnosis 6349.7 6317.1 
Consultations, grouped 6814.6 6777.2 
Consultations at GP practice, telephone or home visit with 
GP or nurse, grouped 
6573.3 6522.3 
Null model 5646.6 
 
8.4.3.6 Adjusted associations with cancer diagnosis by emergency 
admission 
Once adjusted for other characteristics and taken into account clustering of patients at GP 
practices, patient’s age at diagnosis, deprivation status and Charlson Index score remained 
significant predictors of first diagnosis of cancer by emergency admission at the 95% level 
(Table 8.9). Ethnicity and continuity of care score were also associated with risk of diagnosis 
by unplanned admission, although the differences in risk between patient groups for both 
characteristics were not statistically significant. Patients in the oldest age group at diagnosis 
(RR 9.23, 95% CI 4.81-17.7; p<0.0001), living in the most deprived areas (RR 1.23, 95% CI 
1.02-1.49; p=0.032) and patients with a moderate number/severity of comorbidities* (RR 
1.35, 95% CI 1.05-1.75; p=0.020) were most at risk of cancer diagnosis by emergency 
admission.  
  
                                                     
*
Defined by cumulative Charlson Index score of one. 
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Table 8.9 Risk factors for first diagnosis of cancer, crude (log-binomial) and adjusted (Poisson 
with GEE) results using the generalized estimating equations (GEE) method 
Characteristic 
Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Age group at diagnosis (years)  <0.0001  <0.0001 
 0-14 1  1  
15-44 1.43 (0.69-2.96) 0.340 1.22 (0.62-2.43) 0.566 
45-64 8.46 (4.22-17.0) <0.0001 4.77 (2.50-9.10) <0.0001 
65-84 18.1 (9.05-36.1) <0.0001 6.57 (3.42-12.6) <0.0001 
≥85 25.2 (12.5-50.8) <0.0001 9.23 (4.81-17.7) <0.0001 
Sex  <0.0001  0.275 
 Male 1  1  
Female 0.73 (0.64-0.83) <0.0001 0.94 (0.84-1.05) 0.269 
Ethnicity  <0.0001  <0.0001 
 Asian 1  1  
Black 1.29 (0.51-3.26) 0.592 0.75 (0.42-1.33) 0.325 
Mixed 1.21 (0.30-4.88) 0.790 0.80 (0.36-1.76) 0.571 
White 1.55 (0.76-3.17) 0.230 1.06 (0.59-1.89) 0.845 
Other 1.04 (0.38-2.83) 0.945 1.27 (0.62-2.60) 0.512 
Unknown 0.22 (0.11-0.46) <0.0001 0.34 (0.18-0.62) 0.001 
Marital status  <0.0001  0.224 
 Single 1  1  
Married 3.19 (1.78-5.72) <0.0001 1.27 (0.82-1.96) 0.283 
Other status 4.69 (2.41-9.13) <0.0001 1.09 (0.64-1.87) 0.742 
Unknown 3.86 (2.20-6.74) <0.0001 1.35 (0.88-2.05) 0.166 
Deprivation (quintiles)  <0.0001  <0.0001 
 Least deprived 1  1  
Quintiles 2,3,4 2.95 (2.40-3.63) <0.0001 1.14 (0.98-1.32) 0.085 
Most deprived 3.51 (2.98-4.14) <0.0001 1.23 (1.02-1.49) 0.032 
Unknown 4.35 (3.54-5.36) <0.0001 0.63 (0.50-0.79) <0.0001 
Practice region  <0.0001  0.352 
 East Midlands 1  1  
East of England 4.09 (1.71-9.78) 0.002 1.77 (0.78-4.03) 0.170 
London 3.61 (1.47-8.83) 0.005 1.84 (0.78-4.30) 0.161 
North East 3.68 (1.49-9.11) 0.005 2.00 (0.83-4.79) 0.121 
North West 4.17 (1.74-10.0) 0.001 1.75 (0.77-3.98) 0.185 
South Central 2.94 (1.22-7.09) 0.016 1.84 (0.81-4.20) 0.146 
South East Coast 4.63 (1.93-11.1) 0.001 1.82 (0.80-4.13) 0.152 
South West 2.46 (1.02-5.94) 0.046 1.54 (0.68-3.48) 0.301 
West Midlands 2.94 (1.22-7.10) 0.016 1.64 (0.71-3.78) 0.244 
Yorkshire & The Humber 3.12 (1.29-7.50) 0.011 2.15 (0.94-4.91) 0.069 
Time at practice (years)  <0.0001  0.846 
 Low 1  1  
Moderate 1.59 (1.33-1.89) <0.0001 1.02 (0.87-1.20) 0.783 
High 2.06 (1.74-2.44) <0.0001 0.99 (0.84-1.15) 0.866 
Follow-up time (years)  <0.0001  0.581 
 <1 1  1  
1-3 1.61 (1.27-2.03) <0.0001 1.12 (0.90-1.40) 0.308 
4-6 1.73 (1.36-2.20) <0.0001 1.15 (0.92-1.43) 0.209 
7-10 2.24 (1.77-2.84) <0.0001 1.18 (0.92-1.50) 0.186 
Continuity of care  <0.0001  <0.0001 
 Low 1  1  
Moderate 10.7 (9.55-12.1) <0.0001 1.01 (0.87-1.18) 0.895 
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High 10.6 (9.43-12.0) <0.0001 0.99 (0.86-1.14) 0.896 
Not valid 11.3 (10.1-12.7) <0.0001 0.29 (0.25-0.34) <0.0001 
Any consultation before diagnosis  <0.0001  <0.0001 
 No 1  1  
Yes 0.40 (0.35-0.46) <0.0001 0.44 (0.37-0.51) <0.0001 
Consultation before diagnosis
*
  0.031  <0.0001 
 No 1  1  
Yes 0.87 (0.76-0.99) 0.030 0.54 (0.47-0.63) <0.0001 
Consultation ≤30 days before diagnosis  <0.0001  0.119 
 No 1  1  
Yes 6.77 (6.11-7.50) <0.0001 1.14 (0.97 1.34) 0.116 
Consultation ≤7 days before diagnosis  <0.0001  0.022 
 No 1  1  
Yes 6.52 (5.70-7.46) <0.0001 1.34 (1.05-1.71) 0.019 
Referral
†
  <0.0001  0.036 
 No 1  1  
Yes 4.00 (2.89-5.54) <0.0001 1.45 (1.04-2.02) 0.027 
Referral ≤30 days before diagnosis  0.006  0.285 
 No 1  1  
Yes 5.41 (3.06-9.55) <0.0001 1.76 (0.76-4.09) 0.187 
Admission before diagnosis, mean (SD) 0.30 (0.21-0.43) <0.0001 0.30 (0.20-0.46) <0.0001 
Charlson Index score  <0.0001  0.016 
 0 1  1  
1 7.04 (6.27 - 7.92) <0.0001 1.35 (1.05-1.75) 0.020 
≥2 6.10 (5.14 - 7.24) <0.0001 0.83 (0.66-1.04) 0.111 
 
8.4.3.7 Service use 
To better understand the characteristics of patients who were diagnosed with cancer 
through emergency admissions, I compared the access to health services by these patients 
and patients diagnosed through non-emergency routes. I now describe the consultation, 
referral and emergency admission patterns of patients in these two groups. 
8.4.3.8 Consultations 
Patients who had at least one consultation with a GP or nurse at the practice, by telephone 
or home visit in the 7 days immediately before their first cancer diagnosis were at great risk 
of diagnosis via an unplanned admission (adjusted RR 1.34, 95% CI 1.05-1.71; p=0.019). 
During the study period, patients who were diagnosed via non-emergency routes had fewer 
consultations with a GP or nurse at their GP practice, by telephone or home visit before 
                                                     
*
At GP practice, telephone or home visit and with GP or nurse.  
†
Adjusted results for referral are from regression model that included consultations within 7 days of diagnosis.  
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diagnosis (mean 0.25, SD 3.16, consultations) compared to patients diagnosed by unplanned 
admission (mean 7.91, SD 16.3, consultations), t(826)=13.4, p<.001. 
8.4.3.9 Referrals 
No patients had a recorded referral request in the 7 days immediately before their first 
diagnosis of cancer, but patients who had at least one recorded referral request were at 
greater risk of being diagnosed via the emergency route (adjusted RR 1.45, 95% CI 1.04-2.02; 
p=0.027). Few patients with a first cancer diagnosis during the study period had a recorded 
referral request before diagnosis, regardless of diagnosis route (0.53%; n=31/5,870). Among 
the patients diagnosed via the emergency route, the number of referrals before diagnosis 
ranged between 0 and 17 referrals (2.08%; n=17/817). In comparison, the number of 
referrals before diagnosis for patients diagnosed by non-emergency routes fell into a much 
narrower range, between 9 and 5 referrals (n=5,053), t(820)=5.0; p<0.001. 
8.4.3.10 Admissions 
Patients with a greater average number of prior emergency admissions were less likely to be 
diagnosed with cancer via the emergency route (adjusted RR 0.30, 95% CI 0.20-0.46; 
p<0.0001). Regardless of the route to diagnosis, the number of all-cause emergency 
admissions before the first cancer diagnosis was low, ranging between 0 and 2 admissions in 
patients diagnosed via the emergency route (n=817/5,870) and between 0 and 3 admissions 
in patients diagnosed via non-emergency routes (n=5,053/5,870), t(1670)=10.5; p<0.001. 
8.4.4 Discussion 
The two studies presented in this chapter are not directly comparable. Firstly, different 
denominator data were used. Study 1 included all patients with a first time admission for 
cancer while study 2 included all patients with a first time diagnosis for cancer. Yet the 
numerator was the same; both studies identified patient characteristics associated with 
cancer diagnosis by emergency admission. Secondly, different units of measurement were 
used. Study 1 measured ORs while study 2 measured RRs. As the outcome of interest 
(emergency admission for cancer) in study 1 was common (occurrence in more than 10% of 
the sample), the ORs from the first study do not approximate to RRs. Nevertheless, the two 
sets of analyses provide complimentary information to inform policy and practice. Next, I 
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consider the results in respect to the objectives of this chapter (section 8.2.4) and also the 
wider context of cancer care in England. 
8.4.4.1 Summary of main findings 
The first overall objective of this chapter was to measure the rate of first emergency 
(unplanned) admissions for cancer. Between 1999 and 2008, the incidence of first-time 
diagnoses (new cases) of cancer by emergency admission was 2.51 patients per 10,000 
person years. During these ten years, 13.9% of patients who were diagnosed with cancer for 
the first time received their diagnosis during an emergency admission (n=817/5,870). 
Among patients who receive a first-time diagnosis of cancer by admission between 2007/08 
and 2009/10, 21.8% were diagnosed by the emergency route (n=139,351/639,064).  
These estimates also capture temporal trends in cancer diagnoses via the emergency route 
in England. Published national figures have tended to use data from one year; NCIN 
estimated that 23% of cancers were diagnosed by emergency presentations in 2007 and the 
National Audit of Cancer Diagnosis in Primary Care estimated that 12.9% of diagnosed 
cancers in 2009/10 were made along the emergency pathway*.391,401 The validity of the 
results shown in this chapter is supported by their similarity to the external figures, using 
data from the same care settings albeit with far smaller samples. 
As for the second and third objectives to identify patient and practice risk factors for first 
emergency admissions for cancer, the results of the two studies were in concordance. 
Distinct patient groups at greater risk of diagnosis by emergency admission were identified, 
namely older patients (especially aged 85 years or older) and those living in the most 
deprived areas. No breakdown of admissions by cancer type was made in study 2. However, 
grouping by biological system showed cancers of the digestive system to be commonly 
diagnosed by the emergency route. While in study 1, pancreatic cancer had one of the 
highest odds out of all the cancer types for diagnosis by emergency admission. 
                                                     
*
In the Audit, relevant diagnoses were defined as emergency referrals for suspected cancers that were later 
confirmed, including emergency hospital presentations without primary care contact. Estimate excludes 
cancers detected by screening, in-situ carcinomas and non-melanotic carcinomas of the skin.
391
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Practice-level predictors for emergency admissions were investigated in study 1, presenting 
a mixed picture about the suitability of the outcome measure as a primary care safety 
indicator. I will discuss the role of measurement in Chapter 9. Expected correlations 
between this measure and established QOF cancer indicators were not found in adjusted 
results. More promising inverse associations were detected between diagnosis by 
emergency admission and practices’ overall QOF performance, and patient experiences of 
access. Despite this finding, additional quality markers should be used to validate outcomes 
in future research given the well documented equivocal impact of financial incentive 
schemes, and specifically the QOF, on quality improvement.353,408-410 Also, interactions 
between factors need to be explored to better understand findings such as the increased 
odds of diagnosis by the emergency route for patients at practices where none of the GPs 
received their medical qualification in the UK.  
8.4.4.2 Methodological issues 
Studies 1 and 2 were affected by weaknesses inherent to their study designs and the 
sources of data used. For instance, data in HES are entered by professional, typically non-
medically qualified, coders while GPRD data are extracted directly from GP practices and 
may be entered by different types of staff including GPs, nurses, receptionists and trained 
medical coders. One finding of the informal consultations was the advocacy by GPs of 
employing medically qualified staff to enter clinical data into computer systems (Chapter 2 
section 2.6.8).183 The use of these designated coders might improve data accuracy but does 
not negate the issue of inconsistent coding within GP practices if data are processed by 
multiple staff, as well as inter-practice variation due to different coding standards and 
computer systems. Even though there are national NHS clinical coding standards for 
diagnoses and procedures (ICD-10 and OPCS-4 classifications, as well as SNOMED CT), there 
is likely to be variation in coding practices between hospitals and Trusts. 
I now further discuss limitations relating to the main data sources, HES and the GPRD. I will 
then consider potential confounders that did not feature in the analyses yet are of interest 
for future research. 
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8.4.4.3 Limitations of the data and analyses 
As mentioned in section 8.3.2.1 and section 8.4, first recordings of cancer by emergency 
admission may be attributed to pre-existing diagnoses. Accurate case ascertainment was 
difficult in study 1, where only HES data were used. For example, there was no information 
about outpatient appointments to eliminate patients known to be receiving cancer 
treatment. Patients of practices with less than 500 patients were excluded without 
exploration of potential differences between these practices, its patients and the practices 
that were included in analyses. The analyses offer a simple view of the current health care 
situation, with no exploration of interactions between characteristics such as cancer type 
and rurality, or the relationships between practice (and patient) variables, as already 
mentioned in section 8.4.4.1. 
Coding for cancer diagnoses is known to be poor in general practice records.116 By using the 
integrated HES data in the GPRD dataset, I was better able to detect true positive cases of 
first cancer diagnosed by emergency admissions. In section 8.4.4.1, I compared the finding 
that 13.9% of first cancer diagnoses were made by emergency admissions with published 
national estimates and the higher rate calculated in study 1. One plausible reason for the 
low estimate (in contrast to study 1’s rate) lies with the rigorous sampling criteria applied in 
study 2 (section 8.4.2.1 for case ascertainment method). By tracking back to patients’ first 
records in the GPRD dataset and cross-referencing between primary and secondary care 
records, I was able to ascertain first diagnoses over patients’ lifetimes. Other studies on this 
subject tracked back over considerably shorter periods of time (3 years in study 1) and 
therefore the sampling sensitivity in those studies is likely to be poorer than in study 2. 
As set out in Chapter 3 section 3.7, the dataset requested from the GPRD was a random 
sample of 100,000 patients with no specifications about disease status or other patient 
traits. Therefore, the sample for study 2 of this chapter and the sample for analyses in 
Chapter 7 were smaller than if samples for specific disease groups or outcomes of interest 
had been requested instead. As such, the generalisability of results might be affected. This 
weakness is somewhat counter-balanced by the use of nationally representative data and 
robust statistical methods appropriate for the sample size. Additional data triangulation, 
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such as using case notes and patient interviews, would further improve the accuracy of 
identifying first time cancer diagnoses by the unplanned route.  
Not all fields in the GPRD dataset were of a good level of completeness or accuracy. Referral 
rates for suspected cancer are known to differ across the country.83,389-391 This information 
was not available for study 1 but in study 2, the number of recorded referral requests in 
general practice was considerably lower than published numbers. To illustrate, 0.53% of 
patients in study 2 were recorded as having at least one referral request before their first 
cancer diagnosis compared to 86.5% of patients who had a known type of referral in the 
National Audit.391 The stark difference may be partly explained by the narrow definition of 
referral used in study 2, based solely on data from the referrals section of the GPRD dataset 
without cross-referencing with investigations and tests recorded in other data sections. 
Although results by referral for study 2 are included in this chapter for completeness, the 
low numbers mean that these results should not be extrapolated beyond the study. 
8.4.4.4 Case-mix adjustments 
Generic and cancer-specific confounders have been adjusted for in studies 1 and 2. Still, 
there will undoubtedly be factors unaccounted for. Cancer type was only adjusted for in 
study 1. Further analyses should consider cancer types separately as the epidemiology, 
treatment and patient outcomes for different cancer types will not be homogeneous. 
Arguably the most important variable missing from both studies is cancer stage. Linkage of 
HES and/or GPRD to cancer registries and audits will provide staging and treatment 
information required to determine the relationship between diagnosis by the emergency 
route and late diagnosis (as defined in section 8.2.2).389 Extra data on cancer screening and 
waiting times between intervals of care will help to establish which patient groups are most 
affected by poor care and expose the processes that require improvement. However, for 
many sources of cancer data, delays between data collection and publication or availability 
of these data for secondary uses can be obstructive for research purposes.389 
8.4.4.5 Implications for clinical care and health policy 
In conclusion, in this chapter I have presented population-level analyses using recent data to 
determine a range of patient and practice characteristics associated with first diagnoses of 
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cancer by the emergency route, as a proxy measure of delayed diagnosis. The results feed 
into national efforts to improve cancer care in England and echo findings from the 
literature.391,401,411 Cancer research often focuses on short-term survival, typically up to one 
year post-diagnosis or completion of treatment. However, patients, carers and community 
care providers are also interested in longer term prognoses, especially as cancer is often 
now a chronic disease.412 Analyses within a short timeframe may be appropriate if assuming 
that poor patient outcomes are due to delayed diagnosis. Based on this understanding, 
earlier diagnosis by reducing the number of patients diagnosed by the emergency route 
would improve both short and long term patient outcomes. 
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Chapter 9: Discussion 
 
9.1 Chapter overview 
In this final chapter of the thesis, I summarise the results of the analyses 
from Chapters 5 to 8 within the context of the project aims. I then evaluate 
the methodologies applied and consider current understanding of patient 
safety indicators. I discuss the strengths and limitations of the project and 
conclude with suggestions for future applications of patient safety 
indicators in terms of research, clinical practice and health policy.  
 
9.2 Addressing the aims of the project 
I begin by revisiting the aims of this project (Chapter 1 section 1.7) to summarise the key 
findings. This section brings together the findings from Chapters 2, 5, 6, 7 and 8. 
9.2.1 Addressing Aim 1 
- Explore the epidemiology of adverse events in general practice using routinely 
collected data. 
There have been limited and inconsistent reports on the extent of AEs in general practice in 
England, not helped by heterogeneous methods applied in previous studies (Chapter 2 
section Error! Reference source not found.). One of the aims of this project was to provide 
a robust national estimate of AEs, based on data recorded routinely as part of care in 
hospital or general practice. I found low rates of AEs defined by designated diagnosis codes 
for complications of care, DEAs and for first unplanned admissions for cancer (as a proxy 
measure for diagnosis by the emergency route). Analyses of data from NHS Brent (Chapter 5) 
produced an estimated rate of 1.67 AEs per 1,000 consultations (95% CI 1.59-1.74). Data 
from the GPRD (Chapter 6) produced an estimated rate of 6.0 AEs per 1,000 person-years 
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(95% CI 5.74-6.27). These findings are not too dissimilar to those from some previous 
studies, but the inconsistent use of denominator populations and units of measurement 
makes comparisons very difficult.8,24,295 Among patients with diagnosed diabetes, there 
were 3.97 DEAs per 1,000 person years (Chapter 7). The proportion of patients with a first 
emergency admission for cancer ranged between 13.9% and 21.8% of patients diagnosed 
with cancer, with an incidence of 2.51 patients diagnosed by the emergency route per 
10,000 person years (Chapter 8). 
Patient and practice characteristics associated with AEs were examined. Older age, certain 
comorbid conditions and greater service use (GP consultations and emergency admissions) 
were associated with increased risk of an AE identified by a complication of care code, while 
there was variation in risk by GP practice region (Chapters 5 and 6). Older age, more GP 
consultations and having more and/or complex comorbidities were associated with lower 
risk of a DEA in patients with diabetes (Chapter 7). Older age was again associated with 
elevated risk of experiencing the final AE measured in this project, first emergency 
admission for cancer (Chapter 8). Patients living in the most deprived areas were also at 
greater risk of this outcome, along with patients who had certain diagnoses such as 
pancreatic cancer (Chapter 8). Associations between first emergency admission for cancer 
and practice measures of quality varied and did not provide conclusive evidence about the 
suitability of the outcome for use as safety indicator (Chapter 8). 
9.2.2 Addressing Aim 2 
- Examine how routinely collected data can be used in their current state for 
patient safety measurement within existing quality improvement systems. 
The use of data collected locally and nationally for patient safety measurement and 
monitoring was reviewed in Chapter 2. The types of routinely collected data currently used 
for these purposes are limited and mainly originate from secondary care, although there is 
documented use of electronic patient records from GP practices. The focus of these often 
small scale (practice or local level) measurements remains drug-related events, using multi-
sourced data. In fact, the analyses reported in Chapters 5 to 8 illustrated the importance of 
using more than one data source to improve the validity of AE measures. More often than 
not in quality improvement initiatives, patient safety is integrated into other domains of 
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quality and rarely considered on a standalone basis. Within the framework of performance 
monitoring at the PCT- (and future CCG-) level, data on patient safety have been collected 
for benchmarking, to create practice profiles, for service commissioning and in local 
extensions of the QOF programme (Chapter 2).183  
9.2.3 Addressing Aim 3 
- Consider what obstacles there might be against using routinely collected data for 
active patient safety surveillance in general practice, at local and national levels. 
Findings from the literature review and informal consultations reported in Chapter 2 
highlighted difficulties in the use of data to improve patient safety in general practice and 
elsewhere in primary care.183 The key obstacles were poor communication, cultural barriers, 
technical data challenges, inadequate skills and knowledge and management issues. A 
further limitation for monitoring AEs is insufficient clinical detail in most existing routinely 
collected data to determine the preventability and severity of events. Current use of these 
data for patient safety is also hindered by scant awareness of their potential applications in 
general practice or other care settings (Chapter 2 section 2.6.8).183 Reporting of all safety 
incidents involving patients only became mandatory in English primary care in 2012. Before 
this, reporting was sporadic and inconsistent in this setting. Nevertheless, local and national 
incident reporting schemes are main sources of information about AEs, even though there 
are known issues of incomplete event capture and scepticism among clinicians on the 
effectiveness of reporting schemes.183 
9.2.4 Addressing Aim 4 
- Apply adverse events indicators for general practice that have been developed 
from available routinely collected data. 
Results of analyses on the three AE indicators measured in this project have been described 
earlier in this chapter (section 9.2.1) and presented in Chapters 5 to 8. The data sources and 
analysis methods were described in Chapters 3 and 4, respectively. In essence, the first 
indicator was a generic measure of AEs recorded in data routinely collected in general 
practice, to provide a national baseline rate of harm. The second and third measures were 
indicators of outcomes associated with AEs. The former indicator measured emergency 
admissions for diabetic emergencies (DEAs), which is a collective term for diabetic 
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ketoacidosis and diabetic (hyperglycaemic or hypoglycaemic) coma. The latter measured 
first emergency admissions for cancer. While detailed findings are reported in the respective 
Chapters 5, 6, 7 and 8, further discussion of the methods adopted to meet the research aims 
are presented in the following section. 
9.3 Meeting the research aims 
Now I will discuss how the aims were met by evaluating the research methods used in this 
project, the sources of data and the analysis methods applied. 
9.3.1 Research methods 
To address the four aims of this project, multiple methods were applied. While quantitative 
analyses formed the largest component, they were supported by a literature review and 
supplementary informal consultations. As well as providing face validity for the indicators 
explored in this project, the discussions with four GPs and a medical student provided 
snapshot anecdotal evidence of clinical views and experiences of AE measurement using 
routinely collected data. The limitations of these consultations, including the small sample 
and non-random selection, have been described at length elsewhere (Chapter 2 section 
2.6.8).183  
Stringent selection criteria were applied in the literature review which may have been 
overly-restrictive, for example potentially relevant studies on ADRs were excluded (Chapter 
2 section 2.4.4). Relatively few studies were conducted in the UK, with strong dominance 
from US-based studies. Thus there needs to be caution in generalising findings from the 
review to the English health system. The patient groups in reviewed studies were also 
limited, comprising mainly of adult hospital patients. The quality of the studies varied and 
they lacked common measures for elements such as AE severity, where this was considered. 
These limitations may not reflect inadequacies of the review process given the 
comprehensive methodology adhered to, but they may instead accurately portray the 
incomplete and inadequate evidence base on measurement of patient safety in non-acute 
care using routinely collected data. 
In addressing research aims 1 and 4, I examined three distinct AE indicators. The first 
generic measure was to provide a baseline estimate of events that are recorded in local and 
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national datasets. The second and third measures of outcomes associated with AEs were 
selected due to the high prevalence and hence burden to the health system of the 
conditions, the availability of disease-specific indicators and the topical nature of the 
diseases in terms of care improvement. This approach of considering three diverse 
indicators enabled confirmation that AEs potentially attributable to care received in general 
practice can be detected using routinely collected data, either directly from patient records 
or by using more sophisticated tools to deduce harm by proxy. 
Additionally, the implementation of three indicators provided evidence on the suitability of 
routinely collected data for monitoring AEs across a range of diseases and conditions, 
including the simple use of existing complications of care codes for active surveillance. An 
alternative research strategy to the one I adopted would be to focus on a single disease or 
patient group, whereby a more detailed understanding of risk factors and patient outcomes 
might be achieved. However, as this project was exploratory in nature and with the 
unknown compatibility of the available datasets with AE detection, the chosen research 
methods were appropriate. Whether investigating one or multiple diseases or AEs, 
successful research depends on the quality and nature of available data, which I consider in 
the next sub-section. 
9.3.2 Sources of information 
Variable data availability and quality between and within care settings and specialities, and 
the historical lack of a central repository for healthcare data, in England compounds the 
difficulties of conducting research in this field. Further obstacles include costs associated 
with obtaining some datasets and a notorious ethical approval process for certain types of 
studies. An example of the variation in management of services which affects the delivery of 
care in primary care is the non-uniformity in GP practice computer systems, arising from the 
GPSoC scheme. Currently, approximately half of NHS GP practices use computer systems 
from EMIS which offers several different core system products, but there also exists a 
myriad of other systems (Chapter 1 section 1.6.2).128 
One detrimental effect of individual GP practices being able to choose their preferred 
computer system is the potential increase in coding irregularities between systems, 
although these can also occur within systems.183,413 This chaotic data landscape hinders 
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accurate monitoring of AEs, not least because of potential incomparability of findings from 
studies which use data from different computer systems. The divergence in data 
management is emphasised by the fact that until recently, the two largest English primary 
care datasets available for research purposes, QResearch and the GPRD (superseded by 
CPRD), were extracted from practices using different computer systems provided by EMIS 
and INPS, respectively. It should be noted that the new CPRD should have better coverage 
as it houses data from all four of the main computer systems used in English primary care, 
as well as having capacity to link with data from across health and social care.130 
Furthermore, the most comprehensive data yet from GP practices should become available 
through the GPES (Chapter 1 section 1.6.2).134 
9.3.3 Quality of the data 
The value and importance of data triangulation in patient safety indicator research, 
especially for pilot or exploratory studies, has been raised earlier in this chapter (section 
9.2.2).299,300 As discussed previously (Chapter 6 section 6.5.2.1, Chapter 7 section 7.5.7.5 and 
Chapter 8 sections 8.4.4.2 and 8.4.4.3), secondary uses of data collected for purposes other 
than research are reliant on the accuracy and completeness of initial data recording. In the 
case of GPRD data which have been used extensively to study different diseases and 
conditions, there may be under-recording of prevalent conditions.192,193 Analyses of these 
data are also restricted by the inherent coding structures of the datasets, including nuances 
of coding practices in primary and secondary care settings (Chapter 5 section 5.5.2). As 
SNOMED CT becomes more widely adopted as the standard clinical terminology in the NHS, 
there should be positive effects in terms of the consistency, reliability and 
comprehensiveness of recorded data (Chapter 1 section 1.6.3).135  
Potential quality discrepancies beyond the control of original data entry and project 
analyses may also been present. For instance, delays by patients in presenting with 
symptoms or AEs, as well as erroneous recall, may contribute to inaccurate records (Chapter 
6 section 6.5.2.3). To improve the accuracy of sample selection and detection of true cases 
of AEs, verification could use further data sourced from case notes, interviews or other 
material (Chapter 1 section 1.4.2), but this was not feasible in this project (Chapter 8 section 
8.4.4.3). 
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Case mix adjustment was also affected by the limited availability of variables in the main 
study datasets from NHS Brent, the GPRD and HES (Chapter 5 section 5.5.2, Chapter 7 
section 7.5.7.1 and Chapter 8 section 8.4.4.4). There were particularly few GP practice 
variables available in the first two aforementioned datasets, preventing exploration of their 
associations with the measured AEs and patient factors. Given the anonymised nature of 
data from NHS Brent and the GPRD, linkage of these datasets to other sources was not 
possible (Chapter 6 section 6.5.2.2 and Chapter 7 section 7.5.7.4). Practice list size, number 
of GPs and other GP practice data were used in study 1 of Chapter 8 but otherwise 
unavailable. Potential residual practice confounders such as these may be relevant to study 
2 of Chapter 8 and other studies in this project.  
9.3.3.1 Validation of the data 
Another aspect of quality assessment is data validation. There are several methods to 
determine the discriminative and predictive accuracy of measurements. For example, the 
sensitivity and specificity of estimates can be assessed by splitting data into development 
(prediction) and validation datasets. An alternative to this internal form of validation 
(assessments using the same data) is to conduct external assessments using other data 
sources. Both methods are dependent on the accuracy of original data recording.192,414 No 
internal validation using split datasets was performed in this project. The validity of results 
was improved by data triangulation from local and national datasets for the generic 
measure of AEs, although different units of measurement were used in the studies reported 
in Chapters 5 and 6. 
To validate the analyses of DEAs (Chapter 7), results were compared to the literature and 
other published material. The findings were summarised earlier in this chapter (section 9.2.1) 
but of further note is that the comparisons to published national data were hampered by 
small numbers in the study. In spite of this, reasonable data validity was assumed given that 
the calculated rates of diabetes fell within the estimates from three national sources, the 
National Diabetes Audit, QRESEARCH and QOF*. The studies in Chapter 8 on emergency 
                                                     
*
Estimates for the years 2004-2006, where data from the study, National Diabetes Audit, QRESEARCH and QOF 
were all available. 
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admissions for cancer show how multiple data sources can be used to improve case 
ascertainment. Building on the use of only HES data in study 1, patient records from HES and 
the GPRD were cross-matched in study 2 to ensure true identification of first diagnoses of 
cancer. The rates of diagnoses by emergency admission estimated in the two studies were 
compared with each other and other studies from the literature (Chapter 8 section 8.4.4.1). 
9.3.4 Analysis methods 
Validation of data extended beyond assessments of outcomes in this project. The validity of 
some measures commonly applied in health service research is not well known for non-
acute settings. The studies reported in Chapters 6, 7 and 8 applied two sets of comorbidity 
measures, the Charlson Index and the Johns Hopkins ACG case-mix system. For both of 
these measures, there is relatively little published evidence on their uses in primary care 
compared to acute settings, especially in England.216-218,225,226 Neither set of measures 
demonstrated conclusive superiority in its ability to explain variation in the data. For 
example, statistical models containing measures from the Charlson Index performed best in 
predicting the risk of AEs identified from complications of care codes and first emergency 
admissions for cancer (Chapters 6 and 8). However, Expanded Diagnosis Cluster (EDC) 
groups from the ACG system performed best out of all comorbidity measures in predicting 
the risk of death (Chapter 6). 
Technical concerns associated with the comorbidity measures were outlined in Chapter 3 
(section 3.9.4). One conspicuous problem was temporal incongruence, whereby conditions 
and diseases that were resolved before the occurrence of the AEs of interest were not 
recorded as such and hence may have been incorrectly included as valid comorbidities 
(Chapter 3 section 3.9.4.2). Issues with event sequencing also affected the studies presented 
in Chapters 6 and 7, as reverse causality between the outcomes of interest (rates of AEs and 
DEAs, respectively) and service use (GP consultations, referrals and emergency admissions) 
could not be determined. However, in acknowledgement of this methodological weakness, 
additional analyses were conducted where the first AE was the reference point by which 
service use was measured, i.e. calculation of the frequency and nature of service use before 
or after the first AE (Chapter 6 section 6.4.4 and Chapter 7 section 7.4.7). In the studies of 
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Chapter 8, the outcome of interest was the first AE (emergency admission for cancer), thus 
the chronology of service use in relation to the event was easily determined. 
The explanatory factors included in this project were by no means exhaustive but 
exploration of these variables and their relationships with the AEs through multiple 
statistical testing may have generated spurious statistically significant results (Chapter 6 
section 6.5.2). By increasing the threshold for statistical significance in the analyses, 
undesired effects from multiple testing were reduced (Chapter 4 section 4.6.1). Small 
numbers hindered exploration of interactions between variables, although such 
relationships may be present. The issue of small sample size was particularly relevant to the 
study on DEAs in Chapter 7 and the study 2 of Chapter 8 on emergency admissions for 
cancer, which may have resulted in insufficient statistical power to detect even large effects. 
A separate analytical matter relates to regression model selection for the studies in 
Chapters 6 to 8, which was governed by the ability to adjust for clustering of patients at 
individual practices (Chapter 6 sections 6.4.3.2, 6.4.5.2 and 6.4.7.2; Chapter 7 section 7.4.4; 
and Chapter 8 section 8.4.3.5). This factor took priority over the presence of “excess zeros” 
and/or over-dispersion, which may have been better accounted for by models other than 
Poisson with GEE.  
The technical issues of patient clustering, excess zero counts and over-dispersion were all 
considered and solutions offered in Chapter 4 sections 4.8 and 4.9. Where relevant, 
alternative regression models were described in the Results sections of the respective 
chapters, listed previously. Multi-level modelling was described as being particularly suited 
for data containing clustering and over-dispersion (Chapter 4 section 4.9). This statistical 
approach can also accommodate multiple cluster levels (such as the combined clustering of 
patients at practices, clustering of practices within PCTs and clustering of PCTs in 
geographical regions). However, this method cannot be programmed using the SAS PROC 
GENMOD statement and thus, to ensure statistical consistency throughout the project, 
multi-level modelling was not used. Regardless, this method may be used in future research 
as an alternative and more statistically powerful method of analysing clustered and over-
dispersed data. 
Chapter 9: Discussion | 235 
 
9.4 Current knowledge about patient safety indicators 
With confirmation that the project aims were met (section 9.2) and understanding of how 
they were met (section 9.3), I now consider the knowledge about patient safety indicators 
derived from routinely collected data collated in this project. Attention is given to the types 
of measures, how they are applied and assessment of their strengths and weaknesses. 
9.4.1 Range of patient safety indicators 
Through the literature review and informal consultations reported in Chapter 2, measures of 
AEs due to care received in the primary care setting were identified. For three of the 
measures, their feasibility for use as safety indicators was examined using routinely 
collected data from local and national sources. Almost all AE measures were intended for 
adult populations and as stated in section 9.2.2, drug-related events were the most 
prominent type of harm investigated. Health service use as an outcome measure for AEs 
was also commonly reported, typically comprising of unplanned admissions, readmissions 
and death. These endpoints are universally perceived to be undesirable patient outcomes 
and have the advantages of being easy to identify and convenient for benchmarking, but 
they are also crude and sometimes incorrect markers of overall quality as well as safety. 
9.4.2 Uses of patient safety indicators 
To reiterate the statement made at the end of the previous sub-section, measurement must 
be fit for purpose. Evidence is weak but exists for changes in clinical and patient attitudes 
and behaviours in non-acute care settings through the measurement and publication of 
provider performance data.371,415-418 In contrast, there is also the perception among staff in 
primary care that data-driven safety improvement initiatives are resource wasteful and have 
a low impact on safer delivery of care.183 The ability of indicators to improve safety depends 
not only on technical factors (including data quality, validity of the measures and how they 
are applied), but also relies on the willingness of clinicians, managers and policy makers to 
participate in patient safety improvement and to implement and adapt metrics according to 
their respective needs. Therefore, to ensure wider use of routinely collected data for 
monitoring patient safety, cultural change is needed.89,419,420 This is all the more important 
as care continues to be tailored to the individual and patient choice, delineated by the NHS 
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Constitution, is encouraged.421 As unpopular a policy as it is, GP-led commissioning may 
offer the opportunity to develop and implement safety indicators that are locally and 
clinically relevant, as seen in the QOF+ initiative at NHS Hammersmith and Fulham.422 
9.4.3 Strengths and limitations of patient safety indicators 
Routinely collected data can be applied to screen for different types of patient harm in 
general practice. With the presence of only a few data fields, basic surveillance algorithms 
can be implemented which allow for the detection of AEs at local or national levels. The 
accuracy and detail of safety efforts will depend on the available data. For instance, the 
validity of case ascertainment can be improved by data from multiple care settings which 
will invariably require data linkage. However, this method has the advantages of being 
relatively cheap and easy to manipulate, although data linkage may prove to be more 
resource costly depending on required linkage complexity, along with the potential for real-
time monitoring (Chapter 1 section 1.4.2). There are promising signs for improved access 
and quality of data, such as the GPES (Chapter 1 section 1.6.2).134 There is also government 
commitment to electronic care records across health and social care.423 Such potential 
advances in the healthcare data environment support the further research and applications 
of patient safety indicators based on clinical and non-clinical data. 
Safety and quality improvement in healthcare continues to evolve but there is a persisting 
challenge of how to ensure that implemented measures are meaningful and useful for 
different parties of interest, including patients and health professionals. This issue extends 
to the appropriateness of data presentation, while elements such as severity and 
preventability are only crudely captured through current indicators (Chapter 2 sections 2.5.5 
and 2.5.7). There is growing recognition that inclusivity must be integral to plans for 
improving the quality and safety in the NHS, as evident from recent public consultations on 
outcome measures.14 It remains to be seen how well placed current indicators are to 
provide feedback as part of a national safety monitoring system, and in local schemes. Not 
only are there limitations in the range of indicators available and the technical requirements 
for their use (section 9.4.1), but there is also institutionalised weariness and apprehension 
about quality and safety monitoring which must be overcome if patient safety indicators are 
to become firmly established within the safety improvement toolkits.183 
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At present, as remarked in Chapter 2 (section 2.6.6), there is a dearth of knowledge about, 
and consequently also few indicators for, AEs in primary care occurring outside of general 
practice, including community nursing, dentistry and pharmacy. Through a wider range of 
data being collected, improved quality of the data and with greater integration of datasets, 
a more holistic understanding of care spanning all sections of healthcare may be gained 
(section 9.3.3). Earlier in this chapter, I raised the difficulty of measuring the preventability 
of harm (section 9.2.3). Prudently, the focus of AE monitoring has been on incidents that are 
detectable, measureable and amenable to organisational change. Although resources are 
limited, it may also be worthwhile to consider those AEs that are not yet easily detectable 
from routinely collected data as well as ‘near misses’. Even though these incidents may be 
less clinically relevant, especially if they result in no or temporary and less severe harm, 
learning can still be gained from their occurrences and the consequences of these events for 
patients and staff should be explored (section 2.6.5). 
9.5 Strengths and limitations of the project 
In recognition of the broad discipline of primary care and the breadth of the patient safety 
field, I focused on patient harm attributable to care from general practice. I have 
commented on the strengths and weaknesses associated with the overarching methods 
used in the project and those pertaining to individual studies. This section is a summary of 
the project, with attention to research, clinical practice and health policy. 
There are a number of strengths to the research presented in this thesis. Firstly, three 
different AEs were investigated, including a generic measure of harm based on existing 
complications of care codes. Secondly, local and national data were analysed to 
demonstrate the suitability and versatility of routinely collected data for safety 
measurement. Datasets included HES and the GPRD, which are nationally representative 
and widely validated. These data were obtained for the purposes of this project at no 
financial cost*. Thirdly, the GPRD dataset contained patient-level data spanning ten years 
which allowed the exploration of temporal trends in recorded AEs. Fourthly, external 
validation of findings was possible using different datasets for two of the indicators (AEs 
                                                     
*
Data from the GPRD were obtained for free under the now expired MRC licence for academic research.  
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derived from complication of care codes and cancers diagnosed by emergency admissions). 
Additional validation was achieved by comparing results with published literature. Finally, 
patient groups at high risk of AEs as well as adverse and other outcomes were identified.  
Study-specific methodological weaknesses have been discussed in earlier chapters and 
further summarised in section 9.3. The implications of the project’s strengths and limitations 
on patient safety are outlined in the following two sub-sections. 
9.5.1.1 Implications for research 
Research on patient safety indicators derived from routinely collected data in general 
practice remains underdeveloped. Consequently, the field suffers from concentrated efforts 
using limited data sources in the areas of primary care where common types of AEs have 
been identified (Chapter 2). Despite this limitation, it is reasonable to first develop 
measurement expertise in those areas that have been well documented, before applying 
these skills and knowledge to less well understood areas of care and AEs that are harder to 
detect. The baseline estimates from AE measures using complication of care codes in 
Chapters 5 and 6 offer a robust foundation on which to build more sophisticated generic 
and disease or patient group-specific indicators in general practice and elsewhere in primary 
care.  
Future expectations for such measures will no doubt include real-time alerts for unusual 
patterns in processes of care or patient outcomes, indicators for entire care pathways and 
measures that are valid across different health systems. Furthermore, aside from the 
conventional outcomes of hospital admission, readmissions and mortality, new indicators 
must address other neglected outcomes that are of interest to patients and other parties, 
such as quality of life and long term outcomes (Chapter 8 section 8.4.4.5 and section 9.4.3). 
This project has demonstrated the potential to measure AEs using diagnosis codes from 
existing medical classification systems. In general practice and elsewhere in English primary 
care, greater uptake of SNOMED CT will facilitate the international comparability of research 
due to worldwide application of the terminology system (Chapter 1 section 1.6.3).  
Chapter 9: Discussion | 239 
 
9.5.1.2 Implications for clinical practice and policy 
This project was exploratory in nature and selection of indicators relied on published 
material of existing measures. This somewhat pragmatic approach is suitable for research in 
a relatively novel field where methodological handicaps, as undesirable as they may be, can 
inform future studies by highlighting deficits in technical abilities and remaining gaps in 
knowledge. However, to inform practice and health policy, research also needs to be guided 
by clinical need and organisational status, such as the availability of necessary infrastructure 
and resources to implement indicator-based safety surveillance. From the perspective of 
clinical application, each of the three measures from this project can be readily replicated 
for AE monitoring, although their success will be affected by caveats of the measures, the 
data and populations of interest (sections 9.3.1 and 9.4.3). The generic AE measures based 
on complication of care codes may be best suited for active surveillance at either the local 
or national level as minimal modifications are required.  
The results are promising for the continued development of measures using routinely 
collected data to improve patient safety. Service commissioners and policy makers should 
consider refinement of current measures but also encourage new metrics to be developed. 
Attempts to advance indicator development and to better understand patient harm so that 
AEs can be ameliorated, data must be improved. The proposed “paperless” system for 
patient records which will unify information across health and social care will hopefully not 
only add richness and variety to data sources, but will also improve the quality and safety of 
services through availability of patient data at the point of care (section 9.4.3).423 Of 
paramount importance is cooperation between those who manage and use health data 
across all care settings so that the quality, access and uses of these resources can be 
optimised for safety improvement, the delivery of care and management of services. 
9.6 Conclusion 
Few AE measures have been developed specifically for general practice using routinely 
collected data. The studies presented in this thesis demonstrate some of the AEs that can be 
detected using available data, but a much wider range of incidents occurring in general 
practice can also be measured. Examples of how research methods, data sources as well as 
analysis methods influence the choice of indicators for research have been provided. Our 
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current knowledge about the types of patient safety indicators, their uses and their 
strengths and limitations has also been considered. There is scope to expand the application 
of routinely collected data for safety monitoring in the primary care setting, such as real 
time surveillance using complication of care coded measures that are readily available.  
This relatively new field may deliver great benefits to patient safety improvement but for 
there to be progress, there must be local and national commitment to these efforts. As 
stated earlier in this chapter (section 9.4.3), there is currently a government drive for the 
ambitious overhaul of how patient records are managed.
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Appendices 
Appendix 1. Outputs from the project 
Publications related to the project 
1. Bottle A, Tsang C, Parsons C, Majeed A, Soljak M, Aylin P. Association between patient and 
general practice characteristics and unplanned first-time admissions for cancer: observational 
study. Br J Cancer. 2012;107(8):1213-1219. 
2. Tsang C, Majeed A, Aylin P. Consultations with general practitioners on patient safety measures 
based on routinely collected data in primary care. JRSM Short Rep. 2012;3:5. 
3. Tsang C, Palmer W, Bottle A, Majeed A, Aylin P. A Review of Patient Safety Measures Based on 
Routinely Collected Hospital Data. Am J Med Qual. 2012;27(2):154-69.  
4. Tsang C, Majeed A, Aylin P. Routinely recorded patient safety events in primary care: a literature 
review. Fam Pract. 2011;29(1):8-15. 
5. Tsang C, Majeed A, Banarsee R, Gnani S, Aylin P. Adverse events in English general practice: 
analysis of data from electronic patient records. Inform Prim Care. 2010;18(2):117-24. 
 
Conference abstracts related to the project 
1. Bottle A, Tsang C, Parsons C, Majeed A, Soljak M, Aylin P. (2012) Association between patient 
and family practitioner characteristics and first-time emergency admissions for cancer. WONCA 
Europe, Vienna, 4th-7th July 2012 (Oral presentation). 
2. Tsang C, Majeed A, Aylin P. (2010) Adverse events in English general practice: analysis using 
administrative data. International Society for Quality in Health Care Conference, Paris, 11th-13th 
October 2010 (Accepted for oral poster presentation). 
3. Tsang C, Majeed A, Banarsee R, Gnani S, Aylin P. (2010) Adverse events in English general 
practice. Presented at Society of Academic Primary Care Annual Conference, Norwich, 7th-10th 
July (Oral presentation, shortlisted for Early Career Researcher's prize). 
4. Tsang C, Majeed A, Aylin P. (2010) Recording of adverse events in English general practice: 
analysis of data from electronic patient records. Patient Safety Congress, Birmingham, 25th-26th 
May (Poster). 
5. Tsang C, Majeed A, Aylin P. (2010) Recording of adverse events in English general practice: 
analysis of data from electronic patient records. Working Conference Health Services Research in 
Europe, The Hague, 8th-9th April (Abstract published in conference book). 
6. Tsang C, Majeed A, Aylin P. (2010) The use of administrative data to measure adverse events in 
primary care: evidence from the literature. UK Annual Public Health Forum, Bournemouth, 24th-
25th March (Poster). 
7. Tsang C, Aylin P, Majeed A. (2009) Patient safety indicators for primary care. National Patient 
Safety Agency 3rd Annual UK Patient Safety Conference, London, 16th December (Poster). 
8. Tsang C, Aylin P, Majeed A. (2009) Patient safety indicators for primary care. International 
Society for Quality in Health Care Conference, Dublin, 12th-14th October (Poster). 
9. Tsang C, Aylin P, Majeed A. (2009) Patient safety indicators for primary care. Abstract presented 
at the Patient Safety Congress, Birmingham, 31st April-1st May (Poster).  
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Appendix 2. Literature review material 
Table A.1 List of organisations included the website search (Chapter 2) 
Accreditation Canada 
Action Against Medical Accidents 
Agency for Healthcare Research and Quality 
American Hospital Association 
Australian Council for Safety and Quality in Health Care 
Australian Council of Healthcare Standards 
Australian Government 
Australian Institute of Health and Welfare 
Australian Patient Safety Foundation 
Canadian Institute for Health Information 
Canadian Patient Safety Institute 
Danish Society for Patient Safety 
Danish Society for Quality in Health Care 
Department of Health 
Department of Health and Ageing 
European Commission 
European Society for Quality in Healthcare 
Health Foundation 
Healthcare Commission 
Institute for Healthcare Improvement 
Institute for Safe Medication Practices 
Institute for Safe Medication Practices, Canada 
Institute of Medicine 
International Society of Quality in Healthcare 
Joint Commission International 
King's Fund 
Medical Defence Union 
Medical Research Council 
National Audit Office 
National Institute for Clinical Excellence 
National Institute for Health Research 
National Patient Safety Agency 
National Patient Safety Foundation 
NHS Institute for Innovation and Improvement 
NHS Litigation Authority 
Organisation for Economic Co-operation and Development 
Patient Safety Observatory 
Royal Australian College of General Practice 
Royal Australian College of Physicians 
Royal College of General Practitioners 
Royal College of Physicians and Surgeons of Canada 
The Commonwealth Fund 
The Joint Commission 
United States Department of Veteran Affairs - National Center for Patient Safety 
University of Birmingham 
University of California San Francisco-Stanford Evidence-Based Practice Center 
World Health Organization 
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Table A.2 Literature search results from ASSIA: Applied Social Sciences Index and Abstracts 
# Search term Results 
1 Ambulatory care 184 
2 Ambulatory care facilit 3 
3 Ambulatory care physician 0 
4 Family physician* 259 
5 Family Practice 1525 
6 General practice 2685 
7 General practitioner* 3682 
8 Primary care 5868 
9 Primary Health Care 4381 
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 12450 
11 Accident Prevention 51 
12 Outcome assessment* 152 
13 Outcome and Process assessment* 7 
14 Patient outcome* 517 
15 Patient care 2394 
16 Patient safety 460 
17 Quality assessment* 281 
18 Quality improvement* 723 
19 Quality indicator* 146 
20 Healthcare quality indicators 0 
21 Safety assessment* 44 
22 Safety improvement* 19 
23 Safety Management 18 
24 Safety 5725 
25 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 9455 
26 Adverse event* 512 
27 Avoidable complication* 5 
28 Avoidable death* 28 
29 Diagnostic error* 14 
30 Healthcare associated injuries 0 
31 Healthcare associated injury 0 
32 Iatrogenic disease* 9 
33 Medical error* 106 
34 Medication error* 86 
35 Patient safety index 0 
36 Patient safety indicator* 7 
37 Patient safety indices 0 
38 Preventable complication* 6 
39 Sentinel event*. 15 
40 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 757 
41 Administrative data 215 
42 Billing data 7 
43 Billing record* 9 
44 Consultation record* 4 
45 Discharge data 91 
46 Discharge summar* 38 
47 Hospital Information System* 24 
48 Information system* 1090 
49 Hospital record* 104 
50 inpatient data 6 
51 Medical Record* 1012 
52 Electronic data 52 
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53 Electronic record* 34 
54 Computer* medical record* system* 2 
55 Routine data 78 
56 Routinely collected data 45 
57 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 2669 
58 25 or 40 10212 
59 10 and 57 and 58 45 
60 59 limit to English language 42 
 
Search time period: Earliest to 2010. Interface: CSA Illumina. Search method: command. Search strategy: non 
MeSH terms. Search field: keyword. 
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Table A.3 Literature search results from Cochrane Library 
# Search term Results 
1 (Ambulatory care facilit):ti,ab,kw 0 
2 (Ambulatory care physician):ti,ab,kw 317 
3 Ambulatory care  5629 
4 Family Practice  6395 
5 General practice  11957 
6 Family physician*  2864 
7 Primary Health Care  17399 
8 Primary care  22894 
9 General practitioner*  4151 
10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9) 36506 
11 Accident Prevention  1089 
12 Outcome assessment*  35473 
13 Outcome and Process assessment*  9149 
14 Patient outcome*  93544 
15 Patient care  57676 
16 Patient safety  31891 
17 Quality assessment*  22061 
18 Quality improvement*  11881 
19 Quality indicator*  1984 
20 Healthcare quality indicator* 290 
21 Safety assessment*  9309 
22 Safety improvement*  7733 
23 Safety Management  3979 
24 Safety  42642 
25 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 
OR #24) 
160676 
26 Adverse event*  28143 
27 Avoidable complication*  40 
28 Avoidable death*  46 
29 Diagnostic error*  1673 
30 Healthcare associated injur* 257 
31 Iatrogenic disease*  243 
32 Medical error*  8915 
33 Medication error*  1713 
34 Patient safety index  6590 
35 Patient safety indicator*  410 
36 Patient safety indices  6590 
37 Preventable complication*  128 
38 Sentinel event*  51 
39 (#26 OR #27 OR #28 OR #29 OR #30 OR 31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38) 74031 
40 Administrative data  814 
41 Billing data  495 
42 Billing record*  466 
43 Consultation record*  2592 
44 Discharge data  4390 
45 Discharge summar*  1773 
46 Hospital Information System*  7997 
47 Information system*  22908 
48 Hospital record*  25020 
49 inpatient data  3288 
50 Medical Record*  78141 
51 Electronic data  6543 
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52 Electronic record*  7118 
53 Computer* medical record* system*  3636 
54 Routine data  5141 
55 Routinely collected data 419 
56 (#40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 
OR #53 OR #54 OR #55) 
86991 
57 (#10 AND #25 AND #39 AND #56) 9172 
58 (#10 AND ( #25 OR #39 ) AND #56) 17032 
 
**No limit available for language restrictions in advanced search. 
 
Search time period: 1800 to 2009. Search method: advanced. Search strategy: non-MeSH. Search field: title, 
abstract or keywords. 
 
Where terms were mapped, the fields used in the search were: [mp=abstract:ab, keyword :kw, title:ti]. 
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Table A.4 Literature search results from Embase 
# Search term Results 
1 Ambulatory care.mp. or Ambulatory Care/ 8454 
2 "Ambulatory care facilit*".sh,ab,tw,ti,ot,kf,hw,kw. 81 
3 "Ambulatory care physician*".sh,ab,tw,ti,ot,kf,hw,kw. 26 
4 Physicians, Family/ or Family physician*.mp. 35230 
5 Family practice.mp. or Family Practice/ 25199 
6 General practice.mp. 29160 
7 Physician*, Family.mp. 175 
8 Primary Health Care/ or Primary care*.mp. 45436 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 101083 
10 Patient care.mp. or Patient Care/ 95526 
11 Patient safety.mp. 16485 
12 Quality assessment*.mp. 3944 
13 Quality improvement*.mp. 5607 
14 Quality indicator*.mp. 1619 
15 Quality Indicators, Health Care.mp. 1 
16 Safety.mp. or Safety/ 279637 
17 Safety assessment*.mp. 2056 
18 Safety Management/ or Safety Management.mp. 48302 
19 Safety improvement*.mp. 126 
20 Accident Prevention.mp. or Accident Prevention/ 5940 
21 "Outcome Assessment (Health Care)"/ or "Outcome and Process Assessment (Health Care)"/ or 
patient outcome.mp. 
414568 
22 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 746834 
23 Patient safety indicator*.mp. 43 
24 Patient safety index.mp. 1 
25 Patient safety indices.mp. 0 
26 Adverse event*.mp. 40647 
27 Medical error*.mp. 3800 
28 Medication error*.mp. 3840 
29 Sentinel event*.mp. 232 
30 Healthcare associated injury.mp. 1 
31 Healthcare associated injuries.mp. 0 
32 Iatrogenic disease*.mp. 10857 
33 Postoperative Complications/ or Preventable complication*.mp. or Foreign Bodies/ 112023 
34 Avoidable death*.mp. 169 
35 Avoidable complication*.mp. 122 
36 Diagnostic Errors/ or Diagnostic error*.mp. 20084 
37 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 187823 
38 Administrative data.mp. 1436 
39 Medical Records/ or Electronic data.mp. or Medical Records Systems, Computerized/ 42857 
40 Inpatient data.mp. 97 
41 Routine data.mp. 445 
42 Routinely collected data.mp. 297 
43 Hospital Records/ or Hospital record*.mp. 44147 
44 Hospital Information Systems/ or Information Systems/ or Information system*.mp. 24729 
45 Discharge data.mp. 1083 
46 Billing data.mp. 212 
47 Billing record*.mp. 199 
48 Consultation record*.mp. 42 
49 Discharge summary*.mp. 188 
50 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 70721 
51 22 or 37 870381 
52 9 and 50 and 51 1326 
53 limit 52 to English language 1257  
Appendices | 248 
 
 
Search time period: 1980 to 2009 week 34. Interface: Ovid. Search method: advanced. Search strategy: MeSH 
and non-MeSH. 
 
Where terms were mapped, the fields used in the search were: [mp=abstract:ab, keyword heading:kw, 
keyword heading word:kf, original title:ti, subject heading word:sh, text word:tw]. 
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Table A.5 Literature search results from HMIC Health Management Information Consortium 
# Search term Results 
1 Ambulatory care.mp. or Ambulatory Care/ 415 
2 "Ambulatory care facilit*".sh,ab,tw,ti,ot,kf,hw,kw. 8 
3 "Ambulatory care physician*".sh,ab,tw,ti,ot,kf,hw,kw. 6 
4 Physicians, Family/ or Family physician*.mp. 212 
5 Family practice.mp. or Family Practice/ 196 
6 General practice.mp. 14486 
7 Physician*, Family.mp. 8 
8 Primary Health Care/ or Primary care*.mp. 21114 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 31584 
10 Patient care.mp. or Patient Care/ 16756 
11 Patient safety.mp. 1936 
12 Quality assessment*.mp. 497 
13 Quality improvement*.mp. 3067 
14 Quality indicator*.mp. 321 
15 Quality Indicators, Health Care.mp. 0 
16 Safety.mp. or Safety/ 19272 
17 Safety assessment*.mp. 54 
18 Safety Management/ or Safety Management.mp. 82 
19 Safety improvement*.mp. 81 
20 Accident Prevention.mp. or Accident Prevention/ 297 
21 "Outcome Assessment (Health Care)"/ or "Outcome and Process 
Assessment (Health Care)"/ or patient outcome.mp. 
3395 
22 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 40585 
23 Patient safety indicator*.mp. 19 
24 Patient safety index.mp. 0 
25 Patient safety indices.mp. 0 
26 Adverse event*.mp. 661 
27 Medical error*.mp. 247 
28 Medication error*.mp. 397 
29 Sentinel event*.mp. 24 
30 Healthcare associated injury.mp. 2 
31 Healthcare associated injuries.mp. 0 
32 Iatrogenic disease*.mp. 69 
33 Postoperative Complications/ or Preventable complication*.mp. or 
Foreign Bodies/ 
3 
34 Avoidable death*.mp. 121 
35 Avoidable complication*.mp. 9 
36 Diagnostic Errors/ or Diagnostic error*.mp. 21 
37 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36 
1463 
38 Administrative data.mp. 187 
39 Medical Records/ or Electronic data.mp. or Medical Records Systems, 
Computerized/ 
2601 
40 Inpatient data.mp. 4 
41 Routine data.mp. 190 
42 Routinely collected data.mp. 144 
43 Hospital Records/ or Hospital record*.mp. 362 
44 Hospital Information Systems/ or Information Systems/ or 
Information system*.mp. 
6800 
45 Discharge data.mp. 88 
46 Billing data.mp. 12 
47 Billing record*.mp. 6 
48 Consultation record*.mp. 19 
49 Discharge summary*.mp. 32 
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50 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 9872 
51 22 or 37 41330 
52 9 and 50 and 51  181 
 
**No limit available for language restrictions in advanced search. 
Search time period: 1979 to July 2009. Interface: Ovid. Search method: Advanced. Search strategy: non-MeSH. 
 
Where terms were mapped, the fields used in the search were: [mp=abstract:ab, keyword heading:kw, 
keyword heading word:kf, original title:ti, subject heading word:sh, text word:tw]. 
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Table A.6 Literature search results from ISI Web of Science 
# Search term Results 
 1 TS=Ambulatory care facilit* 690 
 2 TS=Ambulatory care physician* 2,258 
 3 TS=Ambulatory care 8,576 
 4 TS=Family Practice 17,521 
 5 TS=General practice 45,968 
 6 TS=Family physician* 14,275 
 7 TS=Primary Health Care 37,131 
 8 TS=Primary care 77,487 
 9 TS=General practitioner* 25,272 
 10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 >100,000 
 11 TS=Accident Prevention 2,211 
 12 TS=Outcome assessment* 38,867 
 13 TS=(Outcome and Process assessment*) 2,837 
 14 TS=Patient outcome* >100,000 
 15 TS=Patient care >100,000 
 16 TS=Patient safety 32,181 
 17 TS=Quality assessment* 65,905 
 18 TS=Quality improvement* 69,766 
 19 TS=Quality indicator* 22,316 
 20 TS=Healthcare quality indicator* 492 
 21 TS=Safety assessment* 24,092 
 22 TS=Safety improvement* 17,804 
 23 TS=Safety Management 25,968 
 24 TS=Safety >100,000 
 25 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or 
#24 
>100,000 
 26 TS=Adverse event* 51,852 
 27 TS=Avoidable complication* 444 
 28 TS=Avoidable death* 595 
 29 TS=Diagnostic error* 6,237 
 30 TS=Healthcare associated injur* 291 
 31 TS=Iatrogenic disease* 2,532 
 32 TS=Medical error* 8,451 
 33 TS=Medication error* 2,862 
 34 TS=Patient safety index 1,489 
 35 TS=Patient safety indicator* 401 
 36 TS=Patient safety indices 119 
 37 TS=Preventable complication* 912 
 38 TS=Sentinel event* 529 
 39 #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 72,419 
 40 TS=Administrative data 7,719 
 41 TS=Billing data 1,087 
 42 TS=Billing record* 590 
 43 TS=Consultation record* 1,985 
 44 TS=Discharge data 28,472 
 45 TS=Discharge summar* 2,282 
 46 TS=Hospital Information System* 7,551 
 47 TS=Information system* >100,000 
 48 TS=Hospital record* 33,491 
 49 TS=inpatient data 7,223 
 50 TS=Medical Record* 47,880 
 51 TS=Electronic data 52,168 
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 52 TS=Electronic record* 13,837 
 53 TS=Computer* medical record* system* 2,197 
 54 TS=Routine data 25,388 
 55 TS=Routinely collected data 1,880 
 56 #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or 
#53 or #54 or #55 
>100,000 
 57 #10 and #25 and #39 and #56 591 
 58 #10 and (#25 or #39) and #56 7,941 
 59 #10 and (#25 or #39) and #56 AND Language=(English) 7,618 
 
Databases searched: Science Citation Index Expanded (SCI-EXPANDED)--1970-present, Social Sciences Citation 
Index (SSCI)--1970-present, Conference Proceedings Citation Index- Science (CPCI-S)--1990-present. Search 
field: title, abstract or keywords. Search method: advanced. Search strategy: non-MeSH.  
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Table A.7 Literature search results from Medline 
# Search term  Results 
1 Ambulatory care.mp. or Ambulatory Care/ 43196 
2 "Ambulatory care facilit*".sh,ab,tw,ti,ot,kf,hw,kw. 9269 
3 "Ambulatory care physician*".sh,ab,tw,ti,ot,kf,hw,kw. 38 
4 Physicians, Family/ or Family physician*.mp. 19899 
5 Family practice.mp. or Family Practice/ 57405 
6 General practice.mp. 26835 
7 Physician*, Family.mp. 13421 
8 Primary Health Care/ or Primary care*.mp. 70600 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 178575 
10 Patient care.mp. or Patient Care/ 108521 
11 Patient safety.mp. 6889 
12 Quality assessment*.mp. 5039 
13 Quality improvement*.mp. 9419 
14 Quality indicator*.mp. 7461 
15 Quality Indicators, Health Care.mp. 6149 
16 Safety.mp. or Safety/ 205460 
17 Safety assessment*.mp. 1969 
18 Safety Management/ or Safety Management.mp. 11097 
19 Safety improvement*.mp. 201 
20 Accident Prevention.mp. or Accident Prevention/ 8143 
21 "Outcome Assessment (Health Care)"/ or "Outcome and Process Assessment (Health Care)"/ or 
patient outcome.mp. 
56656 
22 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 381615 
23 Patient safety indicator*.mp. 111 
24 Patient safety index.mp. 0 
25 Patient safety indices.mp. 0 
26 Adverse event*.mp. 43081 
27 Medical error*.mp. 9100 
28 Medication error*.mp. 8172 
29 Sentinel event*.mp. 403 
30 Healthcare associated injury.mp. 2 
31 Healthcare associated injuries.mp. 0 
32 Iatrogenic disease*.mp. 10970 
33 Postoperative Complications/ or Preventable complication*.mp. or Foreign Bodies/ 263750 
34 Avoidable death*.mp. 248 
35 Avoidable complication*.mp. 158 
36 Diagnostic Errors/ or Diagnostic error*.mp. 26994 
37 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 356819 
38 Administrative data.mp. 1987 
39 Medical Records/ or Electronic data.mp. or Medical Records Systems, Computerized/ 46878 
40 Inpatient data.mp. 127 
41 Routine data.mp. 550 
42 Routinely collected data.mp. 350 
43 Hospital Records/ or Hospital record*.mp. 7110 
44 Hospital Information Systems/ or Information Systems/ or Information system*.mp. 44339 
45 Discharge data.mp. 1371 
46 Billing data.mp. 293 
47 Billing record*.mp. 269 
48 Consultation record*.mp. 64 
49 Discharge summary*.mp. 278 
50 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 94535 
51 22 or 37 704375 
52 9 and 50 and 51 1364 
53 limit 52 to English language 1280  
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Search time period: In-Process & Other Non-Indexed Citations and Ovid MEDLINE 1950 to Present (1950 to 
week 34 2009). Interface: Ovid. Search method: advanced. Search strategy: MeSH and non-MeSH. 
 
Where terms were mapped, the fields used in the search were: [mp=abstract:ab, keyword heading:kw, 
keyword heading word:kf, original title:ti, subject heading word:sh, text word:tw]. 
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Table A.8 Literature search results from PsycINFO 
# Search term Results 
1 Ambulatory care.mp. or Ambulatory Care/ 4791 
2 "Ambulatory care facilit*".sh,ab,tw,ti,ot,kf,hw,kw. 6 
3 "Ambulatory care physician*".sh,ab,tw,ti,ot,kf,hw,kw. 4 
4 Physicians, Family/ or Family physician*.mp. 2073 
5 Family practice.mp. or Family Practice/ 1355 
6 General practice.mp. 2879 
7 Physician*, Family.mp. 106 
8 Primary Health Care/ or Primary care*.mp. 15757 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 24662 
10 Patient care.mp. or Patient Care/ 6329 
11 Patient safety.mp. 531 
12 Quality assessment*.mp. 435 
13 Quality improvement*.mp. 1283 
14 Quality indicator*.mp. 420 
15 Quality Indicators, Health Care.mp. 0 
16 Safety.mp. or Safety/ 25175 
17 Safety assessment*.mp. 150 
18 Safety Management/ or Safety Management.mp. 148 
19 Safety improvement*.mp. 54 
20 Accident Prevention.mp. or Accident Prevention/ 1186 
21 "Outcome Assessment (Health Care)"/ or "Outcome and Process Assessment (Health Care)"/ or 
patient outcome.mp. 
354 
22 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 34132 
23 Patient safety indicator*.mp. 11 
24 Patient safety index.mp. 0 
25 Patient safety indices.mp. 0 
26 Adverse event*.mp. 3852 
27 Medical error*.mp. 229 
28 Medication error*.mp. 154 
29 Sentinel event*.mp. 33 
30 Healthcare associated injury.mp. 0 
31 Healthcare associated injuries.mp. 0 
32 Iatrogenic disease*.mp. 33 
33 Postoperative Complications/ or Preventable complication*.mp. or Foreign Bodies/ 8 
34 Avoidable death*.mp. 21 
35 Avoidable complication*.mp. 3 
36 Diagnostic Errors/ or Diagnostic error*.mp. 162 
37 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 4440 
38 Administrative data.mp. 466 
39 Medical Records/ or Electronic data.mp. or Medical Records Systems, Computerized/ 1145 
40 Inpatient data.mp. 23 
41 Routine data.mp. 57 
42 Routinely collected data.mp. 34 
43 Hospital Records/ or Hospital record*.mp. 629 
44 Hospital Information Systems/ or Information Systems/ or Information system*.mp. 4499 
45 Discharge data.mp. 169 
46 Billing data.mp. 37 
47 Billing record*.mp. 28 
48 Consultation record*.mp. 14 
49 Discharge summary*.mp. 46 
50 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 7006 
51 22 or 37 36972 
52 9 and 50 and 51 36 
53 limit 52 to English language 36  
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Search time period: 1806 to August Week 3 2009. Interface: Ovid. Search method: advanced. Search strategy: 
MeSH and non-MeSH. 
 
Where terms were mapped, the fields used in the search were: [mp=abstract:ab, keyword heading:kw, 
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Appendix 3. Adverse event codes used in Chapters 5 and 6 
Table A.9 READ codes for adverse events mapped to ICD 10 codes 
ICD-10 READ codes 






F10-F19 Mental and behavioural 





All code names within subgroups Eu1.. 
  
[X]Mental and behavioural disorders 
due to psychoactive substance use 
XIX S00-
T98 






Poisoning by drugs, medicaments 
and biological substances 
SL… Poisoning 
     T80-
T88 
Complications of surgical and 
medical care, not elsewhere 
classified 
SP… Surgical and medical complications NEC 
     T82-
T87 
Complications of cardiac and vascular 
prosthetic devices, implants and 
grafts - Complications peculiar to 
reattachment and amputation 
SP0.. Complications of certain procedures 
      Not available in ICD-10 SP1.. Body system complications NEC 
     T81.9 Unspecified complication of 
procedure 
SP2.. Other procedure complication NEC 
     T88.9 Complication of surgical and medical 
care, unspecified 
SP3.. Medical care complication NEC 
     T88.9 Complication of surgical and medical 
care, unspecified 
SPz.. Medical and surgical care complications 
NOS 
Not applicable, mapped to ICD-9 but not ICD-10. TA... Medical accidents to patients during 
surgical and medical care 
TA0.. Accidental cut, puncture, perforation or 
haemorrhage during medical care 
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TA1.. Foreign object left in body during 
procedure 
TA2.. Failure of sterile precautions during 
procedure 
TA3.. Failure in dosage 
TA4.. Mechanical failure of instrument or 
apparatus during procedure 
TA5.. Administration of contaminated blood, 
other fluid, drug or biological substance 
TAy.. Other misadventures during medical 
care 
TAz.. Medical accident to patient NOS 
TB... Medical and surgical procedures as the 
cause of abnormal reaction of patient 
or later complication, without mention 
of misadventure at the time of 
procedure 
TJ... Drugs, medicines and biological 
substances causing adverse effects in 
therapeutic use 
TK… Suicide and self-inflicted injury 
Tz... Causes of injury and poisoning NOS 
XX V01-
Y98 
External causes of 
morbidity and 
mortality 
X60-X84 Intentional self-harm X60-
X84 
All code names within subgroups U2... [X]Intentional self-harm 




Poisoning by and exposure to drugs, 
medicaments and biological 
substances, undetermined intent 
U40.. [X]Poisoning by and exposure to drugs, 
medicaments and biological substances, 
undetermined intent 
   Y40-Y84 Complications of 




Drugs, medicaments and biological 
substances causing adverse effects in 
therapeutic use 
U60.. [X]Drugs, medicaments and biological 
substances causing adverse effects in 
therapeutic use 
     Y60-
Y69 
Misadventures to patients during 
surgical and medical care 
U61.. [X]Misadventures to patients during 
surgical and medical care 
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     Y70-
Y82 
Medical devices associated with 
adverse incidents in diagnostic and 
therapeutic use 
U62.. [X]Medical devices associated with 
adverse incidents in diagnostic and 
therapeutic use 
     Y83 Surgical operation and other surgical 
procedures as the cause of abnormal 
reaction of the patient, or of later 
complication, without mention of 
misadventure at the time of the 
procedure 
U63.. [X]Surgical operation and other surgical 
procedures as the cause of abnormal 
reaction of the patient, or of later 
complication, without mention of 
misadventure at the time of the 
procedure 
     Y84 Other medical procedures as the 
cause of abnormal reaction of the 
patient, or of later complication, 
without mention of misadventure at 
the time of the procedure 
U64.. [X]Other medical procedures causing 
abnormal reaction of the patient, or of 
later complication, without mention of 
misadventure at the time of the 
procedure 
   Y85-Y89 Sequelae of external 
causes of morbidity and 
mortality 
Y88 Sequelae with surgical and medical 
care as external cause 
U73.. [X]Sequelae with surgical and medical 
care as external cause 
     Y88.0 Sequelae of adverse effects caused 
by drugs, medicaments and 
biological substances in therapeutic 
use 
U730. [X]Sequelae of adverse effects caused 
by drugs, medicaments and biological 
substances in therapeutic use 
     Y88.1 Sequelae of misadventures to 
patients during surgical and medical 
procedures 
U731. [X]Sequelae of misadventures to 
patients during surgical and medical 
procedures 
     Y88.2 Sequelae of adverse incidents 
associated with medical devices in 
diagnostic and therapeutic use 
U732. [X]Sequelae of adverse incidents 
associated with medical devices in 
diagnostic and therapeutic use 
     Y88.3 Sequelae of surgical and medical 
procedures as the cause of abnormal 
reaction of the patient, or of later 
complication, without mention of 
misadventure at the time of the 
procedure 
U733. [X]Sequelae of surgical and medical 
procedures as the cause of abnormal 
reaction of the patient, or of later 
complication, without mention of 
misadventure at the time of the 
procedure 
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Source: Date of consultation as provided in the GPRD dataset. From International Statistical Classification of Diseases and Related Health Problems 10th Revision Version 
for 2007, Chapter XIX Injury, poisoning and certain other consequences of external causes (S00-T98) and Chapter XX External causes of morbidity and mortality (V01-Y98) - 
Complications of medical and surgical care (Y40-Y84). 
 
Exclusions 
From Chapter XIX:  
 Frostbite (T33-T35);  
 Toxic effects of substances chiefly nonmedicinal as to source (T51-T65);  
 Other and unspecified effects of external causes (T66-T78); 
 Sequelae of injuries, of poisoning and of other consequences of external cause (T90-98).  
 
From Chapter XX: 
 Accidents (V01-X59);  
 Intentional self-harm (X60-X84);  
 Assault (X85-Y09);  
 Event of undetermined intent (Y10-Y34);  
 Legal intervention and operations of war (Y35-Y36);  
 Sequelae of external causes of morbidity and mortality (Y85-Y89);  
Supplementary factors related to causes of morbidity and mortality classified elsewhere (Y90-Y91, Y96-Y98).  
   Y90-Y98 Supplementary factors 
related to causes of 
morbidity and mortality 
classified elsewhere 
Y95 Nosocomial condition U82.. [X]Nosocomial condition 
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Appendix 4. Results from analyses in Chapters 6 to 8 
Table A.10 Crude associations between comorbidities and risk of having an adverse event, 
results from Poisson regression using the generalized estimating equations (GEE) method 
Characteristic 
Patients, n 
RR (95% CI) P-value All ≥1 adverse 
event 
(%) 
Disease flags  
Composite Charlson Index measure     <0.0001 
 No 59034 921 (1.56) 1  
 Yes 15729 853 (5.42) 3.14 (2.88-3.42) <0.0001 
Cancer     <0.0001 
 No 73651 1687 (2.29) 1  
 Yes 1112 87 (7.82) 3.16 (2.58-3.86) <0.0001 
Cerebrovascular disease     <0.0001 
 No 73620 1677 (2.28) 1  
 Yes 1143 97 (8.49) 3.81 (3.18-4.57) <0.0001 
Congestive heart disease     <0.0001 
 No 65836 1436 (2.18) 1  
 Yes 8927 338 (3.79) 1.46 (1.31-1.63) <0.0001 
Chronic pulmonary disease     <0.0001 
 No 73991 1703 (2.30) 1  
 Yes 772 71 (9.20) 4.52 (3.66-5.59) <0.0001 
Dementia     0.001 
 No 74449 1760 (2.36) 1  
 Yes 314 14 (4.46) 2.45 (1.54-3.90) <0.0001 
Diabetes without complications     <0.0001 
 No 71837 1546 (2.15) 1  
 Yes 2926 228 (7.79) 3.46 (3.06-3.92) <0.0001 
Diabetes with complications     <0.0001 
 No 74526 1745 (2.34) 1  
 Yes 237 29 (12.2) 4.95 (3.59-6.82) <0.0001 
Hemiplegia     <0.0001 
 No 74693 1765 (2.36) 1  
 Yes 70 9 (12.9) 4.40 (2.36-8.19) <0.0001 
Metastatic tumour     <0.0001 
 No 74625 1763 (2.36) 1  
 Yes 138 11 (7.97) 3.36 (1.90-5.92) <0.0001 
Mild liver disease     0.008 
 No 74748 1772 (2.37) 1  
 Yes 15 2 (13.3) 7.62 (2.46-23.7) <0.0001 
Moderate liver disease     <0.0001 
 No 74186 1712 (2.31) 1  
 Yes 577 62 (10.8) 4.76 (3.82-5.93) <0.0001 
Myocardial infarction      0.314 
 No 74669 1770 (2.37) 1  
 Yes 94 4 (4.26) 1.63 (0.68-3.92) 0.276 
Peptic ulcer disease     <0.0001 
 No 74161 1716 (2.31) 1  
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 Yes 602 58 (9.63) 4.08 (3.27-5.09) <0.0001 
Peripheral vascular disease     <0.0001 
 No 74103 1685 (2.27) 1  
 Yes 660 89 (13.5) 5.29 (4.35-6.43) <0.0001 
Renal disease     <0.0001 
 No 72971 1568 (2.15) 1  
 Yes 1792 206 (11.5) 4.50 (3.95-5.13) <0.0001 
Rheumatological disease     <0.0001 
 No 73832 1694 (2.29) 1  
 Yes 931 80 (8.59) 3.26 (2.67-3.98) <0.0001 
Aggregated Disease Groups (ADGs)   
Time Limited: Minor     <0.0001 
 No 31868 407 (1.28) 1  
 Yes 39787 1367 (3.44) 2.14 (1.93-2.38) <0.0001 
Time Limited: Minor-Primary     <0.0001 
 No 19988 224 (1.12) 1  
 Yes 51667 1550 (3.00) 2.13 (1.87-2.43) <0.0001 
Time Limited: Major     <0.0001 
 No 65515 1379 (2.10) 1  
 Yes 6140 395 (6.43) 2.93 (2.64-3.25) <0.0001 
Time Limited: Major-Primary Infections     <0.0001 
 No 58658 730 (1.24) 1  
 Yes 12997 1044 (8.03) 5.77 (5.28-6.31) <0.0001 
Allergies      <0.0001 
 No 61017 1359 (2.23) 1  
 Yes 10638 415 (3.90) 1.54 (1.39-1.70) <0.0001 
Asthma     <0.0001 
 No 63383 1503 (2.37) 1  
 Yes 8272 271 (3.28) 1.28 (1.14-1.45) <0.0001 
Likely to Recur: Discrete     <0.0001 
 No 37295 390 (1.05) 1  
 Yes 34360 1384 (4.03) 3.44 (3.09-3.83) <0.0001 
Likely to Recur: Discrete-Infections     <0.0001 
 No 41171 687 (1.67) 1  
 Yes 30484 1087 (3.57) 1.79 (1.64-1.96) <0.0001 
Likely to Recur: Progressive     <0.0001 
 No 65594 1230 (1.88) 1  
 Yes 6061 544 (8.98) 4.96 (4.53-5.44) <0.0001 
Chronic Medical: Unstable     <0.0001 
 No 41567 388 (0.93) 1  
 Yes 30088 1386 (4.61) 4.57 (4.10-5.09) <0.0001 
Chronic Specialty: Stable-Orthopedic     <0.0001 
 No 58866 921 (1.56) 1  
 Yes 12789 853 (6.67) 4.24 (3.89-4.63) <0.0001 
Chronic Specialty: Stable-Eye      <0.0001 
 No 64724 1353 (2.09) 1  
 Yes 6931 421 (6.07) 2.58 (2.33-2.85) <0.0001 
Chronic Specialty: Stable-Ear, Nose, Throat     <0.0001 
 No 69432 1665 (2.40) 1  
 Yes 2223 109 (4.90) 1.75 (1.45-2.09) <0.0001 
Chronic Specialty: Stable-Eye     <0.0001 
 No 66500 1468 (2.21) 1  
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 Yes 5155 306 (5.94) 2.63 (2.36-2.94) <0.0001 
Chronic Specialty: Unstable-Orthopedic     <0.0001 
 No 69543 1666 (2.40) 1  
 Yes 2112 108 (5.11) 1.85 (1.55-2.22) <0.0001 
Chronic Specialty: Unstable-Ear, Nose, Throat     <0.0001 
 No 71141 1737 (2.44) 1  
 Yes 514 37 (7.20) 2.46 (1.82-3.33) <0.0001 
Chronic Specialty: Unstable-Eye     <0.0001 
 No 66718 1434 (2.15) 1  
 Yes 4937 340 (6.89) 2.97 (2.66-3.30) <0.0001 
Dermatologic     <0.0001 
 No 39540 632 (1.60) 1  
 Yes 32115 1142 (3.56) 1.85 (1.69-2.02) <0.0001 
Injuries/Adverse Effects: Minor     <0.0001 
 No 45948 787 (1.71) 1  
 Yes 25707 987 (3.84) 1.82 (1.67-1.99) <0.0001 
Injuries/Adverse Effects: Major     <0.0001 
 No 53408 880 (1.65) 1  
 Yes 18247 894 (4.90) 2.66 (2.44-2.90) <0.0001 
Psychosocial: Time Limited, Minor     <0.0001 
 No 64468 1345 (2.09) 1  
 Yes 7187 429 (5.97) 2.56 (2.32-2.83) <0.0001 
Psychosocial: Recurrent or Persistent, Stable     <0.0001 
 No 55752 1076 (1.93) 1  
 Yes 15903 698 (4.39) 2.13 (1.95-2.32) <0.0001 
Psychosocial: Recurrent or Persistent, Unstable     <0.0001 
 No 66278 1537 (2.32) 1  
 Yes 5377 237 (4.41) 2.00 (1.77-2.27) <0.0001 
Signs/Symptoms: Minor     <0.0001 
 No 34668 301 (0.87) 1  
 Yes 36987 1473 (3.98) 3.81 (3.39-4.29) <0.0001 
Signs/Symptoms: Uncertain     <0.0001 
 No 30302 225 (0.74) 1  
 Yes 41353 1549 (3.75) 4.09 (3.58-4.67) <0.0001 
Signs/Symptoms: Major      <0.0001 
 No 48093 630 (1.31) 1  
 Yes 23562 1144 (4.86) 3.40 (3.10-3.73) <0.0001 
Discretionary     <0.0001 
 No 46770 641 (1.37) 1  
 Yes 24885 1133 (4.55) 2.83 (2.58-3.10) <0.0001 
See and Reassure     <0.0001 
 No 66255 1409 (2.13) 1  
 Yes 5400 365 (6.76) 2.87 (2.59-3.19) <0.0001 
Prevention/Administrative     <0.0001 
 No 22144 172 (0.78) 1  
 Yes 49511 1602 (3.24) 3.43 (2.95-3.99) <0.0001 
Malignancy     <0.0001 
 No 67767 1486 (2.19) 1  
 Yes 3888 288 (7.41) 3.11 (2.77-3.50) <0.0001 
Pregnancy     0.003 
 No 66008 1579 (2.39) 1  
 Yes 5647 195 (3.45) 1.25 (1.09-1.44) 0.002 
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Dental     <0.0001 
 No 68512 1604 (2.34) 1  
 Yes 3143 170 (5.41) 2.06 (1.78-2.37) <0.0001 
Collapsed Aggregated Diagnosis Groups (CADGs)  
Acute Minor     <0.0001 
 No 8414 41 (0.49) 1  
 Yes 63241 1733 (2.74) 4.41 (3.25-5.99) <0.0001 
Acute Major     <0.0001 
 No 18653 29 (0.16) 1  
 Yes 53002 1745 (3.29) 16.5 (11.6-23.3) <0.0001 
Likely to Recur     <0.0001 
 No 13106 63 (0.48) 1  
 Yes 58549 1711 (2.92) 4.65 (3.65-5.91) <0.0001 
Asthma     <0.0001 
 No 63383 1503 (2.37) 1  
 Yes 8272 271 (3.28) 1.28 (1.14-1.45) <0.0001 
Chronic Medical: Unstable     <0.0001 
 No 54911 719 (1.31) 1  
 Yes 16744 1055 (6.30) 4.72 (4.32-5.16) <0.0001 
Chronic Medical: Stable     <0.0001 
 No 39917 347 (0.87) 1  
 Yes 31738 1427 (4.50) 4.72 (4.22-5.29) <0.0001 
Chronic Specialty: Stable     <0.0001 
 No 62965 1275 (2.02) 1  
 Yes 8690 499 (5.74) 2.49 (2.27-2.74) <0.0001 
Eye/Dental     <0.0001 
 No 63696 1335 (2.10) 1  
 Yes 7959 439 (5.52) 2.46 (2.23-2.71) <0.0001 
Chronic Specialty: Unstable     <0.0001 
 No 64477 1341 (2.08) 1  
 Yes 7178 433 (6.03) 2.64 (2.39-2.91) <0.0001 
Psychosocial     <0.0001 
 No 49996 831 (1.66) 1  
 Yes 21659 943 (4.35) 2.44 (2.24-2.67) <0.0001 
Preventive/Administrative     <0.0001 
 No 22144 172 (0.78) 1  
 Yes 49511 1602 (3.24) 3.43 (2.95-3.99) <0.0001 
Pregnancy     0.003 
 No 66008 1579 (2.39) 1  
 Yes 5647 195 (3.45) 1.25 (1.09-1.44) 0.002 
Expanded Diagnosis Clusters (EDCs) groups     <0.0001 
 Low 23266 43 (0.18) 1  
 Moderate 26506 302 (1.14) 4.10 (3.00-50.6) <0.0001 
 High 24991 1429 (5.72) 17.8 (13.2-23.9) <0.0001 
Major Expanded Diagnosis Clusters (MEDCs)  
Administrative     <0.0001 
 No 23563 188 (0.80) 1  
 Yes 48092 1586 (3.30) 3.44 (2.97-3.98) <0.0001 
Allergy     <0.0001 
 No 52261 1074 (2.06) 1  
 Yes 19394 700 (3.61) 1.54 (1.40-1.68) <0.0001 
Cardiovascular     <0.0001 
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 No 55262 732 (1.32) 1  
 Yes 16393 1042 (6.36) 4.62 (4.23-5.05) <0.0001 
Dental     <0.0001 
 No 63781 1379 (2.16) 1  
 Yes 7874 395 (5.02) 2.12 (1.92-2.35) <0.0001 
Ear, Nose, Throat     <0.0001 
 No 27322 416 (1.52) 1  
 Yes 44333 1358 (3.06) 1.63 (1.47-1.81) <0.0001 
Endocrine     <0.0001 
 No 63678 1272 (2.00) 1  
 Yes 7977 502 (6.29) 3.06 (2.78-3.36) <0.0001 
Eye     <0.0001 
 No 47267 830 (1.76) 1  
 Yes 24388 944 (3.87) 1.96 (1.80-2.14) <0.0001 
Female reproductive system     <0.0001 
 No 50463 1048 (2.08) 1  
 Yes 21192 726 (3.43) 1.42 (1.30-1.55) <0.0001 
Gastrointestinal/hepatic     <0.0001 
 No 47191 664 (1.41) 1  
 Yes 24464 1110 (4.54) 2.88 (2.63-3.15) <0.0001 
General signs and symptoms     <0.0001 
 No 47845 641 (1.34) 1  
 Yes 23810 1133 (4.76) 3.09 (2.82-3.39) <0.0001 
General surgery     <0.0001 
 No 34443 295 (0.86) 1  
 Yes 37212 1479 (3.97) 3.93 (3.48-4.42) <0.0001 
Genetic     0.001 
 No 71089 1743 (2.45) 1  
 Yes 566 31 (5.48) 1.86 (1.33-2.61) <0.0001 
Genito-urinary     <0.0001 
 No 50155 766 (1.53) 1  
 Yes 21500 1008 (4.69) 2.71 (2.48-2.95) <0.0001 
Hematologic     <0.0001 
 No 65363 1384 (2.12) 1  
 Yes 6292 390 (6.20) 2.79 (2.52-3.09) <0.0001 
Infections     <0.0001 
 No 54300 1124 (2.07) 1  
 Yes 17355 650 (3.75) 1.64 (1.50-1.79) <0.0001 
Malignancies     <0.0001 
 No 67535 1474 (2.18) 1  
 Yes 4120 300 (7.28) 3.08 (2.75-3.46) <0.0001 
Musculoskeletal     <0.0001 
 No 26800 207 (0.77) 1  
 Yes 44855 1567 (3.49) 3.67 (3.19-4.22) <0.0001 
Neonatal     0.040 
 No 70400 1748 (2.48) 1  
 Yes 1255 26 (2.07) 0.70 (0.48-1.01) 0.054 
Neurologic     <0.0001 
 No 39311 422 (1.07) 1  
 Yes 32344 1352 (4.18) 3.45 (3.11-3.83) <0.0001 
Nutrition     <0.0001 
 No 68873 1614 (2.34) 1  
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 Yes 2782 160 (5.75) 2.21 (1.91-2.57) <0.0001 
Psychosocial     <0.0001 
 No 50820 880 (1.73) 1  
 Yes 20835 894 (4.29) 2.29 (2.10-2.50) <0.0001 
Reconstructive     <0.0001 
 No 63467 1412 (2.22) 1  
 Yes 8188 362 (4.42) 1.83 (1.65-2.03) <0.0001 
Renal     <0.0001 
 No 67738 1407 (2.08) 1  
 Yes 3917 367 (9.37) 4.12 (3.71-4.58) <0.0001 
Respiratory     <0.0001 
 No 41275 587 (1.42) 1  
 Yes 30380 1187 (3.91) 2.42 (2.20-2.66) <0.0001 
Rheumatologic     <0.0001 
 No 66339 1408 (2.12) 1  
 Yes 5316 366 (6.88) 2.95 (2.66-3.28) <0.0001 
Skin     <0.0001 
 No 22589 263 (1.16) 1  
 Yes 49066 1511 (3.08) 2.09 (1.85-2.37) <0.0001 
Toxic effects/Adverse events     <0.0001 
 No 67679 765 (1.13) 1  
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Table A.11 Crude associations between comorbidities and risk of emergency admission, results 
from Poisson regression using the generalized estimating equations (GEE) method 
Characteristic 
Patients with ≥1 admission, n 
RR (95% CI) P-value All ≥1 adverse 
event 
(%) 
Disease flags      
Composite Charlson Index measure     <0.0001 
 No 11085 402 (3.63) 1  
 Yes 5525 437 (7.91) 2.48 (2.44-2.52) <0.0001 
Cancer     <0.0001 
 No 16040 777 (4.84) 1  
 Yes 570 62 (10.9) 5.40 (5.23-5.56) <0.0001 
Cerebrovascular disease     <0.0001 
 No 16108 794 (4.93) 1  
 Yes 502 45 (8.96) 2.59 (2.49-2.70) <0.0001 
Congestive heart disease     <0.0001 
 No 13904 670 (4.82) 1  
 Yes 2706 169 (6.25) 1.40 (1.37-1.43) <0.0001 
Chronic pulmonary disease     <0.0001 
 No 16224 806 (4.97) 1  
 Yes 386 33 (8.55) 4.86 (4.67-5.05) <0.0001 
Dementia     <0.0001 
 No 16474 831 (5.04) 1  
 Yes 136 8 (5.88) 2.33 (2.12-2.55) <0.0001 
Diabetes without complications     <0.0001 
 No 15469 728 (4.71) 1  
 Yes 1141 111 (9.73) 2.36 (2.30-2.43) <0.0001 
Diabetes with complications     <0.0001 
 No 16497 825 (5.00) 1  
 Yes 113 14 (12.4) 3.21 (2.97-3.46) <0.0001 
Hemiplegia     <0.0001 
 No 16579 834 (5.03) 1  
 Yes 31 5 (16.1) 10.1 (9.35-11.0) <0.0001 
Metastatic tumour     <0.0001 
 No 16536 833 (5.04) 1  
 Yes 74 6 (8.11) 9.64 (9.03-10.3) <0.0001 
Mild liver disease     <0.0001 
 No 16599 837 (5.04) 1  
 Yes 11 2 (18.2) 11.3 (9.41-13.5) <0.0001 
Moderate liver disease     <0.0001 
 No 16349 814 (4.98) 1  
 Yes 261 25 (9.58) 3.39 (3.23-3.57) <0.0001 
Myocardial infarction      <0.0001 
 No 16569 837 (5.05) 1  
 Yes 41 2 (4.88) 3.18 (2.82-3.59) <0.0001 
Peptic ulcer disease     <0.0001 
 No 16347 811 (4.96) 1  
 Yes 263 28 (10.7) 2.57 (2.43-2.71) <0.0001 
Peripheral vascular disease     <0.0001 
 No 16292 790 (4.85) 1  
 Yes 318 49 (15.4) 3.67 (3.51-3.84) <0.0001 
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Renal disease     <0.0001 
 No 15829 722 (4.56) 1  
 Yes 781 117 (15.0) 3.05 (2.96-3.14) <0.0001 
Rheumatological disease     <0.0001 
 No 16185 791 (4.89) 1  
 Yes 425 48 (11.3) 2.45 (2.34-2.56) <0.0001 
Aggregated Disease Groups (ADGs)   
Time Limited: Minor     <0.0001 
 No 5485 167 (3.04) 1  
 Yes 10968 672 (6.13) 1.52 (1.49-1.55) <0.0001 
Time Limited: Minor-Primary     <0.0001 
 No 3222 73 (2.27) 1  
 Yes 13231 766 (5.79) 1.47 (1.44-1.50) <0.0001 
Time Limited: Major     <0.0001 
 No 14084 624 (4.43) 1  
 Yes 2369 215 (9.08) 2.98 (2.92-3.04) <0.0001 
Time Limited: Major-Primary Infections     <0.0001 
 No 11922 305 (2.56) 1  
 Yes 4531 534 (11.8) 2.24 (2.20-2.27) <0.0001 
Allergies     <0.0001 
 No 13449 621 (4.62) 1  
 Yes 3004 218 (7.26) 1.21 (1.18-1.23) <0.0001 
Asthma     <0.0001 
 No 14179 696 (4.91) 1  
 Yes 2274 143 (6.29) 1.23 (1.20-1.26) <0.0001 
Likely to Recur: Discrete     <0.0001 
 No 6133 146 (2.38) 1  
 Yes 10320 693 (6.72) 2.25 (2.21-2.29) <0.0001 
Likely to Recur: Discrete-Infections     <0.0001 
 No 7655 278 (3.63) 1  
 Yes 8798 561 (6.38) 1.67 (1.64-1.70) <0.0001 
Likely to Recur: Progressive     <0.0001 
 No 13835 555 (4.01) 1  
 Yes 2618 284 (10.9) 3.03 (2.97-3.09) <0.0001 
Chronic Medical: Unstable     <0.0001 
 No 6777 143 (2.11) 1  
 Yes 9676 696 (7.19) 2.66 (2.61-2.71) <0.0001 
Chronic Specialty: Stable-Orthopedic     <0.0001 
 No 11394 399 (3.50) 1  
 Yes 5059 440 (8.70) 3.27 (3.21-3.32) <0.0001 
Chronic Specialty: Stable-Eye     <0.0001 
 No 13979 624 (4.46) 1  
 Yes 2474 215 (8.69) 1.77 (1.73-1.81) <0.0001 
Chronic Specialty: Stable-Ear, Nose, Throat     <0.0001 
 No 15719 777 (4.94) 1  
 Yes 734 62 (8.45) 1.51 (1.45-1.56) <0.0001 
Chronic Specialty: Stable-Eye     <0.0001 
 No 14554 684 (4.70) 1  
 Yes 1899 155 (8.16) 1.96 (1.91-2.00) <0.0001 
Chronic Specialty: Unstable-Orthopedic     <0.0001 
 No 15762 782 (4.96) 1  
 Yes 691 57 (8.25) 1.62 (1.56-1.68) <0.0001 
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Chronic Specialty: Unstable-Ear, Nose, 
Throat 
    <0.0001 
 No 16260 822 (5.06) 1  
 Yes 193 17 (8.81) 1.38 (1.28-1.49) <0.0001 
Chronic Specialty: Unstable-Eye     <0.0001 
 No 14514 653 (4.50) 1  
 Yes 1939 186 (9.59) 2.34 (2.28-2.39) <0.0001 
Dermatologic     <0.0001 
 No 7820 268 (3.43) 1  
 Yes 8633 571 (6.61) 1.23 (1.21-1.25) <0.0001 
Injuries/Adverse Effects: Minor     <0.0001 
 No 9051 343 (3.79) 1  
 Yes 7402 496 (6.70) 1.34 (1.32-1.36) <0.0001 
Injuries/Adverse Effects: Major     <0.0001 
 No 10896 388 (3.56) 1  
 Yes 5557 451 (8.12) 1.69 (1.66-1.72) <0.0001 
Psychosocial: Time Limited, Minor     <0.0001 
 No 14046 609 (4.34) 1  
 Yes 2407 230 (9.56) 1.89 (1.85-1.93) <0.0001 
Psychosocial: Recurrent or Persistent, 
Stable 
    <0.0001 
 No 11509 475 (4.13) 1  
 Yes 4944 364 (7.36) 1.69 (1.66-1.72) <0.0001 
Psychosocial: Recurrent or Persistent, 
Unstable 
    <0.0001 
 No 14563 707 (4.85) 1  
 Yes 1890 132 (6.98) 2.23 (2.17-2.28) <0.0001 
Signs/Symptoms: Minor     <0.0001 
 No 5482 111 (2.02) 1  
 Yes 10971 728 (6.64) 2.05 (2.01-2.09) <0.0001 
Signs/Symptoms: Uncertain     <0.0001 
 No 4309 70 (1.62) 1  
 Yes 12144 769 (6.33) 2.36 (2.31-2.41) <0.0001 
Signs/Symptoms: Major     <0.0001 
 No 8498 263 (3.09) 1  
 Yes 7955 576 (7.24) 2.62 (2.58-2.67) <0.0001 
Discretionary     <0.0001 
 No 8487 275 (3.24) 1  
 Yes 7966 564 (7.08) 1.88 (1.85-1.91) <0.0001 
See and Reassure     <0.0001 
 No 14466 641 (4.43) 1  
 Yes 1987 198 (9.96) 1.89 (1.85-1.93) <0.0001 
Prevention/Administrative     <0.0001 
 No 3125 67 (2.14) 1  
 Yes 13328 772 (5.79) 2.15 (2.10-2.20) <0.0001 
Malignancy     <0.0001 
 No 14698 681 (4.63) 1  
 Yes 1755 158 (9.00) 4.16 (4.07-4.24) <0.0001 
Pregnancy     <0.0001 
 No 14525 730 (5.03) 1  
 Yes 1928 109 (5.65) 1.51 (1.47-1.55) <0.0001 
Dental     <0.0001 
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 No 15395 746 (4.85) 1  
 Yes 1058 93 (8.79) 1.51 (1.46-1.55) <0.0001 
Collapsed Aggregated Diagnosis Groups (CADGs) 
Acute Minor     <0.0001 
 No 994 11 (1.11) 1  
 Yes 15459 828 (5.36) 1.92 (1.84-2.00) <0.0001 
Acute Major     <0.0001 
 No 2025 4 (0.20) 1  
 Yes 14428 835 (5.79) 3.19 (3.09-3.29) <0.0001 
Likely to Recur     <0.0001 
 No 1538 17 (1.11) 1  
 Yes 14915 822 (5.51) 2.22 (2.15-2.29) <0.0001 
Asthma     <0.0001 
 No 14179 696 (4.91) 1  
 Yes 2274 143 (6.29) 1.23 (1.20-1.26) <0.0001 
Chronic Medical: Unstable     <0.0001 
 No 9896 296 (2.99) 1  
 Yes 6557 543 (8.28) 3.78 (3.72-3.85) <0.0001 
Chronic Medical: Stable     <0.0001 
 No 6395 124 (1.94) 1  
 Yes 10058 715 (7.11) 2.64 (2.60-2.69) <0.0001 
Chronic Specialty: Stable     <0.0001 
 No 13432 578 (4.30) 1  
 Yes 3021 261 (8.64) 1.74 (1.70-1.77) <0.0001 
Eye/Dental      <0.0001 
 No 13636 608 (4.46) 1  
 Yes 2817 231 (8.20) 1.85 (1.81-1.88) <0.0001 
Chronic Specialty: Unstable     <0.0001 
 No 13821 606 (4.38) 1  
 Yes 2632 233 (8.85) 2.13 (2.08-2.17) <0.0001 
Psychosocial     <0.0001 
 No 9701 345 (3.56) 1  
 Yes 6752 494 (7.32) 2.00 (1.96-2.03) <0.0001 
Preventive/Administrative     <0.0001 
 No 3125 67 (2.14) 1  
 Yes 13328 772 (5.79) 2.15 (2.10-2.20) <0.0001 
Pregnancy     <0.0001 
 No 14525 730 (5.03) 1  
 Yes 1928 109 (5.65) 1.51 (1.47-1.55) <0.0001 
Expanded Diagnosis Clusters (EDCs) groups     <0.0001 
 Low 2074 6 (0.29) 1  
 Moderate 5251 112 (2.13) 1.90 (1.83-1.97) <0.0001 
 High 9285 721 (7.77) 4.66 (4.51-4.82) <0.0001 
Major Expanded Diagnosis Clusters (MEDCs)  
Administrative     <0.0001 
 No 3436 74 (2.15) 1  
 Yes 13017 765 (5.88) 2.10 (2.05-2.14) <0.0001 
Allergy     <0.0001 
 No 11143 483 (4.33) 1  
 Yes 5310 356 (6.70) 1.26 (1.24-1.28) <0.0001 
Cardiovascular     <0.0001 
 No 10553 312 (2.96) 1  
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 Yes 5900 527 (8.93) 2.62 (2.58-2.67) <0.0001 
Dental     <0.0001 
 No 13932 630 (4.52) 1  
 Yes 2521 209 (8.29) 1.52 (1.49-1.55) <0.0001 
Ear, Nose, Throat     <0.0001 
 No 4990 170 (3.41) 1  
 Yes 11463 669 (5.84) 1.25 (1.22-1.27) <0.0001 
Endocrine     <0.0001 
 No 13509 579 (4.29) 1  
 Yes 2944 260 (8.83) 2.43 (2.39-2.48) <0.0001 
Eye     <0.0001 
 No 9243 368 (3.98) 1  
 Yes 7210 471 (6.53) 1.53 (1.51-1.56) <0.0001 
Female reproductive system     <0.0001 
 No 10198 472 (4.63) 1  
 Yes 6255 367 (5.87) 1.41 (1.38-1.43) <0.0001 
Gastrointestinal/hepatic     <0.0001 
 No 8498 279 (3.28) 1  
 Yes 7955 560 (7.04) 2.33 (2.29-2.37) <0.0001 
General signs and symptoms     <0.0001 
 No 8781 256 (2.92) 1  
 Yes 7672 583 (7.60) 2.07 (2.03-2.10) <0.0001 
General surgery     <0.0001 
 No 5216 105 (2.01) 1  
 Yes 11237 734 (6.53) 2.33 (2.28-2.37) <0.0001 
Genetic     <0.0001 
 No 16239 827 (5.09) 1  
 Yes 214 12 (5.61) 3.98 (3.80-4.16) <0.0001 
Genito-urinary     <0.0001 
 No 9434 303 (3.21) 1  
 Yes 7019 536 (7.64) 2.04 (2.00-2.07) <0.0001 
Hematologic     <0.0001 
 No 13871 629 (4.53) 1  
 Yes 2582 210 (8.13) 2.95 (2.89-3.01) <0.0001 
Infections     <0.0001 
 No 11428 475 (4.16) 1  
 Yes 5025 364 (7.24) 1.45 (1.42-1.47) <0.0001 
Malignancies     <0.0001 
 No 14599 672 (4.60) 1  
 Yes 1854 167 (9.01) 4.09 (4.01-4.18) <0.0001 
Musculoskeletal     <0.0001 
 No 3999 62 (1.55) 1  
 Yes 12454 777 (6.24) 1.91 (1.87-1.95) <0.0001 
Neonatal     0.053 
 No 16138 829 (5.14) 1  
 Yes 315 10 (3.17) 0.94 (0.89-1.00) 0.055 
Neurologic     <0.0001 
 No 6409 167 (2.61) 1  
 Yes 10044 672 (6.69) 2.25 (2.21-2.29) <0.0001 
Nutrition     <0.0001 
 No 15443 753 (4.88) 1  
 Yes 1010 86 (8.51) 1.91 (1.86-1.97) <0.0001 
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Psychosocial     <0.0001 
 No 9974 369 (3.70) 1  
 Yes 6479 470 (7.25) 1.94 (1.91-1.97) <0.0001 
Reconstructive     <0.0001 
 No 13849 651 (4.70) 1  
 Yes 2604 188 (7.22) 1.54 (1.51-1.58) <0.0001 
Renal     <0.0001 
 No 14810 640 (4.32) 1  
 Yes 1643 199 (12.1) 2.93 (2.87-3.00) <0.0001 
Respiratory     <0.0001 
 No 7282 241 (3.31) 1  
 Yes 9171 598 (6.52) 1.89 (1.86-1.92) <0.0001 
Rheumatologic     <0.0001 
 No 14433 646 (4.48) 1  
 Yes 2020 193 (9.55) 2.27 (2.22-2.32) <0.0001 
Skin     <0.0001 
 No 3848 96 (2.49) 1  
 Yes 12605 743 (5.89) 1.34 (1.31-1.37) <0.0001 
Toxic effects/Adverse events     <0.0001 
 No 14910 322 (2.16) 1  
 Yes 1543 517 (33.5) 2.54 (2.48-2.60) <0.0001 
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Table A.12 Crude associations between comorbidities and risk of death, results from log-
binomial regression using the generalized estimating equations (GEE) method 
Characteristic 
Deaths, n 
RR (95% CI) P-value All ≥1 adverse 
event 
(%) 
Disease flags  
Composite Charlson Index measure     <0.0001 
 No 1723 42 (2.44) 1  
 Yes 2240 136 (6.07) 4.87 (4.58-5.17) <0.0001 
Cancer     <0.0001 
 No 3498 149 (4.26) 1  
 Yes 465 29 (6.24) 8.63 (7.99-9.32) <0.0001 
Cerebrovascular disease     <0.0001 
 No 3553 157 (4.42) 1  
 Yes 410 21 (5.12) 7.30 (6.72-7.94) <0.0001 
Congestive heart disease     <0.0001 
 No 3303 150 (4.54) 1  
 Yes 660 28 (4.24) 1.45 (1.33-1.57) <0.0001 
Chronic pulmonary disease     <0.0001 
 No 3528 152 (4.31) 1  
 Yes 435 26 (5.98) 11.6 (10.8-12.5) <0.0001 
Dementia     <0.0001 
 No 3793 172 (4.53) 1  
 Yes 170 6 (3.53) 10.4 (9.36-11.6) <0.0001 
Diabetes without complications     <0.0001 
 No 3495 142 (4.06) 1  
 Yes 468 36 (7.69) 3.23 (2.95-3.53) <0.0001 
Diabetes with complications     <0.0001 
 No 3902 174 (4.46) 1  
 Yes 61 4 (6.56) 4.81 (3.87-5.99) <0.0001 
Hemiplegia     <0.0001 
 No 3949 176 (4.46) 1  
 Yes 14 2 (14.2) 3.70 (2.32-5.92) <0.0001 
Metastatic tumour     <0.0001 
 No 3867 170 (4.40) 1  
 Yes 96 8 (8.33) 13.2 (11.7-14.8) <0.0001 
Mild liver disease     <0.0001 
 No 3941 176 (4.47) 1  
 Yes 22 2 (9.09) 4.34 (3.01-6.27) <0.0001 
Moderate liver disease     <0.0001 
 No 3953 176 (4.45) 1  
 Yes 10 2 (20.0) 12.3 (8.62-17.7) <0.0001 
Myocardial infarction      <0.0001 
 No 3775 172 (4.56) 1  
 Yes 188 6 (3.19) 6.25 (5.53-7.06) <0.0001 
Peptic ulcer disease     <0.0001 
 No 3826 164 (4.29) 1  
 Yes 137 14 (10.2) 4.32 (3.72-5.02) <0.0001 
Peripheral vascular disease     <0.0001 
 No 3755 158 (4.21) 1  
 Yes 208 20 (9.62) 6.10 (5.42-6.85) <0.0001 
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Renal disease     <0.0001 
 No 3737 151 (4.04) 1  
 Yes 226 27 (12.0) 2.41 (2.13-2.74) <0.0001 
Rheumatological disease     <0.0001 
 No 3781 165 (4.36) 1  
 Yes 182 13 (7.14) 3.74 (3.27-4.28) <0.0001 
Aggregated Disease Groups (ADGs)   
Time Limited: Minor     0.031 
 No 1790 49 (2.74) 1  
 Yes 2089 129 (6.18) 0.94 (0.88-0.99) 0.031 
Time Limited: Minor-Primary     <0.0001 
 No 1203 32 (2.66) 1  
 Yes 2676 146 (5.46) 0.86 (0.81-0.92) <0.0001 
Time Limited: Major     <0.0001 
 No 2890 116 (4.01) 1  
 Yes 989 62 (6.27) 3.65 (3.41-3.91) <0.0001 
Time Limited: Major-Primary Infections     <0.0001 
 No 2673 87 (3.25) 1  
 Yes 1206 91 (7.55) 2.04 (1.91-2.17) <0.0001 
Allergies     <0.0001 
 No 3479 150 (4.31) 1  
 Yes 400 28 (7.00) 0.66 (0.60-0.73) <0.0001 
Asthma     0.120 
 No 3461 155 (4.48) 1  
 Yes 418 23 (5.50) 0.93 (0.84-1.02) 0.124 
Likely to Recur: Discrete     <0.0001 
 No 1462 37 (2.53) 1  
 Yes 2417 141 (5.83) 1.79 (1.68-1.91) <0.0001 
Likely to Recur: Discrete-Infections     0.021 
 No 2298 66 (2.87) 1  
 Yes 1581 112 (7.08) 0.93 (0.87-0.99) 0.021 
Likely to Recur: Progressive     <0.0001 
 No 2531 90 (3.56) 1  
 Yes 1348 88 (6.53) 5.76 (5.42-6.12) <0.0001 
Chronic Medical: Unstable     <0.0001 
 No 1102 17 (1.54) 1  
 Yes 2777 161 (5.80) 3.48 (3.25-3.73) <0.0001 
Chronic Specialty: Stable-Orthopedic     <0.0001 
 No 1521 41 (2.70) 1  
 Yes 2358 137 (5.81) 7.14 (6.71-7.59) <0.0001 
Chronic Specialty: Stable-Eye     <0.0001 
 No 3214 130 (4.04) 1  
 Yes 665 48 (7.22) 1.93 (1.78-2.09) <0.0001 
Chronic Specialty: Stable-Ear, Nose, Throat     <0.0001 
 No 3708 166 (4.48) 1  
 Yes 171 12 (7.02) 1.44 (1.24-1.67) <0.0001 
Chronic Specialty: Stable-Eye     <0.0001 
 No 3117 132 (4.23) 1  
 Yes 762 46 (6.04) 3.15 (2.93-3.40) <0.0001 
Chronic Specialty: Unstable-Orthopedic     <0.0001 
 No 3715 172 (4.63) 1  
 Yes 164 6 (3.66) 1.45 (1.25-1.69) <0.0001 
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Chronic Specialty: Unstable-Ear, Nose, Throat     0.087 
 No 3842 177 (4.61) 1  
 Yes 37 1 (2.70) 1.33 (0.98-1.82) 0.071 
Chronic Specialty: Unstable-Eye     <0.0001 
 No 3094 131 (4.23) 1  
 Yes 785 47 (5.99) 3.43 (3.19-3.69) <0.0001 
Dermatologic     <0.0001 
 No 2531 80 (3.16) 1  
 Yes 1348 98 (7.27) 0.66 (0.61-0.70) <0.0001 
Injuries/Adverse Effects: Minor     0.004 
 No 2571 91 (3.54) 1  
 Yes 1308 87 (6.65) 0.91 (0.85-0.97) 0.004 
Injuries/Adverse Effects: Major     <0.0001 
 No 2540 85 (3.35) 1  
 Yes 1339 93 (6.95) 1.54 (1.45-1.64) <0.0001 
Psychosocial: Time Limited, Minor     <0.0001 
 No 3202 129 (4.03) 1  
 Yes 677 49 (7.24) 1.90 (1.75-2.05) <0.0001 
Psychosocial: Recurrent or Persistent, Stable     <0.0001 
 No 2794 119 (4.26) 1  
 Yes 1085 59 (5.44) 1.36 (1.27-1.46) <0.0001 
Psychosocial: Recurrent or Persistent, Unstable     <0.0001 
 No 2972 133 (4.48) 1  
 Yes 907 45 (4.96) 3.76 (3.51-4.03) <0.0001 
Signs/Symptoms: Minor     <0.0001 
 No 1444 23 (1.59) 1  
 Yes 2435 155 (6.37) 1.58 (1.48-1.68) <0.0001 
Signs/Symptoms: Uncertain     <0.0001 
 No 1141 15 (1.31) 1  
 Yes 2738 163 (5.95) 1.76 (1.64-1.88) <0.0001 
Signs/Symptoms: Major     <0.0001 
 No 1674 44 (2.63) 1  
 Yes 2205 134 (6.08) 2.69 (2.53-2.86) <0.0001 
Discretionary     <0.0001 
 No 2112 78 (3.69) 1  
 Yes 1767 100 (5.66) 1.57 (1.48-1.67) <0.0001 
See and Reassure     <0.0001 
 No 3409 138 (4.05) 1  
 Yes 470 40 (8.51) 1.69 (1.54-1.86) <0.0001 
Prevention/Administrative     <0.0001 
 No 957 18 (1.88) 1  
 Yes 2922 160 (5.48) 1.37 (1.27-1.47) <0.0001 
Malignancy     <0.0001 
 No 2778 100 (3.60) 1  
 Yes 1101 78 (7.08) 6.91 (6.49-7.35) <0.0001 
Pregnancy     <0.0001 
 No 3809 175 (4.59) 1  
 Yes 70 3 (4.29) 0.22 (0.17-0.27) <0.0001 
Dental     0.002 
 No 3746 171 (4.56) 1  
 Yes 133 7 (5.26) 0.77 (0.65-0.92) 0.003 
Collapsed Aggregated Diagnosis Groups (CADGs)  
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Acute Minor     <0.0001 
 No 538 3 (0.56) 1  
 Yes 3341 175 (5.24) 0.83 (0.76-0.90) <0.0001 
Acute Major     <0.0001 
 No 471 2 (0.42) 1  
 Yes 3408 176 (5.16) 2.55 (2.32-2.80) <0.0001 
Likely to Recur     0.026 
 No 658 5 (0.76) 1  
 Yes 3221 173 (5.37) 1.10 (1.01-1.19) 0.028 
Asthma     0.120 
 No 3461 155 (4.48) 1  
 Yes 418 23 (5.50) 0.93 (0.84-1.02) 0.124 
Chronic Medical: Unstable     <0.0001 
 No 835 6 (0.72) 1  
 Yes 3044 172 (5.65) 12.0 (11.1-12.9) <0.0001 
Chronic Medical: Stable     <0.0001 
 No 1046 14 (1.34) 1  
 Yes 2833 164 (5.79) 3.41 (3.18-3.65) <0.0001 
Chronic Specialty: Stable     <0.0001 
 No 3102 122 (3.93) 1  
 Yes 777 56 (7.21) 1.82 (1.68-1.96) <0.0001 
Eye/Dental     <0.0001 
 No 3011 129 (4.28) 1  
 Yes 868 49 (5.65) 2.31 (2.15-2.48) <0.0001 
Chronic Specialty: Unstable     <0.0001 
 No 2942 127 (4.32) 1  
 Yes 937 51 (5.44) 2.86 (2.67-3.07) <0.0001 
Psychosocial     <0.0001 
 No 1991 73 (3.67) 1  
 Yes 1888 105 (5.56) 2.19 (2.06-2.33) <0.0001 
Preventive/Administrative     <0.0001 
 No 957 18 (1.88) 1  
 Yes 2922 160 (5.48) 1.37 (1.27-1.47) <0.0001 
Pregnancy     <0.0001 
 No 3809 175 (4.59) 1  
 Yes 70 3 (4.29) 0.22 (0.17-0.27) <0.0001 
Expanded Diagnosis Clusters (EDCs) groups  <0.0001 
 Low 654  (0) 1  
 Moderate 1181 26 (2.20) 1.58 (1.43-1.74) <0.0001 
 High 2128 152 (7.14) 3.01 (2.75-3.30) <0.0001 
Major Expanded Diagnosis Clusters (MEDCs)  
Administrative     <0.0001 
 No 961 16 (1.66) 1  
 Yes 2918 162 (5.55) 1.49 (1.39-1.60) <0.0001 
Allergy     <0.0001 
 No 3023 126 (4.17) 1  
 Yes 856 52 (6.07) 0.76 (0.71-0.82) <0.0001 
Cardiovascular     <0.0001 
 No 1505 37 (2.46) 1  
 Yes 2374 141 (5.94) 5.32 (5.00-5.66) <0.0001 
Dental     0.017 
 No 3407 147 (4.31) 1  
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 Yes 472 31 (6.57) 1.12 (1.02-1.23) 0.016 
Ear, Nose, Throat     <0.0001 
 No 1914 67 (3.50) 1  
 Yes 1965 111 (5.65) 0.63 (0.60-0.67) <0.0001 
Endocrine     <0.0001 
 No 2720 97 (3.57) 1  
 Yes 1159 81 (6.99) 3.40 (3.19-3.63) <0.0001 
Eye     <0.0001 
 No 2069 79 (3.82) 1  
 Yes 1810 99 (5.47) 1.70 (1.59-1.80) <0.0001 
Female reproductive system     <0.0001 
 No 3256 134 (4.12) 1  
 Yes 623 44 (7.06) 0.46 (0.42-0.50) <0.0001 
Gastrointestinal/hepatic     <0.0001 
 No 1938 56 (2.89) 1  
 Yes 1941 122 (6.29) 1.93 (1.82-2.05) <0.0001 
General signs and symptoms     <0.0001 
 No 1992 55 (2.76) 1  
 Yes 1887 123 (6.52) 1.90 (1.79-2.02) <0.0001 
General surgery     <0.0001 
 No 1417 32 (2.26) 1  
 Yes 2462 146 (5.93) 1.61 (1.51-1.71) <0.0001 
Genetic     <0.0001 
 No 3813 171 (4.48) 1  
 Yes 66 7 (10.6) 2.17 (1.73-2.73) <0.0001 
Genito-urinary     <0.0001 
 No 2174 61 (2.81) 1  
 Yes 1705 117 (6.86) 1.83 (1.72-1.95) <0.0001 
Hematologic     <0.0001 
 No 2930 116 (3.96) 1  
 Yes 949 62 (6.53) 3.37 (3.14-3.60) <0.0001 
Infections     <0.0001 
 No 3072 122 (3.97) 1  
 Yes 807 56 (6.94) 0.82 (0.76-0.89) <0.0001 
Malignancies     <0.0001 
 No 2753 98 (3.56) 1  
 Yes 1126 80 (7.10) 6.70 (6.30-7.13) <0.0001 
Musculoskeletal     <0.0001 
 No 997 21 (2.11) 1  
 Yes 2882 157 (5.45) 1.73 (1.61-1.85) <0.0001 
Neonatal     <0.0001 
 No 3859 176 (4.56) 1  
 Yes 20 2 (10.0) 0.29 (0.19-0.45) <0.0001 
Neurologic     <0.0001 
 No 1164 28 (2.41) 1  
 Yes 2715 150 (5.52) 2.84 (2.65-3.03) <0.0001 
Nutrition     <0.0001 
 No 3651 156 (4.27) 1  
 Yes 228 22 (9.65) 1.55 (1.36-1.76) <0.0001 
Psychosocial     <0.0001 
 No 2233 88 (3.94) 1  
 Yes 1646 90 (5.47) 1.80 (1.69-1.91) <0.0001 
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Reconstructive     <0.0001 
 No 3114 127 (4.08) 1  
 Yes 765 51 (6.67) 1.90 (1.77-2.05) <0.0001 
Renal     <0.0001 
 No 3292 129 (3.92) 1  
 Yes 587 49 (8.35) 3.08 (2.84-3.35) <0.0001 
Respiratory     <0.0001 
 No 1466 41 (2.80) 1  
 Yes 2413 137 (5.68) 2.24 (2.10-2.38) <0.0001 
Rheumatologic     <0.0001 
 No 3102 121 (3.90) 1  
 Yes 777 57 (7.34) 3.13 (2.90-3.36) <0.0001 
Skin     <0.0001 
 No 1579 42 (2.66) 1  
 Yes 2300 136 (5.91) 0.67 (0.63-0.71) <0.0001 
Toxic effects/Adverse events     <0.0001 
 No 3545 88 (2.48) 1  
 Yes 334 90 (27.0) 1.60 (1.44-1.79) <0.0001 
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Table A.13 Read coding of diabetes 
Code READ or OXMIS description 
C10.. Diabetes mellitus                                                                                                                                                                                      
C100. Diabetes mellitus with no mention of complication                                                                                                                                                      
C1000 Diabetes mellitus, juvenile type, with no mention of complication                                                                                                                                      
C1001 Diabetes mellitus, adult onset, with no mention of complication                                                                                                                                        
C100z Diabetes mellitus NOS with no mention of complication                                                                                                                                                  
C101. Diabetes mellitus with ketoacidosis                                                                                                                                                                    
C1010 Diabetes mellitus, juvenile type, with ketoacidosis                                                                                                                                                    
C1011 Diabetes mellitus, adult onset, with ketoacidosis                                                                                                                                                      
C101y Other specified diabetes mellitus with ketoacidosis                                                                                                                                                    
C101z Diabetes mellitus NOS with ketoacidosis                                                                                                                                                                
C102. Diabetes mellitus with hyperosmolar coma                                                                                                                                                               
C1020 Diabetes mellitus, juvenile type, with hyperosmolar coma                                                                                                                                               
C1021 Diabetes mellitus, adult onset, with hyperosmolar coma                                                                                                                                                 
C102z Diabetes mellitus NOS with hyperosmolar coma                                                                                                                                                           
C103. Diabetes mellitus with ketoacidotic coma                                                                                                                                                               
C1030 Diabetes mellitus, juvenile type, with ketoacidotic coma                                                                                                                                               
C1031 Diabetes mellitus, adult onset, with ketoacidotic coma                                                                                                                                                 
C103y Other specified diabetes mellitus with coma                                                                                                                                                            
C103z Diabetes mellitus NOS with ketoacidotic coma                                                                                                                                                           
C104. Diabetes mellitus with renal manifestation                                                                                                                                                             
C1040 Diabetes mellitus, juvenile type, with renal manifestation                                                                                                                                             
C1041 Diabetes mellitus, adult onset, with renal manifestation                                                                                                                                               
C104y Other specified diabetes mellitus with renal complications                                                                                                                                             
C104z Diabetes mellitus with nephropathy NOS                                                                                                                                                                 
C105. Diabetes mellitus with ophthalmic manifestation                                                                                                                                                        
C1050 Diabetes mellitus, juvenile type, with ophthalmic manifestation                                                                                                                                        
C1051 Diabetes mellitus, adult onset, with ophthalmic manifestation                                                                                                                                          
C105y Other specified diabetes mellitus with ophthalmic complications                                                                                                                                        
C105z Diabetes mellitus NOS with ophthalmic manifestation                                                                                                                                                    
C106. Diabetes mellitus with neurological manifestation                                                                                                                                                      
C1060 Diabetes mellitus, juvenile type, with neurological manifestation                                                                                                                                      
C1061 Diabetes mellitus, adult onset, with neurological manifestation                                                                                                                                        
C106y Other specified diabetes mellitus with neurological complications                                                                                                                                      
C106z Diabetes mellitus NOS with neurological manifestation                                                                                                                                                  
C107. Diabetes mellitus with peripheral circulatory disorder                                                                                                                                                 
C1070 Diabetes mellitus, juvenile type, with peripheral circulatory disorder                                                                                                                                 
C1071 Diabetes mellitus, adult onset, with peripheral circulatory disorder                                                                                                                                   
C1072 Diabetes mellitus, adult with gangrene                                                                                                                                                                 
C1073 IDDM with peripheral circulatory disorder                                                                                                                                                              
C1074 NIDDM with peripheral circulatory disorder                                                                                                                                                             
C107y Other specified diabetes mellitus with peripheral circulatory complications                                                                                                                            
C107z Diabetes mellitus NOS with peripheral circulatory disorder                                                                                                                                             
C108. Insulin dependent diabetes mellitus                                                                                                                                                                    
C1080 Insulin-dependent diabetes mellitus with renal complications                                                                                                                                           
C1081 Insulin-dependent diabetes mellitus with ophthalmic complications                                                                                                                                      
C1082 Insulin-dependent diabetes mellitus with neurological complications                                                                                                                                    
C1083 Insulin dependent diabetes mellitus with multiple complications                                                                                                                                        
C1084 Unstable insulin dependent diabetes mellitus                                                                                                                                                           
C1085 Insulin dependent diabetes mellitus with ulcer                                                                                                                                                         
C1086 Insulin dependent diabetes mellitus with gangrene                                                                                                                                                      
C1087 Insulin dependent diabetes mellitus with retinopathy                                                                                                                                                   
C1088 Insulin dependent diabetes mellitus - poor control                                                                                                                                                     
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C1089 Insulin dependent diabetes maturity onset                                                                                                                                                              
C108A Insulin-dependent diabetes without complication                                                                                                                                                        
C108B Insulin dependent diabetes mellitus with mononeuropathy                                                                                                                                                
C108C Insulin dependent diabetes mellitus with polyneuropathy                                                                                                                                                
C108D Insulin dependent diabetes mellitus with nephropathy                                                                                                                                                   
C108E Insulin dependent diabetes mellitus with hypoglycaemic coma                                                                                                                                            
C108F Insulin dependent diabetes mellitus with diabetic cataract                                                                                                                                             
C108G Insulin dependent diabetes mellitus with peripheral angiopathy                                                                                                                                         
C108H Insulin dependent diabetes mellitus with arthropathy                                                                                                                                                   
C108J Insulin dependent diabetes mellitus with neuropathic arthropathy                                                                                                                                       
C108y Other specified diabetes mellitus with multiple complications                                                                                                                                          
C108z Unspecified diabetes mellitus with multiple complications                                                                                                                                              
C109. Non-insulin dependent diabetes mellitus                                                                                                                                                                
C1090 Non-insulin-dependent diabetes mellitus with renal complications                                                                                                                                       
C1091 Non-insulin-dependent diabetes mellitus with ophthalmic complications                                                                                                                                  
C1092 Non-insulin-dependent diabetes mellitus with neurological complications                                                                                                                                
C1093 Non-insulin-dependent diabetes mellitus with multiple complications                                                                                                                                    
C1094 Non-insulin dependent diabetes mellitus with ulcer                                                                                                                                                     
C1095 Non-insulin dependent diabetes mellitus with gangrene                                                                                                                                                  
C1096 Non-insulin-dependent diabetes mellitus with retinopathy                                                                                                                                               
C1097 Non-insulin dependent diabetes mellitus - poor control                                                                                                                                                 
C1099 Non-insulin-dependent diabetes mellitus without complication                                                                                                                                           
C109A Non-insulin dependent diabetes mellitus with mononeuropathy                                                                                                                                            
C109B Non-insulin dependent diabetes mellitus with polyneuropathy                                                                                                                                            
C109C Non-insulin dependent diabetes mellitus with nephropathy                                                                                                                                               
C109D Non-insulin dependent diabetes mellitus with hypoglycaemic coma                                                                                                                                        
C109E Non-insulin dependent diabetes mellitus with diabetic cataract                                                                                                                                         
C109F Non-insulin-dependent diabetes mellitus with peripheral angiopathy                                                                                                                                     
C109G Non-insulin dependent diabetes mellitus with arthropathy                                                                                                                                               
C109H Non-insulin dependent diabetes mellitus with neuropathic arthropathy                                                                                                                                   
C109J Insulin treated Type 2 diabetes mellitus                                                                                                                                                               
C109K Hyperosmolar non-ketotic state in type 2 diabetes mellitus                                                                                                                                             
C10A. Malnutrition-related diabetes mellitus                                                                                                                                                                 
C10A0 Malnutrition-related diabetes mellitus with coma                                                                                                                                                       
C10A1 Malnutrition-related diabetes mellitus with ketoacidosis                                                                                                                                               
C10A2 Malnutrition-related diabetes mellitus with renal complications                                                                                                                                        
C10A3 Malnutrition-related diabetes mellitus with ophthalmic complications                                                                                                                                   
C10A4 Malnutrition-related diabetes mellitus with neurological complications                                                                                                                                 
C10A5 Malnutrition-related diabetes mellitus with peripheral circulatory complications                                                                                                                       
C10A6 Malnutrition-related diabetes mellitus with multiple complications                                                                                                                                     
C10A7 Malnutrition-related diabetes mellitus without complications                                                                                                                                           
C10AW Malnutrition-related diabetes mellitus with unspecified complications                                                                                                                                  
C10AX Malnutrition-related diabetes mellitus with other specified complications                                                                                                                              
C10B. Diabetes mellitus induced by steroids                                                                                                                                                                  
C10B0 Steroid induced diabetes mellitus without complication                                                                                                                                                 
C10C. Diabetes mellitus autosomal dominant                                                                                                                                                                   
C10D. Diabetes mellitus autosomal dominant type 2                                                                                                                                                            
C10E. Type 1 diabetes mellitus                                                                                                                                                                               
C10E0 Type 1 diabetes mellitus with renal complications                                                                                                                                                      
C10E1 Type 1 diabetes mellitus with ophthalmic complications                                                                                                                                                 
C10E2 Type 1 diabetes mellitus with neurological complications                                                                                                                                               
C10E3 Type 1 diabetes mellitus with multiple complications                                                                                                                                                   
C10E4 Unstable type 1 diabetes mellitus                                                                                                                                                                      
C10E5 Type 1 diabetes mellitus with ulcer                                                                                                                                                                    
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C10E6 Type 1 diabetes mellitus with gangrene                                                                                                                                                                 
C10E7 Type 1 diabetes mellitus with retinopathy                                                                                                                                                              
C10E8 Type 1 diabetes mellitus - poor control                                                                                                                                                                
C10E9 Type 1 diabetes mellitus maturity onset                                                                                                                                                                
C10EA Type 1 diabetes mellitus without complication                                                                                                                                                          
C10EB Type 1 diabetes mellitus with mononeuropathy                                                                                                                                                           
C10EC Type 1 diabetes mellitus with polyneuropathy                                                                                                                                                           
C10ED Type 1 diabetes mellitus with nephropathy                                                                                                                                                              
C10EE Type 1 diabetes mellitus with hypoglycaemic coma                                                                                                                                                       
C10EF Type 1 diabetes mellitus with diabetic cataract                                                                                                                                                        
C10EG Type 1 diabetes mellitus with peripheral angiopathy                                                                                                                                                    
C10EH Type 1 diabetes mellitus with arthropathy                                                                                                                                                              
C10EJ Type 1 diabetes mellitus with neuropathic arthropathy                                                                                                                                                  
C10EK Type 1 diabetes mellitus with persistent proteinuria                                                                                                                                                   
C10EL Type 1 diabetes mellitus with persistent microalbuminuria                                                                                                                                              
C10EM Type 1 diabetes mellitus with ketoacidosis                                                                                                                                                             
C10EN Type 1 diabetes mellitus with ketoacidotic coma                                                                                                                                                        
C10EP Type 1 diabetes mellitus with exudative maculopathy                                                                                                                                                    
C10EQ Type 1 diabetes mellitus with gastroparesis                                                                                                                                                            
C10ER Latent autoimmune diabetes mellitus in adult                                                                                                                                                           
C10F. Type 2 diabetes mellitus                                                                                                                                                                               
C10F0 Type 2 diabetes mellitus with renal complications                                                                                                                                                      
C10F1 Type 2 diabetes mellitus with ophthalmic complications                                                                                                                                                 
C10F2 Type 2 diabetes mellitus with neurological complications                                                                                                                                               
C10F3 Type 2 diabetes mellitus with multiple complications                                                                                                                                                   
C10F4 Type 2 diabetes mellitus with ulcer                                                                                                                                                                    
C10F5 Type 2 diabetes mellitus with gangrene                                                                                                                                                                 
C10F6 Type 2 diabetes mellitus with retinopathy                                                                                                                                                              
C10F7 Type 2 diabetes mellitus - poor control                                                                                                                                                                
C10F9 Type 2 diabetes mellitus without complication                                                                                                                                                          
C10FA Type 2 diabetes mellitus with mononeuropathy                                                                                                                                                           
C10FB Type 2 diabetes mellitus with polyneuropathy                                                                                                                                                           
C10FC Type 2 diabetes mellitus with nephropathy                                                                                                                                                              
C10FD Type 2 diabetes mellitus with hypoglycaemic coma                                                                                                                                                       
C10FE Type 2 diabetes mellitus with diabetic cataract                                                                                                                                                        
C10FF Type 2 diabetes mellitus with peripheral angiopathy                                                                                                                                                    
C10FG Type 2 diabetes mellitus with arthropathy                                                                                                                                                              
C10FH Type 2 diabetes mellitus with neuropathic arthropathy                                                                                                                                                  
C10FJ Insulin treated Type 2 diabetes mellitus                                                                                                                                                               
C10FK Hyperosmolar non-ketotic state in type 2 diabetes mellitus                                                                                                                                             
C10FL Type 2 diabetes mellitus with persistent proteinuria                                                                                                                                                   
C10FM Type 2 diabetes mellitus with persistent microalbuminuria                                                                                                                                              
C10FN Type 2 diabetes mellitus with ketoacidosis                                                                                                                                                             
C10FP Type 2 diabetes mellitus with ketoacidotic coma                                                                                                                                                        
C10FQ Type 2 diabetes mellitus with exudative maculopathy                                                                                                                                                    
C10FR Type 2 diabetes mellitus with gastroparesis                                                                                                                                                            
C10FS Maternally inherited diabetes mellitus                                                                                                                                                                 
C10G. Secondary pancreatic diabetes mellitus                                                                                                                                                                 
C10G0 Secondary pancreatic diabetes mellitus without complication                                                                                                                                            
C10H. Diabetes mellitus induced by non-steroid drugs                                                                                                                                                         
C10H0 Diabetes mellitus induced by non-steroid drugs without complication                                                                                                                                    
C10J. Insulin autoimmune syndrome                                                                                                                                                                            
C10J0 Insulin autoimmune syndrome without complication                                                                                                                                                       
C10K. Type A insulin resistance                                                                                                                                                                              
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C10K0 Type A insulin resistance without complication                                                                                                                                                         
C10L. Fibrocalculous pancreatopathy                                                                                                                                                                          
C10L0 Fibrocalculous pancreatopathy without complication                                                                                                                                                     
C10M. Lipoatrophic diabetes mellitus                                                                                                                                                                         
C10M0 Lipoatrophic diabetes mellitus without complication                                                                                                                                                    
C10N. Secondary diabetes mellitus                                                                                                                                                                            
C10N0 Secondary diabetes mellitus without complication                                                                                                                                                       
C10N1 Cystic fibrosis related diabetes mellitus                                                                                                                                                              
C10y. Diabetes mellitus with other specified manifestation                                                                                                                                                   
C10y0 Diabetes mellitus, juvenile type, with other specified manifestation                                                                                                                                   
C10y1 Diabetes mellitus, adult onset, with other specified manifestation                                                                                                                                     
C10yy Other specified diabetes mellitus with other specified complications                                                                                                                                   
C10yz Diabetes mellitus NOS with other specified manifestation                                                                                                                                               
C10z. Diabetes mellitus with unspecified complication                                                                                                                                                        
C10z0 Diabetes mellitus, juvenile type, with unspecified complication                                                                                                                                        
C10z1 Diabetes mellitus, adult onset, with unspecified complication                                                                                                                                          
C10zy Other specified diabetes mellitus with unspecified complications                                                                                                                                       
C10zz Diabetes mellitus NOS with unspecified complication                                                                                                                                                    
L180. Diabetes mellitus during pregnancy, childbirth and the puerperium 
L1800 Diabetes mellitus - unspecified whether during pregnancy or the puerperium 
L1801 Diabetes mellitus during pregnancy - baby delivered 
L1802 Diabetes mellitus in the puerperium - baby delivered during current episode of care 
L1803 Diabetes mellitus during pregnancy - baby not yet delivered 
L1804 Diabetes mellitus in the pueperium - baby delivered during previous episode of care 
L1805 Pre-existing diabetes mellitus, insulin-dependent 
L1806 Pre-existing diabetes mellitus, non-insulin-dependent 
L1807 Pre-existing malnutrition-related diabetes mellitus 
L1808 Diabetes mellitus arising in pregnancy 
L1809 Gestational diabetes mellitus 
L180X Pre-existing diabetes mellitus, unspecified 
L180z Diabetes mellitus during pregnancy, childbirth or the puerperium NOS 
Q441. Neonatal diabetes mellitus       
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Table A.14 Codes and terms associated with diabetes, Read codes 
Read code Domain Read term 
9360 Administration Patient held diabetic record issued 
13AB. History/symptoms Diabetic lipid lowering diet 
13AC. History/symptoms Diabetic weight reducing diet 
13B1. History/symptoms Diabetic diet 
13L4. History/symptoms Diabetic child 
2BBP. Examination/signs O/E - right eye background diabetic retinopathy 
2BBQ. Examination/signs O/E - left eye background diabetic retinopathy 
2BBR. Examination/signs O/E - right eye preproliferative diabetic retinopathy 
2BBS. Examination/signs O/E - left eye preproliferative diabetic retinopathy 
2BBT. Examination/signs O/E - right eye proliferative diabetic retinopathy 
2BBV. Examination/signs O/E - left eye proliferative diabetic retinopathy 
2BBW. Examination/signs O/E - right eye diabetic maculopathy 
2BBX. Examination/signs O/E - left eye diabetic maculopathy 
66A.. Preventative procedures Diabetic monitoring 
66A1. Preventative procedures Initial diabetic assessment 
66A2. Preventative procedures Follow-up diabetic assessment 
66A3. Preventative procedures Diabetic on diet only 
66A4. Preventative procedures Diabetic on oral treatment 
66A5. Preventative procedures Diabetic on insulin 
66A6. Preventative procedures Last hypo. attack 
66A7. Preventative procedures Frequency of hypo. attacks 
66A70 Preventative procedures Frequency of hospital treated hypoglycaemia 
66A71 Preventative procedures Frequency of GP or paramedic treated hypoglycaemia 
66A8. Preventative procedures Has seen dietician - diabetes 
66A9. Preventative procedures Understands diet - diabetes 
66AA. Preventative procedures Injection sites 
66Aa. Preventative procedures Diabetic diet - poor compliance 
66AB. Preventative procedures Urine sugar charts 
66Ab. Preventative procedures Diabetic foot examination 
66AC. Preventative procedures Blood sugar charts 
66Ac. Preventative procedures Diabetic peripheral neuropathy screening 
66AD. Preventative procedures Fundoscopy - diabetic check 
66Ad. Preventative procedures Hypoglycaemic attack requiring 3rd party assistance 
66AE. Preventative procedures Feet examination 
66Ae. Preventative procedures HBA1c target 
66AF. Preventative procedures Attends out-patients 
66Af. Preventative procedures Patient diabetes education review 
66AG. Preventative procedures Diabetic drug side effects 
66Ag. Preventative procedures Insulin needles changed daily 
66AH. Preventative procedures Diabetic treatment changed 
66Ah. Preventative procedures Insulin needles changed for each injection 
66AH0 Preventative procedures Conversion to insulin 
66AI. Preventative procedures Diabetic - good control 
66Ai. Preventative procedures Diabetic 6 month review 
66Ai. Preventative procedures Diabetic 6 month review 
66AJ. Preventative procedures Diabetic - poor control 
66Aj. Preventative procedures Insulin needles changed less than once a day 
66AJ0 Preventative procedures Chronic hyperglycaemia 
66AJ1 Preventative procedures Brittle diabetes 
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66AJ2 Preventative procedures Loss of hypoglycaemic warning 
66AJ3 Preventative procedures Recurrent severe hypos 
66AJz Preventative procedures Diabetic - poor control NOS 
66AK. Preventative procedures Diabetic - cooperative patient 
66Ak. Preventative procedures Diabetic monitoring - lower risk albumin excretion 
66Ak. Preventative procedures Diabetic monitoring - lower risk albumin excretion 
66AL. Preventative procedures Diabetic-uncooperative patient 
66Al. Preventative procedures Diabetic monitoring - higher risk albumin excretion 
66Al. Preventative procedures Diabetic monitoring - higher risk albumin excretion 
66AM. Preventative procedures Diabetic - follow-up default 
66Am. Preventative procedures Insulin dose changed 
66AN. Preventative procedures Date diabetic treatment start 
66An. Preventative procedures Diabetes type 1 review 
66AO. Preventative procedures Date diabetic treatment stopp. 
66Ao. Preventative procedures Diabetes type 2 review 
66AP. Preventative procedures Diabetes: practice programme 
66Ap. Preventative procedures Insulin treatment initiated 
66AQ. Preventative procedures Diabetes: shared care programme 
66Aq. Preventative procedures Diabetic foot screen 
66AR. Preventative procedures Diabetes management plan given 
66AS. Preventative procedures Diabetic annual review 
66AT. Preventative procedures Annual diabetic blood test 
66AU. Preventative procedures Diabetes care by hospital only 
66AV. Preventative procedures Diabetic on insulin and oral treatment 
66AW. Preventative procedures Diabetic foot risk assessment 
66AX. Preventative procedures Diabetes: shared care in pregnancy - diabetologist and obstetrician 
66AY. Preventative procedures Diabetic diet - good compliance 
66AZ. Preventative procedures Diabetic monitoring NOS 
66b1. Preventative procedures Diabetic monitoring not required 
68A7. Preventative procedures Diabetic retinopathy screening 
68A8. Preventative procedures Digital retinal screening 
68A9. Preventative procedures Diabetic retinopathy screening offered 
68AA. Preventative procedures Digital retinal screening offered 
68AB. Preventative procedures Diabetic digital retinopathy screening offered 
8A12. Other theraputic procedures Diabetic crisis monitoring 
8A13. Other theraputic procedures Diabetic stabilisation 
8CA41 Other theraputic procedures Pt advised re diabetic diet 
8CE0. Other theraputic procedures Diabetic leaflet given 
8H2J. Other theraputic procedures Admit diabetic emergency 
8H3O. Other theraputic procedures Non-urgent diabetic admission 
8H7C. Other theraputic procedures Refer, diabetic liaison nurse 
8HBG. Other theraputic procedures Diabetic retinopathy 12 month review 
8HBG. Other theraputic procedures Diabetic retinopathy 12 month review 
8HBH. Other theraputic procedures Diabetic retinopathy 6 month review 
8HHy. Other theraputic procedures Referral to diabetic register 
8HTk. Other theraputic procedures Referral to diabetic eye clinic 
8I3X. Other theraputic procedures Diabetic retinopathy screening refused 
8I57. Other theraputic procedures Patient held diabetic record declined 
8I6G. Other theraputic procedures Diabetic foot examination not indicated 
93C4. Administration Patient consent given for addition to diabetic register 
9N1i. Administration Seen in diabetic foot clinic 
9N1Q. Administration Seen in diabetic clinic 
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9N1v. Administration Seen in diabetic eye clinic 
9NND. Administration Under care of diabetic foot screener 
F3450 Disorders Diabetic mononeuritis multiplex 
F35z0 Disorders Diabetic mononeuritis NOS 
F372. Disorders Polyneuropathy in diabetes 
F3720 Disorders Acute painful diabetic neuropathy 
F3721 Disorders Chronic painful diabetic neuropathy 
F3722 Disorders Asymptomatic diabetic neuropathy 
F3813 Disorders Myasthenic syndrome due to diabetic amyotrophy 
F3y0. Disorders Diabetic mononeuropathy 
F420. Disorders Diabetic retinopathy 
F4200 Disorders Background diabetic retinopathy 
F4201 Disorders Proliferative diabetic retinopathy 
F4202 Disorders Preproliferative diabetic retinopathy 
F4203 Disorders Advanced diabetic maculopathy 
F4204 Disorders Diabetic maculopathy 
F4205 Disorders Advanced diabetic retinal disease 
F4206 Disorders Non proliferative diabetic retinopathy 
F4207 Disorders High risk proliferative diabetic retinopathy 
F4208 Disorders High risk non proliferative diabetic retinopathy 
F420z Disorders Diabetic retinopathy NOS 
F4407 Disorders Diabetic iritis 
G73y0 Disorders Diabetic peripheral angiopathy 
M0372 Disorders Cellulitis in diabetic foot 
M2710 Disorders Ischaemic ulcer diabetic foot 
M2711 Disorders Neuropathic diabetic ulcer - foot 
M2712 Disorders Mixed diabetic ulcer - foot 
R0542 [D]Symptoms,signs,ill-def.cond [D]Gangrene of toe in diabetic 
R0543 [D]Symptoms,signs,ill-def.cond [D]Widespread diabetic foot gangrene 
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Table A.15 READ codes for DKA and coma mapped to ICD 10 codes 
ICD 10 code Condition Read code Read description 
E10.0 Insulin-dependent diabetes mellitus with 
coma 
Diabetic:  
· coma with or without ketoacidosis  
· hyperosmolar coma  
· hypoglycaemic coma  






Diabetes mellitus, juvenile type, with 
ketoacidotic coma 
 
Type 1 diabetes mellitus with 
hypoglycaemic coma  
 
Type 1 diabetes mellitus with ketoacidotic 
coma 
E10.1 Insulin-dependent diabetes mellitus with 
ketoacidosis 
Diabetic:  
· acidosis  
· ketoacidosis  




Type 1 diabetes mellitus with ketoacidosis 
 
Diabetes mellitus, juvenile type, with 
ketoacidosis 
E11.0 Non-insulin-dependent diabetes mellitus 
with coma 
Diabetic:  
· coma with or without ketoacidosis  
· hyperosmolar coma  
· hypoglycaemic coma  







Diabetes mellitus, adult onset, with 
ketoacidotic coma 
 
Type 2 diabetes mellitus with 
hypoglycaemic coma 
 
Type 2 diabetes mellitus with ketoacidotic 
coma 
E11.1 Non-insulin-dependent diabetes mellitus 
with ketoacidosis 
Diabetic:  
· acidosis  
· ketoacidosis  




Type 2 diabetes mellitus with ketoacidosis 
 




E12.0 Malnutrition-related diabetes mellitus 
with coma 
Diabetic:  
· coma with or without ketoacidosis  
· hyperosmolar coma  
· hypoglycaemic coma  
Hyperglycaemic coma NOS 
C10A0 Malnutrition-related diabetes mellitus 
with coma 
 
E12.1 Malnutrition-related diabetes mellitus 
with ketoacidosis 
Diabetic:  
· acidosis  
· ketoacidosis  
without mention of coma 
C10A1 Malnutrition-related diabetes mellitus 
with ketoacidosis 
E13.0 Other specified diabetes mellitus with 
coma 
Diabetic:  
· coma with or without ketoacidosis  
· hyperosmolar coma  
· hypoglycaemic coma  
Hyperglycaemic coma NOS 
C103y Other specified diabetes mellitus with 
coma 
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E13.1 Other specified diabetes mellitus with 
ketoacidosis 
Diabetic:  
· acidosis  
· ketoacidosis  
without mention of coma 
C101y Other specified diabetes mellitus with 
ketoacidosis 
E14.0 Unspecified diabetes mellitus with coma 
Diabetic:  
· coma with or without ketoacidosis  
· hyperosmolar coma  
· hypoglycaemic coma  
Hyperglycaemic coma NOS 
C103z Diabetes mellitus NOS with ketoacidotic 
coma 
 
E14.1 Unspecified diabetes mellitus with 
ketoacidosis 
Diabetic:  
· acidosis  
· ketoacidosis  
without mention of coma 
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Table A.16 Aggregated regions by Strategic Health Authority (SHA) cluster 
Original region  Strategic Health Authority cluster 
Missing N/A 
North East NHS North of England 
North West NHS North of England 
Yorkshire & The Humber NHS North of England 
East Midlands NHS Midlands and East 
West Midlands NHS Midlands and East 
East of England NHS Midlands and East 
South West NHS South of England 
South Central NHS South of England 
London NHS London 
South East Coast NHS South of England 
Northern Ireland N/A 
Scotland  N/A 
Wales  N/A 
 
Source: Department of Health, 2011.
358
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Table A.17 Associations between comorbidities and diabetic emergency admission (DEA) in 
patients with diabetes, crude results from Poisson regression 
Characteristic 
Patients with diabetes, n 





Chronic pulmonary disease     0.014 
 No 1125 27 (2.40) 1  
 Yes 234 2 (0.85) 0.24 (0.06-0.99) 0.048 
Congestive heart disease     0.998 
 No 1280 27 (2.11) 1  
 Yes 79 2 (2.53) 1.00 (0.24-4.16) 0.998 
Dementia     0.270 
 No 1348 28 (2.08) 1  
 Yes 11 1 (9.09) 3.90 (0.53-28.4) 0.179 
Diabetes with complication     0.016 
 No 1249 26 (2.08) 1  
 Yes 110 3 (2.73) 2.91 (1.34-6.33) 0.007 
Mild liver disease     0.148 
 No 1354 28 (2.07) 1  
 Yes 5 1 (20.9) 6.75 (0.93-49.2) 0.059 
Myocardial infarction     0.617 
 No 1302 28 (2.15) 1  
 Yes 57 1 (1.75) 0.63 (0.09-4.56) 0.643 
Peptic ulcer     0.647 
 No 1309 28 (2.14) 1  
 Yes 50 1 (2.00) 0.65 (0.09-4.72) 0.669 
Peripheral vascular disease     0.229 
 No 1270 28 (2.20) 1  
 Yes 89 1 (1.12) 0.36 (0.05-2.61) 0.312 
Aggregated Disease Groups (ADGs)  
Time Limited: Minor     0.166 
 No 383 10 (2.61) 1  
 Yes 976 19 (1.95) 0.62 (0.32-1.20) 0.154 
Time Limited: Minor-Primary     0.968 
 No 255 6 (2.35) 1  
 Yes 1104 23 (2.08) 0.98 (0.41-2.35) 0.968 
Time Limited: Major     <0.0001 
 No 1054 28 (2.66) 1  
 Yes 305 1 (0.33) 0.09 (0.01-0.67) 0.019 
Time Limited: Major-Primary Infections     0.099 
 No 856 17 (1.99) 1  
 Yes 503 12 (2.39) 1.70 (0.91-3.19) 0.098 
Allergies     0.411 
 No 1143 20 (1.75) 1  
 Yes 216 9 (4.17) 1.38 (0.65-2.91) 0.397 
Asthma     0.209 
                                                     
*
DEA – Diabetic emergency admission refers to admissions for hyperglycaemic or hypoglycaemic emergencies, 
namely, diabetic ketoacidosis or diabetic coma. 
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 No 1170 26 (2.22) 1  
 Yes 189 3 (1.59) 0.50 (0.16-1.64) 0.254 
Likely to Recur: Discrete     0.004 
 No 316 11 (3.48) 1  
 Yes 1043 18 (1.73) 0.37 (0.20-0.71) 0.003 
Likely to Recur: Discrete-Infections     0.020 
 No 601 14 (2.33) 1  
 Yes 758 15 (1.98) 0.47 (0.25-0.90) 0.022 
Likely to Recur: Progressive     0.032 
 No 802 13 (1.62) 1  
 Yes 557 16 (2.87) 1.99 (1.05-3.77) 0.034 
Chronic Specialty: Stable-Orthopedic     0.375 
 No 489 9 (1.84) 1  
 Yes 870 20 (2.30) 1.36 (0.68-2.74) 0.385 
Chronic Specialty: Stable-Eye     0.002 
 No 1029 26 (2.53) 1  
 Yes 330 3 (0.91) 0.22 (0.07-0.73) 0.013 
Chronic Specialty: Stable-Eye     0.004 
 No 1085 27 (2.49) 1  
 Yes 274 2 (0.73) 0.20 (0.05-0.83) 0.026 
Chronic Specialty: Unstable-Eye     0.364 
 No 906 19 (2.10) 1  
 Yes 453 10 (2.21) 1.35 (0.71-2.55) 0.359 
Dermatologic      0.482 
 No 644 16 (2.48) 1  
 Yes 715 13 (1.82) 0.80 (0.43-1.50) 0.481 
Injuries/Adverse Effects: Minor     0.025 
 No 711 18 (2.53) 1  
 Yes 648 11 (1.70) 0.48 (0.25-0.93) 0.030 
Injuries/Adverse Effects: Major     <0.0001 
 No 882 10 (1.13) 1  
 Yes 477 19 (3.98) 4.93 (2.40-10.1) <0.0001 
Psychosocial: Time Limited, Minor     0.111 
 No 1016 22 (2.17) 1  
 Yes 343 7 (2.04) 1.71 (0.90-3.27) 0.102 
Psychosocial: Recurrent or Persistent, Stable     0.366 
 No 879 19 (2.16) 1  
 Yes 480 10 (2.08) 1.34 (0.71-2.53) 0.363 
Psychosocial: Recurrent or Persistent, Unstable     0.039 
 No 1164 25 (2.15) 1  
 Yes 195 4 (2.05) 2.25 (1.10-4.62) 0.027 
Signs/Symptoms: Minor     0.270 
 No 326 10 (3.07) 1  
 Yes 1033 19 (1.84) 0.67 (0.33-1.34) 0.255 
Signs/Symptoms: Uncertain     0.457 
 No 239 4 (1.67) 1  
 Yes 1120 25 (2.23) 1.45 (0.52-4.09) 0.479 
Signs/Symptoms: Major     0.743 
 No 488 10 (2.05) 1  
 Yes 871 19 (2.18) 1.12 (0.57-2.21) 0.745 
Discretionary     0.256 
 No 576 13 (2.26) 1  
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 Yes 783 16 (2.04) 0.69 (0.37-1.30) 0.254 
See and Reassure     0.002 
 No 1120 28 (2.50) 1  
 Yes 239 1 (0.42) 0.11 (0.02-0.83) 0.032 
Prevention/Administrative     0.528 
 No 130 4 (3.08) 1  
 Yes 1229 25 (2.03) 0.71 (0.25-1.98) 0.509 
Malignancy     0.130 
 No 1136 27 (2.38) 1  
 Yes 223 2 (0.90) 0.44 (0.14-1.44) 0.177 
Pregnancy     0.408 
 No 1287 28 (2.18) 1  
 Yes 72 1 (1.39) 0.48 (0.07-3.47) 0.464 
Dental     0.011 
 No 1247 25 (2.00) 1  
 Yes 112 4 (3.57) 2.94 (1.39-6.19) 0.005 
Collapsed Aggregated Diagnosis Groups (CADGs) 
Acute Minor     0.123 
 No 77 4 (5.19) 1  
 Yes 1282 25 (1.95) 0.40 (0.14-1.12) 0.082 
Acute Major     0.398 
 No 90 1 (1.11) 1  
 Yes 1269 28 (2.21) 2.13 (0.29-15.5) 0.456 
Likely to Recur     0.618 
 No 97 3 (3.09) 1  
 Yes 1262 26 (2.06) 0.73 (0.23-2.37) 0.602 
Asthma     0.209 
 No 1170 26 (2.22) 1  
 Yes 189 3 (1.59) 0.50 (0.16-1.64) 0.254 
Chronic Medical: Unstable     0.224 
 No 326 6 (1.84) 1  
 Yes 1033 23 (2.23) 1.66 (0.70-3.97) 0.251 
Chronic Specialty: Stable     <0.0001 
 No 976 26 (2.66) 1  
 Yes 383 3 (0.78) 0.19 (0.06-0.61) 0.005 
Eye/Dental     0.906 
 No 991 23 (2.32) 1  
 Yes 368 6 (1.63) 0.96 (0.48-1.93) 0.906 
Chronic Specialty: Unstable     0.770 
 No 846 19 (2.25) 1  
 Yes 513 10 (1.95) 1.10 (0.58-2.08) 0.769 
Psychosocial     0.895 
 No 618 16 (2.59) 1  
 Yes 741 13 (1.75) 1.04 (0.55-1.96) 0.895 
Preventive/Administrative     0.528 
 No 130 4 (3.08) 1  
 Yes 1229 25 (2.03) 0.71 (0.25-1.98) 0.509 
Pregnancy     0.408 
 No 1287 28 (2.18) 1  
 Yes 72 1 (1.39) 0.48 (0.07-3.47) 0.464 
Expanded Diagnosis Clusters (EDCs) groups     0.001 
 Low 436 9 (2.06) 1  
Appendices | 292 
 
 
 Moderate 466 15 (3.22) 1.57 (0.77-3.22) 0.217 
 High 457 5 (1.09) 0.31 (0.11-0.89) 0.029 
Major Expanded Diagnosis Clusters (MEDCs) 
Administrative     0.802 
 No 116 3 (2.59) 1  
 Yes 1243 26 (2.09) 0.86 (0.26-2.78) 0.798 
Allergy     0.772 
 No 938 17 (1.81) 1  
 Yes 421 12 (2.85) 0.91 (0.46-1.79) 0.773 
Cardiovascular     0.002 
 No 338 10 (2.96) 1  
 Yes 1021 19 (1.86) 0.35 (0.19-0.66) 0.001 
Dental     0.189 
 No 1092 22 (2.01) 1  
 Yes 267 7 (2.62) 1.60 (0.81-3.16) 0.174 
Ear, Nose, Throat     0.301 
 No 449 7 (1.56) 1  
 Yes 910 22 (2.42) 1.49 (0.68-3.23) 0.319 
Eye     0.929 
 No 518 10 (1.93) 1  
 Yes 841 19 (2.26) 0.97 (0.50-1.87) 0.929 
Female reproductive system     0.936 
 No 964 19 (1.97) 1  
 Yes 395 10 (2.53) 1.03 (0.52-2.03) 0.936 
Gastrointestinal/hepatic     0.339 
 No 526 9 (1.71) 1  
 Yes 833 20 (2.40) 1.39 (0.69-2.80) 0.350 
General signs and symptoms     <0.0001 
 No 541 16 (2.96) 1  
 Yes 818 13 (1.59) 0.29 (0.15-0.56) <0.0001 
General surgery     0.284 
 No 300 5 (1.67) 1  
 Yes 1059 24 (2.27) 1.62 (0.63-4.15) 0.312 
Genetic     0.001 
 No 1307 27 (2.07) 1  
 Yes 52 2 (3.85) 5.30 (2.34-12.0) <0.0001 
Genito-urinary     0.001 
 No 631 18 (2.85) 1  
 Yes 728 11 (1.51) 0.35 (0.17-0.68) 0.002 
Hematologic     0.003 
 No 1011 27 (2.67) 1  
 Yes 348 2 (0.57) 0.24 (0.07-0.77) 0.016 
Infections     0.343 
 No 932 18 (1.93) 1  
 Yes 427 11 (2.58) 1.37 (0.72-2.59) 0.338 
Malignancies     0.096 
 No 1123 27 (2.40) 1  
 Yes 236 2 (0.85) 0.41 (0.13-1.34) 0.142 
Musculoskeletal     0.007 
 No 197 6 (3.05) 1  
 Yes 1162 23 (1.98) 0.35 (0.17-0.70) 0.003 
Neonatal     0.342 
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 No 1349 28 (2.08) 1  
 Yes 10 1 (10.0) 3.12 (0.43-22.7) 0.262 
Neurologic     0.320 
 No 320 6 (1.88) 1  
 Yes 1039 23 (2.21) 1.52 (0.64-3.63) 0.343 
Nutrition     0.054 
 No 1166 27 (2.32) 1  
 Yes 193 2 (1.04) 0.31 (0.08-1.29) 0.109 
Psychosocial     0.646 
 No 663 16 (2.41) 1  
 Yes 696 13 (1.87) 1.16 (0.62-2.18) 0.647 
Reconstructive     0.001 
 No 1094 19 (1.74) 1  
 Yes 265 10 (3.77) 3.00 (1.60-5.66) 0.001 
Renal     0.979 
 No 999 22 (2.20) 1  
 Yes 360 7 (1.94) 0.99 (0.49-1.99) 0.979 
Respiratory     0.328 
 No 469 10 (2.13) 1  
 Yes 890 19 (2.13) 0.72 (0.38-1.37) 0.321 
Rheumatologic     0.001 
 No 1053 27 (2.56) 1  
 Yes 306 2 (0.65) 0.17 (0.04-0.69) 0.014 
Skin     0.264 
 No 310 8 (2.58) 1  
 Yes 1049 21 (2.00) 0.65 (0.32-1.34) 0.246 
Toxic effects/Adverse events     0.658 
 No 1193 26 (2.18) 1  
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Table A.18 Associations between comorbidities and diabetic emergency admission (DEA) in 
patients with diabetes, crude results from Poisson regression using the generalized estimating 
equations (GEE) method  
Characteristic 
Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Disease groups 
Chronic pulmonary disease  0.014  0.008 
 No 1  1  
 Yes 0.24 (0.06-0.99) 0.048 0.24 (0.06-0.97) 0.045 
Congestive heart disease  0.998  0.998 
 No 1  1  
 Yes 1.00 (0.24-4.16) 0.998 1.00 (0.23-4.28) 0.998 
Dementia  0.270  0.448 
 No 1  1  
 Yes 3.90 (0.53-28.4) 0.179 3.90 (0.56-27.0) 0.168 
Diabetes with complication  0.016  0.396 
 No 1  1  
 Yes 2.91 (1.34-6.33) 0.007 2.91 (0.60-14.1) 0.185 
Mild liver disease  0.148  0.378 
 No 1  1  
 Yes 6.75 (0.93-49.2) 0.059 6.75 (1.19-38.4) 0.031 
Myocardial infarction  0.617  0.563 
 No 1  1  
 Yes 0.63 (0.09-4.56) 0.643 0.63 (0.09-4.42) 0.638 
Peptic ulcer  0.647  0.607 
 No 1  1  
 Yes 0.65 (0.09-4.72) 0.669 0.65 (0.09-4.70) 0.668 
Peripheral vascular disease  0.229  0.136 
 No 1  1  
 Yes 0.36 (0.05-2.61) 0.312 0.36 (0.05-2.61) 0.312 
Aggregated Disease Groups (ADGs)  
Time Limited: Minor  0.166  0.367 
 No 1  1  
 Yes 0.62 (0.32-1.20) 0.154 0.62 (0.24-1.58) 0.313 
Time Limited: Minor-Primary  0.968  0.969 
 No 1  1  
 Yes 0.98 (0.41-2.35) 0.968 0.98 (0.41-2.38) 0.969 
Time Limited: Major  <0.0001  0.001 
 No 1  1  
 Yes 0.09 (0.01-0.67) 0.019 0.09 (0.01-0.70) 0.021 
Time Limited: Major-Primary Infections  0.099  0.275 
 No 1  1  
 Yes 1.70 (0.91-3.19) 0.098 1.70 (0.76-3.83) 0.200 
Allergies  0.411  0.466 
 No 1  1  
 Yes 1.38 (0.65-2.91) 0.397 1.38 (0.60-3.18) 0.450 
Asthma  0.209  0.124 
 No 1  1  
 Yes 0.50 (0.16-1.64) 0.254 0.50 (0.17-1.50) 0.217 
Likely to Recur: Discrete  0.004  0.142 
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 No 1  1  
 Yes 0.37 (0.20-0.71) 0.003 0.37 (0.15-0.93) 0.035 
Likely to Recur: Discrete-Infections  0.020  0.159 
 No 1  1  
 Yes 0.47 (0.25-0.90) 0.022 0.47 (0.20-1.12) 0.087 
Likely to Recur: Progressive  0.032  0.176 
 No 1  1  
 Yes 1.99 (1.05-3.77) 0.034 1.99 (0.79-5.02) 0.144 
Chronic Specialty: Stable-Orthopedic  0.375  0.474 
 No 1  1  
 Yes 1.36 (0.68-2.74) 0.385 1.36 (0.58-3.19) 0.477 
Chronic Specialty: Stable-Eye  0.002  0.009 
 No 1  1  
 Yes 0.22 (0.07-0.73) 0.013 0.22 (0.07-0.77) 0.018 
Chronic Specialty: Stable-Eye  0.004  0.003 
 No 1  1  
 Yes 0.20 (0.05-0.83) 0.026 0.20 (0.05-0.80) 0.023 
Chronic Specialty: Unstable-Eye  0.364  0.596 
 No 1  1  
 Yes 1.35 (0.71-2.55) 0.359 1.35 (0.49-3.74) 0.566 
Dermatologic  0.482  0.621 
 No 1  1  
 Yes 0.80 (0.43-1.50) 0.481 0.80 (0.32-1.97) 0.624 
Injuries/Adverse Effects: Minor  0.025  0.139 
 No 1  1  
 Yes 0.48 (0.25-0.93) 0.030 0.48 (0.20-1.13) 0.093 
Injuries/Adverse Effects: Major  <0.0001  0.006 
 No 1  1  
 Yes 4.93 (2.4-10.1) <0.0001 4.93 (2.19-11.1) <0.0001 
Psychosocial: Time Limited, Minor  0.111  0.403 
 No 1  1  
 Yes 1.71 (0.90-3.27) 0.102 1.71 (0.61-4.84) 0.310 
Psychosocial: Recurrent or Persistent, Stable  0.366  0.576 
 No 1  1  
 Yes 1.34 (0.71-2.53) 0.363 1.34 (0.52-3.47) 0.544 
Psychosocial: Recurrent or Persistent, Unstable  0.039  0.394 
 No 1  1  
 Yes 2.25 (1.10-4.62) 0.027 2.25 (0.59-8.65) 0.237 
Signs/Symptoms: Minor  0.270  0.350 
 No 1  1  
 Yes 0.67 (0.33-1.34) 0.255 0.67 (0.30-1.49) 0.322 
Signs/Symptoms: Uncertain  0.457  0.408 
 No 1  1  
 Yes 1.45 (0.52-4.09) 0.479 1.45 (0.54-3.89) 0.457 
Signs/Symptoms: Major  0.743  0.810 
 No 1  1  
 Yes 1.12 (0.57-2.21) 0.745 1.12 (0.44-2.86) 0.813 
Discretionary  0.256  0.443 
 No 1  1  
 Yes 0.69 (0.37-1.30) 0.254 0.69 (0.30-1.63) 0.402 
See and Reassure  0.002  0.002 
 No 1  1  
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 Yes 0.11 (0.02-0.83) 0.032 0.11 (0.02-0.86) 0.035 
Prevention/Administrative  0.528  0.566 
 No 1  1  
 Yes 0.71 (0.25-1.98) 0.509 0.71 (0.24-2.04) 0.520 
Malignancy  0.130  0.185 
 No 1  1  
 Yes 0.44 (0.14-1.44) 0.177 0.44 (0.10-2.06) 0.299 
Pregnancy  0.408  0.297 
 No 1  1  
 Yes 0.48 (0.07-3.47) 0.464 0.48 (0.07-3.26) 0.450 
Dental  0.011  0.344 
 No 1  1  
 Yes 2.94 (1.39-6.19) 0.005 2.94 (0.69-12.4) 0.143 
Collapsed Aggregated Diagnosis Groups (CADGs) 
Acute Minor  0.123  0.212 
 No 1  1  
 Yes 0.40 (0.14-1.12) 0.082 0.40 (0.15-1.09) 0.073 
Acute Major  0.398  0.258 
 No 1  1  
 Yes 2.13 (0.29-15.5) 0.456 2.13 (0.33-13.7) 0.427 
Likely to Recur  0.618  0.632 
 No 1  1  
 Yes 0.73 (0.23-2.37) 0.602 0.73 (0.24-2.25) 0.586 
Asthma  0.209  0.124 
 No 1  1  
 Yes 0.50 (0.16-1.64) 0.254 0.50 (0.17-1.50) 0.217 
Chronic Medical: Unstable  0.224  0.208 
 No 1  1  
 Yes 1.66 (0.70-3.97) 0.251 1.66 (0.72-3.84) 0.233 
Chronic Specialty: Stable  <0.0001  0.005 
 No 1  1  
 Yes 0.19 (0.06-0.61) 0.005 0.19 (0.05-0.64) 0.008 
Eye/Dental  0.906  0.945 
 No 1  1  
 Yes 0.96 (0.48-1.93) 0.906 0.96 (0.28-3.23) 0.946 
Chronic Specialty: Unstable  0.770  0.859 
 No 1  1  
 Yes 1.10 (0.58-2.08) 0.769 1.10 (0.39-3.07) 0.855 
Psychosocial  0.895  0.930 
 No 1  1  
 Yes 1.04 (0.55-1.96) 0.895 1.04 (0.41-2.68) 0.930 
Preventive/Administrative  0.528  0.566 
 No 1  1  
 Yes 0.71 (0.25-1.98) 0.509 0.71 (0.24-2.04) 0.520 
Pregnancy  0.408  0.297 
 No 1  1  
 Yes 0.48 (0.07-3.47) 0.464 0.48 (0.07-3.26) 0.450 
Expanded Diagnosis Clusters (EDCs) groups  0.001  0.039 
 Low 1  1  
 Moderate 1.57 (0.77-3.22) 0.217 1.57 (0.53-4.66) 0.415 
 High 0.31 (0.11-0.89) 0.029 0.31 (0.09-1.03) 0.055 
Major Expanded Diagnosis Clusters (MEDCs) 
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Administrative  0.802  0.811 
 No 1  1  
 Yes 0.86 (0.26-2.78) 0.798 0.86 (0.26-2.83) 0.801 
Allergy  0.772  0.806 
 No 1  1  
 Yes 0.91 (0.46-1.79) 0.773 0.91 (0.41-2.00) 0.805 
Cardiovascular  0.002  0.119 
 No 1  1  
 Yes 0.35 (0.19-0.66) 0.001 0.35 (0.14-0.88) 0.025 
Dental  0.189  0.503 
 No 1  1  
 Yes 1.60 (0.81-3.16) 0.174 1.60 (0.50-5.17) 0.430 
Ear, Nose, Throat  0.301  0.378 
 No 1  1  
 Yes 1.49 (0.68-3.23) 0.319 1.49 (0.6-3.69) 0.394 
Eye  0.929  0.954 
 No 1  1  
 Yes 0.97 (0.50-1.87) 0.929 0.97 (0.35-2.67) 0.954 
Female reproductive system  0.936  0.949 
 No 1  1  
 Yes 1.03 (0.52-2.03) 0.936 1.03 (0.44-2.39) 0.949 
Gastrointestinal/hepatic  0.339  0.522 
 No 1  1  
 Yes 1.39 (0.69-2.80) 0.350 1.39 (0.48-4.04) 0.540 
General signs and symptoms  <0.0001  0.036 
 No 1  1  
 Yes 0.29 (0.15-0.56) <0.0001 0.29 (0.12-0.68) 0.005 
General surgery  0.284  0.248 
 No 1  1  
 Yes 1.62 (0.63-4.15) 0.312 1.62 (0.66-4.01) 0.294 
Genetic  0.001  0.343 
 No 1  1  
 Yes 5.30 (2.34-12.0) <0.0001 5.30 (1.00-28.0) 0.050 
Genito-urinary  0.001  0.054 
 No 1  1  
 Yes 0.35 (0.17-0.68) 0.002 0.35 (0.15-0.82) 0.016 
Hematologic  0.003  0.018 
 No 1  1  
 Yes 0.24 (0.07-0.77) 0.016 0.24 (0.05-1.12) 0.069 
Infections  0.343  0.561 
 No 1  1  
 Yes 1.37 (0.72-2.59) 0.338 1.37 (0.52-3.61) 0.529 
Malignancies  0.096  0.144 
 No 1  1  
 Yes 0.41 (0.13-1.34) 0.142 0.41 (0.09-1.92) 0.260 
Musculoskeletal  0.007  0.265 
 No 1  1  
 Yes 0.35 (0.17-0.70) 0.003 0.35 (0.11-1.13) 0.080 
Neonatal  0.342  0.485 
 No 1  1  
 Yes 3.12 (0.43-22.7) 0.262 3.12 (0.46-21.0) 0.242 
Neurologic  0.320  0.291 
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 No 1  1  
 Yes 1.52 (0.64-3.63) 0.343 1.52 (0.66-3.49) 0.320 
Nutrition  0.054  0.023 
 No 1  1  
 Yes 0.31 (0.08-1.29) 0.109 0.31 (0.08-1.21) 0.092 
Psychosocial  0.646  0.762 
 No 1  1  
 Yes 1.16 (0.62-2.18) 0.647 1.16 (0.45-2.96) 0.757 
Reconstructive  0.001  0.124 
 No 1  1  
 Yes 3.00 (1.60-5.66) 0.001 3.00 (1.12-8.04) 0.028 
Renal  0.979  0.984 
 No 1  1  
 Yes 0.99 (0.49-1.99) 0.979 0.99 (0.39-2.50) 0.984 
Respiratory  0.328  0.545 
 No 1  1  
 Yes 0.72 (0.38-1.37) 0.321 0.72 (0.28-1.87) 0.501 
Rheumatologic  0.001  0.004 
 No 1  1  
 Yes 0.17 (0.04-0.69) 0.014 0.17 (0.04-0.72) 0.016 
Skin  0.264  0.490 
 No 1  1  
 Yes 0.65 (0.32-1.34) 0.246 0.65 (0.22-1.91) 0.438 
Toxic effects/Adverse events  0.658  0.708 
 No 1  1  
 Yes 0.80 (0.28-2.24) 0.667 0.80 (0.22-2.86) 0.728 
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Table A.19 Associations between comorbidities and death in patients with diabetes, crude 
results from log-binomial regression 
Characteristic Deaths, n 





Chronic pulmonary disease     0.882 
 No 212 7 (3.30) 1  
 Yes 44 0 - 1.01 (0.88 - 1.16) 0.881 
Congestive heart disease     0.73 
 No 214 6 (2.80) 1  
 Yes 42 1 (2.38) 1.02 (0.90-1.17) 0.723 
Dementia     0.893 
 No 252 6 (2.38) 1  
 Yes 4 1 (25.0) 0.97 (0.62-1.51) 0.898 
Diabetes with complication     0.019 
 No 221 7 (3.17) 1  
 Yes 35 0 - 1.17 (1.07-1.29) 0.001 
Myocardial infarction     0.054 
 No 235 7 (2.98) 1  
 Yes 21 0 - 1.17 (1.06-1.31) 0.003 
Peptic ulcer     0.054 
 No 243 7 (2.88) 1  
 Yes 13 0 - 1.06 (0.86-1.30) 0.003 
Peripheral vascular disease     0.864 
 No 226 7 (3.10) 1  
 Yes 30 0 - 1.01 (0.87-1.19) 0.861 
Aggregated Disease Groups (ADGs) 
Time Limited: Minor     0.1 
 No 84 3 (3.57) 1 - 
 Yes 172 4 (2.33) 0.91 (0.83-1.01) 0.082 
Time Limited: Minor-Primary     0.038 
 No 58 2 (3.45) 1  
 Yes 198 5 (2.53) 0.89 (0.80-0.98) 0.017 
Time Limited: Major     0.028 
 No 167 7 (4.19) 1  
 Yes 89 0 - 1.12 (1.02-1.24) 0.019 
Time Limited: Major-Primary Infections     0.263 
 No 156 3 (1.92) 1  
 Yes 100 4 (4.00) 0.94 (0.84-1.05) 0.274 
Allergies     0.681 
 No 228 7 (3.07) 1  
 Yes 28 0 - 1.04 (0.89-1.21) 0.666 
Asthma     0.683 
 No 223 6 (2.69) 1  
 Yes 33 1 (3.03) 1.03 (0.89-1.19) 0.669 
                                                     
 
*
DEA – Diabetic emergency admission refers to admissions for hyperglycaemic or hypoglycaemic emergencies, 
namely, diabetic ketoacidosis or diabetic coma. 
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Likely to Recur: Discrete     0.912 
 No 67 1 (1.49) 1  
 Yes 189 6 (3.17) 0.99 (0.88-1.12) 0.912 
Likely to Recur: Discrete-Infections     0.447 
 No 112 4 (3.57) 1  
 Yes 144 3 (2.08) 0.96 (0.87-1.06) 0.443 
Likely to Recur: Progressive     0.61 
 No 116 4 (3.45) 1  
 Yes 140 3 (2.14) 1.03 (0.93-1.14) 0.612 
Chronic Medical: Stable     0.748 
 No 61 3 (4.92) 1  
 Yes 195 4 (2.05) 0.98 (0.87-1.10) 0.744 
Chronic Specialty: Stable-Orthopedic     0.023 
 No 205 6 (2.93) 1  
 Yes 51 1 (1.96) 0.86 (0.74-1.00) 0.046 
Chronic Specialty: Stable-Eye     0.138 
 No 193 6 (3.11) 1  
 Yes 63 1 (1.59) 0.91 (0.80-1.04) 0.167 
Chronic Specialty: Unstable-Eye     0.251 
 No 152 6 (3.95) 1  
 Yes 104 1 (0.96) 0.94 (0.84-1.05) 0.26 
Dermatologic     0.263 
 No 156 6 (3.85) 1  
 Yes 100 1 (1.00) 0.94 (0.84-1.05) 0.274 
Injuries/Adverse Effects: Minor     0.998 
 No 149 6 (4.03) 1  
 Yes 107 1 (0.93) 1.00 (0.90-1.11) 0.998 
Injuries/Adverse Effects: Major     0.708 
 No 156 2 (1.28) 1  
 Yes 100 5 (5.00) 1.02 (0.92-1.13) 0.706 
Psychosocial: Time Limited, Minor     0.083 
 No 201 5 (2.49) 1  
 Yes 55 2 (3.64) 0.89 (0.77-1.03) 0.115 
Psychosocial: Recurrent or Persistent, Stable     0.768 
 No 182 5 (2.75) 1  
 Yes 74 2 (2.70) 0.98 (0.88-1.10) 0.771 
Psychosocial: Recurrent or Persistent, Unstable     0.038 
 No 198 6 (3.03) 1  
 Yes 58 1 (1.72) 1.13 (1.02-1.25) 0.017 
Signs/Symptoms: Minor     0.784 
 No 65 3 (4.62) 1  
 Yes 191 4 (2.09) 0.98 (0.88-1.10) 0.781 
Signs/Symptoms: Uncertain     0.581 
 No 45 1 (2.22) 1  
 Yes 211 6 (2.84) 0.96 (0.85-1.09) 0.564 
Signs/Symptoms: Major     0.304 
 No 83 5 (6.02) 1  
 Yes 173 2 (1.16) 0.95 (0.85-1.05) 0.287 
Discretionary     0.47 
 No 116 4 (3.45) 1  
 Yes 140 3 (2.14) 0.96 (0.87-1.07) 0.468 
See and Reassure     0.724 
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 No 209 7 (3.35) 1  
 Yes 47 0 - 1.02 (0.90-1.16) 0.717 
Prevention/Administrative     0.955 
 No 38 0 - 1  
 Yes 218 7 (3.21) 1.00 (0.86-1.15) 0.955 
Malignancy     0.465 
 No 176 6 (3.41) 1  
 Yes 80 1 (1.25) 0.96 (0.85-1.08) 0.477 
Dental     0.714 
 No 245 7 (2.86) 1  
 Yes 11 0 - 0.95 (0.72-1.26) 0.732 
Collapsed Aggregated Disease Groups (CADGs) 
Acute Minor     0.14 
 No 16 2 (12.5) 1  
 Yes 240 5 (2.08) 0.87 (0.76-0.99) 0.033 
Acute Major     0.613 
 No 14 1 (7.14) 1  
 Yes 242 6 (2.48) 1.06 (0.82-1.37) 0.641 
Likely to Recur     0.906 
 No 22 1 (4.55) 1  
 Yes 234 6 (2.56) 1.01 (0.84-1.22) 0.907 
Asthma     0.683 
 No 223 6 (2.69) 1  
 Yes 33 1 (3.03) 1.03 (0.89-1.19) 0.669 
Chronic Medical: Unstable     0.567 
 No 30 2 (6.67) 1  
 Yes 226 5 (2.21) 0.96 (0.83-1.11) 0.54 
Chronic Specialty: Stable     0.006 
 No 197 6 (3.05) 1  
 Yes 59 1 (1.69) 0.84 (0.72-0.97) 0.016 
Eye/Dental     0.088 
 No 184 6 (3.26) 1  
 Yes 72 1 (1.39) 0.90 (0.80-1.02) 0.111 
Chronic Specialty: Unstable     0.318 
 No 140 6 (4.29) 1  
 Yes 116 1 (0.86) 0.95 (0.85-1.05) 0.322 
Psychosocial     0.917 
 No 123 4 (3.25) 1  
 Yes 133 3 (2.26) 1.00 (0.90-1.10) 0.917 
Preventive/Administrative     0.955 
 No 38 0 - 1  
 Yes 218 7 (3.21) 1.00 (0.86-1.15) 0.955 
Expanded Disease Cluster (EDC) groups     0.134 
 Low 89 4 (4.49) 1  
 Moderate 90 3 (3.33) 0.92 (0.82-1.03) 0.156 
 High 77 0 - 0.88 (0.78-1.00) 0.055 
Major Expanded Disease Clusters (MEDCs) 
Administrative     0.685 
 No 32 0 - 1  
 Yes 224 7 (3.13) 1.03 (0.88-1.22) 0.697 
Allergy     0.573 
 No 191 6 (3.14) 1  
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 Yes 65 1 (1.54) 1.03 (0.92-1.16) 0.562 
Cardiovascular     0.605 
 No 48 2 (4.17) 1  
 Yes 208 5 (2.40) 1.04 (0.90-1.19) 0.618 
Dental     0.492 
 No 219 7 (3.20) 1  
 Yes 37 0 - 0.95 (0.81-1.11) 0.517 
Ear, Nose, Throat     0.016 
 No 114 3 (2.63) 1  
 Yes 142 4 (2.82) 0.88 (0.80-0.98) 0.014 
Eye     0.255 
 No 80 4 (5.00) 1  
 Yes 176 3 (1.70) 0.94 (0.85-1.04) 0.234 
Female reproductive system     0.817 
 No 206 5 (2.43) 1  
 Yes 50 2 (4.00) 1.02 (0.89-1.15) 0.814 
Gastrointestinal/hepatic     0.343 
 No 106 5 (4.72) 1  
 Yes 150 2 (1.33) 0.95 (0.86-1.05) 0.336 
General signs and symptoms     0.968 
 No 97 5 (5.15) 1  
 Yes 159 2 (1.26) 1.00 (0.90-1.11) 0.968 
General surgery     0.175 
 No 63 2 (3.17) 1  
 Yes 193 5 (2.59) 0.92 (0.83-1.03) 0.142 
Genito-urinary     0.016 
 No 129 4 (3.10) 1  
 Yes 127 3 (2.36) 0.88 (0.80-0.98) 0.017 
Hematologic     0.994 
 No 177 7 (3.95) 1  
 Yes 79 0 - 1.00 (0.89-1.12) 0.994 
Infections     0.564 
 No 181 5 (2.76) 1  
 Yes 75 2 (2.67) 1.03 (0.93-1.15) 0.554 
Malignancies     0.677 
 No 175 6 (3.43) 1  
 Yes 81 1 (1.23) 0.98 (0.87-1.09) 0.682 
Musculoskeletal     0.581 
 No 50 1 (2.00) 1  
 Yes 206 6 (2.91) 0.97 (0.85-1.09) 0.566 
Neurologic     0.555 
 No 34 1 (2.94) 1  
 Yes 222 6 (2.7) 1.05 (0.89-1.23) 0.576 
Nutrition     0.009 
 No 226 6 (2.65) 1  
 Yes 30 1 (3.33) 1.20 (1.10-1.31) <0.0001 
Psychosocial     0.334 
 No 144 4 (2.78) 1  
 Yes 112 3 (2.68) 0.95 (0.86-1.06) 0.339 
Reconstructive     0.992 
 No 191 4 (2.09) 1  
 Yes 65 3 (4.62) 1.00 (0.89-1.13) 0.992 
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Renal     0.001 
 No 185 6 (3.24) 1  
 Yes 71 1 (1.41) 0.82 (0.72-0.94) 0.004 
Respiratory     0.097 
 No 79 3 (3.8) 1  
 Yes 177 4 (2.26) 0.91 (0.82-1.01) 0.076 
Rheumatologic     0.536 
 No 195 6 (3.08) 1  
 Yes 61 1 (1.64) 1.04 (0.93-1.17) 0.521 
Skin     0.005 
 No 83 4 (4.82) 1  
 Yes 173 3 (1.73) 0.86 (0.78-0.95) 0.002 
Toxic effects/Adverse events     0.567 
 No 226 4 (1.77) 1  
 Yes 30 3 (10.0) 1.05 (0.90-1.21) 0.54 
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Table A.20 Associations between comorbidities and death in patients with diabetes, crude 
results from log-binomial regression using the generalized estimating equations (GEE) method  
Characteristic 
Crude Adjusted 
RR (95% CI) P-value RR (95% CI) P-value 
Disease groups 
Chronic pulmonary disease  0.882  0.888 
 No 1  1  
 Yes 1.01 (0.88-1.16) 0.881 1.01 (0.88-1.17) 0.888 
Congestive heart disease  0.730  0.707 
 No 1  1  
 Yes 1.02 (0.90-1.17) 0.723 1.02 (0.90-1.16) 0.704 
Dementia  0.893  0.896 
 No 1  1  
 Yes 0.97 (0.62-1.51) 0.898 0.97 (0.62-1.51) 0.898 
Diabetes with complication  0.019  0.006 
 No 1  1  
 Yes 1.17 (1.07-1.29) 0.001 1.17 (1.06-1.29) 0.001 
Myocardial infarction  0.054  0.016 
 No 1  1  
 Yes 1.17 (1.06-1.31) 0.003 1.17 (1.05-1.31) 0.004 
Peptic ulcer  0.639  0.623 
 No 1  1  
 Yes 1.06 (0.86-1.30) 0.605 1.06 (0.86-1.30) 0.610 
Peripheral vascular disease  0.864  0.860 
 No 1  1  
 Yes 1.01 (0.87-1.19) 0.861 1.01 (0.87-1.18) 0.859 
Aggregated Disease Groups (ADGs) 
Time Limited: Minor  0.100  0.076 
 No 1  1  
 Yes 0.91 (0.83-1.01) 0.082 0.91 (0.83-1.01) 0.069 
Time Limited: Minor-Primary  0.038  0.031 
 No 1  1  
 Yes 0.89 (0.80-0.98) 0.017 0.89 (0.80-0.98) 0.018 
Time Limited: Major  0.028  0.020 
 No 1  1  
 Yes 1.12 (1.02-1.24) 0.019 1.12 (1.02-1.24) 0.016 
Time Limited: Major-Primary Infections  0.263  0.243 
 No 1  1  
 Yes 0.94 (0.84-1.05) 0.274 0.94 (0.85-1.04) 0.250 
Allergies  0.681  0.670 
 No 1  1  
 Yes 1.04 (0.89-1.21) 0.666 1.04 (0.89-1.21) 0.663 
Asthma  0.683  0.661 
 No 1  1  
 Yes 1.03 (0.89-1.19) 0.669 1.03 (0.90-1.19) 0.659 
Likely to Recur: Discrete  0.912  0.913 
 No 1  1  
 Yes 0.99 (0.88-1.12) 0.912 0.99 (0.88-1.12) 0.913 
Likely to Recur: Discrete-Infections  0.447  0.485 
 No 1  1  
 Yes 0.96 (0.87-1.06) 0.443 0.96 (0.86-1.08) 0.485 
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Likely to Recur: Progressive  0.610  0.595 
 No 1  1  
 Yes 1.03 (0.93-1.14) 0.612 1.03 (0.93-1.13) 0.596 
Chronic Medical: Unstable  0.748  0.752 
 No 1  1  
 Yes 0.98 (0.87-1.10) 0.744 0.98 (0.87-1.11) 0.750 
Chronic Specialty: Stable-Orthopedic  0.023  0.063 
 No 1  1  
 Yes 0.86 (0.74-1.00) 0.046 0.86 (0.72-1.01) 0.072 
Chronic Specialty: Stable-Eye  0.138  0.160 
 No 1  1  
 Yes 0.91 (0.8-1.04) 0.167 0.91 (0.80-1.04) 0.173 
Chronic Specialty: Unstable-Eye  0.251  0.242 
 No 1  1  
 Yes 0.94 (0.84-1.05) 0.260 0.94 (0.85-1.04) 0.241 
Dermatologic  0.263  0.260 
 No 1  1  
 Yes 0.94 (0.84-1.05) 0.274 0.94 (0.85-1.04) 0.256 
Injuries/Adverse Effects: Minor  0.998  0.998 
 No 1  1  
 Yes 1.00 (0.90-1.11) 0.998 1.00 (0.90-1.12) 0.998 
Injuries/Adverse Effects: Major  0.708  0.703 
 No 1  1  
 Yes 1.02 (0.92-1.13) 0.706 1.02 (0.92-1.13) 0.702 
Psychosocial: Time Limited, Minor  0.083  0.101 
 No 1  1  
 Yes 0.89 (0.77-1.03) 0.115 0.89 (0.78-1.03) 0.110 
Psychosocial: Recurrent or Persistent, Stable  0.768  0.756 
 No 1  1  
 Yes 0.98 (0.88-1.10) 0.771 0.98 (0.88-1.10) 0.756 
Psychosocial: Recurrent or Persistent, Unstable  0.038  0.029 
 No 1  1  
 Yes 1.13 (1.02-1.25) 0.017 1.13 (1.02-1.26) 0.021 
Signs/Symptoms: Minor  0.784  0.769 
 No 1  1  
 Yes 0.98 (0.88-1.10) 0.781 0.98 (0.88-1.10) 0.767 
Signs/Symptoms: Uncertain  0.581  0.624 
 No 1  1  
 Yes 0.96 (0.85-1.09) 0.564 0.96 (0.83-1.12) 0.620 
Signs/Symptoms: Major  0.304  0.265 
 No 1  1  
 Yes 0.95 (0.85-1.05) 0.287 0.95 (0.86-1.04) 0.259 
Discretionary  0.470  0.450 
 No 1  1  
 Yes 0.96 (0.87-1.07) 0.468 0.96 (0.87-1.06) 0.448 
See and Reassure  0.724  0.720 
 No 1  1  
 Yes 1.02 (0.90-1.16) 0.717 1.02 (0.90-1.17) 0.719 
Prevention/Administrative  0.955  0.955 
 No 1  1  
 Yes 1.00 (0.86-1.15) 0.955 1.00 (0.86-1.15) 0.955 
Malignancy  0.465  0.506 
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 No 1  1  
 Yes 0.96 (0.85-1.08) 0.477 0.96 (0.85-1.09) 0.511 
Dental  0.714  0.713 
 No 1  1  
 Yes 0.95 (0.72-1.26) 0.732 0.95 (0.73-1.24) 0.715 
Collapsed Aggregated Disease Groups (CADGs) 
Acute Minor  0.140  0.068 
 No 1  1  
 Yes 0.87 (0.76-0.99) 0.033 0.87 (0.76-0.99) 0.034 
Acute Major  0.613  0.625 
 No 1  1  
 Yes 1.06 (0.82-1.37) 0.641 1.06 (0.83-1.36) 0.633 
Likely to Recur  0.906  0.901 
 No 1  1  
 Yes 1.01 (0.84-1.22) 0.907 1.01 (0.85-1.21) 0.901 
Asthma  0.683  0.661 
 No 1  1  
 Yes 1.03 (0.89-1.19) 0.669 1.03 (0.90-1.19) 0.659 
Chronic Medical: Unstable  0.567  0.559 
 No 1  1  
 Yes 0.96 (0.83-1.11) 0.540 0.96 (0.82-1.11) 0.548 
Chronic Specialty: Stable  0.006  0.042 
 No 1  1  
 Yes 0.84 (0.72-0.97) 0.016 0.84 (0.70-1.00) 0.048 
Eye/Dental  0.088  0.106 
 No 1  1  
 Yes 0.90 (0.80-1.02) 0.111 0.90 (0.80-1.03) 0.117 
Chronic Specialty: Unstable  0.318  0.331 
 No 1  1  
 Yes 0.95 (0.85-1.05) 0.322 0.95 (0.85-1.06) 0.331 
Psychosocial  0.917  0.910 
 No 1  1  
 Yes 1.00 (0.90-1.10) 0.917 1.00 (0.90-1.09) 0.910 
Preventive/Administrative  0.955  0.955 
 No 1  1  
 Yes 1.00 (0.86-1.15) 0.955 1.00 (0.86-1.15) 0.955 
Expanded Disease Cluster (EDC) groups  0.134  0.140 
 Low 1  1  
 Moderate 0.92 (0.82-1.03) 0.156 0.92 (0.80-1.05) 0.223 
 High 0.88 (0.78-1.00) 0.055 0.88 (0.78-1.00) 0.050 
Major Expanded Disease Clusters (MEDCs) 
Administrative  0.685  0.703 
 No 1  1  
 Yes 1.03 (0.88-1.22) 0.697 1.03 (0.87-1.22) 0.706 
Allergy  0.573  0.555 
 No 1  1  
 Yes 1.03 (0.92-1.16) 0.562 1.03 (0.93-1.16) 0.552 
Cardiovascular  0.605  0.590 
 No 1  1  
 Yes 1.04 (0.90-1.19) 0.618 1.04 (0.91-1.18) 0.594 
Dental  0.492  0.511 
 No 1  1  
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 Yes 0.95 (0.81-1.11) 0.517 0.95 (0.81-1.11) 0.515 
Ear, Nose, Throat  0.016  0.031 
 No 1  1  
 Yes 0.88 (0.80-0.98) 0.014 0.88 (0.79-0.99) 0.028 
Eye  0.255  0.275 
 No 1  1  
 Yes 0.94 (0.85-1.04) 0.234 0.94 (0.84-1.05) 0.267 
Female reproductive system  0.817  0.826 
 No 1  1  
 Yes 1.02 (0.89-1.15) 0.814 1.02 (0.89-1.16) 0.826 
Gastrointestinal/hepatic  0.343  0.337 
 No 1  1  
 Yes 0.95 (0.86-1.05) 0.336 0.95 (0.86-1.05) 0.332 
General signs and symptoms  0.968  0.968 
 No 1  1  
 Yes 1.00 (0.90-1.11) 0.968 1.00 (0.90-1.11) 0.968 
General surgery  0.175  0.116 
 No 1  1  
 Yes 0.92 (0.83-1.03) 0.142 0.92 (0.84-1.02) 0.106 
Genito-urinary  0.016  0.012 
 No 1  1  
 Yes 0.88 (0.80-0.98) 0.017 0.88 (0.80-0.97) 0.013 
Hematologic  0.994  0.994 
 No 1  1  
 Yes 1.00 (0.89-1.12) 0.994 1.00 (0.90-1.11) 0.994 
Infections  0.564  0.555 
 No 1  1  
 Yes 1.03 (0.93-1.15) 0.554 1.03 (0.93-1.15) 0.552 
Malignancies  0.677  0.701 
 No 1  1  
 Yes 0.98 (0.87-1.09) 0.682 0.98 (0.86-1.10) 0.703 
Musculoskeletal  0.581  0.618 
 No 1  1  
 Yes 0.97 (0.85-1.09) 0.566 0.97 (0.84-1.11) 0.614 
Neurologic  0.555  0.553 
 No 1  1  
 Yes 1.05 (0.89-1.23) 0.576 1.05 (0.90-1.22) 0.556 
Nutrition  0.009  0.002 
 No 1  1  
 Yes 1.20 (1.10-1.31) <<0.00011 1.20 (1.09-1.31) <0.0001 
Psychosocial  0.334  0.307 
 No 1  1  
 Yes 0.95 (0.86-1.06) 0.339 0.95 (0.86-1.05) 0.307 
Reconstructive  0.992  0.992 
 No 1  1  
 Yes 1.00 (0.89-1.13) 0.992 1.00 (0.88-1.13) 0.992 
Renal  0.001  0.003 
 No 1  1  
 Yes 0.82 (0.72-0.94) 0.004 0.82 (0.72-0.94) 0.003 
Respiratory  0.097  0.069 
 No 1  1  
 Yes 0.91 (0.82-1.01) 0.076 0.91 (0.83-1.00) 0.055 
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Rheumatologic  0.536  0.558 
 No 1  1  
 Yes 1.04 (0.93-1.17) 0.521 1.04 (0.92-1.18) 0.556 
Skin  0.005  0.002 
 No 1  1  
 Yes 0.86 (0.78-0.95) 0.002 0.86 (0.79-0.94) 0.001 
Toxic effects/Adverse events  0.567  0.508 
 No 1  1  
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Table A.21 ICD-10 codes for cancer mapped to Read codes 
ICD-10 code ICD-10 term Read code Read term 
C00-C14 Malignant neoplasms of lip, oral cavity and 
pharynx 
B0… Malignant neoplasm of lip, oral cavity 
and pharynx 
C15-C26 Malignant neoplasms of digestive organs B1… Malignant neoplasm of digestive organs 
and peritoneum 
C30-C39 Malignant neoplasms of respiratory and 
intrathoracic organs 
B2... Malignant neoplasm of respiratory tract 
and intrathoracic organs 
C40-C41 Malignant neoplasms of bone and articular 
cartilage 
B3... Malignant neoplasm of bone, 
connective tissue, skin and breast 
C43-C44 Melanoma and other malignant neoplasms 
of skin 
B3... Malignant neoplasm of bone, 
connective tissue, skin and breast 
C45-C49 Malignant neoplasms of mesothelial and 
soft tissue 
B3... Malignant neoplasm of bone, 
connective tissue, skin and breast 
C50-C50 Malignant neoplasm of breast B3... Malignant neoplasm of bone, 
connective tissue, skin and breast 
C51-C58 Malignant neoplasms of female genital 
organs 
B4... Malignant neoplasm of genitourinary 
organ 
C60-C63 Malignant neoplasms of male genital organs B4... Malignant neoplasm of genitourinary 
organ 
C64-C68 Malignant neoplasms of urinary tract B4... Malignant neoplasm of genitourinary 
organ 
C69-C72 Malignant neoplasms of eye, brain and 
other parts of central nervous system 
B5... Malignant neoplasm of other and 
unspecified sites 
C73-C75 Malignant neoplasms of thyroid and other 
endocrine glands 
B6... Malignant neoplasm of lymphatic and 
haemopoietic tissue 
C76-C80 Malignant neoplasms of ill-defined, 
secondary and unspecified sites 
B5... Malignant neoplasm of other and 
unspecified sites 
C81-C96 Malignant neoplasms, stated or presumed 
to be primary, of lymphoid, 
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Table A.22 Excluded diagnoses, ICD-10 codes mapped to Read codes 
ICD-10 category Read category Cancer type 
C44 B33.. Other malignant neoplasms of skin 
C97-C97 ByuE Malignant neoplasms of independent (primary) multiple sites   
D00-D09 B8…, ByuF. In situ neoplasms   
D10-D36 B7…, ByuG. Benign neoplasms   
D37-D48 B9…, BA…, ByuH. Neoplasms of uncertain or unknown behaviour   
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